

**POISONS STANDARD 2015**

I, ANTHONY GILL, a delegate of the Secretary to the Department of Health for the purposes of paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989* (the Act) and acting in accordance with the Secretary’s power under that paragraph of the Act, prepare this new Poisons Standard, in substitution for the current Poisons Standard.

(Signed by)

ANTHONY GILL

Delegate of the Secretary to the Department of Health

Dated this 5 February 2015

1. **Citation**

This instrument is the *Poisons Standard 2015*.

1. **The New Poisons Standard**

The Poisons Standard 2015 consists of the Standard for the Uniform Scheduling of Medicines and Poisons No. 6 (the SUSMP6) as set out in Schedule 1.

1. **Commencement**

The Poisons Standard 2015 commences on the day after registration.

**Schedule 1-**Standard for the Uniform Scheduling of Medicines and Poisons No. 6

**STANDARD FOR THE UNIFORM SCHEDULING OF**

**MEDICINES AND POISONS**

**No. 6**

February 2015

Reasons for scheduling delegates’ final decisions can be accessed from the TGA website, at <https://www.tga.gov.au/reasons-scheduling-delegates-final-decisions>

Futher inquiries in relation to this document should be directed to:

|  |  |
| --- | --- |
| The Secretary  Chemicals Scheduling Secretariat (MDP88)  Office of Chemical Safety  Department of Health  GPO Box 9848  CANBERRA ACT 2601  or by email to [Chemicals.Scheduling@health.gov.au](mailto:Chemicals.Scheduling@health.gov.au) | The Secretary  Medicines Scheduling Secretariat (MD122) Communications and Secretariat Therapeutic Goods Administration PO Box 100 WODEN ACT 2606  or by email to [Medicines.Scheduling@tga.gov.au](mailto:Medicines.Scheduling@tga.gov.au) |

Media Liaison Unit

Australian Government Department of Health

**Contents**

[**INTRODUCTION** ii](#_Toc408306082)

[CLASSIFICATION iii](#_Toc408306083)

[PRINCIPLES OF SCHEDULING iii](#_Toc408306084)

[READING THE SCHEDULES iv](#_Toc408306085)

[**PART 1** 2](#_Toc408306088)

[**INTERPRETATION** 2](#_Toc408306089)

[**PART 2** 10](#_Toc408306090)

[**CONTROL ON MEDICINES AND POISONS** 10](#_Toc408306091)

[SECTION ONE LABELS 10](#_Toc408306092)

[SECTION TWO CONTAINERS 20](#_Toc408306108)

[**PART 3** 28](#_Toc408306116)

[**MISCELLANEOUS REGULATIONS** 28](#_Toc408306117)

[SECTION ONE ADVERTISING 28](#_Toc408306118)

[SECTION TWO SALE OR SUPPLY 28](#_Toc408306119)

[SECTION 3 STORAGE 29](#_Toc408306124)

[**PART 4** 31](#_Toc408306125)

[**THE SCHEDULES** 31](#_Toc408306126)

[SCHEDULE 1 32](#_Toc408306127)

[SCHEDULE 2 33](#_Toc408306128)

[SCHEDULE 3 48](#_Toc408306129)

[SCHEDULE 4 54](#_Toc408306130)

[SCHEDULE 5 131](#_Toc408306131)

[SCHEDULE 6 158](#_Toc408306132)

[SCHEDULE 7 196](#_Toc408306133)

[SCHEDULE 8 207](#_Toc408306134)

[SCHEDULE 9 210](#_Toc408306135)

[SCHEDULE 10 216](#_Toc408306136)

[**PART 5** 221](#_Toc408306139)

[**THE APPENDICES** 221](#_Toc408306140)

[APPENDIX A 222](#_Toc408306141)

[APPENDIX B 225](#_Toc408306143)

[APPENDIX C (see SCHEDULE 10) 234](#_Toc408306146)

[APPENDIX D 235](#_Toc408306147)

[APPENDIX E 237](#_Toc408306149)

[APPENDIX F 252](#_Toc408306153)

[APPENDIX G 276](#_Toc408306155)

[APPENDIX H 277](#_Toc408306157)

[APPENDIX I 278](#_Toc408306159)

[APPENDIX J 279](#_Toc408306160)

[APPENDIX K 282](#_Toc408306162)

[APPENDIX L 285](#_Toc408306165)

# **INTRODUCTION**

The Poisons Standard 2015, which, under section 2 above consists of the *Standard for the Uniform Scheduling of Medicines and Poisons* (the Standard, or the SUSMP), is made under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989*, and is a compilation of the decisions made under section 52D of the same Act. The SUSMP should be read in conjunction with the *Scheduling Policy Framework* (SPF) of the Australian Health Ministers' Advisory Council. Further information on the scheduling amendments and the SPF can be accessed at www.tga.gov.au. Refer to Part 1, Interpretation, on page 2 below for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).

The SUSMP serves two key purposes.

Firstly, the SUSMP contains the decisions of the Secretary of the Department of Health or the Secretary's delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.

Secondly, the SUSMP includes model provisions for labelling, containers, storage and possession of poisons in general, which are intended to be adopted for use in each jurisdiction of Australia, according to local requirements and local law. Other government agencies may also impose controls on certain products, for example cosmetics.

The requirements for labelling and containers in the SUSMP are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.

Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in the SUSMP as they are covered by Safe Work Australia's *National Code of Practice for the Labelling of Workplace Substances* [NOHSC: 2012(1994)].Note, however that this exemption does not extend to controls on supply of these poisons.

The SUSMP is presented with a view to promoting uniform:

* scheduling of poisons throughout Australia;
* signal headings on labels for poisons throughout Australia;
* labelling and packaging requirements for poisons throughout Australia;
* additional controls on the availability and use of poisons in Australia.

The various Commonwealth Acts, legislative instruments and other documents which integrate with the SUSMP include:

* the *Agricultural and Veterinary Chemicals Code Act 1994*
* the *Agricultural and Veterinary Chemicals Code Regulations 1995*
* the *Therapeutic Goods Act 1989*
* Therapeutic Goods Order 69 – *General requirements for labels for medicines*
* Therapeutic Goods Order 80 – *Child-Resistant Packaging Requirements for Medicines*
* the *Required Advisory Statements for Medicine Labels* (RASML).

## CLASSIFICATION

Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.

**Schedule 1.** This Schedule is intentionally blank.

**Schedule 2. Pharmacy Medicine** – Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.

**Schedule 3. Pharmacist Only Medicine** – Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.

**Schedule 4. Prescription Only Medicine,** or **Prescription Animal Remedy** – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.

**Schedule 5. Caution** – Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.

**Schedule 6. Poison** – Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.

**Schedule 7. Dangerous Poison** – Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply.

**Schedule 8. Controlled Drug** – Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.

**Schedule 9. Prohibited Substance** – Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

**Schedule 10/**

**Appendix C. Substances of such danger to health as to warrant prohibition of sale, supply and use -** Substances which are prohibited for the purpose or purposes listed for each poison.

## PRINCIPLES OF SCHEDULING

Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.

This Standard lists poisons in nine Schedules according to the degree of control recommended to be exercised over their availability to the public.

Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.

For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.

Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this Standard, the method by which it is implemented in the States and Territories may vary.

Schedule 10/Appendix C contains a list of substances or preparations, the sale, supply or use of which should be prohibited because of their known dangerous properties.

Substances in products which have been considered for scheduling, but have been exempted from this Standard, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).

## READING THE SCHEDULES

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type.

Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.

Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (‘reverse scheduling’), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.

Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Part 1, Interpretation, subparagraph 1(2).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using this Standard to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A and B, the Index and the Cross Reference Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:

**Group Example**

the parent acid of salts “oxalic acid” to find sodium oxalate

the radical of a salt “chromates” to find potassium

chromate

the element “arsenic” to find arsenic trioxide

a chemical group with similar “hydrocarbons, liquid” to find

toxicological or pharmacological kerosene

activity

a pharmacological group “anabolic steroidal agents” to find

“androsterone”

### **Availability of poisons**

The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.

These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.

Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not indicate:

* that the poison is available; nor
* that is has been approved or is efficacious for any use that may be specified in a Schedule; nor
* does it negate any obligation for registration of a therapeutic good, or agricultural or veterinary chemical product containing that poison.

### **Preparations containing poisons listed in two or more Schedules**

If a preparation contains two or more poisons, the provisions relating to each of the Schedules in which those poisons are included apply.

Where it is not possible to comply both with a provision relating to one of those Schedules and with a provision relating to another of those Schedules, the provision of the more restrictive Schedule applies, unless a contrary intention is indicated in the Schedules or relevant legislation.

The Schedules listed in order of greatest to least restriction on access and availability are 9, 10, 8, 4, 7, 3, 2, 6, 5.

Schedule 1 is not currently in use.

Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this Standard. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.

| **Appendix** | **Title** | **Purpose/ controls imposed** |
| --- | --- | --- |
| Appendix A | General exemptions | List of classes of products or uses exempted from this Standard. |
| Appendix B | Substances considered not to require control by scheduling | List of poisons exempted from scheduling. |
| Appendix C | Appendix is intentionally left blank |  |
| Appendix D | Additional controls on possession or supply of poisons included in Schedule 4 or 8 | List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. |
| Appendix E | First aid instructions for poisons | First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix F | Warning statements and general safety directions for poisons | Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix G | Dilute preparations | Concentration cut-offs for specified poisons, below which the requirements of the Standard do not apply |
| Appendix H | Schedule 3 medicines permitted to be advertised | List of medicines included in Schedule 3 that are permitted to be advertised to the public. |
| Appendix I | Appendix is intentionally left blank |  |
| Appendix J | Conditions for availability and use of Schedule 7 poisons | List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. |
| Appendix K | Human medicines required to be labelled with a sedation warning | List of human medicines required to be labelled with a warning regarding their sedation potential. |
| Appendix L | Requirements for dispensing labels for medicines | Requirements applying to labels attached to medicines at the time of dispensing. |

This page is intentionally blank.

# **PART 1**

# **INTERPRETATION**

**1.** (1) In this Standard, unless the contrary intention appears —

“**Agricultural chemical**” means a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:

(a) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing;

(b) destroying a plant;

(c) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity;

(d) modifying an effect of another agricultural chemical;

(e) attracting a pest for the purpose of destroying it; or

(f) any active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be an agricultural chemical product;

but does not include:

(g) a veterinary chemical.

“**Agricultural chemical product**” has the meaning defined in the *Agricultural and Veterinary Chemicals Code Act 1994*.

“**Animal**” means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.

**“Animal feed premix”** means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.

“**Appropriate authority**” means:

(a) in the Australian Capital Territory, ACT Government Health Directorate;

(b) for the purpose of providing an exemption from all or part of paragraphs 2 to 12 in Part 2 of this Standard by the Australian Pesticides and Veterinary Medicines Authority, the Chief Executive Officer or their delegate;

(c) in New South Wales, the Director-General of the NSW Ministry of Health;

(d) in the Northern Territory, the Chief Health Officer of the Department of Health;

(e) in Queensland, the Chief Executive of Queensland Health;

(f) in South Australia, the Chief Executive of the Department for Health and Ageing;

(g) in Tasmania, the Secretary of the Department of Health and Human Services;

(h) for the purpose of providing an exemption from all or part of Section 1.1 to Section 1.5.3 of this Standard by the Therapeutic Goods Administration, the National Manager or their delegate;

(i) in Victoria, the Secretary to the Department of Health;

(j) in Western Australia, the Chief Executive Officer of the Department of Health.

**“Approved name”** means:

(a) in relation to a poison that is for human therapeutic use, the name approved for use by the Therapeutic Goods Administration;

(b) in relation to a poison that is for animal or agricultural use, the name approved for use by the Australian Pesticides and Veterinary Medicines Authority;

(c) in relation to all other poisons:

(i) the name used in an entry in these Schedules; or, if no such name is given,

(ii) the English name recommended by Standards Australia as the common name for the poison; or, if no such name is given,

(iii) the English name given to the poison by the International Organization for Standardization; or, if no such name is given,

(iv) the English name given to the poison by the British Standards Institution; or, if no such name is given,

(v) the name that would comply with the requirements of part (a) or (b) of this definition, or, if no such name is given,

(vi) the English name given to the poison by the European Committee for Standardization (CEN); or, if no such name is given,

(vii) the international non-proprietary name recommended for the poison by the World Health Organization; or, if no such name is given,

(viii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the *International Cosmetic Ingredient Dictionary & Handbook* published by the Personal Care Products Council of America; or, if no such name is given,

(ix) the accepted scientific name or the name descriptive of the true nature and origin of the poison.

**“Australian Code for the Transport of Dangerous Goods by Road and Rail”** means the seventh edition of the document of that name.

“**Authorised prescriber**” means a registered medical, dental or veterinary practitioner or such other person authorised by the appropriate authority.

**“Blood”** means whole blood extracted from human donors.

“**Blood components**” means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.

**“Child-resistant closure”** means:

(a) a closure that complies with the requirements for a child-resistant closure in the Australian Standard AS 1928-2007 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages* (ISO 8317:2003, MOD);

(b) a closure approved by an order made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989;* or

(c) in the case of a can fitted with a press-on lid, a lid of the design known as “double tight” or “triple tight”.

See also "Non-access packaging**”**.

**“Child-resistant packaging”** means packaging that:

(a) complies with the requirements of the Australian Standard AS 1928-2007 entitled

*Child resistant packaging – Requirements and testing procedures for reclosable packages* (ISO 8317:2003, MOD);

(b) is reclosable and complies with the requirements of at least one of the following Standards:

(i) the International Organization for Standardization Standard ISO 8317:2003 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages*;

(ii) the British Standards Institution Standard BS EN ISO 8317:2004 entitled

*Child-resistant packaging. Requirements and testing procedures for reclosable packages*;

(iii) the Canadian Standards Association Standard CSA Z76.1-06 entitled *Reclosable Child-Resistant Packages;*

(iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, entitled *Poison prevention packaging standards* and Section 1700.20, entitled *Testing procedure for special packaging*;

(c) is approved as child-resistant by any order made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(d) is in the form of blister or strip packaging in which a unit of use is individually protected until the time of release and that complies with Section 3 (Requirements for non-reclosable packages) of Australian Standard AS 1928-2001 entitled *Child-resistant packages.*

See also "Non-access packaging".

**“Compounded**” in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.

***“*Cosmetic*”*** means:

(a) a substance or preparation intended for placement in contact with any external part of the human body, including:

(i) the mucous membranes of the oral cavity; and

(ii) the teeth;

with a view to:

(iii) altering the odours of the body; or

(iv) changing its appearance; or

(v) cleansing it; or

(vi) maintaining it in good condition; or

(vii) perfuming it; or

(viii) protecting it.

“**Debitterised neem seed oil**” means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.

**“Dermal use”** means application to the skin primarily for localised effect.

**“Designated solvent”** means the following:

acetone

dimethylformamide

N-(N-dodecyl)-2-pyrrolidone

hydrocarbons, liquid

methanol when included in Schedule 5

methyl ethyl ketone

methyl isoamyl ketone

methyl isobutyl ketone

N-methyl-2-pyrrolidone

N-(N-octyl)-2- pyrrolidone

phenyl methyl ketone

styrene

tetrachloroethylene

1,1,1-trichloroethane

**“Dispensing label”** means the label attached to the immediate container of a substance for therapeutic use at the time of dispensing.

**“Distributor”** means a person who imports, sells or otherwise supplies a poison.

**“Divided preparation”** means a preparation manufactured and packed as discrete pre-measured dosage units prior to sale or supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.

**“Dosage unit”** means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.

**“Drug”** means a poison intended for human or animal therapeutic use.

**“Essential oils”** means products obtained from natural raw materials either by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation. For scheduling purposes it also means:

(a) oils of equivalent composition derived through synthetic means; or

(b) prepared mixtures of oils of equivalent composition comprising a mixture of synthetic and natural components.

**“External”** in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.

**“First Schedule Paint”** means a paint containing the specified proportion of any substance in the First Group to Part 2 of this Standard.

**“Free formaldehyde”** includes all hydrated and non-hydrated formaldehyde present in aqueous solution, including methylene glycol.

**“Graphic material”** means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.

**“Height”** in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.

**“Hemp seed oil”** means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.

**“Immediate container**” includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.

**“Immediate wrapper”** means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.

**“Internal use”** means administration:

(a) orally, except for topical effect in the mouth; or

(b) for absorption and the production of a systemic effect;

(i) by way of a body orifice other than the mouth; or

(ii) parenterally, other than by application to unbroken skin.

**“Label”** means:

(a) a written statement on a container of a poison; and

(b) in relation to a therapeutic good, includes a display of printed information about the product:

(i) on, or attached to, the good;

(ii) on, or attached to, a container or primary pack in which the good is supplied; or

(iii) supplied with such a container or pack.

**“Main label”** means, where there are two or more labels on a container or a label is divided into two or more portions:

(a) the part of a label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and

(b) where there are two or more labels or two or more portions of a single label – that label or portion of the label where the product name is more or most conspicuously shown; or

(c) where the product name is equally conspicuous on two or more labels or portions of a label – each such label or portion.

**“Manufacturer”** means a person who manufactures, produces, or packs a poison.

**“Measure pack”** means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.

**“Medicine”** means any poison for therapeutic use**.**

*Note: To be preceded by “human” or “veterinary” where restriction of the “medicine” to human or animal use is intended.*

**“Name and address”** means the name and address, in Australia, of the manufacturer or distributor of a poison but does not include a post office, cable, telegraphic or code address. Where such manufacturer or distributor is a company incorporated in accordance with the appropriate law of any State or Territory of the Commonwealth of Australia or a firm registered under the Business Names Act of any State or Territory, the inclusion in the label of the registered name of the corporation or firm or its branch or its division and the city or town in which a registered office is situated shall be deemed to comply with the requirements.

**“Non-access packaging**” is packaging that complies with the requirements of Australian Standard AS4710-2001 entitled *Packages for chemicals not intended for access or contact with their contents by humans*, in relation to products that are not intended for human therapeutic use.

See also "Child-resistant closure" and "Child-resistant packaging”.”.

**“Non-volatile content”** in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580-301.1-2005entitled *Paints and related materials – Methods of test – Non-volatile content by mass*.

“**Oromucosal use**” means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.

**“Paint”**, without limiting the ordinary meaning, includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.

**“Pesticide”** means any substance or mixture of substances used or intended to be used:

(a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or

(b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.

**“Poison”** means any substance or preparation included in a Schedule to this Standard.

**“Primary pack”** means the pack in which a poison and its immediate container or immediate wrapper or measure pack are presented for sale or supply.

**“Required Advisory Statements for Medicine Labels”** means the document made under subsection 3(5A) of the *Therapeutic Goods Act 1989* by the Therapeutic Goods Administration.

**“Restricted flow insert”** means a restriction fitted, or moulded, in the neck of a container which:

(a) cannot readily be removed from the container by manual force; and

(b) limits the delivery of the contents to drops each of which is not more than 200 microlitres.

**“Second Schedule Paint”** means a paint containing the specified proportion of any substance in the Second Group to Part 2 Section 7 of this Standard.

**“Selected container”** means:

(a) an injection vial having a nominal capacity of ten millilitres or less;

(b) a single use syringe; or

(c) any other container for substances for therapeutic use having a nominal capacity of ten millilitres or less.

**“Solid”** is considered to include “powder” for the purposes of scheduling.

**“Therapeutic good”** has the meaning defined in theCommonwealth*Therapeutic Goods Act 1989.*

**“Therapeutic use”** means use in or in connection with:

(a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals;

(b) influencing, inhibiting or modifying a physiological process in human beings or animals;

(c) testing the susceptibility of human beings or animals to a disease or ailment;

(d) influencing, controlling or preventing conception in persons or animals;

(e) testing for pregnancy in persons or animals; or

(f) the replacement or modification of parts of the anatomy in persons or animals.

**“Tinter”** means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.

**“Topical use”** means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.

**“Toy”** means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of fourteen years.

**“Transdermal use”** means application to the skin primarily for systemic effect.

**“Veterinary chemical”** means a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:

(a) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest;

(b) curing or alleviating an injury suffered by the animal;

(c) modifying the physiology of the animal:

(i) so as to alter its natural development, productivity, quality or reproductive capacity; or

(ii) so as to make it more manageable;

(d) modifying the effect of another veterinary chemical

(e) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a), (b), (c) or (d); or

(f) any active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be an veterinary chemical product;

but does not include:

(g) an agricultural chemical.

**“Veterinary chemical product”** has the meaning defined in the *Agricultural and Veterinary Chemicals Code Act 1994*.

**“Writing”** includes the visible representation or reproduction of words or figures in any form, and “to write” and “written” have corresponding meanings.

(2) Unless the contrary intention appears a reference to a substance in a Schedule or an Appendix to this Standard includes:

(a) that substance prepared from natural sources or artificially; and

(b) where the substance is a plant (other than a plant included in Schedule 8 or 9), that plant or any part of that plant when packed or prepared for therapeutic use; and

(c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative; and

(d) every alkaloid of the substance and every salt of such an alkaloid; and

(e) every stereoisomer of the substance and every salt of such a stereoisomer; and

(f) every recombinant form of the substance; and

(g) a preparation or admixture containing any proportion of the substance,

but does not include:

(h) a preparation or product included in Appendix A, or a substance and the reason for its entry in Appendix B; or

(i) a substance included in Appendix G at a concentration not exceeding the concentration specified in column 2 of that Appendix in respect of that substance; or

(j) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8; or

(k) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the *Standards for Active Constituents*, as published by the Australian Pesticides and Veterinary Medicines Authority.

(3) Unless the contrary intention appears where a concentration, strength or quantity is specified in a Schedule or an Appendix to this Standard in respect of a substance:

(a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance that is listed in the Schedule or Appendix; and

(b) the expression “one per cent” means:

(i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of the preparation; or

(ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 gram of the substance per 100 grams of the preparation; and

(iii) any expression of greater or lesser percentages shall have a corresponding meaning; and

(c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.

(4) A reference to a boiling or distillation temperature in the Schedules means that temperature at an atmospheric pressure of 101.325 kPa (760 millimetres of mercury).

# **PART 2**

# **CONTROL ON MEDICINES AND POISONS**

## SECTION ONE LABELS

## 1.1 General requirements

(1**)** A person must not sell or supply a poison unless it is labelled in accordance with Part 2 Section 1 of this Standard .

(2) Any word, expression or statement required by this Standard to be written on a label or container must be written:

(a) on the outside face of the label or container; and

(b) in the English language; and

(c) in durable characters; and

(d) in a colour or colours to provide a distinct contrast to the background colour; and

(e) in letters at least 1.5 millimetres in height.

**(**3) Section 1.1(2)(e) does not apply to a word, expression or statement on a container which has a capacity of 20 millilitres or less, or on the label of such a container if:

(a) an appropriate authority approves the use of smaller letters; and

(b) the letters are at least 1 millimetre in height.

(4) The label must be printed on, or securely attached to:

(a) the outside of the immediate container; and

(b) if the immediate container is enclosed in a primary pack, the outside of that primary pack.

## 1.2 Immediate wrapper

(1) A poison enclosed in an immediate wrapper must be contained in a primary pack labelled in accordance with Section 1.3 of this Standard; and

(2) the immediate wrapper must be conspicuously labelled with:

(a) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and

(b) the approved name of the poison; and

(c) a statement of the quantity or strength of the poison in accordance with   
 Section 1.4 of this Standard.

## 1.3 Primary packs and immediate containers

(1) The primary pack and immediate container of a poison must be labelled as follows:

1. with the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the following table:

Schedule Purpose Signal words required

2 for any purpose **PHARMACY MEDICINE**

3 for any purpose **PHARMACIST ONLY MEDICINE**

4 for human use **PRESCRIPTION ONLY MEDICINE**

4 for animal use **PRESCRIPTION ANIMAL REMEDY**

5 for any purpose **CAUTION**

6 for any purpose **POISON**

7 for any purpose **DANGEROUS POISON**

8 for any purpose **CONTROLLED DRUG**

written:

(i) on the first line or lines of the main label; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least half the height of the largest letter or numeral on the label but need not be larger than:

(A) 6 millimetres on labels for packages having a nominal capacity of   
2 litres or less; or

(B) 15 millimetres on labels for packages having a nominal capacity of more than 2 litres; and

(iv) if the poison:

(A) is a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail* or a statement of the principal hazard of the poison, written on that line; or

(B) is not a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on that line;

(b) if the poison is a Schedule 8 poison, with the cautionary statement –

**POSSESSION WITHOUT AUTHORITY ILLEGAL**

written:

(i) on a separate line or lines immediately below the signal words required by Section1.3(1)(a); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal words; and

(iv) with no other statement written on the same line;

(c) with the cautionary statement –

**KEEP OUT OF REACH OF CHILDREN**

written:

(i) on a separate line or lines:

(A) immediately below the signal word or words required by Section 1.3(1)(a); or

(B) where the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by Section 1.3(1)(b), on the line immediately below that statement; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(d) if the poison is a dry chlorinating compound containing more than 10 per cent of available chlorine, **except** for preparations certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, with the cautionary statement –

**FIRE AND EXPLOSION HAZARD**

written:

(i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by Section 1.3(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(e) if the poison is an alkaline salt in a dishwashing machine product, with the cautionary statement –

**BURNS SKIN AND THROAT**

written:

(i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by Section 1.3(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line of the main label;

(f) if the poison is an aqueous solution of paraquat, with the cautionary statements –

**CAN KILL IF SWALLOWED**

**DO NOT PUT IN DRINK BOTTLES**

**KEEP LOCKED UP**

written:

(i) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by Section1.3(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same lines of the main label;

(g) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if safety directions are required on the label by Section 1.3(1)(n), with the cautionary statement –

**READ SAFETY DIRECTIONS BEFORE OPENING**

**OR USING**

or with the cautionary statement –

**READ SAFETY DIRECTIONS**

written:

(i) on a separate line or lines;

(A) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by Section (1)(c); or

(B) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(h) if the poison meets the criteria for a ‘flammable liquid’ in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, with the cautionary statement –

**FLAMMABLE**

written on the main label in bold-face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the *Australian Code for the Transport of Dangerous Goods by Road and Rail*;

(i) if the poison is for the treatment of animals, with the cautionary statement –

**FOR ANIMAL TREATMENT ONLY**

written on the main label in bold-face sans serif capital letters of uniform thickness;

(j) if the poison is a Schedule 5 poison intended for any purpose other than internal or pesticidal use, with the cautionary statement –

DO NOT SWALLOW

written in sans serif capital letters on the main label or as part of the directions for use;

(k) with the approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with Section 1.4:

(i) if the poison is for human therapeutic use, written in accordance with orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act, 1989*; or

(ii) if the poison is not for human therapeutic use, written in bold-face sans serif capital letters on the main label, unless:

(A) a list of approved names is required; and

(B) it is impractical to include the list on the main label; and

(C) an appropriate authority has authorised its inclusion on another part of the label; or

(iii) if the poison is a Schedule 5 poison referred to in column 1 of the following table the appropriate name opposite thereto in column 2 may be used as the approved name:

**TABLE**

**Column 1 Column 2**

Alkaline salts Alkaline salts

Amines for use as curing Aliphatic amines or

agents for epoxy resins aromatic amines

(unless separately specified

in the Schedules)

Epoxy resins, liquid Liquid epoxy resins

Hydrocarbons, liquid Liquid hydrocarbons

Quaternary ammonium Quaternary ammonium

compounds compound(s)

(iv) if a poison contains a mixture of designated solvents in excess of 25 per cent of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25 per cent, the approved names of those solvents may be expressed as follows:

(A) where the designated solvent is a liquid hydrocarbon as “liquid hydrocarbons”; or

(B) where the designated solvent is a ketone as “ketones”; or

(C) in any other case as “solvents” or “other solvents”;

(l) if the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, with the following expression written immediately below the approved name or the list of declared contents –

**AN ANTICHOLINESTERASE COMPOUND**

(i) the requirements of Section 1.3(1)(l) do not apply to:

(A) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or

(B) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or

(C) an organophosphorus compound or carbamate contained in a

pressurised spray pack for household use;

(m) for any poison other than a poison for human therapeutic use labelled in accordance with Therapeutic Goods Order 69 *General requirements for labels for medicines* or in an agricultural or veterinary chemical product labelled in compliance with the *Agricultural and Veterinary Chemicals Code Act 1994*, if the poison is prepared, packed or sold for a specific purpose, with clear and adequate directions for use unless:

(i) the poison is included in Schedule 4 or Schedule 8; or

(ii) it is impractical to include such directions on the label and:

(A) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”; and

(B) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label; and

(C) the insert is enclosed in the primary pack;

(n) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if use of the poison may be harmful to the user, with appropriate safety directions (see Appendix F), grouped together as a distinct section of the label and prefaced by the words –

**SAFETY DIRECTIONS**

written in bold-face capital letters;

(o) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if any warning statement or statements are required for the poison (see Appendix F), with that warning statement or those statements grouped together:

(i) if safety directions are included on the label, immediately after the words “SAFETY DIRECTIONS”; or

(ii) if there are no safety directions, immediately preceding the directions for use;

(p) if the poison is not for human internal use and is not a Schedule 3, Schedule 4 or Schedule 8 poison, with appropriate first aid instructions (see Appendix E):

(i) grouped together and prefaced by the words –

**FIRST AID**

written in bold-face capital letters; or

(ii) if a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

(A) written on each immediate container as specified in Section 1.3(1)(p)(i); and

(B) replaced on the primary pack with the statement –

FIRST AID: See inner packs;

(q) with the name and address of the manufacturer or distributor.

(2) For the purposes of Section 1.3(1)(a)(iii) the term “largest letter or numeral” does not include:

(a) a single letter or numeral which is larger than other lettering on the label; or

(b) an affix forming part of the trade name; or

(c) in the case of a poison for therapeutic use, numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.

## 1.4 Statements of quantity, proportion or strength

**(1)**  The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:

(a) if the poison is for human therapeutic use, in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*;

(b) if the poison is for a purpose or purposes other than human therapeutic use and:

(i) if the poison is in a pressurised spray aerosol preparation, as the mass of the poison per stated mass of the preparation;

(ii) if the poison is a liquid in a liquid preparation, as the mass or volume of the poison per stated volume of the preparation;

(iii) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume of the poison per stated mass of the preparation;

(iv) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the poison per stated volume of the preparation;

(v) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;

(vi) if the poison is a gas in a liquid preparation, as the mass of the poison per stated volume of the preparation;

(vii) if the poison is a gas in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;

(viii) if the poison is a gas in a gaseous preparation, as the mass of the poison per stated mass of the preparation;

(c) if the poison is a solution of a mineral acid, the proportion of the acid (un-neutralised by any bases present in the preparation) in a preparation may be expressed as the un-neutralised mass of the acid per stated mass of the preparation;

(d) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:

contains not more than 10 per cent of (*insert* *name of the metal*); or

contains not more than 30 per cent of (*insert name of the metal*); or

contains more than 30 per cent of (*insert name of the metal*);

(e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5 per cent of the product;

(f) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint;

(g) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.

(h) For the purposes of Section 1.4(1)(g) “derivative” includes alkaloid.

## 1.5 Exemptions

### **1.5.1 Selected containers and measure packs**

**(1)**  The requirements of Section 1.3 do not apply to an immediate container that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which Section 1.5.2 (1) and (2) apply) when:

(a) the immediate container is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(b) the immediate container is:

(i) packed in a primary pack labelled in accordance with Section 1.3; and

(ii) labelled with:

(A) the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the table to Section 1.3(1)(a); and

(B) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with Section 1.4; and

(C) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(D) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

### **1.5.2 Ampoules, pre-filled syringes and injection vials**

**(1)** The requirements of Section 1.3 do not apply to a selected container, or an ampoule (other than an ampoule to which Section 1.5.2(2) applies) when:

(a) the selected container or ampoule is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(b) the selected container or ampoule is:

(i) packed in a primary pack labelled in accordance with Section 1.3; and

(ii) labelled with:

(A) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with Section 1.4; and

(B) with the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(C) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

**(2)** The requirements of Section 1.3 do not apply to a selected container that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:

(a) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(b) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is:

(i) packed in a primary pack labelled in accordance with Section 1.3; and

(ii) the strip is labelled in accordance with Section 1.5.2; and

(iii) the ampoule is labelled with:

(A) the approved name of the poison or the trade name of the product; and

(B) the quantity, proportion or strength of the poison in accordance with Section 1.4.

### **1.5.3 Transport containers and wrappings**

**(1)** The labelling requirements of this Standard do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.

### **1.5.4 Dispensary, industrial, laboratory and manufacturing poisons**

**(1)** The labelling requirements of this Standard do not apply to a poison that:

(a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and

(b) is labelled in accordance with Safe Work Australia's *National Code of Practice for the Labelling of Workplace Substances* [NOHSC: 2012(1994)].

### **1.5.5 Exemptions from label requirements in certain circumstances**

(1) The labelling requirements of Sections 1.3 to 1.5.3 do not apply to a poison where an appropriate authority has granted a labelling exemption in whole or in part for these sections for a specified product; and

(2) the labelling exemption from an appropriate authority referred to in Section 1.5.5(1) is limited to no more than 12 months from the effective date of the decision for retail supply of the product; and

(3) for the avoidance of doubt this paragraph does not apply to exemptions issued under Section 1.3(1)(m)(ii)(B) of this Standard.

### **1.5.6 Dispensed medicines**

**(1)** Unless otherwise specified by regulation:

(a) The labelling requirements of this Standard do not apply to a medicine that:

(i) is supplied by an authorised prescriber or other person authorised to supply and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or

(ii) is supplied on and in accordance with a prescription written by an authorised prescriber and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or

(iii) is prepared and supplied by a pharmacist for an individual patient and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard.

(b) A person must not supply a dispensed medicine for human use containing:

1. a poison listed in column 1 of the table at Appendix L Part 2 of this Standard unless it is clearly labelled with the warning statement(s) specified in column 2 of that table; or

(ii) a poison listed in Appendix K unless it is clearly labelled with a sedation warning (being statement 39, 40 or 90 as specified in Appendix F Part 1 of this Standard).

### **1.5.7 Gas cylinders**

**(1)** The requirements of Sections 1.3(1)(a)(iv), 1.3(1)(c)(iv), and 1.3(1)(g)(iv) do not apply to a cylinder containing a poison that is a compressed gas.

### **1.5.8 Paints**

**(1)** The requirements of Section 1.3 do not apply to:

(a) paint (other than a paint for therapeutic or cosmetic use) which:

(i) contains only Schedule 5 poisons; or

(ii) is a First Group or Second Group paint that is labelled with:

(A) the word “WARNING”, written in bold-face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and

(B) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and

(C) the appropriate warnings specified for the paint in Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and

(D) the name and proportion of the First Group or Second Group poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint; or

(b) a tinter which contains:

(a) only Schedule 5 poisons; or

(b) a poison included in the First Group or Second Group in Part 2 Section 7, provided that it is labelled with the name and proportion of that poison, and where the poison is a metal or metal salt, the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”.

### **1.5.9 Camphor and naphthalene**

**(1)** The labelling requirements of Section1.1(2)(d) and Section 1.3 do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:

(1) complies with Section 2.7; and

(2) is sold or supplied in a primary pack labelled in accordance with Section 1.1 and Section 1.3.

### **1.6 Prohibitions**

**(1)** A label used in connection with any poison must not include:

(a) any reference to this Standard, or any comment on, reference to, or explanation of any expression required by this Standard that directly or by implication contradicts, qualifies or modifies such expression; or

(b) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by the Government or any government authority unless required by legislation; or

(c) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or

(d) any trade name or description that:

(i) represents any single constituent of a compound preparation; or

(ii) misrepresents the composition or any property or quality of the poison; or

(iii) gives any false or misleading indication of origin or place of manufacture of the poison.

**(2)** A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure:

(a) any expression required by this Standard to be written or embossed on the container or pack; or

(b) any of the ribs or embossed or printed words required by paragraph 21, 22 or 23 as appropriate.

## 

## SECTION TWO CONTAINERS

**2.1 Containers for poisons other than Schedule 5 poisons**

(1) A person must not sell or supply a poison unless the immediate container complies with the requirements of Sections 2.1 and 2.3 to 2.7 of this Standard.

(2) If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of 2 litres or less, the container must comply with Australian Standard AS 2216-1997, entitled *Packaging for poisonous substances*.

(3) Notwithstanding Section 2.1(2), a poison which is in Schedule 6 and is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216-1997, entitled *Packaging for poisonous substances,* if:

(a) the other safety factors are not diminished; and

(b) the container has a restricted flow insert and a child-resistant closure.

(4) If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of more than 2 litres, the container must:

(a) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances*; and

(b) have the word “POISON”:

(ia) in sans serif capital letters the height of which is at least one thirty second part of the length, height or width of the container, whichever is the greatest:

(A) embossed; or

(B) indelibly written in a colour in distinct contrast to the background colour;

(ii) on the side or shoulder of the container.

## 2.2 Containers for Schedule 5 poisons

(1) The container in which any Schedule 5 poison is sold or supplied must:

(a) comply with the container requirements of Sections 2.1(2) or 2.1(4); or

(b) be readily distinguishable from a container in which food, wine or other beverage is sold; and

(i) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances*, excluding paragraph 1.4.3;

(ii) be securely closed and, except when containing a preparation for use on one occasion only, be capable of being re-closed to prevent spillage of its contents; and

(iii) have the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” embossed or indelibly written thereon, or printed on a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.

(2) Notwithstanding Section 2.2(1), the following Schedule 5 poisons namely:

(a) methylated spirit(s);

(b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;

(c) petrol;

(d) toluene; or

(e) xylene,

must not be sold or supplied in a bottle or jar having a nominal capacity of 2 litres or less, unless the immediate container complies with the container requirements specified in Section 2.1(2).

## 2.3 Approved containers

(1) Notwithstanding subparagraphs 21, 22 and 23 a poison may be packed in a container that does not comply with the tactile identification requirements of Australian Standard AS2216-1997 entitled *Packaging for poisonous substances* or the requirements of Section 2.1(4)(b) or Section 2.2(1)(b)(iii) if:

(a) the other safety factors are not diminished;

(b) the container is for a specific purpose; and

(c) an appropriate authority has approved the use of the container for that purpose.

## 2.4 Child-resistant closures

(1) If a poison, other than a poison included in a therapeutic good packaged in a manner compliant with orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*, listed in column 1 of the following table is sold or supplied in a container having a nominal capacity specified for that poison in column 2, it must be closed with a child-resistant closure.

Alkaline salts included in Schedule 5, All sizes  
when packed and labelled as dishwashing

machine tablets.

Alkaline salts included in Schedule 5, 5 litres /kilograms or less  
when packed and labelled as dishwashing

machine liquids, solids or gels.

Alkaline salts included in Schedule 5, when 2.5 litres or less

packed and labelled as a food additive.

Anise oil when included in Schedule 5. 200 millilitres or less

Basil oil when included in Schedule 5. 200 millilitres or less

Bay oil when included in Schedule 6. 200 millilitres or less

Cajuput oil when included in Schedule 6. 200 millilitres or less

Cassia oil when included in Schedule 5. 200 millilitres or less

Cineole when included in Schedule 6. 2 litres or less

Cinnamon bark oil when included 200 millilitres or less

in Schedule 5.

Cinnamon leaf oil when included in Schedule 6. 200 millilitres or less

Clove oil when included in Schedule 6. 200 millilitres or less

Essential oils when included in Schedule 6 200 millilitres or less

because of their natural camphor component.

Ethylene glycol when included in Schedule 6. 5 litres or less

Ethylene glycol when included in 5 litres or less

Schedule 5 in preparations containing

more than 50 per cent of ethylene glycol.

Eucalyptus oil when included in Schedule 6. 2 litres or less

Eugenol when included in Schedule 6. 200 millilitres or less

Hydrocarbons, liquid, when packed 5 litres or less

as kerosene, lamp oil, mineral turpentine,

thinners, reducers, white petroleum spirit

or dry cleaning fluid.

Hydrochloric acid when included in Schedule 6. 5 litres or less

*Leptospermum scoparium* oil (manuka oil) 200 millilitres or less

when included in Schedule 6

Marjoram oil when included in Schedule 5. 200 millilitres or less

Melaleuca oil (tea-tree oil) when included 200 millilitres or less

in Schedule 6.

Methylated spirit excluding preparations or 5 litres or less

admixtures.

Methyl salicylate and preparations containing 200 millilitres or less

more than 50 per cent of methyl salicylate.

Nutmeg oil when included in Schedule 5. 200 millilitres or less

Oil of turpentine. 5 litres or less

Pennyroyal oil when included in Schedule 6. 200 millilitres or less

Potassium hydroxide as such. 2.5 litres or less

Potassium hydroxide in oven, hot plate or 5 litres or less

drain cleaners when included in Schedule 6

**except** when in pressurised spray packs.

d-Pulegone when included in Schedule 6. 200 millilitres or less

Sage oil (Dalmatian) when included 200 millilitres or less

in Schedule 6.

Sodium hydroxide as such. 2.5 litres or less

Sodium hydroxide in oven, hot plate or 5 litres or less

drain cleaners when included in Schedule 6

**except** when in pressurised spray packs.

Thujone when included in Schedule 6. 200 millilitres or less

Thyme oil when included in Schedule 5. 200 millilitres or less

(2) The manufacturer or packer of a poison must ensure that the child-resistant closure is appropriate for the container and the poison and that it retains its child-resistant properties for the expected life of the poison.

## 2.5 Schedule 8 poisons

(1) A person who supplies any Schedule 8 poison must ensure that the Schedule 8 poison is packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.

(2) This paragraph does not apply to the supply of a Schedule 8 poison by an:

(a) authorised prescriber or other authorised supplier;

(b) pharmacist on the prescription of an authorised prescriber;

(c) pharmacist employed at a hospital, on the written requisition of a medical practitioner, a dentist or the nurse or midwife in charge of the ward in which the Schedule 8 poison is to be used or stored; or

(d) nurse or midwife on the direction in writing of an authorised prescriber.

## 2.6 Exemptions

(1) Section 2.1(2), Section 2.1(4) and Section 2.2 do not apply to the immediate container of a poison prepared, packed and sold:

(a) for human internal or animal internal use; or

(b) as a solid or semi-solid preparation for human external or animal external use; or

(c) as a paint, other than a paint for therapeutic or cosmetic use; or

(d) in containers having a nominal capacity of 15 millilitres or less; or

(e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or

(f) solely for dispensary, industrial, laboratory or manufacturing purposes.

(2) Section 2.4 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.

(3) The tactile identification or embossing required by Section 2.1(2), Section 2.1(4) and Section (2.2) of this Standard or Australian Standard AS 2216-1997 entitled Packaging for poisonous substances do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.

## 2.7 Camphor and naphthalene

(1) The container requirements of Section 2.1(2) do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:

(a) in normal use, prevents removal or ingestion of its contents; and

(b) is incapable of reacting with the poison; and

(c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and

(d) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.

(2) A person must not sell or supply camphor or naphthalene in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.

## 2.8 Prohibitions

(1) A person must not sell or supply a poison in a container which has the name of another poison embossed or indelibly marked thereon.

(2) A person must not sell any poison which is for internal use or any food, drink or condiment in a container prescribed by Sections 2.1(2), 2.1(4) and Section 2.2 of this Standard.

(3) A person must not sell any poison in a container that is not readily distinguishable from a container in which food, alcohol, other beverage or condiment is sold..

**SECTION THREE STORAGE**

**3.1 General requirements**

1. A person who sells or supplies Schedule 6 poisons by way of retail sale must keep those poisons in such a way as to prevent access by children.
2. A person who sells or supplies Schedule 7 poisons must not keep those poisons for retail sale in any areas or in any area or in any manner that allows physical access by any person unless they are:
3. the owner of the retail establishment; or
4. an employee of the owner; or
5. legally permitted to purchase the substance and are under the supervision of the owner or an employee of the owner.

(3) Controls on storage of Schedule 2, 3, 4 and 8 poisons require referral to Part 3 of this Standard and relevant legislation**.**

**SECTION FOUR DISPOSAL**

**4.1 General requirements**

1. A person must not dispose of or cause to be disposed of a Schedule 5, Schedule 6 or Schedule 7 poison in any place or manner that constitutes or is likely to constitute a risk to public health or safety.
2. Controls on disposal of Schedule 2, 3, 4 and 8 poisons require referral to relevant legislation.

**SECTION FIVE RECORD KEEPING**

**5.1 General Requirements**

1. A person who sells or supplies Schedule 7 poisons must keep a record of:

(a) Name and address of seller or supplier and purchaser; and

(b) Date of order and supply; and

(c) Approved name or trade name that identifies the poison to be supplied or sold; and

(d) Quantity supplied or sold; and

(e) Proof of purchaser authorisation must be recorded in jurisdictions where an authorisation is required for purchase.

1. Records for sale or supply of Schedule 7 poisons must be kept for a minimum period of five years.
2. Controls on record keeping for sale or supply of Schedule 2, 3, 4 and 8 poisons require referral to relevant legislation.

**SECTION SIX SALE, SUPPLY, POSSESSION, or USE**

**6.1 General Requirements for Schedule 5 and Schedule 6 Product samples**

1. A person must not sell or supply or distribute free a product sample containing a Schedule 5 or Schedule 6 poison in any manner unless the recipient has the opportunity to refuse at the time of sale or supply.
2. A person must not sell or supply or distribute free a product sample containing a Schedule 5 or Schedule 6 poison in an unsolicited manner for example via the post / mailbox or attached to any other product.
3. A person must not sell or supply a Schedule 5 or Schedule 6 poison product sample in a manner that does not promote disposal in accordance with section four.

**6.2 Schedule 7 Poisons**

1. A person must not possess or use a Schedule 7 poison for domestic or domestic garden purposes.
2. A person must not sell or supply:

(a) a Schedule 7 poison for domestic or domestic garden purposes; or

(b) a Schedule 7 poison being a liquid preparation containing paraquat unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell; or

(c) a Schedule 7 poison for which an authorisation to purchase, possess or use is required by the appropriate authority unless the purchaser produces his or her authorisation.

1. A person must not sell, supply or distribute free product samples containing Schedule 7 poisons.

**6.3 Schedule 10/Appendix C poisons**

1. A person must not knowingly have in his or her possession or sell, supply or use a poison listed in Schedule 10/Appendix C of this Standard for the purpose or purposes indicated in relation to that poison in Schedule 10/Appendix C;

**6.4 Hawking**

1. A person must not sell by way of hawking a Schedule 7 poison.
2. Controls on sale or supply or sale by way of hawking of Schedule 2, 3, 4 and 8 poisons require referral to Part 3 of this Standard and relevant legislation.

**SECTION SEVEN/Appendix I PAINT OR TINTERS**

**7.1 General Requirements**

(1) A person must not manufacture, sell, supply or use a First Group Paint for application to:

(a) a roof or any surface to be used for the collection or storage of potable water; or

(b) furniture; or

(c) any fence, wall, post, gate or building (interior or exterior) other than a building which is used exclusively for industrial purposes or mining or any oil terminal; or

(d) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.

1. A person must not manufacture, sell, supply or use a paint or tinter containing more than 0.1% Lead (the proportion of Lead for the purposes of this section is calculated as a percentage of the element present in the non-volatile content of the paint).

(3) A person must not manufacture, sell, supply or use a paint for application to toys unless the paint complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012 entitled *Safety of toys Part 3: Migration of certain elements* (ISO 8124-03:2010, MOD).

(4) A person must not manufacture, sell, supply, or use a paint or tinter containing a pesticide except a fungicide, algicide, bactericide or antifouling agent.

**The First Group**

The proportion of a substance for the purposes of this Group is calculated as a percentage of the element present in the non-volatile content of the paint.

**Substance Proportion**

ANTIMONY or antimony compounds other than more than 5 per cent

antimony titanate pigments

BARIUM salts **except** barium sulfate or barium metaborate more than 5 per cent

CADMIUM or cadmium compounds more than 0.1 per cent

CHROMIUM as chromates of ammonia, barium, potassium more than 5 per cent

sodium, strontium or zinc

SELENIUM or selenium compounds more than 0.1 per cent

**The Second Group**

**Substance Proportion**

DICHLOROMETHANE (methylene chloride) more than 5 per cent by wt

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates more than 10 per cent by vol

TOLUENE more than 50 per cent by vol

XYLENE more than 50 per cent by vol

# **PART 3**

# **MISCELLANEOUS REGULATIONS**

(It is recommended that the States and Territories implement regulations which   
provide controls similar to those included in this Part of the Standard.)

## SECTION ONE ADVERTISING

**3.1 General requirements**

(1) A person must not include any reference to a poison included in:

(a) Schedule 3 unless included in Appendix H; or

(b) Schedule 4 or Schedule 8,

of this Standard in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.

(2) A person must not include any reference to a poison included in Schedule 9 or Schedule 10/Appendix C of this Standard in any advertisement.

## SECTION TWO SALE OR SUPPLY

## 3.2 Schedule 2 poisons

(1) A person, other than a pharmacist (or an assistant under the direction of a pharmacist) or a medical, dental or veterinary practitioner in the lawful practice of their professions, must not sell or supply a Schedule 2 poison unless licensed to do so.

(2) A person is not eligible to be granted a licence to sell a Schedule 2 poison by way of retail sale unless:

(a) he or she is carrying on the business of selling goods by retail; and

(b) the premises from which the poison will be sold is more than 25 kilometres by the shortest practical route from the nearest pharmacy; and

(c he or she produces such evidence, as may be required, that he or she is a fit and proper person to be so licensed.

## 3.3 Schedule 3 poisons

(1) A person, other than a pharmacist, or a medical, dental or veterinary practitioner, in the lawful practice of his or her profession, must not sell or supply a Schedule 3 poison.

(2) The person who sells or supplies a Schedule 3 poison must:

(a) provide adequate instructions for use, either written or verbal, at the time of supply or sale; and

(b) label the container with his or her name or the name of the pharmacy and the address from which it was sold or supplied; and

(c) if required by regulation, make a record of the transaction in a prescription book or other approved recording system.

## 3.4 Schedule 4 poisons

**(1)** A person, other than a medical, dental or veterinary practitioner in the ordinary course of their professions or a pharmacist dispensing a legal prescription must not sell or supply a Schedule 4 poison.

**(2)** Section 3.4(1) does not apply to a pharmacist who sells or supplies a Schedule 4 poison, other than a poison excepted by regulation from this provision, without a prescription if:

(a) the patient is under medical treatment with the poison and continuation of medication is essential; and

(b) the quantity sold or supplied does not exceed 3 days' medication; and

(c) the pharmacist is satisfied that an emergency exists.

**(3)** Section 3.2(1), Sections 3.3(1) and (2) and Section 3.4(1) do not apply to sale by way of wholesale dealing to a pharmacist, medical practitioner, veterinary practitioner, dentist or a person licensed or otherwise authorised to possess, sell or supply such poisons.

## 3.5 Prohibitions on sale, prescribing and possession

**(1)** A person must not:

(a) sell or supply, other than by way of wholesale dealing, or prescribe a poison listed in Appendix D paragraphs 1, 2, 3 or 4 except in accordance with the provisions indicated for that poison in Appendix D; or

(b) knowingly have in his or her possession a poison listed in Appendix D paragraph 5 without authority.

## SECTION 3 STORAGE

**3.6** A person who sells or supplies Schedule 2 poisons must keep those poisons in such a way that public access to advice from a pharmacist is available if required.

**3.7** A person who sells or supplies Schedule 3 or Schedule 4 poisons must keep those poisons in a part of the premises to which the public does not have access.

This page is intentionally blank.

# **PART 4**

# **THE SCHEDULES**

## SCHEDULE 1

This Schedule is intentionally blank.

## SCHEDULE 2

(Substances marked are listed in Appendix C)

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use **except** when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids; or

(b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids.

ALOXIPRIN.

AMETHOCAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMOROLFINE in preparations for topical use **except** in preparations for the treatment of tinea pedis.

ANTAZOLINE in eye drops.

ASPIRIN **except**:

(a) when included in Schedule 4, 5 or 6;

(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:

(i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and

(ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:

(i) packed in blister or strip packaging or in a container with a child-resistant closure;

(ii) in a primary pack of not more than 25 tablets or capsules, each containing 325  mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and

(iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:

(i) packed in blister or strip packaging or in a container with a child-resistant

closure;

(ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and

(iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ATROPA BELLADONNA (belladonna):

(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE (excluding atropine methonitrate) for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

AZELAIC ACID in dermal preparations.

AZELASTINE:

(a) in preparations for nasal use; or

(b) in topical eye preparations containing 0.05 per cent or less of azelastine.

BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

(a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide **except** in preparations containing 5 per cent or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use, **except** in preparations for dermal use.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or

(b) in preparations for the treatment of tinea pedis.

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

CARBETAPENTANE **except** in preparations containing 0.5 per cent or less of carbetapentane.

CARBOCISTEINE.

CETIRIZINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

1. in a primary pack containing not more than 5 days’ supply; and
2. labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CHLOPHEDIANOL.

CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol **except** in preparations containing 0.5 per cent or less of chlorbutol.

CHLOROFORM in preparations for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 0.5 per cent or less of chloroform.

CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

CICLOPIROX:

1. in preparations for dermal use containing 2 per cent or less of ciclopirox **except** in preparations for the treatment of tinea pedis; or
2. in preparations for application to the nails containing 8 per cent or less of ciclopirox.

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.

CINNAMEDRINE.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

CODEINE in preparations for the treatment of coughs and colds when:

1. not combined with any other opiate substance;
2. compounded with one or more other therapeutically active substances, of which at least one is phenylephrine and not more than one is an analgesic substance:
3. in divided preparations containing 10 mg or less of codeine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of codeine;

1. labelled with a recommended daily dose not exceeding 60 mg of codeine; and

(d) in packs containing not more than 6 days' supply at the maximum dose recommended on the label.

CREOSOTE derived from wood other than beechwood for human therapeutic use, **except** in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.

DATURA spp. for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) for oral use when:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** for smoking or burning.

DATURA TATULA (stramonium) for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** for smoking or burning.

DELPHINIUM STAPHISAGRIA **except** in preparations containing 0.2 per cent or less of *Delphinium staphisagria*.

DESLORATADINE in preparations for oral use.

DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.

DIBROMOPROPAMIDINE for ophthalmic use.

DICLOFENAC when:

1. in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac;
2. in preparations for dermal use containing 4 per cent or less of diclofenac **except** in preparations for dermal use containing 1 per cent or less of diclofenac or for the treatment of solar keratosis; or
3. in transdermal preparations for topical use containing 140 mg or less of diclofenac.

DIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:

(a) containing 5 mg or less of dihydrocodeine per dosage unit;

(b) packed in blister or strip packaging or in a container with a child-resistant closure;

(c) enclosed in primary packs containing 25 or less dosage units; and

(d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.

DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DUBOISIA LEICHHARDTII for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ECONAZOLE for human use in dermal preparations **except** in preparations for the treatment of tinea pedis.

ETAFEDRINE.

ETHER for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 10 per cent or less of ether.

ETHYLMORPHINE when:

(a) compounded with one or more other therapeutically active substances:

(i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine;

(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.

ETOFENAMATE in preparations for external use.

FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.

FELBINAC in preparations for external use.

FEXOFENADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

1. in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and
2. labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.

FLUORIDES for human use:

(a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or

(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:

(i) for therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels* **except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of *Required Advisory Statements for Medicine Labels;* or

(ii) for non-therapeutic use when labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less,

**except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less,

**except** in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLURBIPROFEN in preparations for topical oral use when:

(a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit; or

(b) in undivided preparations containing 0.25 per cent or less, or 10 mg or less per dose, of flurbiprofen.

FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

FOLIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

FOLINIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

FORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or

(b) in other preparations containing 0.2 per cent or less of free formaldehyde.

GUAIPHENESIN in a modified release dosage form of 1200 mg or less of guaiphenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.

GELSEMIUM SEMPERVIRENS.

GLUTARALDEHYDE for human therapeutic use.

HEXACHLOROPHANE in preparations for human use containing 3 per cent or less of hexachlorophane **except**:

(a) in preparations containing 0.75 per cent or less of hexachlorophane; or

(b) in preparations for use on infants, as specified in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:

(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:

(i) in undivided preparations in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories.

HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone **except:**

1. in hair preparations containing 0.3 per cent or less of hydroquinone; or
2. in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.

8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1 per cent or less of such substances.

HYOSCINE (excluding hyoscine butylbromide):

(a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

HYOSCYAMINE:

(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2  mg or less total solanaceous alkaloids.

HYOSCYAMUS NIGER for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** in a pack containing 0.03 mg or less of total solanaceous alkaloids.

IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:

(a) in liquid preparations when sold in the manufacturer’s original pack containing 8 grams or less of ibuprofen; or

(b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units **except** when:

(i) as the only therapeutically active constituent (other than phenylephrine or when combined with an effervescent agent);

(ii) packed in blister or strip packaging or in a container with a child-resistant closure;

(iii) in a primary pack containing not more than 25 dosage units;

(iv) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(v) not labelled for the treatment of children 6 years of age or less; and

(vi) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.

INDANAZOLINE.

INDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.

IODINE:

(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or

(b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors),

**except** in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.

IPRATROPIUM in preparations for nasal use.

IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use **except**:

(a) when included in Schedule 4; or

(b) when labelled with a recommended daily dose of 24 mg or less of iron:

(i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or

(ii) in divided preparations:

(A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or

(B) containing 5 mg or less of iron per dosage unit.

ISOCONAZOLE for human use in dermal preparations.

ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.

KETOCONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the

scalp; or

(b) in preparations for the treatment of tinea pedis.

KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.

LEVOCABASTINE in topical eye or nasal preparations.

LIGNOCAINE in preparations for topical use other than eye drops:

(a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.

LITHIUM in preparations for dermal use containing 1 per cent or less of lithium **except**:

(a) when present as an excipient at 0.25 per cent or less of lithium; or

(b) in preparations containing 0.01 per cent or less of lithium.

LOBELIA INFLATA **except** for smoking or burning.

LOBELINE **except** in preparations for smoking or burning.

LODOXAMIDE in preparations for ophthalmic use.

LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less **except** in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LORATADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(a) in a primary pack containing 5 dosage units or less; and

(b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.

MEBENDAZOLE for human therapeutic use.

MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

MEPYRAMINE for dermal use.

MERCUROCHROME in preparations for external use containing 2 per cent or less of mercurochrome **except** when included in Schedule 6.

MERCURY for external use in preparations containing 0.5 per cent or less of mercury.

METHOXAMINE in preparations for external use **except** in preparationscontaining 1 per cent or less of methoxamine.

METHOXYPHENAMINE.

METHYLEPHEDRINE.

MICONAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.

MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

NAPHAZOLINE.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NICLOSAMIDE for human therapeutic use.

NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.

NOSCAPINE.

NYSTATIN in dermal preparations.

OXETACAINE (oxethazaine) in preparations for internal use.

OXICONAZOLE for dermal use **except** in preparations for the treatment of tinea pedis.

OXYMETAZOLINE.

PAPAVERINE **except** when included in Schedule 4.

PARACETAMOL for therapeutic use **except**:

(a) when included in Schedule 4;

(b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesinor when combined with effervescent agents) when:

1. enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;
2. compliant with the requirements of the *Required Advisory Statements for Medicine Labels;*
3. not labelled for the treatment of children 6 years of age or less; and
4. not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin; or

(c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:

1. packed in blister or strip packaging or in a container with a child-resistant closure;
2. in a primary pack containing not more than 20 tablets or capsules;
3. compliant with the requirements of *the Required Advisory Statements for Medicine Labels*;
4. not labelled for the treatment of children 6 years of age or less; and
5. not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin.

PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or

(b) in other preparations containing 0.2 per cent or less of free formaldehyde.

PENCICLOVIR for external use for the treatment of herpes labialis.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

(a) in eye drops; or

(b) when combined with one or more other therapeutically active substances in oral preparations when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations for external use containing 3 per cent or less of such substances.

PHENYLEPHRINE **except**:

(a) when included in Schedule 4;

(b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or

(c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.

PHOLCODINE:

(a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or

(b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10 per cent or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.

PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.

PROMETHAZINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

PROPAMIDINE for ophthalmic use.

PYRANTEL for human therapeutic use.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.

PYRITHIONE ZINC for human therapeutic use, **except** in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days' supply **except** in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units.

SALICYLAMIDE **except** when included in Schedule 4.

SELENIUM in preparations for human therapeutic use **except**:

(a) for topical use containing 3.5 per cent or less of selenium sulfide;

(b) when included in Schedule 4; or

(c) for oral use with a recommended daily dose of 150 micrograms or less.

SILVER for therapeutic use **except**:

(a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(b) in other preparations containing 1 per cent or less of silver.

SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

SQUILL **except** in preparations containing 1 per cent or less of squill.

SULCONAZOLE in preparations for dermal use.

TERBINAFINE for dermal use **except** in preparations for the treatment of tinea pedis.

TETRACHLOROETHYLENE for human therapeutic use.

TETRAHYDROZOLINE.

THIABENDAZOLE for human therapeutic use.

TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.

TRAMAZOLINE.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses

are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing triprolidine in the bed-time dose where the day and night

doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

TUAMINOHEPTANE.

TYMAZOLINE.

XYLOMETAZOLINE.

ZINC CHLORIDE for human dermal use **except** in preparations containing 5 per cent or less of zinc chloride.

## SCHEDULE 3

ADRENALINE in preparations containing 1 per cent or less of adrenaline **except** in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.

AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.

AZATADINE in oral preparations.

BROMPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use.

CHLORAMPHENICOL for ophthalmic use only.

CHLORBUTOL in preparations for human use **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5 per cent or less of chlorbutol.

CHLORPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

CIMETIDINE in a primary pack containing not more than 14 days' supply.

CLEMASTINE in preparations for oral use.

CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CODEINE when:

(a) not combined with any other opiate substance;

(b) compounded with one or more other therapeutically active substances, of which not more than one is an analgesic substance:

(i) in divided preparations containing 12 mg or less of codeine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of codeine;

(c) labelled with a recommended daily dose not exceeding 100 mg of codeine; and

(d) in packs containing not more than 5 days' of supply at the maximum dose recommended on the label,

**except** when included in Schedule 2.

CYCLIZINE in preparations for oral use.

CYPROHEPTADINE in oral preparations.

DEXCHLORPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units **except** when included in Schedule 2.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or

(b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine,

**except** when included in Schedule 2.

DI-IODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.

DIMENHYDRINATE in oral preparations **except** when included in Schedule 2.

DIMETHINDENE in oral preparations.

DIPHENHYDRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.

DITHRANOL for therapeutic use.

DOXYLAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

ECONAZOLE in preparations for vaginal use.

ERYTHRITYL TETRANITRATE for therapeutic use.

ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days supply.

FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).

FLAVOXATE.

FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUORIDES for human topical use:

(a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure **except** when included in or expressly excluded from Schedule 2; or

(b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion **except**:

(i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less; or

(iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

GLUCAGON.

GLYCERYL TRINITRATE:

(a) in preparations for oral use; or

(b) in preparations for rectal use.

GLYCOPYRRONIUM **except** when included in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:

(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:

(i) in undivided preparations, in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories,

**except** when included in Schedule 2.

IBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen in a primary pack containing not more than 50 dosage units when labelled:

(a) with a recommended daily dose of 1200 mg or less of ibuprofen; and

(b) not for the treatment of children under 12 years of age,

**except** when included in or expressly excluded from Schedule 2.

INOSITOL NICOTINATE.

ISOCONAZOLE in preparations for vaginal use.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

LEVONORGESTREL for emergency post-coital contraception.

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MAGNESIUM SULFATE for human therapeutic use in divided oral preparations **except** when containing 1.5 g or less of magnesium sulfate per recommended daily dose.

Malathion in preparations for human external use **except** in preparations containing 2 per cent or less of malathion.

MANNITYL HEXANITRATE for therapeutic use.

MEPYRAMINE in oral preparations.

METHDILAZINE in oral preparations.

METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

MICONAZOLE for human use in topical preparations:

(a) for the treatment of oral candidiasis; or

(b) for vaginal use.

NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit **except**:

(a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(b) nicotinamide.

NICOTINYL ALCOHOL **except** in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.

NYSTATIN in preparations for topical use **except** when included in Schedule 2.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.

OXICONAZOLE in preparations for vaginal use.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

PARACETAMOL when combined with ibuprofen in a primary pack containing 30 dosage units or less.

PHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROMETHAZINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of children under 2 years of age.

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:

(a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or

(b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

SALBUTAMOL as the only therapeutically active substance:

(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or

(b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID in preparations for dermal use **except** in preparations containing 40 per cent or less of salicylic acid.

SANTONIN.

SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.

TERBUTALINE as the only therapeutically active substance:

(a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or

(b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.

TIOCONAZOLE in preparations for vaginal use.

TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.

TRIMEPRAZINE:

(a) in solid oral preparations **except** when included in Schedule 2; or

(b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL,

**except** in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.

## SCHEDULE 4

(Substances marked # are listed in Appendix D)

ABACAVIR.

ABATACEPT.

ABIRATERONE ACETATE.

ABCIXIMAB.

ACAMPROSATE CALCIUM.

ACARBOSE.

ACEBUTOLOL.

ACEPROMAZINE.

ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

ACETARSOL.

ACETAZOLAMIDE.

ACETOHEXAMIDE.

ACETYL ISOVALERYLTYLOSIN.

ACETYLCARBROMAL.

ACETYLCHOLINE.

ACETYLCYSTEINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYLSTROPHANTHIDIN.

ACICLOVIR **except** in preparations containing 5 per cent or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.

ACIPIMOX.

# ACITRETIN.

ACLIDINIUM BROMIDE.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp. **except**:

(a) when included in Schedule 2;

(b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or

(c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACRIVASTINE.

ADALIMUMAB.

ADAPALENE.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRAFINIL.

ADRENALINE. **except**:

(a) when included in Schedule 3; or

(b) in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.

ADRENOCORTICAL HORMONES except when separately specified in these Schedules.

AFAMELANOTIDE.

afatinib dimaleate.

AFLIBERCEPT.

AGALSIDASE.

AGLEPRISTONE.

AGOMELATINE.

ALATROFLOXACIN MESYLATE.

ALBENDAZOLE **except**:

(a) when included in Schedule 5 or 6; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.

ALCLOMETASONE **except** when included in Schedule 3.

ALCURONIUM.

ALDESLEUKIN.

ALDOSTERONE.

# ALEFACEPT.

ALEMTUZUMAB.

ALENDRONIC ACID.

ALFACALCIDOL.

ALFUZOSIN.

ALGLUCERASE.

ALGLUCOSIDASE.

ALISKIREN.

ALLERGENS.

ALLOPURINOL.

ALLYLOESTRENOL.

ALOGLIPTIN.

ALOSETRON.

ALPHA1-PROTEINASE INHIBITOR (HUMAN).

ALPHADOLONE.

ALPHAXALONE.

ALPRENOLOL.

ALPROSTADIL.

ALSEROXYLON.

ALTEPLASE.

ALTRENOGEST.

ALTRETAMINE (hexamethylmelamine).

AMANTADINE.

AMBENONIUM CHLORIDE.

# AMBRISENTAN.

AMBUCETAMIDE.

AMBUTONIUM BROMIDE.

AMCINONIDE.

AMETHOCAINE **except**:

(a) when included in Schedule 2; or

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINOCAPROIC ACID.

AMINOGLUTETHIMIDE.

5-AMINOLEVULINIC ACID.

AMINOMETRADINE.

AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE **except** when included in Schedule 3.

AMINOPTERIN.

4-AMINOPYRIDINE for therapeutic use.

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

AMIPHENAZOLE.

AMISOMETRADINE.

AMISULPRIDE.

AMITRIPTYLINE.

AMLODIPINE.

AMMI VISNAGA.

AMMONIUM BROMIDE for therapeutic use.

AMODIAQUINE.

AMOROLFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

AMOXAPINE.

AMOXYCILLIN.

AMPHOMYCIN.

AMPHOTERICIN.

AMPICILLIN.

AMPRENAVIR.

AMRINONE.

AMSACRINE.

AMYL NITRITE.

AMYLOBARBITONE when packed and labelled for injection.

AMYLOCAINE.

# ANABOLIC STEROIDAL AGENTS.

ANAGRELIDE.

ANAKINRA.

ANASTROZOLE.

ANCESTIM.

ANCROD and its immunoglobulin antidote.

ANECORTAVE.

# ANDROGENIC STEROIDAL AGENTS.

# ANDROISOXAZOLE.

# ANDROSTANOLONE.

# ANDROSTENEDIOL.

# ANDROSTENEDIONE.

ANGIOTENSIN AMIDE.

ANIDULAFUNGIN.

ANISTREPLASE.

ANTAZOLINE **except** when included in Schedule 2.

ANTIBIOTIC SUBSTANCES **except**:

(a) when separately specified in these Schedules; or

(b) nisin.

ANTIGENS for human therapeutic use **except** when separately specified in this Schedule.

ANTIHISTAMINES **except**:

(a) when included in Schedule 2 or 3; or

(b) when separately specified in this Schedule.

ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

APIXABAN.

APOCYNUM spp.

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREPITANT.

APRONAL.

APROTININ.

ARECOLINE.

ARIPIPRAZOLE.

ARSENIC for human therapeutic use **except** when separately specified in these Schedules.

ARTEMETHER.

ARTICAINE.

ASENAPINE.

ASPIRIN:

(a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or

(b) for injection.

ASTEMIZOLE.

# ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

ATOVAQUONE.

ATRACURIUM BESYLATE.

ATROPA BELLADONNA (belladonna) **except** when included in Schedule 2.

ATROPINE **except** when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVILAMYCIN **except**:

(a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or

(b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AXITINIB.

AVOPARCIN.

AZACITIDINE.

AZACYCLONOL.

AZAPERONE.

AZAPROPAZONE.

AZARIBINE.

AZATADINE **except** when included in Schedule 3.

AZATHIOPRINE.

AZELAIC ACID **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 1 per cent or less of azelaic acid for non-human use.

AZELASTINE **except** when included in Schedule 2.

AZITHROMYCIN.

AZLOCILLIN.

AZTREONAM.

BACAMPICILLIN.

BACITRACIN.

BACLOFEN.

BALSALAZIDE.

BAMBERMYCIN (flavophospholipol) **except**:

(a) when included in Schedule 6; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

BAMBUTEROL.

BAMETHAN.

BAMIPINE.

BARBITURATES **except** when separately specified in these Schedules.

BASILIXIMAB.

BAZEDOXIFENE.

BECAPLERMIN.

BECLAMIDE.

BECLOMETHASONE **except** when included in Schedule 2.

BELATACEPT.

BELIMUMAB.

BEMEGRIDE.

BENACTYZINE.

BENAZEPRIL.

BENDAMUSTINE.

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENSERAZIDE.

BENZATHINE PENICILLIN.

BENZHEXOL.

BENZILONIUM.

BENZOCAINE **except**:

(a) when included in Schedule 2;

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

# BENZODIAZEPINE derivatives **except** when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for human therapeutic use **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.

BENZPHETAMINE.

BENZTHIAZIDE.

BENZTROPINE (benzatropine).

BENZYDAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use.

BENZYLPENICILLIN.

BEPRIDIL.

BERACTANT.

BESIFLOXACIN.

BETAHISTINE.

BETAMETHASONE.

BETAXOLOL.

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

# BEXAROTENE.

BEZAFIBRATE.

BICALUTAMIDE.

BIFONAZOLE **except**:

(a) when included in Schedule 2;

(b) in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

BIMATOPROST.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, **except**:

(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per or less; or

(b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, **except** bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.

BISOPROLOL.

BIVALIRUDIN.

BLEOMYCIN.

BOCEPREVIR.

# BOLANDIOL.

# BOLASTERONE.

# BOLAZINE.

# BOLDENONE (dehydrotestosterone).

# BOLENOL.

# BOLMANTALATE.

BORON, including boric acid and borax, for human therapeutic use **except**:

(a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose;

(b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not for paediatric or antifungal use; or

(c) when present as an excipient.

BORTEZOMIB.

# BOSENTAN.

BOSUTINIB.

BOTULINUM TOXINS for human use **except** when separately specified in these Schedules.

BRENTUXIMAB VEDOTIN.

BRETYLIUM TOSYLATE.

BRIMONIDINE.

BRINZOLAMIDE.

# BROMAZEPAM.

BROMIDES, inorganic, for therapeutic use **except** when separately specified in

these Schedules.

BROMOCRIPTINE.

BROMOFORM for therapeutic use.

BROMPHENIRAMINE **except** when included in Schedule 2 or 3.

BROMVALETONE.

BRUGMANSIA spp.

BUCLIZINE **except** when included in Schedule 3.

BUDESONIDE **except** when included in Schedule 2.

BUFEXAMAC **except**:

(a) in preparations for dermal use containing 5 per cent or less of bufexamac; or

(b) in suppositories.

BUMETANIDE.

BUPHENINE.

BUPIVACAINE **except** when included in Schedule 5.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.

BUTOCONAZOLE **except** when included in Schedule 3.

BUTRACONAZOLE.

BUTYL AMINOBENZOATE **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

CABAZITAXEL.

CABERGOLINE.

CADMIUM COMPOUNDS for human therapeutic use.

CALCIPOTRIOL.

CALCITONIN.

CALCITRIOL.

CALCIUM CARBIMIDE for therapeutic use.

CALCIUM HYDROXYLAPATITE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

CALCIUM POLYSTYRENE SULPHONATE.

CALOTROPIS GIGANTEA.

CALOTROPIS PROCERA.

# CALUSTERONE.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANAGLIFLOZIN.

CANAKINUMAB.

CANDESARTAN CILEXETIL.

CANDICIDIN.

CANINE TICK ANTI-SERUM.

CANTHARIDIN.

CAPECITABINE.

CAPREOMYCIN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

CARBAMAZEPINE.

CARBARYL for human therapeutic use.

CARBAZOCHROME.

CARBENICILLIN.

CARBENOXOLONE for internal use.

CARBETOCIN.

CARBIDOPA.

CARBIMAZOLE.

CARBOCROMEN.

CARBOPLATIN.

CARBOPROST.

CARBROMAL.

CARBUTAMIDE.

CARBUTEROL.

CARGLUMIC ACID (N-carbomoyl-L-glutamic acid)

CARINDACILLIN.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.

CASPOFUNGIN.

CATHINE.

CATUMAXOMAB.

CEFACETRILE.

CEFACLOR.

CEFADROXIL.

CEFALORIDINE.

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOVECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFQUINOME.

CEFTAROLINE FOSAMIL.

CEFSULODIN.

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAXONE.

CEFUROXIME.

CELECOXIB.

CELIPROLOL.

CEPHAELIS ACUMINATA (ipecacuanha) **except** in preparations containing 0.2 per cent or less of emetine.

CEPHAELIS IPECACUANHA **except** in preparations containing 0.2 per cent or less of emetine.

CEPHALEXIN.

CEPHALONIUM.

CEPHALOTHIN.

CEPHRADINE.

CERIVASTATIN.

CERTOLIZUMAB PEGOL.

CERULETIDE.

CETIRIZINE **except**

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing not more than 5 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CETRORELIX.

CETUXIMAB.

CHENODEOXYCHOLIC ACID.

CHLORAL FORMAMIDE.

CHLORAL HYDRATE **except** in preparations for topical use containing 2 per cent or less of chloral hydrate.

CHLORALOSE **except** when included in Schedule 6.

CHLORAMBUCIL.

CHLORAMPHENICOL **except** when included in Schedule 3.

# CHLORANDROSTENOLONE.

CHLORAZANIL.

CHLORCYCLIZINE.

# CHLORDIAZEPOXIDE.

CHLORMERODRIN.

CHLORMETHIAZOLE.

CHLORMEZANONE.

CHLOROFORM for use in anaesthesia.

# 4-CHLOROMETHANDIENONE.

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.

CHLOROQUINE.

CHLOROTHIAZIDE.

CHLOROTRIANISENE.

# CHLOROXYDIENONE.

CHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

CHLORPHENTERMINE.

CHLORPROMAZINE.

CHLORPROPAMIDE.

CHLORPROTHIXENE.

CHLORQUINALDOL for human topical use.

CHLORTETRACYCLINE **except** when included in Schedule 5.

CHLORTHALIDONE.

CHLORZOXAZONE.

CHOLERA VACCINE.

CHOLESTYRAMINE (colestyramine) for human therapeutic use.

CHYMOPAPAIN for human therapeutic use.

CICLACILLIN.

CICLESONIDE.

CICLOPIROX **except**:

1. when included in Schedule 2 or 3; or
2. in preparations for the treatment of tinea pedis.

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CILOSTAZOL.

CIMETIDINE **except** when included in Schedule 3.

CINACALCET.

CINCHOCAINE **except** when included in Schedule 2.

CINOXACIN.

CIPROFLOXACIN.

CISAPRIDE.

CISATRACURIUM BESYLATE.

CISPLATIN.

CITALOPRAM.

CLADRIBINE.

CLANOBUTIN.

CLARITHROMYCIN.

CLAVULANIC ACID.

CLEMASTINE **except** when included in Schedule 3.

CLEMIZOLE.

CLENBUTEROL.

CLEVIDIPINE.

CLIDINIUM BROMIDE.

CLINDAMYCIN.

CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical use **except** when separately specified in this Schedule.

CLOBAZAM.

CLOBETASOL.

CLOBETASONE (clobetasone-17-butyrate) **except** when included in Schedule 3.

CLOCORTOLONE.

CLODRONIC ACID (includes sodium clodronate).

CLOFARABINE.

CLOFAZIMINE.

CLOFENAMIDE.

CLOFIBRATE.

# CLOMIPHENE.

CLOMIPRAMINE.

CLOMOCYCLINE.

# CLONAZEPAM.

CLONIDINE.

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

# CLORAZEPATE.

CLOREXOLONE.

CLORPRENALINE.

# CLOSTEBOL (4-chlorotestosterone).

CLOTRIMAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

CLOXACILLIN.

# CLOZAPINE.

COBALT for human therapeutic use **except** as dicobalt edetate in preparations for the treatment of cyanide poisoning.

COBICISTAT.

CODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 30 mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1 per cent or less of codeine,

**except** when included in Schedule 2 or 3.

CO-DERGOCRINE.

COLASPASE.

COLCHICINE.

COLCHICUM AUTUMNALE.

COLESTIPOL.

COLFOSCERIL PALMITATE for human therapeutic use.

COLISTIN.

COLLAGEN in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.

CONVALLARIA KEISKI.

CONVALLARIA MAJALIS.

COPPER COMPOUNDS for human use **except**:

(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

(c) in other preparations containing 5 per cent or less of copper compounds.

# CORIFOLLITROPIN ALFA.

CORONILLA spp.

CORTICOSTERONE.

CORTICOTROPHIN.

CORTISONE.

CO-TRIMOXAZOLE.

COUMARIN for therapeutic use (excluding when present as an excipient).

CRIZOTINIB.

CROFELEMER.

CRYSTAL VIOLET for human use **except** when used as a dermal marker.

CUPRIMYXIN.

CURARE.

CYCLANDELATE.

CYCLIZINE **except** when included in Schedule 3.

CYCLOBENZAPRINE.

# CYCLOFENIL.

CYCLOHEXIMIDE.

CYCLOPENTHIAZIDE.

CYCLOPENTOLATE.

CYCLOPHOSPHAMIDE.

CYCLOPROPANE for therapeutic use.

CYCLOSERINE.

CYCLOSPORIN.

CYCLOTHIAZIDE.

CYCRIMINE.

CYMARIN.

CYPROHEPTADINE **except** when included in Schedule 3.

CYPROTERONE.

CYSTEAMINE for human therapeutic use.

CYTARABINE.

DABRAFENIB MESILATE.

DABIGATRAN.

DACARBAZINE.

DACLIZUMAB.

DACTINOMYCIN.

DALFOPRISTIN.

DALTEPARIN (includes dalteparin sodium).

DANAPAROID (includes danaparoid sodium).

# DANAZOL.

DANTHRON for human use.

DANTROLENE.

DAPAGLIFLOZIN.

DAPOXETINE.

DAPSONE.

DAPTOMYCIN.

# DARBEPOETIN.

DARIFENACIN.

DARUNAVIR.

DATURA spp. **except**:

(a) when included in Schedule 2; or

(b) when separately specified in this Schedule.

DASATINIB.

DATURA STRAMONIUM (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DATURA TATULA (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DAUNORUBICIN.

DEANOL for therapeutic use.

DEBRISOQUINE.

DECAMETHONIUM.

DEFERASIROX.

DEFERIPRONE.

DEFLAZACORT.

DEGARELIX.

# DEHYDROCHLOROMETHYLTESTOSTERONE.

DEHYDROCORTICOSTERONE.

DELAVIRDINE (includes delavirdine mesylate).

DEMBREXINE **except** when included in Schedule 5.

DEMECARIUM.

DEMECLOCYCLINE.

DENOSUMAB.

DEOXYCORTONE.

DEOXYRIBONUCLEASE **except**:

(a) when separately specified in this Schedule; or

(b) for external use.

DERACOXIB.

DESFERRIOXAMINE.

DESFLURANE.

DESIPRAMINE.

DESIRUDIN.

DESLANOSIDE.

DESLORATADINE **except** when included in Schedule 2.

DESLORELIN.

DESMOPRESSIN (D.D.A.V.P.).

DESOGESTREL.

DESONIDE.

DESOXYMETHASONE.

DESVENLAFAXINE.

DETOMIDINE.

DEXAMETHASONE.

DEXCHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

DEXFENFLURAMINE.

DEXMEDETOMIDINE.

DEXTROMETHORPHAN (excluding its stereoisomers) **except** when included in Schedule 2.

# DEXTROPROPOXYPHENE:

(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or

(b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.

DEXTRORPHAN (excluding its stereoisomers).

DIAMTHAZOLE.

DIAVERIDINE.

# DIAZEPAM.

DIAZOXIDE.

DIBENZEPIN.

DIBOTERMIN.

DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.

DICHLORALPHENAZONE.

DICHLOROPHEN for human therapeutic use.

DICHLORPHENAMIDE.

DICLOFENAC **except:**

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use unless:

(i) for the treatment of solar keratosis; or

(ii) containing more than 4 per cent of diclofenac.

DICLOXACILLIN.

DICYCLOMINE.

DIDANOSINE.

DIENESTROL.

DIENOGEST.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLPROPION.

DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.

DIFLORASONE.

DIFLOXACIN.

DIFLUCORTOLONE.

DIFLUNISAL.

DIGITALIS LANATA.

DIGITALIS PURPUREA.

DIGITOXIN.

DIGOXIN.

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).

DIHYDRALAZINE.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine,

**except** when included in Schedule 2 or 3.

DIHYDROERGOTOXINE.

# DIHYDROLONE.

DIHYDROSTREPTOMYCIN.

DIHYDROTACHYSTEROL.

DI-IODOHYDROXYQUINOLINE (iodoquinol) **except**:

(a) when included in Schedule 3; or

(b) for human internal use.

DIISOPROPYLAMINE DICHLOROACETATE.

DILTIAZEM.

DIMENHYDRINATE **except** when included in Schedule 2 or 3.

DIMERCAPROL.

# DIMETHANDROSTANOLONE.

# DIMETHAZINE.

DIMETHINDENE **except** when included in Schedule 3.

DIMETHOTHIAZINE.

DIMETHOXANATE.

DIMETHYL FUMARATE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use **except**:

(a) when included in Schedule 6; or

(b) in *in vitro* test kits.

DIMETRIDAZOLE.

2,4-DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use **except** when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use **except** when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use **except** when separately specified in these Schedules.

# DINOPROST.

# DINOPROSTONE.

DIPERODON.

DIPHEMANIL **except** in preparations for dermal use.

DIPHENHYDRAMINE **except** when included in Schedule 2 or 3.

DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate **except** when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHTHERIA TOXOID.

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DIRLOTAPIDE.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE **except** when included in Schedule 6.

DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

DOLUTEGRAVIR.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORIPENEM.

DORNASE.

DORZOLAMIDE.

DOTHIEPIN.

DOXANTRAZOLE.

DOXAPRAM.

DOXAZOSIN.

DOXEPIN.

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE **except** when included in Schedule 2 or 3.

DRONEDARONE.

DROPERIDOL.

DROSPIRENONE.

# DROSTANOLONE.

DROTRECOGIN.

DUBOISIA LEICHHARDTII **except** when included in Schedule 2.

DUBOISIA MYOPOROIDES **except** when included in Schedule 2.

DULOXETINE.

DUTASTERIDE.

DYDROGESTERONE.

ECONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

ECOTHIOPATE (includes ecothiopate iodide).

ECTYLUREA.

ECULIZUMAB.

EDETIC ACID for human therapeutic use **except**:

(a) in preparations containing 0.25 per cent or less of edetic acid;

(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or

(c) in contact lens preparations.

EDOXUDINE.

EDROPHONIUM.

EFALIZUMAB.

EFAVIRENZ.

EFLORNITHINE.

EFORMOTEROL.

ELETRIPTAN.

ELOSULFASE ALFA.

ELTENAC.

ELTROMBOPAG.

ELVITEGRAVIR.

EMEPRONIUM.

EMETINE **except** in preparations containing 0.2 per cent or less of emetine.

EMPAGLIFLOZIN.

EMTRICITABINE.

ENALAPRIL.

# ENESTEBOL.

ENFLURANE for therapeutic use.

ENFUVIRTIDE.

# ENOBOSARM.

ENOXACIN.

ENOXAPARIN.

ENOXIMONE.

ENPROSTIL.

ENROFLOXACIN.

ENTACAPONE.

ENTECAVIR.

EPHEDRA spp. **except** in preparations containing 0.001 per cent or less of ephedrine.

# EPHEDRINE.

EPICILLIN.

EPINASTINE.

EPIRUBICIN.

# EPITIOSTANOL.

EPLERENONE.

# EPOETINS.

EPOPROSTENOL.

EPROSARTAN.

EPTIFIBATIDE.

ERGOMETRINE.

ERGOT.

ERGOTAMINE.

ERGOTOXINE.

ERIBULIN MESYLATE.

ERLOTINIB.

ERTAPENEM.

ERYSIMUM spp.

ERYTHROMYCIN.

# ERYTHROPOIETIN.

# ERYTHROPOIETINS **except** when separately specified in these Schedules.

ESCITALOPRAM.

ESMOLOL.

ESOMEPRAZOLE **except** when included in Schedule 3.

ESTRAMUSTINE.

ESTROPIPATE (piperazine oestrone sulfate).

ETANERCEPT.

ETHACRYNIC ACID.

ETHAMBUTOL.

ETHAMIVAN.

ETHANOLAMINE in preparations for injection.

ETHCHLORVYNOL.

ETHER for use in anaesthesia.

ETHINAMATE.

ETHINYLOESTRADIOL.

ETHIONAMIDE.

ETHISTERONE.

ETHOGLUCID.

ETHOHEPTAZINE.

ETHOPROPAZINE.

ETHOSUXIMIDE.

ETHOTOIN.

ETHOXZOLAMIDE.

ETHYL CHLORIDE for human therapeutic use.

# ETHYLDIENOLONE.

ETHYLHEXANEDIOL for animal use.

ETHYLMORPHINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine;

**except** when included in Schedule 2.

# ETHYLOESTRENOL.

ETHYNODIOL.

ETIDOCAINE.

ETIDRONIC ACID (includes disodium etidronate):

(a) for internal use; or

(b) in topical preparations **except** in preparations containing 1 per cent or less of etidronic acid.

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE **except** when included in Schedule 2.

ETONOGESTREL.

ETOPOSIDE.

ETORICOXIB.

ETRAVIRINE.

# ETRETINATE.

EVEROLIMUS.

EXEMESTANE.

EXENATIDE.

EZETIMIBE.

FAMCICLOVIR **except** when included in Schedule 3.

FAMOTIDINE **except** when included in Schedule 2.

FEBUXOSTAT.

FELBINAC **except** when included in Schedule 2.

FELODIPINE.

FELYPRESSIN.

FENBUFEN.

FENCAMFAMIN.

FENCLOFENAC.

FENFLURAMINE.

FENOFIBRATE.

FENOLDOPAM.

FENOPROFEN.

FENOTEROL.

FENPIPRAMIDE.

FENPIPRANE.

FENPROPOREX.

FENPROSTALENE.

FEXOFENADINE except:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.

FIBRINOLYSIN **except** for external use.

FIDAXOMICIN.

FILGRASTIM.

FINASTERIDE.

FINGOLIMOD.

FIROCOXIB.

FLECAINIDE.

FLEROXACIN.

FLOCTAFENINE.

FLORFENICOL.

FLUANISONE.

FLUCLOROLONE.

FLUCLOXACILLIN.

FLUCONAZOLE **except** when included in Schedule 3.

FLUCYTOSINE.

FLUDARABINE.

FLUDROCORTISONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETHASONE.

FLUMETHIAZIDE.

FLUNISOLIDE.

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUORESCEIN in preparations for injection.

FLUORIDES in preparations for human use **except** when included in or expressly excluded from Schedule 2 or 3.

FLUOROMETHOLONE.

FLUOROURACIL.

FLUOXETINE.

# FLUOXYMESTERONE.

FLUPENTHIXOL.

FLUPHENAZINE.

FLUPROSTENOL.

FLURANDRENOLONE.

# FLURAZEPAM.

FLURBIPROFEN **except** when included in Schedule 2.

FLUROXENE for human therapeutic use.

FLUSPIRILENE.

FLUTAMIDE.

FLUTICASONE **except** when included in Schedule 2.

FLUVASTATIN.

FLUVOXAMINE.

FOLIC ACID in preparations for human use for injection.

FOLINIC ACID in preparations for human use for injection.

FOLLICLE-STIMULATING HORMONE except when separately specified in this Schedule.

# FOLLISTATIN.

# FOLLITROPIN ALPHA.

# FOLLITROPIN BETA.

FOMIVIRSEN.

FONDAPARINUX.

# FORMEBOLONE.

FORMESTANE.

FOSAMPRENAVIR.

FOSAPREPITANT.

FOSCARNET.

FOSFESTROL (diethylstilboestrol diphosphate).

FOSINOPRIL.

FOSPHENYTOIN.

FOTEMUSTINE.

FRAMYCETIN.

FULVESTRANT.

FURALTADONE.

# FURAZABOL.

FURAZOLIDONE.

FUROSEMIDE (frusemide).

FUSIDIC ACID.

GABAPENTIN.

GALANTAMINE.

GALANTHUS spp.

GALLAMINE.

GALSULFASE.

GANCICLOVIR.

GANIRELIX.

GATIFLOXACIN.

GEFITINIB.

GEMCITABINE.

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

GEMTUZUMAB OZOGAMICIN.

GENTAMICIN.

GESTODENE.

GESTONORONE.

GESTRINONE.

GHRH INJECTABLE PLASMID.

GITALIN.

GLATIRAMER ACETATE.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLISOXEPIDE.

GLUTATHIONE for parenteral use.

# GLUTETHIMIDE.

GLYCERYL TRINITRATE **except** when included in Schedule 3.

GLYCOPYRRONIUM in preparations for injection.

GLYMIDINE.

GnRH VACCINE.

GOLIMUMAB.

GONADORELIN.

GONADOTROPHIC HORMONES except when separately specified in this Schedule.

GOSERELIN.

GRAMICIDIN.

GRANISETRON.

GREPAFLOXACIN.

GRISEOFULVIN.

GUAIPHENESIN for human therapeutic use **except**:

(a) when included in Schedule 2;

(b) in oral liquid preparations containing 2 per cent or less of guaiphenesin; or

(c) in divided preparations containing 200 mg or less of guaiphenesin per dosage unit.

GUANABENZ.

GUANACLINE.

GUANETHIDINE.

GUANIDINE for therapeutic use.

HACHIMYCIN.

HAEMATIN.

HAEMOPHILUS INFLUENZAE VACCINE.

HALCINONIDE.

HALOFANTRINE.

HALOFENATE.

HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.

HALOPERIDOL.

HALOTHANE for therapeutic use.

HEMEROCALLIS (*Hemerocallis flava*).

HEPARINS for internal use **except** when separately specified in this Schedule.

HEPATITIS A VACCINE.

HEPATITIS B VACCINE.

HETACILLIN.

HEXACHLOROPHANE:

(a) in preparations for use on infants; or

(b) in other preparations **except**:

(i) when included in Schedule 2 or 6; or

(ii) in preparations containing 0.75 per cent or less of hexachlorophane.

HEXAMETHONIUM.

HEXETIDINE for human internal use.

HEXOBENDINE.

HEXOCYCLIUM.

HEXOPRENALINE.

HISTAMINE for therapeutic use **except** in preparations containing 0.5 per cent or less of histamine.

HMG-CoA REDUCTASE INHIBITORS (including "statins") **except** when separately specified in these Schedules.

HOMATROPINE.

HUMAN CHORIONIC GONADATROPHIN **except** in pregnancy test kits.

HUMAN PAPILLOMAVIRUS VACCINE.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:

(a) for tissue augmentation;

(b) for cosmetic use; or

(c) for the treatment of animals.

HYDRALAZINE.

HYDRARGAPHEN.

HYDROCHLOROTHIAZIDE.

HYDROCORTISONE:

(a) for human use **except** when included in Schedule 2 or 3; or

(b) for the treatment of animals.

HYDROCYANIC ACID for therapeutic use.

HYDROFLUMETHIAZIDE.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use **except**:

1. when included in Schedule 2; or
2. in hair preparations containing 0.3 per cent or less of hydroquinone; or
3. in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.

HYDROXYCHLOROQUINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

HYDROXYPROGESTERONE.

# HYDROXYSTENOZOL.

HYDROXYUREA.

HYDROXYZINE.

HYGROMYCIN.

HYOSCINE **except** when included in Schedule 2.

HYOSCYAMINE **except** when included in Schedule 2.

HYOSCYAMUS NIGER **except**:

(a) when included in Schedule 2; or

(b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in this Schedule.

HYPROMELLOSE in preparations for injection.

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBOGAINE.

IBRITUMOMAB.

IBUFENAC.

IBUPROFEN **except**:

(a) when included in or expressly excluded from Schedule 2 or 3; or

(b) in preparations for dermal use.

IBUTEROL.

IBUTILIDE.

ICATIBANT.

IDARUBICIN.

IDOXURIDINE **except** in preparations containing 0.5 per cent or less of idoxuridine for dermal use.

IDURSULFASE.

IFOSFAMIDE.

ILOPROST.

IMATINIB.

IMEPITOIN.

IMIDAPRIL.

IMIGLUCERASE.

IMIPENIM.

IMIPRAMINE.

IMIQUIMOD.

IMMUNOGLOBULINS for human parenteral use **except** when separately specified in these Schedules.

INDACATEROL.

INDAPAMIDE.

INDINAVIR.

INDOMETHACIN **except** when included in Schedule 2.

INDOPROFEN.

INDORAMIN**.**

INFLIXIMAB.

INFLUENZA AND CORYZA VACCINES:

(a) for parenteral use; or

(b) for nasal administration.

INGENOL MEBUTATE.

INSULIN GLARGINE.

# INSULIN-LIKE GROWTH FACTOR I.

# INSULIN-LIKE GROWTH FACTORS **except** when separately specified in this Schedule.

INSULINS.

INTERFERONS.

INTERLEUKINS **except** when separately specified in these Schedules.

IODOTHIOURACIL.

IPILIMUMAB.

IPRATROPIUM **except** when included in Schedule 2.

IPRIFLAVONE.

IPRINDOLE.

IPRONIAZID.

IRBESARTAN.

IRINOTECAN.

IRON COMPOUNDS in injectable preparations for human use.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

ISOCARBOXAZID.

ISOCONAZOLE **except** when included in Schedule 2, 3 or 6.

ISOETARINE.

ISOFLURANE for therapeutic use.

ISOMETHEPTENE.

ISONIAZID.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE **except** when included in Schedule 2.

ISOSORBIDE DINITRATE **except** when included in Schedule 3.

ISOSORBIDE MONONITRATE.

# ISOTRETINOIN.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVABRADINE.

IVACAFTOR.

IVERMECTIN:

(a) for human use; or

(b) for the treatment of mange in dogs.

IXABEPILONE.

JAPANESE ENCEPHALITIS VACCINE.

KANAMYCIN.

KETANSERIN **except** in topical veterinary preparations containing 0.5 per cent or less of ketanserin.

# KETAZOLAM.

KETOCONAZOLE **except**:

(a) when included in Schedule 2;

(b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

KETOPROFEN **except**:

(a) in preparations for dermal use; or

(b) when included in Schedule 3.

KETOROLAC (includes ketoralac trometamol).

KETOTIFEN **except** when included in Schedule 2.

KHELLIN.

KITASAMYCIN **except**:

(a) when included in Schedule 5 ; or

(b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.

LABETALOL.

LACIDIPINE.

LACOSAMIDE.

LAMIVUDINE.

LAMOTRIGINE.

LANATOSIDES.

LANREOTIDE.

LANSOPRAZOLE **except** when included in Schedule 3.

LANTHANUM for therapeutic use.

LAPATINIB.

LARONIDASE.

LAROPIPRANT.

LATAMOXEF.

LATANOPROST.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection **except**:

(a) when present as an excipient; or

(b) when separately specified in these Schedules.

LEAD for human therapeutic use.

LEFETAMINE.

LEFLUNOMIDE.

# LENALIDOMIDE.

LENOGRASTIM.

LEPIRUDIN.

LEPTAZOL.

LERCANIDIPINE.

LETROZOLE.

LEUPRORELIN.

LEVALLORPHAN.

LEVAMISOLE:

(a) for human therapeutic use; or

(b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM.

LEVOBUNOLOL.

LEVOBUPIVACAINE.

LEVOCABASTINE **except** when included in Schedule 2.

LEVODOPA.

LEVOMEPROMAZINE.

LEVONORGESTREL **except** when included in Schedule 3.

LEVOSIMENDAN.

LIDOFLAZINE.

LIGNOCAINE **except**:

(a) when included in Schedules 2 or 5;

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances per dosage unit; or

(c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.

LINAGLIPTIN.

LINCOMYCIN.

LINDANE for human therapeutic use **except** when included in Schedule 2.

LINEZOLID.

LIOTHYRONINE.

LIRAGLUTIDE.

LISINOPRIL.

LISURIDE.

LITHIUM for therapeutic use **except**:

(a) when included in Schedule 2;

(b) when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or

(c) in preparations containing 0.01 per cent or less of lithium.

LIXISENATIDE.

LODOXAMIDE **except** when included in Schedule 2.

LOFEXIDINE.

LOGIPARIN for internal use.

LOMEFLOXACIN.

LOMUSTINE.

LOPERAMIDE **except:**

(a)when included in Schedule 2; or

(b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LOPINAVIR.

# LOPRAZOLAM.

LORACARBEF.

LORATADINE **except**:

1. when included in Schedule 2; or
2. in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
3. in a primary pack containing 5 dosage units or less; and
4. labelled with a recommended daily dose not exceeding 10 mg of loratadine.

# LORAZEPAM.

# LORMETAZEPAM.

LOSARTAN.

LOTEPREDNOL.

LOXAPINE.

LUMEFANTRINE.

LUMIRACOXIB.

LURASIDONE.

# LUTEINISING HORMONE except in ovulation test kits.

LYMECYCLINE.

MACITENTAN for human use.

MAFENIDE **except** when included in Schedule 6.

MANDRAGORA OFFICINARUM.

MANNOMUSTINE.

MAPROTILINE.

MARAVIROC.

MARBOFLOXACIN.

MAROPITANT.

MAVACOXIB.

MAZINDOL.

MEASLES VACCINE.

MEBANAZINE.

MEBEVERINE.

MEBHYDROLIN.

# MEBOLAZINE.

MEBUTAMATE.

MECAMYLAMINE.

MECASERMIN.

MECILLINAM.

MECLOCYCLINE.

MECLOFENAMATE.

MECLOFENOXATE.

MECLOZINE **except** when included in Schedule 2.

# MEDAZEPAM.

MEDETOMIDINE.

MEDIGOXIN (methyldigoxin).

MEDROXYPROGESTERONE.

MEDRYSONE.

MEFENAMIC ACID **except** when included in Schedule 2.

MEFENOREX.

MEFLOQUINE.

MEFRUSIDE.

MEGESTROL.

MELAGATRAN.

MELATONIN for human use.

MELENGESTROL **except** when included in Schedule 6.

MELOXICAM.

MELPHALAN.

MEMANTINE.

MENINGOCOCCAL VACCINE.

MENOTROPHIN.

MEPACRINE.

MEPENZOLATE.

MEPHENESIN.

MEPHENTERMINE.

MEPINDOLOL.

# MEPITIOSTANE.

MEPIVACAINE.

MEPROBAMATE.

MEPTAZINOL.

MEPYRAMINE **except** when included in Schedule 2 or 3.

MEQUITAZINE.

MERCAPTOMERIN.

MERCAPTOPURINE.

MERCUROCHROME **except** when included in Schedule 2 or 6.

MERCURY for cosmetic or therapeutic use **except**:

(a) when separately specified in these Schedules; or

(b) in a sealed device which prevents access to the mercury.

MEROPENEM.

MERSALYL.

# MESABOLONE.

MESALAZINE.

MESNA.

# MESTANOLONE (androstalone).

# MESTEROLONE.

MESTRANOL.

# METANDIENONE.

METARAMINOL.

# METENOLONE.

METERGOLINE.

METFORMIN.

METHACHOLINE.

METHACYCLINE.

METHALLENOESTRIL.

# METHANDRIOL.

METHANTHELINIUM.

METHAZOLAMIDE.

METHDILAZINE **except** when included in Schedule 3.

# METHENOLONE.

METHICILLIN.

METHIMAZOLE.

METHISAZONE.

METHIXENE.

METHOCARBAMOL.

METHOHEXITONE.

METHOIN.

METHOTREXATE.

METHOXAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 1 per cent or less of methoxamine.

METHOXSALEN.

METHOXYFLURANE.

METHSUXIMIDE.

METHYCLOTHIAZIDE.

METHYL AMINOLEVULINATE.

#METHYLANDROSTANOLONE.

# METHYLCLOSTEBOL.

METHYLDOPA.

METHYLENE BLUE in preparations for injection.

METHYLERGOMETRINE.

METHYL MERCURY for therapeutic use.

METHYLNALTREXONE.

METHYLPENTYNOL.

METHYLPHENOBARBITONE.

METHYLPREDNISOLONE.

METHYL SALICYLATE in preparations for internal therapeutic use.

# METHYLTESTOSTERONE.

METHYLTHIOURACIL.

# METHYLTRIENOLONE.

METHYPRYLONE.

METHYSERGIDE.

METOCLOPRAMIDE **except** when included in Schedule 3.

METOLAZONE.

METOPROLOL.

# METRIBOLONE.

METRIFONATE (trichlorfon) for human therapeutic use.

METRONIDAZOLE.

METYRAPONE.

MEXILETINE.

MEZLOCILLIN.

MIANSERIN.

MIBEFRADIL.

# MIBOLERONE.

MICAFUNGIN.

MICONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

# MIDAZOLAM.

MIDODRINE.

MIFEPRISTONE.

MIGLITOL.

MIGLUSTAT.

MILBEMYCIN OXIME **except** when included in Schedule 5.

MILRINONE.

MINOCYCLINE.

MINOXIDIL **except** when included in Schedule 2.

MIRABEGRON.

MIRTAZAPINE.

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

MITRATAPIDE.

MIVACURIUM CHLORIDE.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

MOLINDONE.

MOMETASONE **except** when included in Schedule 2.

MONENSIN **except**:

(a) when included in Schedule 5 or 6; or

(b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use **except** in cosmetic nail preparations containing 0.02 per cent or less of monobenzone or alkyl ethers of hydroquinone.

MONOCLONAL ANTIBODIES for therapeutic use **except**:

(a) in diagnostic test kits; or

(b) when separately specified in these Schedules.

MONTELUKAST.

MOPERONE.

MORAZONE.

MORICIZINE.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin **except** when included in Schedule 5.

MOXIFLOXACIN.

MOXONIDINE.

MUMPS VACCINE.

MUPIROCIN.

MURAGLITAZAR.

MUROMONAB.

MUSTINE (nitrogen mustard).

MYCOPHENOLIC ACID (includes mycophenolate mofetil).

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE.

NALIDIXIC ACID.

NALMEFENE.

NALORPHINE.

NALOXONE.

NALTREXONE.

# NANDROLONE.

NAPROXEN **except** when included in Schedule 3 or in Schedule 2.

NARASIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARATRIPTAN.

NATALIZUMAB.

NATAMYCIN **except** for use as a food additive.

NATEGLINIDE.

NEBACUMAB.

NEBIVOLOL.

NEDOCROMIL.

NEFAZODONE.

NEFOPAM.

NELFINAVIR (includes nelfinavir mesylate).

NEOMYCIN.

NEOSTIGMINE.

NEPAFENAC.

NERIUM OLEANDER.

NESIRITIDE.

NETILMICIN.

NEVIRAPINE.

NIALAMIDE.

NICARDIPINE.

NICERGOLINE.

NICOFURANOSE.

NICORANDIL.

NICOTINE in preparations for human therapeutic use except for use as an aid in withdrawal from tobacco smoking in preparations for oromucosal or transdermal use.

NICOTINIC ACID for human therapeutic use **except**:

(a) when separately specified in these Schedules;

(b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(c) nicotinamide.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILOTINIB.

NILUTAMIDE.

NIMESULIDE.

NIMODIPINE.

NIMORAZOLE.

NIRIDAZOLE.

NISOLDIPINE.

NITISINONE.

# NITRAZEPAM.

NITRENDIPINE.

NITRIC OXIDE for human therapeutic use.

NITROFURANTOIN.

NITROFURAZONE.

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NIZATIDINE **except** when included in Schedule 2.

NOMEGESTROL.

NOMIFENSINE.

NORADRENALINE.

# 19-NORANDROSTENEDIOL.

# 19-NORANDROSTENEDIONE.

# NORANDROSTENOLONE.

# NORBOLETHONE.

# NORCLOSTEBOL.

NORELGESTROMIN.

# NORETHANDROLONE.

NORETHISTERONE.

NORFLOXACIN.

NORGESTREL.

NORIBOGAINE.

NORMAL HUMAN IMMUNOGLOBULIN.

# NORMETHANDRONE.

NORTRIPTYLINE.

NOVOBIOCIN.

NOXIPTYLINE.

NYSTATIN **except** when included in Schedule 2 or 3.

OCLACITNIB.

OCRIPLASMIN.

OCTAMYLAMINE.

OCTATROPINE.

OCTREOTIDE.

OCTYL NITRITE.

OESTRADIOL **except** when included in Schedule 5.

OESTRIOL.

OESTROGENS **except** when separately specified in these Schedules.

OESTRONE.

OFATUMUMAB.

OFLOXACIN.

OLANZAPINE.

OLEANDOMYCIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDRIN.

OLMESARTAN.

OLODATEROL.

OLOPATADINE.

OLSALAZINE.

OMALIZUMAB.

OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.

OMEPRAZOLE **except** when included in Schedule 3.

ONDANSETRON.

OPIPRAMOL.

ORBIFLOXACIN.

ORCIPRENALINE.

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:

(a) when separately specified in these Schedules; or

(b) in preparations containing 2 per cent or less of malathion for external use.

ORLISTAT **except** when included in Schedule 3.

ORNIDAZOLE.

ORNIPRESSIN.

ORPHENADRINE.

ORTHOPTERIN.

OSELTAMIVIR.

OUABAIN.

# OVANDROTONE.

# OXABOLONE.

OXACILLIN.

OXALIPLATIN.

# OXANDROLONE.

OXAPROZIN.

# OXAZEPAM.

OXCARBAZEPINE.

OXEDRINE for human internal use **except** in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.

OXETACAINE (oxethazaine) **except** when included in Schedule 2.

OXICONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for the treatment of tinea pedis.

OXITROPIUM.

OXOLAMINE.

OXOLINIC ACID.

OXPENTIFYLLINE (pentoxifylline).

OXPRENOLOL.

OXYBUPROCAINE.

OXYBUTYNIN.

# OXYMESTERONE.

# OXYMETHOLONE.

OXYPHENBUTAZONE.

OXYPHENCYCLIMINE.

OXYPHENONIUM.

OXYTETRACYCLINE **except** when included in Schedule 5.

OXYTOCIN.

PACLITAXEL.

PALIFERMIN.

PALIPERIDONE.

PALIVIZUMAB.

PALONOSETRON.

PAMAQUIN.

PAMIDRONIC ACID (includes disodium pamidronate).

PANCREATIC ENZYMES **except**:

(a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or

(b) when separately specified in these Schedules.

PANCURONIUM.

PANITUMUMAB.

PANTOPRAZOLE **except** when included in Schedule 3.

PAPAVERINE in preparations for injection.

PARACETAMOL:

(a) when combined with aspirin or salicylamide or any derivative of these substances **except** when separately specified in these Schedules;

(b) when combined with ibuprofen in a primary pack containing more than 30 dosage units;

(c) in slow release tablets or capsules containing more than 665 mg of paracetamol;

(d) in non-slow release tablets or capsules containing more than 500 mg of paracetamol;

(e) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol; or

(f) for injection.

PARALDEHYDE.

PARAMETHADIONE.

PARAMETHASONE.

PARECOXIB.

PARICALCITOL.

PAROMOMYCIN.

PAROXETINE.

PASIREOTIDE.

PAZOPANIB.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGFILGRASTIM.

PEGINTERFERON.

PEGVISOMANT.

PEMETREXED.

PEMOLINE.

PEMPIDINE.

PENBUTOLOL.

PENCICLOVIR **except** when included in Schedule 2.

PENETHAMATE.

PENICILLAMINE.

PENTAERYTHRITYL TETRANITRATE.

PENTAGASTRIN.

PENTAMETHONIUM.

PENTAMIDINE (includes pentamidine isethionate).

PENTHIENATE.

PENTOBARBITONE when packed and labelled for injection.

PENTOLINIUM.

PENTOSAN POLYSULFATE SODIUM.

# PERAMPANEL.

PERGOLIDE.

PERHEXILINE.

PERICYAZINE.

PERINDOPRIL.

PERMETHRIN for human therapeutic use **except** in preparations containing 5 per cent or less of permethrin.

PERPHENAZINE.

PERTUSSIS ANTIGEN.

PERTUZUMAB.

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENAGLYCODOL.

PHENAZONE **except** when included in Schedule 2 or 5.

PHENAZOPYRIDINE.

PHENELZINE.

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE **except** when included in Schedule 2 or 3.

PHENISATIN.

PHENOBARBITONE.

PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.

PHENOXYBENZAMINE.

PHENOXYMETHYLPENICILLIN.

PHENSUXIMIDE.

# PHENTERMINE.

PHENTHIMENTONIUM.

PHENTOLAMINE.

PHENYLBUTAZONE.

PHENYLEPHRINE:

(a) in preparations for injection; or

(b) in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine.

PHENYLPROPANOLAMINE.

PHENYLTOLOXAMINE.

PHENYTOIN.

PHOLCODINE:

(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5 per cent or less of pholcodine,

**except** when included in Schedule 2.

PHOSPHODIESTERASE TYPE 5 INHIBITORS **except**:

(a) when separately specified in these Schedules; or

(b) when present as an unmodified, naturally occurring substance.

PHTHALYLSULFATHIAZOLE.

PHYSOSTIGMINE.

PICROTOXIN.

PILOCARPINE **except** in preparations containing 0.025 per cent or less of pilocarpine.

PIMECROLIMUS.

PIMOBENDAN.

PIMOZIDE.

PINACIDIL.

PINDOLOL.

PIOGLITAZONE.

PIPECURONIUM.

PIPEMIDIC ACID.

PIPENZOLATE.

PIPER METHYSTICUM (kava) in preparations for human use **except** when included on the Australian Register of Therapeutic Goods in preparations:

(a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:

(i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or

(ii) the amount of dried whole or peeled rhizome in the teabag does not exceed 3 g;

and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or

(c) in dermal preparations.

PIPERACILLIN.

PIPERIDINE.

PIPERIDOLATE.

PIPOBROMAN.

PIPOTHIAZINE.

PIPRADROL.

PIRACETAM.

PIRBUTEROL.

PIRENOXINE (catalin).

PIRENZEPINE.

PIRETANIDE.

PIROXICAM **except** in preparations for dermal use.

PIRPROFEN.

PITAVASTATIN.

PITUITARY HORMONES **except** when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN.

PLICAMYCIN.

PLERIXAFOR.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM EMODI (podophyllin) for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM PELTATUM (podophyllin) for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

POLIDEXIDE.

POLIOMYELITIS VACCINE.

POLYACRYLAMIDE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYCAPROLACTONE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYMYXIN.

POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, **except** when separately specified in these Schedules.

POLYTHIAZIDE.

PORACTANT.

POSACONAZOLE.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:

(a) when containing less than 550 mg of potassium chloride per dosage unit;

(b) in preparations for oral rehydration therapy;

(c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or

(d) in preparations for enteral feeding.

POTASSIUM PERCHLORATE for therapeutic use.

PRACTOLOL.

PRADOFLOXACIN.

PRALATREXATE.

PRALIDOXIME.

PRAMIPEXOLE.

PRAMOCAINE.

PRAMPINE.

# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).

PRASUGREL.

PRAVASTATIN.

# PRAZEPAM.

PRAZIQUANTEL for human therapeutic use.

PRAZOSIN.

PREDNISOLONE.

PREDNISONE.

PREGABALIN.

PREGNENOLONE.

PRENALTEROL.

PRENYLAMINE.

PRILOCAINE **except** when included in Schedule 2.

PRIMAQUINE.

PRIMIDONE.

PROBENECID.

PROBUCOL.

PROCAINAMIDE.

PROCAINE.

PROCAINE PENICILLIN.

PROCARBAZINE.

PROCHLORPERAZINE **except** when included in Schedule 3.

PROCYCLIDINE **except** when included in Schedule 2.

PROGESTERONE **except** when included in Schedule 5.

PROGESTOGENS **except** when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

PROLINTANE.

PROMAZINE.

PROMETHAZINE **except** when included in Schedule 2 or 3.

PROMOXOLANE.

PROPAFENONE.

PROPAMIDINE for therapeutic use except when included in Schedule 2.

PROPANIDID.

PROPANTHELINE.

PROPENTOFYLLINE.

# PROPETANDROL.

PROPIONIBACTERIUM ACNES for therapeutic use.

PROPOFOL.

PROPRANOLOL.

PROPYLHEXEDRINE.

PROPYLTHIOURACIL.

PROPYPHENAZONE.

PROQUAZONE.

PROSCILLARIDIN.

PROSTAGLANDINS **except** when separately specified in this Schedule.

PROSTIANOL.

PROTAMINE.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

PROTOVERATRINES.

PROTRIPTYLINE.

PROXYMETACAINE.

PRUCALOPRIDE.

PSEUDOEPHEDRINE **except** when included in Schedule 3.

PYRAZINAMIDE.

PYRIDINOLCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use **except**:

(a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIMETHAMINE.

PYROVALERONE.

PYRVINIUM.

# QUAZEPAM.

QUETIAPINE.

QUINAGOLIDE.

QUINAPRIL.

# QUINBOLONE.

QUINETHAZONE.

QUINIDINE.

QUININE for human therapeutic use **except** when the maximum recommended daily dose is 50 mg or less of quinine.

QUINISOCAINE (dimethisoquin).

QUINUPRISTIN.

RABEPRAZOLE **except** when included in Schedule 3.

RABIES VACCINE.

RACTOPAMINE **except** when included in Schedule 5.

RALOXIFENE.

RALTEGRAVIR.

RALTITREXED.

RAMIPRIL.

RANIBIZUMAB.

RANITIDINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units.

RAPACURONIUM.

RASAGILINE.

RASBURICASE.

RAUWOLFIA SERPENTINA.

RAUWOLFIA VOMITORIA.

RAZOXANE.

REBOXETINE.

RED YEAST RICE for human therapeutic use.

REGORAFENIB.

REMOXIPRIDE.

REPAGLINIDE.

RESERPINE.

RETAPAMULIN.

RETEPLASE.

RETIGABINE.

RIBAVIRIN.

RIDAFOROLIMUS.

RIFABUTIN.

RIFAMPICIN.

RIFAMYCIN.

RIFAPENTINE.

RIFAXIMIN.

RILPIVIRINE.

RILUZOLE.

RIMEXOLONE.

RIMITEROL.

RIMONABANT.

RIOCIGUAT.

RISEDRONIC ACID.

RISPERIDONE.

RITODRINE.

RITONAVIR.

RITUXIMAB.

RIVAROXABAN.

RIVASTIGMINE.

RIZATRIPTAN.

ROBENACOXIB.

ROCURONIUM.

ROFECOXIB.

ROFLUMILAST.

ROLITETRACYCLINE.

romidepsin.

ROMIFIDINE.

ROMIPLOSTIM.

RONIDAZOLE.

ROPINIROLE.

ROPIVACAINE.

ROSIGLITAZONE.

ROSOXACIN.

ROSUVASTATIN.

ROTIGOTINE.

# ROXIBOLONE.

ROXITHROMYCIN.

RUBELLA VACCINE.

RUBOXISTAURIN.

RUPATADINE.

RUXOLITINIB.

SALBUTAMOL **except** when included in Schedule 3.

SALCATONIN.

SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.

SALINOMYCIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

SALMETEROL.

SAPROPTERIN.

SAQUINAVIR.

SAXAGLIPTIN.

SCHOENOCAULON OFFICINALE (sabadilla) **except** in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of *Schoenocaulon officinale*.

SCOPOLIA CARNIOLICA for therapeutic use.

# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).

SELEGILINE.

SELENIUM:

(a) for human oral use with a recommended daily dose of more than 300 micrograms; or

(b) for the treatment of animals **except**:

(i) when included in Schedule 6 or 7;

(ii) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;

(iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;

(iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or

(v) in feeds containing 1 g/tonne or less of selenium.

SERELAXIN.

SERMORELIN.

SERTINDOLE.

SERTRALINE.

SEVELAMER.

SEVOFLURANE.

SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules.

SIBUTRAMINE.

# SILANDRONE.

SILDENAFIL.

SILICONES for intra-ocular use.

SILVER SULFADIAZINE.

SIMEPREVIR.

SIMVASTATIN.

SIROLIMUS.

SISOMICIN (sisomycin).

SITAGLIPTIN.

# SITAXENTAN.

SODIUM BROMIDE for therapeutic use.

SODIUM CELLULOSE PHOSPHATE for human internal use.

SODIUM CROMOGLYCATE **except** when included in Schedule 2.

SODIUM MORRHUATE in preparations for injection.

SODIUM NITROPRUSSIDE for human therapeutic use.

SODIUM PHOSPHATE in preparations for oral laxative use.

SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.

SODIUM SALICYLATE in preparations for injection for the treatment of animals.

SODIUM TETRADECYLSULFATE in preparations for injection.

SOFOSBUVIR.

SOLASODINE.

SOLIFENACIN.

SOMATOSTATIN.

SOMATOTROPIN EQUINE.

# SOMATROPIN (human growth hormone).

SONTOQUINE.

SORAFENIB.

SOTALOL.

SPARFLOXACIN.

SPARTEINE.

SPECTINOMYCIN.

SPIRAMYCIN.

SPIRAPRIL.

SPIRONOLACTONE.

# STANOLONE.

# STANOZOLOL.

STAVUDINE.

# STENBOLONE.

STEROID HORMONES except when separately specified in these Schedules.

STILBOESTROL (diethylstilboestrol).

STREPTODORNASE.

STREPTOKINASE.

STREPTOMYCIN.

STRONTIUM RANELATE.

STROPHANTHINS.

STROPHANTHUS spp.

STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.

STRYCHNOS spp. **except** in preparations containing 1 mg or less per litre or per kilogram of strychnine.

STYRAMATE.

SUCCIMER.

SUGAMMADEX.

SULBACTAM.

SULCONAZOLE **except** when included in Schedule 2.

SULFACETAMIDE **except** when included in Schedule 3 or 5.

SULFADIAZINE **except** when included in Schedule 5.

SULFADIMETHOXINE.

SULFADIMIDINE **except** when included in Schedule 5.

SULFADOXINE.

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE **except** when included in Schedule 5.

SULFAMETHIZOLE.

SULFAMETHOXAZOLE.

SULFAMETHOXYDIAZINE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE **except** when included in Schedule 5.

SULFATROXAZOLE.

SULFINPYRAZONE.

SULFOMYXIN.

SULFONAMIDES **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 3, 5 or 6; or

(c) when packed and labelled solely for use as a herbicide.

SULFONMETHANE (sulfonal and alkyl sulfonals).

SULINDAC.

SULTAMICILLIN.

SULTHIAME.

SUMATRIPTAN.

SUNITINIB.

SUPROFEN.

SUTILAINS.

SUXAMETHONIUM.

SUXETHONIUM.

SUVOREXANT.

TACRINE.

TACROLIMUS.

TADALAFIL.

TAFLUPROST.

TALIGLUCERASE ALFA.

TAMOXIFEN.

TAMSULOSIN.

TANACETUM VULGARE **except** in preparations containing 0.8 per cent or less of oil of tansy.

TASONERMIN.

TAZAROTENE.

TAZOBACTAM.

T-CELL RECEPTOR ANTIBODY.

TEGAFUR.

TEGASEROD.

TELAPREVIR.

TELITHROMYCIN.

TEICOPLANIN.

TELBIVUDINE.

TELMISARTAN.

# TEMAZEPAM.

TEMOZOLOMIDE.

TEMSIROLIMUS.

TENECTEPLASE.

TENIPOSIDE.

TENOFOVIR.

TENOXICAM.

TEPOXALIN.

TERAZOSIN.

TERBINAFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TERBUTALINE **except** when included in Schedule 3.

TERFENADINE.

TERIFLUNOMIDE.

# TERIPARATIDE.

TERLIPRESSIN.

TERODILINE.

TEROPTERIN.

# TESTOLACTONE.

# TESTOSTERONE **except** when included in Schedule 6.

TETANUS ANTITOXIN **except** when used for short-term protection or treatment of tetanus in animals.

TETANUS TOXOID for human use.

TETRABENAZINE.

TETRACOSACTRIN.

TETRACYCLINE **except** when included in Schedule 5.

TETRAETHYLAMMONIUM.

TETROXOPRIM.

# THALIDOMIDE.

THENYLDIAMINE.

THEOPHYLLINE **except** when included in Schedule 3.

THEVETIA PERUVIANA.

THEVETIN.

THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.

THIAMBUTOSINE.

THIAZOSULFONE.

THIETHYLPERAZINE.

THIOACETAZONE.

THIOCARLIDE.

THIOGUANINE.

# THIOMESTERONE (tiomesterone).

THIOPENTONE.

THIOPROPAZATE.

THIOPROPERAZINE.

THIORIDAZINE.

THIOSTREPTON.

THIOTEPA.

THIOTHIXENE.

THIOURACIL.

THIOUREA for therapeutic use **except** in preparations containing 0.1 per cent or less of thiourea.

THYMOXAMINE (includes thymoxamine hydrochloride).

THYROID **except** when separately specified in this Schedule.

THYROTROPHIN.

THYROXINE (includes thyroxine sodium).

TIAGABINE.

TIAMULIN.

TIAPROFENIC ACID.

TIARAMIDE.

TIBOLONE.

TICAGRELOR.

TICARCILLIN.

TICLOPIDINE.

TIEMONIUM.

TIENILIC ACID.

TIGECYCLINE.

TIGLOIDINE.

TILDIPIROSIN.

TILETAMINE.

TILMICOSIN.

TILUDRONIC ACID (includes disodium tiludronate).

TIMOLOL.

TINIDAZOLE.

TINZAPARIN (includes tinzaparin sodium).

TIOCONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TIOTROPIUM.

TIPEPIDINE.

TIPRANAVIR.

TIRILAZAD.

TIROFIBAN.

TOBRAMYCIN.

TOCAINIDE.

TOCERANIB.

TOCILIZUMAB.

TOLAZAMIDE.

TOLAZOLINE.

TOLBUTAMIDE.

TOLCAPONE.

TOLFENAMIC ACID.

TOLMETIN.

TOLONIUM.

TOLPROPAMINE.

TOLRESTAT.

TOLTERODINE.

TOLVAPTAN.

TOPIRAMATE.

TOPOTECAN.

TORASEMIDE.

TOREMIFENE.

TOXOIDS for human parenteral use **except** when separately specified in these Schedules.

TRAMADOL.

TRANDOLAPRIL.

trametinib dimethyl sulfoxide.

TRANEXAMIC ACID **except** in preparations containing 3 per cent or less of cetyl tranexamate hydrochloride for dermal cosmetic use.

TRANYLCYPROMINE.

TRASTUZUMAB.

Trastuzumab emtansine.

TRAVOPROST.

TRAZODONE.

# TRENBOLONE (trienbolone, trienolone) **except** when included in Schedule 5.

TREOSULPHAN.

TREPROSTINIL.

# TRESTOLONE.

TRETAMINE.

# TRETINOIN.

TRIACETYLOLEANDOMYCIN.

TRIAMCINOLONE **except** when included in Schedule 2 or 3.

TRIAMTERENE.

TRIAZIQUONE.

# TRIAZOLAM.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID for human dermal use **except** when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE for therapeutic use.

TRICLOFOS.

TRICYCLAMOL.

TRIDIHEXETHYL.

TRIETHANOLAMINE when in preparations for tattoo removal.

TRIFLUOPERAZINE.

TRIFLUPERIDOL.

TRIFLUPROMAZINE.

TRILOSTANE.

TRIMEPRAZINE **except** when included in Schedule 2 or 3.

TRIMETAPHAN.

TRIMETHOPRIM.

TRIMIPRAMINE.

TRIMUSTINE.

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

TRIOXYSALEN.

TRIPELENNAMINE.

TRIPLE ANTIGEN VACCINE.

TRIPROLIDINE **except** when included in Schedule 2 or 3.

TRIPTORELIN.

TROGLITAZONE.

TROMETAMOL in preparations for injection **except** in preparations containing 3 per cent or less of trometamol.

TROPICAMIDE.

TROPISETRON.

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use **except** in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.

TUBERCULIN.

TUBOCURARINE.

TULATHROMYCIN.

TULOBUTEROL.

TYLOSIN.

TYPHOID VACCINE.

UMECLIDINIUM.

UNOPROSTONE.

URACIL.

URAPIDIL.

URETHANE (excluding its derivatives) for therapeutic use.

# UROFOLLITROPIN.

UROKINASE.

URSODEOXYCHOLIC ACID.

USTEKINUMAB.

VACCINES for human therapeutic use **except** when separately specified in this Schedule.

VACCINES, veterinary live virus except:

(a) poultry vaccines;

(b) pigeon pox vaccine; or

(c) scabby mouth vaccine.

VACCINIA VIRUS VACCINE.

VALACICLOVIR.

VALDECOXIB.

VALGANCICLOVIR.

VALNOCTAMIDE.

VALPROIC ACID.

VALSARTAN.

VANCOMYCIN.

VANDETANIB.

VARDENAFIL.

VARENICLINE.

VARICELLA VACCINE.

VASOPRESSIN.

VECURONIUM.

VEDAPROFEN.

vEDOLIZUMAB.

VELAGLUCERASE ALFA.

VEMURAFENIB.

VENLAFAXINE.

VERAPAMIL.

VERATRUM spp. **except** when separately specified in this Schedule.

VERNAKALANT.

VERTEPORFIN.

VIDARABINE.

VIGABATRIN.

VILANTEROL.

VILDAGLIPTIN.

VILOXAZINE.

VINBLASTINE.

VINCAMINE.

VINCRISTINE.

VINDESINE.

VINFLUNINE.

VINORELBINE.

VINYL ETHER for therapeutic use.

VIRGINIAMYCIN **except** when included in Schedule 5.

VISMODEGIB.

VISNADINE.

VITAMIN A for human th**e**rapeutic or cosmetic use except:

(a) in preparations for topical use containing 1 per cent or less of Vitamin A;

(b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or

(c) in preparations for parenteral nutrition replacement.

VITAMIN D for human internal therapeutic use **except:**

1. in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or
2. when included in Schedule 3.

VORICONAZOLE.

VORINOSTAT.

VORTIOXETINE.

WARFARIN for therapeutic use.

XAMOTEROL.

XANTHINOL NICOTINATE.

XIMELAGATRAN.

XIPAMIDE.

XYLAZINE.

YOHIMBINE.

ZAFIRLUKAST.

ZALCITABINE.

ZALEPLON.

ZANAMIVIR.

ZERANOL **except** when included in Schedule 6.

ZIDOVUDINE.

ZILPATEROL.

ZIMELDINE.

ZINC COMPOUNDS for human internal use **except**:

(a) in preparations with a recommended daily dose of 25 mg or less of zinc; or

(b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ZIPRASIDONE.

ZOLAZEPAM.

ZOLEDRONIC ACID.

ZOLMITRIPTAN.

ZOLPIDEM.

ZONISAMIDE.

ZOPICLONE.

ZOXAZOLAMINE.

ZUCLOPENTHIXOL.

## SCHEDULE 5

ABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin.

ABSCISIC ACID.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH3COOH) **except**:

(a) when included in Schedule 2 or 6; or

(b) for therapeutic use.

ACETONE **except** in preparations containing 25 per cent or less of designated solvents.

ACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.

AFOXOLANER for the treatment and prevention of flea infestations and control of ticks in dogs in oral divided preparations each containing 140 mg or less of afoxolaner per dosage unit.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole **except** in intraruminal implants each containing 3.85 g or less of albendazole.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

(a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5;

(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5;

(c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(d) in liquid or semi-solid preparations, the pH of which is more than 11.5, unless:

(i) in food additive preparations for domestic use; or

(ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5,

**except** when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or less of alkoxylated fatty alkylamine polymer **except** in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN in preparations containing 10 per cent or less of allethrin **except**:

(a) in insecticidal mats; or

(b) in other preparations containing 1 per cent or less of allethrin.

ALLOXYDIM.

ALPHA-CYPERMETHRIN:

(a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or

(b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.

AMETRYN.

AMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.

AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

AMINOPYRALID in water soluble gel formulations containing 0.5 per cent or less of aminopyralid.

AMITROLE.

AMINOCYCLOPYRACHLOR.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia **except**:

(a) in preparations for human internal therapeutic use;

(b) in preparations for inhalation when absorbed in an inert solid material; or

(c) in preparations containing 0.5 per cent or less of free ammonia.

AMMONIUM THIOCYANATE **except** in preparations containing 10 per cent or less of ammonium thiocyanate.

ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of anise oil.

ASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.

ATRAZINE.

AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.

AZOXYSTROBIN.

BACILLUS THURINGIENSIS delta endotoxin encapsulated in killed *Pseudomonas fluorescens*.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.

BASIL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 5 per cent or less of methyl chavicol.

BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFU)/mL or less of *Beauveria bassiana*.

BENALAXYL.

BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.

BENTAZONE.

BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride **except** in preparations containing 5 per cent or less of benzalkonium chloride.

BENZOFENAP.

BENZOYL PEROXIDE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 5 per cent or less of benzoyl peroxide.

BERGAMOT OIL except:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.4 per cent or less of bergamot oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

BETACYFLUTHRIN:

(a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or

(b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.

BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3 per cent or less of total bifluorides.

BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin **except** in preparations containing 1 per cent or less of bioallethrin.

BIORESMETHRIN **except** in preparations containing 10 per cent or less of bioresmethrin.

BISPYRIBAC **except** in preparations containing 10 per cent or less of bispyribac.

BORIC ACID (excluding its salts) and BORAX **except**:

(a) when included in Schedule 4;

(b) in preparations, other than insect baits, containing 1 per cent or less of boron; or

(c) in hand cleaning preparations.

BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF3).

BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.

BUPIVACAINE in aqueous gel preparations containing 0.5 per cent or less of bupivacaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.

BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin.

BUTHIDAZOLE.

BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.

BUTRALIN.

BUTROXYDIM.

CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor **except**:

(a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(c) in rosemary oil, sage oil (Spanish), or lavandin oils; or

(d) in preparations containing 2.5 per cent or less of camphor.

CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide **except** in preparations containing 9 per cent or less of carbamide peroxide.

CARBARYL:

(a) in preparations containing 10 per cent or less of carbaryl **except** when included in Schedule 4; or

(b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.

CASSIA OIL **except**:

(a) in food additives;

(b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or

(c) in other preparations containing 2 per cent or less of cassia oil.

CHLORFENAC.

CHLORFENAPYR. in preparations containing 0.5 per cent or less of chlorfenapyr.

CHLORFENSON.

CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine **except**:

(a) in preparations containing 1 per cent or less of chlorhexidine; or

(b) when in solid preparations.

CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, **except**:

(a) when separately specified in these Schedules;

(b) sodium hypochlorite preparations with a pH of less than 11.5;

(c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(d) liquid preparations containing less than 2 per cent of available chlorine; or

(e) other preparations containing 4 per cent or less of available chlorine.

CHLORNIDINE.

CHLOROCRESOL **except** in preparations containing 3 per cent or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

(a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;

(b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or

(c) in other preparations containing 5 per cent or less of chlorpyrifos,

**except** in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CHLORTHAL-DIMETHYL.

CINMETHYLIN.

CINNAMON BARK OIL **except**:

(a) in food additives; or

(b) in preparations containing 2 per cent or less of cinnamon bark oil.

CLETHODIM.

CLIMBAZOLE in preparations containing 40 per cent or less of climbazole **except** in preparations containing 2 per cent or less of climbazole.

CLOFENTEZINE.

CLOPYRALID.

CLOQUINTOCET-MEXYL.

CLORSULON.

CLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil **except** in preparations containing 25 per cent or less of clove oil.

COPPER ACETATE in preparations containing 20 per cent or less of copper acetate **except** in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper **except** in preparations containing 1 per cent or less of copper.

COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide **except** in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER OXIDES in preparations containing 25 per cent or less of copper oxides **except**:

(a) in preparations for internal use;

(b) in marine paints; or

(c) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride **except** in preparations containing 12.5 per cent or less of copper oxychloride.

COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate **except**:

(a) in preparations for internal use; or

(b) in other preparations containing 5 per cent or less of copper sulfate.

COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.

4-CPA.

CYANATRYN.

CYANOACRYLATE ESTERS in contact adhesives **except**:

(a) when labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or

(b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:

(i) labelled with the approved name or trade name of the poison, the quantity and the warning:

Can cause eye injury. Instantly bonds skin; and

(ii) enclosed in a primary pack labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

CYANURIC ACID (excluding its salts and derivatives).

CYANTRANILIPROLE.

CYAZOFAMID.

CYCLOHEXANONE PEROXIDE.

CYCLOPROTHRIN **except** in preparations containing 10 per cent or less of cycloprothrin.

CYCLOXYDIM.

CYFLUFENAMID.

CYFLUTHRIN:

(a) in wettable powders containing 10 per cent or less of cyfluthrin;

(b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or

(c) in emulsions containing 5 per cent or less of cyfluthrin.

cyhalofop-butyl.

CYMIAZOLE.

CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.

CYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin.

CYPROCONAZOLE **except** in preparations containing 10 per cent or less of cyproconazole.

CYPRODINIL.

CYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine **except** in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE for the treatment of animals:

(a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or

(b) in undivided preparations containing 5 per cent or less of cythioate.

2,4-D in preparations containing 20 per cent or less of 2,4-D.

DAMINOZIDE.

2,4-DB.

DECOQUINATE:

DELTAMETHRIN:

1. when impregnated in plastic resin strip material containing 4 per cent or less of deltamethrin;
2. in aqueous preparations containing 5 per cent or less of deltamethrin when no organic solvent other than a glycol is present;
3. in wettable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 grams or less of the formulation;
4. in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or
5. in other preparations containing 0.5 per cent or less of deltamethrin,

**except**:

1. in factory prepared mosquito nets containing 1 per cent or less deltamethrin; or
2. in preparations containing 0.1 per cent or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4-DES.

DIAFENTHIURON.

N,N-DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.

DIAZINON in dust preparations containing 2 per cent or less of diazinon.

DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.

DICHLONE.

para-DICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, **except** in:

(a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(b) liquid preparations containing less than 2 per cent of available chlorine; or

(c) other preparations containing 4 per cent or less of available chlorine.

DICHLOROMETHANE (methylene chloride) **except**:

(a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane;

(b) in other preparations in pressurised spray packs; or

(c) in paints and tinters containing 5 per cent or less of dichloromethane.

DICHLOROPHEN for the treatment of animals.

DICHLORVOS:

(a) when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;

(b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or

(c) in pressurised spray packs containing 10 grams or less of dichlorvos.

DICLOBUTRAZOL.

DICLORAN.

DICOFOL.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine **except** in preparations containing 5 per cent or less of diethanolamine.

DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except:**

(a) in paints or paint tinters;

(b) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or

(c) in other preparations containing 2.5 per cent or less of diethylene glycol.

DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10 per cent or less of diethylene glycol monobutyl ether.

DIETHYLTOLUAMIDE (DEET) **except**:

(a) in medicines for human therapeutic use containing 20 per cent or less of diethyltoluamide, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations for human use, other than medicines, containing 20 per cent or less of diethyltoluamide, when labelled with the warning statement:

**WARNING**: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or

(c) in preparations other than for human use containing 20 per cent or less of diethyltoluamide.

DIFENOCONAZOLE.

DIFLUBENZURON.

DIMETHICODIETHYLBENZALMALONATE **except** when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.

DIMETHIRIMOL.

DIMETHOMORPH **except** in preparations containing 10 per cent or less of dimethomorph.

DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.

DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide **except** in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DINICONAZOLE.

DI-N-PROPYL ISOCINCHOMERONATE **except** in preparations containing 25 per cent or less of di-N-propyl isocinchomeronate.

DIPHENAMID.

DITHIOPYR.

N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

EMAMECTIN in preparations containing 2 per cent or less of emamectin.

EMODEPSIDE in preparations:

(a) containing 2.5 per cent or less of emodepside for the external treatment of animals; or

(b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.

EPOXICONAZOLE.

EPOXY RESINS, LIQUID.

EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.

ESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin **except** in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.

1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE.

ETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of ethanolamine **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 5 per cent or less of ethanolamine.

ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.

ETHOFUMESATE.

ETHOXYQUIN **except** in preparations containing 10 per cent or less of ethoxyquin.

ETHOXYSULFURON.

ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

(a) in paints or paint tinters;

(b) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or

(c) in other preparations containing 2.5 per cent or less of ethylene glycol.

ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use **except** in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.

ETRIDIAZOLE.

EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol **except** in preparations containing 25 per cent or less of eugenol.

EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (*Corymbia citriodora*) , **except** in preparations containing 40 per cent or less of extract of lemon eucalyptus.

FENARIMOL.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENCHLORAZOLE-ETHYL.

FENOPROP.

FENOXAPROP-ETHYL.

FENOXAPROP-P-ETHYL.

FENSON.

FENTHION:

(a) in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or

(b) in preparations containing 10 per cent or less of fenthion.

FIPRONIL in preparations containing 10 per cent or less of fipronil **except** in preparations containing 0.05 per cent or less of fipronil.

FLAMPROP-METHYL.

FLAMPROP-M-METHYL.

FLAZASULFURON.

FLORASULAM.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUBENDIAMIDE.

FLUCHLORALIN.

FLUDIOXONIL **except** in preparations containing 10 per cent or less of fludioxonil.

FLUMETHRIN:

(a) when impregnated in plastic resin strip material containing 3 per cent or less offlumethrin; or

(b) in oil based preparations containing 1 per cent or less of flumethrin.

flumiclorac pentyl.

FLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:

(a) in preparations for human use; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

FLURALANER for the treatment and preventation of flea infestations and control of ticks in dogs in oral divided preparations each containing 1400 mg or less of fluralaner per dosage unit.

FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.

FLUXAPYROXAD.

FORAMSULFURON.

FORMIC ACID (excluding its salts and derivatives) **except** in preparations containing 0.5 per cent or less of formic acid.

FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.

FURALAXYL.

FURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.

GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.

GLUFOSINATE-AMMONIUM.

GLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYPHOSATE.

HALOSULFURON-METHYL.

HEXACONAZOLE **except** in preparations containing 5 per cent or less of hexaconazole.

HEXAZINONE in preparations containing 25 per cent or less of hexazinone.

HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:

(a) toluene and xylene when included in Schedule 6;

(b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;

(c) food grade and pharmaceutical grade white mineral oils;

(d) in solid or semi-solid preparations;

(e) in preparations containing 25 per cent or less of designated solvents;

(f) in preparations packed in pressurised spray packs;

(g) in adhesives packed in containers each containing 50 grams or less of adhesive;

(h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or

(i) in other preparations when packed in containers with a capacity of 2 mL or less.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) **except**:

(a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or

(b) for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.

HYDROGEN PEROXIDE (excluding its salts and derivatives):

(a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide **except** in hair dyes containing 6 per cent or less of hydrogen peroxide; or

(b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide **except** in preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H2SiF6).

IMAZALIL.

IMAZAMOX **except** in preparations containing 25 per cent or less of imazamox.

IMAZAPIC **except** in preparations containing 25 per cent or less of imazapic.

IMAZAPYR **except** in preparations containing 25 per cent or less of imazapyr.

IMAZETHAPYR **except** in preparations containing 25 per cent or less of imazethapyr.

IMIDACLOPRIDin preparations containing 20 per cent or less of imidacloprid **except** in preparations containing 5 per cent or less of imidacloprid.

IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin **except** in preparations containing 10 per cent or less of imiprothrin.

INDOXACARB (includes the R and S enantiomers) in preparations containing 1 per cent or less of

indoxacarb.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) ) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate **except**:

(a) in aqueous preparations not for cosmetic use containing 10 per cent or less 3-iodo-2-propynyl butyl carbamate; or

(b) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IODOSULFURON-METHYL-SODIUM.

IPCONAZOLE in preparations containing 2 per cent or less of ipconazole.

IRON COMPOUNDS:

(a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):

(i) in preparations for injection containing 20 per cent or less of iron **except** in preparations containing 0.1 per cent or less of iron; or

(ii) in other preparations containing 4 per cent or less of iron **except**:

(A) in liquid or gel preparations containing 0.1 per cent or less of iron; or

(B) in animal feeds or feed premixes; or

(b) in garden preparations **except** in preparations containing 4 per cent or less of iron.

ISOEUGENOL in preparations containing 25 per cent or less of isoeugenol **except** in preparations containing 10 per cent or less of isoeugenol.

ISOPHORONE.

ISOXABEN.

ISOXAFLUTOLE.

IVERMECTIN for use in animals:

(a) in preparations for the prophylaxis of heartworm in cats and dogs;

(b) in intraruminal implants containing 160 mg or less of ivermectin;

(c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or

(d) in other preparations containing 2 per cent or less of ivermectin.

KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

LAMBDA-CYHALOTHRIN:

(a) in aqueous preparations containing 1 per cent or less of lambda- cyhalothrin; or

(b) in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.

LEAD COMPOUNDS in preparations for use as hair cosmetics.

LEMON OIL **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.05 per cent or less of lemon oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals **except**:

(a) when included in Schedule 4; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LIGNOCAINE in aqueous gel preparations containing 4.5 per cent or less of lignocaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.

LIME OIL **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.5 per cent or less of lime oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LINDANE in preparations containing 10 per cent or less of lindane **except** when included in Schedule 2 or 4.

LUFENURON **except**:

(a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or

(b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.

MAGNESIUM CHLORATE **except** in preparations containing 10 per cent or less of magnesium chlorate.

MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.

MALATHION in preparations containing 10 per cent or less of malathion except:

(a) for human therapeutic use; or

(b) in dust preparations containing 2 per cent or less of malathion.

MANCOZEB.

MANDIPROPAMID.

MARJORAM OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of marjoram oil.

MCPA:

(a) in preparations containing25 per cent or less of MCPA (acid); or

(b) in preparations containing 50 per cent or less of the salts and esters of MCPA.

MCPB.

MEBENDAZOLE for the treatment of animals:

(a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or

(b) in undivided preparations containing 25 per cent or less of mebendazole.

MECLOFENAMIC ACID for the treatment of animals.

MECOPROP in preparations containing 2 per cent or less of mecoprop.

MEFENPYR-DIETHYL.

MEPIQUAT.

MESOTRIONE.

METAFLUMIZONE.

METALAXYL in preparations containing 35 per cent or less of metalaxyl.

METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.

METHABENZTHIAZURON.

METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol **except** in preparations containing 2 per cent or less of methanol.

METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) **except**:

(a) when included in preparations or admixtures; or

(b) when packed in containers having a capacity of more than 5 litres.

METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.

METHYL ETHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ISOBUTYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

N-METHYL-2-PYRROLIDONE:

(a) when packed in single use containers having a capacity of 2 mL or less; or

(b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate except:

(a) in preparations for therapeutic use; or

(b) in preparations containing 5 per cent or less of methyl salicylate.

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.

METIRAM.

METHOFLUTHRIN in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk.

METOLACHLOR.

METRAFENONE in preparations containing 50 per cent or less of metrafenone.

MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.

MILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MONEPANTEL.

MORANTEL in preparations containing 25 per cent or less of morantel **except** in preparations containing 10 per cent or less of morantel.

MOXIDECTIN:

(a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5 per cent or less of moxidectin;

(b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or

(c) for internal use for the treatment of animals:

(i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or

(ii) in other preparations containing 2 per cent or less of moxidectin.

MYCLOBUTANIL.

NAA **except** in preparations containing 25 per cent or less of NAA.

NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.

NAPTALAM.

NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO3) **except** in preparations containing 0.5 per cent or less of nitric acid.

NITROSCANATE for the treatment of animals.

NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 **except**:

(a) when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;

(b) in preparations containing 12.5 per cent or less of nonoxinol 9; or

(c) in preparations for human use.

NORBORMIDE.

NUTMEG OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of nutmeg oil.

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE **except** in preparations containing 10 per cent or less of

N-octyl bicycloheptene dicarboximide.

N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of:

1. N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or
2. N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

OESTRADIOL in implant preparations for growth promotion in animals.

OLEANDOMYCIN in animal feed premixes for growth promotion.

OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.

ORANGE OIL (BITTER) **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 1.4 per cent or less of orange oil (bitter);

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

OXADIARGYL.

OXADIXYL.

OXANTEL EMBONATE for the treatment of animals.

OXFENDAZOLE for the treatment of animals.

OXIBENDAZOLE for the treatment of animals.

OXYCARBOXIN.

OXYTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

OXYTHIOQUINOX.

PACLOBUTRAZOL.

PENCONAZOLE.

PENDIMETHALIN.

PENFLUFEN.

PENTHIOPYRAD **except** in preparations containing 20 per cent or less of penthiopyrad.

PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.

PERMETHRIN (excluding preparations for human therapeutic use):

(a) in preparations containing 25 per cent or less of permethrin; or

(b) in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less,

**except** in preparations containing 2 per cent or less of permethrin.

PETROL **except** preparations containing 25 per cent or less of petrol.

PHENAZONE for the external treatment of animals.

PHENISOPHAM.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, **except** in preparations containing 3 per cent or less of such substances.

PHENYL METHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

ortho-PHENYLPHENOL **except** in preparations containing 5 per cent or less of o-phenylphenol.

PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of phosphonic acid (H3PO3).

PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H3PO4) **except**:

(a) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);

(b) in solid or semi-solid preparations; or

(c) in professional dental kits.

ortho-PHTHALALDEHYDE in preparations containing 1 per cent or less of ortho-phthalaldehyde.

PICARIDIN **except** in preparations containing 20 per cent or less of picaridin.

PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.

PINOXADEN in preparations containing 10 per cent or less of pinoxaden.

PIPERAZINE for animal use.

PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.

POLIHEXANIDE **except** in preparations containing 5 percent or less of polihexanide.

POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts **except** in preparations containing 1 per cent or less of polixetonium salts.

POLYETHANOXY (15) TALLOW AMINE.

POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS.

POTASSIUM CHLORATE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 10 per cent or less of potassium chlorate.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi-solid preparations, the pH of which is more than 11.5 **except** in food additive preparations for domestic use.

POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of potassium metabisulphite.

POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite **except**:

(a) in preparations containing 0.5 per cent or less of potassium nitrite;

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or

(b) liquid or semi-solid preparations, the pH of which is less than 2.5.

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin **except** in insecticidal mats containing 1 per cent or less of prallethrin.

PROFOXYDIM **except** in preparations containing 20 per cent or less of profoxydim.

PROGESTERONE:

(a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or

(b) in implant preparations for growth promotion in cattle.

PROHEXADIONE CALCIUM.

PROMETRYN.

PROPAMOCARB.

PROPANIL.

PROPAQUIZAFOP.

PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, **except**:

(a) in preparations containing 30 per cent or less of propionic acid; or

(b) for therapeutic use.

PROPOXUR:

(a) when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;

(b) in dust preparations containing 3 per cent or less of propoxur;

(c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;

(d) in pressurised spray packs containing 2 per cent or less of propoxur; or

(e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

PROPYZAMIDE.

PROTHIOCONAZOLE-DESCHLORO **except** in preparations containing 0.5 per cent or less of prothioconazole-deschloro.

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE **except** in preparations containing 0.5 per cent or less of prothioconazole-triazolidinethione.

PYMETROZINE.

PYRACLOSTROBIN.

PYRAFLUFEN-ETHYL.

PYRASULFOTOLE.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 10 per cent or less of such substances.

PYRIDABEN in preparations containing 25 per cent or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

PYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint **except** in paints containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint.

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds **except**:

(a) when separately specified in these Schedules;

(b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(c) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1 per cent or less of quinine.

QUINTOZENE.

QUIZALOFOP-P-ETHYL in aqueous preparations containing 40 per cent or less of

quizalofop-p-ethyl.

RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.

RESMETHRIN in preparations containing 10 per cent or less of resmethrin.

RIMSULFURON.

ROBENIDINE **except** in preparations containing 20 per cent or less of robenidine.

SAFLUFENACIL in water dispersible granule preparations.

SALICYLANILIDE.

SEDAXANE.

SELAMECTIN **except** in preparations containing 12 per cent or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:

(a) barium silicofluoride when separately specified in this Schedule; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin **except** in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM CHLORATE **except** in preparations containing 10 per cent or less of sodium chlorate.

SODIUM DIACETATE **except** in preparations containing 60 per cent or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE **except** in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE **except** in preparations containing 10 per cent or less of sodium hydrogen sulfate.

SODIUM HYDROSULFITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium hydrosulfite.

SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi-solid preparations, the pH of which is more than 11.5 **except** in food additive preparations for domestic use.

SODIUM LAURETH-6 CARBOXYLATE **except** in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.

SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium metabisulphite.

SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite **except**:

(a) in preparations containing 0.5 per cent or less of sodium nitrite;

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or less of sodium percarbonate **except** in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use **except** in preparations containing 10 per cent or less of sodium polystyrene sulphonate.

SODIUM STANNATE **except** in preparations for cosmetic use containing 1 per cent or less of sodium stannate.

SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.

SPINETORAM.

SPINOSAD **except** in aqueous suspensions containing 25 per cent or less of spinosad.

STAR ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of star anise oil.

STYRENE (excluding its derivatives).

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFADIMIDINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMERAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid (H3NO3S).

SULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFOMETURON-METHYL.

SULFOXAFLOR in preparations containing 25 per cent or less of sulfoxaflor.

SYMPHYTUM spp. (Comfrey) for dermal use.

2,3,6-TBA.

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10 per cent or less of TDE.

TEBUCONAZOLE.

TEBUFENOZIDE.

TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.

TEMEPHOS:

(a) in liquid preparations containing 10 per cent or less of temephos;

(b) in powders containing 2 per cent or less of temephos; or

(c) in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 mL or less.

TEPRALOXYDIM.

TERBUTRYN.

1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE in cosmetic preparations, **except** in preparations containing 0.15 per cent or less of 1, 3, 5, 7-tetraazatricyclo [3.3.1.13,7] decane.

TETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene **except**:

(a) when included in Schedule 2;

(b) in preparations for the treatment of animals; or

(c) when absorbed into an inert solid.

TETRACHLORVINPHOS **except** in animal feeds containing 0.2 per cent or less of tetrachlorvinphos.

TETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole.

TETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

TETRAMETHRIN [(R, cis): (R, trans) = 20:80] **except** in pressurised spray packs.

THIABENDAZOLE:

(a) for the treatment of animals; or

(b) when packed and labelled for use as a fungicide **except** in preparations containing 50 per cent or less of thiabendazole.

THIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.

THIAZOPYR.

THIFENSULFURON.

THIOBENCARB.

THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.

THIOPHANATE-METHYL in preparations containing 25 per cent or less of thiophanate-methyl.

THYME OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of thyme oil.

TIOCARBAZIL.

TOLCLOFOS-METHYL.

TOLTRAZURIL.

TRALKOXYDIM.

TRENBOLONE in implant preparations for growth promotion in animals.

TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.

TRIADIMENOL.

TRI-ALLATE.

TRIBENURON-METHYL.

TRICHLOROACETIC ACID, alkali salts of.

1,1,1-TRICHLOROETHANE **except**:

(a) in preparations packed in pressurised spray packs;

(b) in preparations containing 25 per cent or less of designated solvents;

(c) in preparations, other than writing correction fluids or thinners for writing correction fluidsin containers having a capacity of 50 mL or less; or

(d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:

(i) the word “Trichloroethane” written in letters not less than 1 mm in height and in

distinct contrast to the background; and

(ii) the expression:

**WARNING** − DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;

written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.

TRIDIPHANE.

TRIETAZINE.

TRIETHANOLAMINE (excluding its salts and derivatives) **except:**

(a) when in Schedule 4;or

(b) in preparations containing 5 per cent or less of triethanolamine.

TRIFLOXYSTROBIN.

TRIFLUMIZOLE.

TRIFLUMURON.

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE **except** in preparations containing 30 per cent or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:

Avoid contact with eyes and skin; and

Wash hands after handling.

TRINEXAPAC-ETHYL **except**:

(a) when packed in a sealed water-soluble measure pack; or

(b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.

3,6,9-TRIOXAUNDECANEDIOIC ACID **except** in preparations containing 5 per cent or less of

3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.

TRITICONAZOLE.

TURPENTINE OIL **except** in preparations containing 25 per cent or less of turpentine oil.

VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.

VERNOLATE.

WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.

ZINEB.

## SCHEDULE 6

ABAMECTIN:

1. in preparations for pesticidal use containing 4 per cent or less of abamectin **except** when included in Schedule 5; or
2. in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.

ACEPHATE.

ACETAMIPRID **except** in preparations containing 1 per cent or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) **except** when included in Schedule 2.

ACETIC ANHYDRIDE excluding its derivatives.

ACIFLUORFEN.

ACINITRAZOLE **except** in preparations containing 20 per cent or less of acinitrazole.

ALBENDAZOLE for the treatment of animals **except:**

(a) when included in Schedule 5; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALDRIN.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:

(a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.

ALKOXYLATED FATTY ALKYLAMINE POLYMER **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN **except**:

(a) when included in Schedule 5;

(b) in insecticidal mats containing 20 per cent or less of allethrin; or

(c) in other preparations containing 1 per cent or less of allethrin.

ALPHA-CYPERMETHRIN:

(a) in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or

(b) in other preparations containing 10 per cent or less of alpha-cypermethrin,

**except** when included in Schedule 5.

AMICARBAZONE.

AMIDITHION.

AMINOCARB in preparations containing 25 per cent or less of aminocarb.

AMINOETHOXYVINYLGLYCINE **except** in preparations containing 15 per cent or less of aminoethoxyvinylglycine.

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

AMINOPYRALID **except** when included in Schedule 5.

AMITRAZ.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) **except**:

(a) when included in Schedule 5;

(b) in preparations for human internal therapeutic use;

(c) in preparations for inhalation when absorbed in an inert solid material; or

(d) in preparations containing 0.5 per cent or less of ammonia.

AMMONIUM PERSULFATE in hair preparations.

ANILINE (excluding its salts and derivatives) **except** in preparations containing 1 per cent or less of aniline.

ANTIMONY COMPOUNDS **except**:

(a) when included in Schedule 4;

(b) antimony chloride in polishes;

(c) antimony titanate pigments in paint; or

(d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.

ARSENIC:

(a) in ant poisons containing 0.4 per cent or less of arsenic;

(b) in animal feed premixes containing 4 per cent or less of arsenic; or

(c) in preparations for the treatment of animals **except** thiacetarsamide when included in Schedule 4,

**except** when separately specified in this Schedule.

ASPIRIN for the treatment of animals **except** when included in Schedule 4 or 5.

AZACONAZOLE **except** in preparations containing 1 per cent or less of azaconazole.

AZADIRACHTA INDICA (Neem) including its extracts and derivatives **except**:

(a) when included in Schedule 5;

(b) in preparations for human internal use;

(c) debitterised neem seed oil;

(d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.

AZAMETHIPHOS.

AZOBENZENE.

BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

BARIUM SALTS **except**:

(a) when included in Schedule 5;

(b) barium sulfate; or

(c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile content of the paint or tinter.

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) **except**:

(a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or

(b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN;

If in eyes wash out immediately with water; and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

BAY OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of bay oil.

BEAUVERIA BASSIANA **except** when included in Schedule 5.

BENDIOCARB:

(a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;

(b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;

(c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or

(d) when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb,

**except** when included in Schedule 5.

BENQUINOX.

BENSULIDE.

BENZALKONIUM CHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of benzalkoniumchloride.

1,2-benzenediol.

6-BENZYLADENINE **except** in preparations containing 2 per cent or less of 6-benzyladenine.

BERYLLIUM.

BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin **except** when included in Schedule 5.

BETA-CYPERMETHRIN.

BHC (excluding lindane).

BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin except in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3 per cent or less of total bifluorides **except** when included in Schedule 5.

BIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of bioallethrin.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine,

or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and

N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;

REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;

Avoid contact with skin;

Wear protective gloves when mixing or using; and

Ensure adequate ventilation when using.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine,

or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and

N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;

REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;

Avoid contact with skin;

Wear protective gloves when mixing or using; and

Ensure adequate ventilation when using.

BITHIONOL for treatment of animals.

BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF3) **except** when included in Schedule 5.

BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.

BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.

BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.

BROMOFORM **except** when included in Schedule 4.

BROMOPHOS.

BROMOPHOS-ETHYL.

BROMOXYNIL.

BROMUCONAZOLE **except** when included in Schedule 5.

BROTIANIDE.

BUNAMIDINE.

BUTACARB.

BUTOXYCARBOXIM **except** when included in Schedule 5.

2-BUTOXYETHANOL and its ACETATES **except** in preparations containing 10 per cent or less of such substances.

2-BUTOXY-2’-THIOCYANODIETHYL ETHER.

BUTYRIC ACID in preparations for use as insect lures.

CACODYLIC ACID:

(a) in animal feed premixes containing 4 per cent or less of arsenic; or

(b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.

CADMIUM COMPOUNDS **except**:

(a) when included in Schedule 4; or

(b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tinter.

CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.

CAJUPUT OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations containing 25 per cent or less of cajuput oil; or

(f) in oils containing 25 per cent or less of cajuput oil.

CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.

CAMBENDAZOLE.

CAMPHOR **except**:

(a) when included in Schedule 4 or 5;

(b) when enclosed in an inhaler device which prevents ingestion of its contents;

(c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;

(d) in liquid preparations containing 2.5 per cent or less of camphor;

(e) in essential oils when the camphor is present as a natural component of the oil:

(i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAPTAN.

CARBARYL **except** when included in Schedule 4 or 5.

CARBON DISULFIDE.

CARBAMIDE PEROXIDE **except**:

(a) when included in Schedule 5; or

(b) in other preparations containing 9 per cent or less of carbamide peroxide.

CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use **except** in wash-off preparations containing 1 per cent or less of castor oil, monomaleate.

CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.

CHLORDANE.

CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr **except** when included in Schedule   5.

CHLORFENETHOL.

CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine **except**:

(a) when included in Schedule 5;

(b) in preparations containing 1 per cent or less of chlorhexidine; or

(c) when in solid preparations.

CHLORINATING COMPOUNDS **except**:

(a) when included in Schedule 5;

(b) when separately specified in these Schedules;

(c) sodium hypochlorite preparations with a pH of less than 11.5;

(d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(e) in liquid preparations containing less than 2 per cent of available chlorine; or

(f) in other preparations containing 4 per cent or less of available chlorine.

CHLORMEQUAT.

CHLOROFORM **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10 per cent or less of chloroform.

ALPHA-CHLOROHYDRIN.

CHLOROPHACINONE.

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL

(uniconazole-p) **except** in preparations containing 5 per cent or less of

(E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.

CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.

CHLOROTHALONIL **except** in water-based paint containing 0.5 per cent or less of chlorothalonil.

2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE.

CHLORPYRIFOS **except**:

(a) when included in Schedule 5; or

(b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORPYRIFOS-METHYL.

CHLORTHIAMID.

CHROMATES (including dichromates) **except** in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.

CHROMIUM TRIOXIDE (excluding its salts and derivatives).

CINEOLE **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations containing 25 per cent or less of cineole;

(f) in oils containing 25 per cent or less of cineole; or

(g) in rosemary oil or camphor oil (white).

CINNAMON LEAF OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of cinnamon leaf oil.

CLIMBAZOLE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 2 per cent or less of climbazole.

CLODINAFOP-PROPARGYL.

CLOMAZONE.

CLOSANTEL.

CLOTHIANIDIN **except** when included in Schedule 5.

CLOTRIMAZOLE for external treatment of animals.

CLOVE OIL **except**:

(a) when included in Schedule 5;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in preparations containing 25 per cent or less of clove oil.

N-COCO-1,3-DIAMINOPROPANE.

COCOYL GLYCINATE in cosmetic preparations **except**:

(a) in leave-on preparations containing 5 per cent or less of cocoyl glycinate; or

(b) in wash-off preparations containing 30 per cent or less of cocoyl glycinate and, when containing more than 5 per cent of cocoyl glycinate labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

COPPER ACETATE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS **except**:

(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;

(c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;

(d) in feed additives containing 1 per cent or less of copper; or

(e) in other preparations containing 5 per cent or less of copper compounds.

COPPER HYDROXIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

COPPER OXIDES **except**:

(a) when included in Schedule 5;

(b) in preparations for internal use;

(c) in marine paints; or

(d) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5 per cent of less of copper oxychloride.

COPPER SULFATE **except**:

(a) when included in Schedule 5;

(b) in preparations for internal use; or

(c) in other preparations containing 5 per cent or less of copper sulfate.

COUMAPHOS:

(a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or

(b) in other preparations containing 5 per cent or less of coumaphos.

COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl **except** when included in Schedule 5.

CREOSOTE derived from wood other than beechwood **except**:

(a) when included in Schedule 2;

(b) in preparations for human therapeutic use containing 10 per cent or less of creosote derived from wood other than beechwood; or

(c) in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.

CROTOXYPHOS.

CRUFOMATE.

CYANAMIDE.

CYANAZINE.

CYCLANILIDE.

N-cyclohexyldiazeniumdioxy-potassium.

CYFLUTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.

CYOMETRINIL.

CYPERMETHRIN **except** when included in Schedule 5.

CYPHENOTHRIN **except** when included in Schedule 5.

CYSTEAMINE for cosmetic use **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE **except** when included in Schedule 5.

2,4-D **except** when included in Schedule 5.

DAZOMET.

DELTAMETHRIN:

1. in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;
2. in wettable granular preparations containing 25 per cent or less of deltamethrin;
3. in water-dispersible tablets each containing 500 mg or less of deltamethrin;
4. in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or

1. in other preparations containing 3 per cent or less of deltamethrin,

**except:**

1. when included in Schedule 5;
2. in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or
3. in preparations containing 0.1 per cent or less of deltamethrin.

DERQUANTEL.

DIAZINON **except** when included in Schedule 5.

DICAMBA (including its salts and derivatives) **except** when included in Schedule 5.

DICHLOBENIL.

DICHLOFENTHION.

DICHLOFLUANID.

ortho-DICHLOROBENZENE.

DICHLOROETHYL ETHER.

DICHLOROISOCYANURIC ACID **except**:

(a) when included in Schedule 5;

(b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(c) in liquid preparations containing less than 2 per cent of available chlorine; or

(d) in other preparations containing 4 per cent or less of available chlorine.

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.

DICHLOROPHEN **except**:

(a) when included in Schedules 4 or 5; or

(b) in fabrics other than when:

(i) for human therapeutic use; or

(ii) as part of a registered pesticidal product.

1,2-DICHLOROPROPANE.

2,4-DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50 per cent or less of dichlorvos **except** when included in Schedule 5.

DICLOFOP-METHYL.

DICYCLANIL **except** in preparations containing 5 per cent or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM SALTS **except** in preparations containing 1 per cent or less of didecyldimethylammonium salts labelled with the statement:

Avoid contact with eyes.

DIELDRIN.

DIETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of diethanolamine.

DIETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in paints or paint tinters;

(c) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or

(d) in other preparations containing 2.5 per cent or less of diethylene glycol.

DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.

DIFENZOQUAT.

DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.

5,6-DIHYDROXYINDOLINE.

DIMETHENAMID-P.

DIMETHIPIN.

DIMETHOATE.

DIMETHYLACETAMIDE **except** when included in Schedule 5.

DIMETHYLFORMAMIDE **except**:

(a) when included in Schedule 5; or

(b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone):

(a) when not for therapeutic use; or

(b) for the treatment of animals:

(i) when combined with no other therapeutic substance(s);

(ii) in liquid preparations containing copper salicylate and 1 per cent or less of methyl salicylate as the only other therapeutic substances; or

(iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide.

DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DIOXACARB.

DIOXANE.

DIPHACINONE.

DIQUAT in preparations containing 20 per cent or less of diquat.

DISULFIRAM **except** when included in Schedule 4.

DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.

DITHIANON.

DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.

DIUREDOSAN.

N-(N-DODECYL)-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

DODINE.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.

ECONAZOLE for external treatment of animals.

EMAMECTIN in preparations containing 5 per cent or less of emamectin **except** when included in Schedule 5.

EMODEPSIDE for the treatment of animals **except** when included in Schedule 5.

ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.

ENDOTHAL in preparations containing 20 per cent or less of endothal.

EPTC.

ESBIOTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE **except** when included in Schedule 5.

ETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations containing 5 per cent or less of ethanolamine.

ETHEPHON (excluding its salts and derivatives).

ETHER **except**:

(a) when included in Schedule 2, 4 or 5; or

(b) in preparations containing 10 per cent or less of ether.

ETHIOFENCARB.

ETHOATE-METHYL.

ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.

ETHYL BROMIDE.

Ethyl formate when packed and labelled for use as a fumigant.

ETHYLENE CHLOROHYDRIN.

ETHYLENE DICHLORIDE.

ETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in paints or paint tinters;

(c) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or

(d) in other preparations containing 2.5 per cent or less of ethylene glycol.

ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 10 per cent or less of such substances.

ETRIMFOS.

EUCALYPTUS OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of eucalyptus oil.

EUGENOL **except**:

(a) when included in Schedule 5;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in preparations containing 25 per cent or less of eugenol.

FAMPHUR in preparations containing 20 per cent or less of famphur.

FEBANTEL **except**:

(a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or

(b) in undivided preparations containing 10 per cent or less of febantel.

FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.

FENAZAFLOR.

FENBUTATIN OXIDE.

FENCHLORPHOS.

FENITROTHION.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENPYROXIMATE.

FENTHION in preparations containing 60 per cent or less of fenthion **except** when included in Schedule 5.

FENVALERATE.

FIPRONIL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.05 per cent or less of fipronil.

FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.

FLONICAMID.

FLUAZIFOP-BUTYL.

FLUAZIFOP-P-BUTYL.

FLUAZINAM.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

fluensulfone.

FLUMETHRIN **except** when included in Schedule 5.

FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.

FLUORIDES **except**:

(a) when included in Schedule 5;

(b) in preparations for human use; or

(c) in preparations containing 15 mg/kg or less of fluoride ion.

FLUPROPANATE.

FLUQUINCONAZOLE.

FLUSILAZOL.

FLUTRIAFOL **except** in fertilisers containing 0.5 per cent or less of flutriafol.

FLUVALINATE **except** when included in Schedule 5.

FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:

(a) for human therapeutic use;

(b) in oral hygiene preparations;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;

(d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

FORMOTHION.

FOSPIRATE **except** when included in Schedule 5.

FUMAGILLIN.

FURFURAL **except** in preparations containing 0.1 per cent or less of furfural.

GLUTARALDEHYDE **except**:

(a) when included in Schedule 2 or 5; or

(b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYCERYL THIOGLYCOLLATE in hair waving preparations **except** when labelled with directions for use that include the statement:

Wear protective gloves when using. Keep out of eyes.

GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical **except**:

(a) in cosmetic preparations for salon use only, when labelled in accordance with Safe Work Australia’s *National Code of Practice for the Labelling of Workplace Substances* [NOHSC:2012(1994)];

(b) in preparations containing 5 per cent or less of glycolic acid; or

(c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.

GUANIDINE **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 1 per cent or less of guanidine.

GUAZATINE.

HALOXON.

HALOXYFOP.

HEPTACHLOR.

HEXACHLOROPHANE in preparations for the treatment of animals.

HEXAZINONE **except** when included in Schedule 5.

HEXYLOXYETHANOL **except** in preparations containing 10 per cent or less of hexyloxyethanol.

HYDRAMETHYLNON **except** when included in Schedule 5.

HYDRAZINE.

HYDROCHLORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations for therapeutic use; or

(c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride **except** when included in Schedule 5.

HYDROGEN PEROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen peroxide; or

(c) in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROQUINONE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10 per cent or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H2SiF6) **except** when included in Schedule 5.

IMIDACLOPRID **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of imidacloprid.

IMIDOCARB.

iminoctadine trialbesilate.

IMIPROTHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of imiprothrin.

INDAZIFLAM.

INDOXACARB (includes the R and S enantiomers) **except** when included in Schedule 5.

IODINE (excluding its salts, derivatives and iodophors) **except**:

(a) when included in Schedule 2; or

(b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.

IODOPHORS **except** in preparations containing 1.5 per cent or less of available iodine.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) **except:**

(a) when included in Schedule 5;

(b) in aqueous preparations not for cosmetic use containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate (Iodocarb); or

(c) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IOXYNIL.

IPCONAZOLE **except** when included in Schedule 5.

IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals **except**:

(a) when included in Schedule 5;

(b) in liquid or gel preparations containing 0.1 per cent or less of iron; or

(c) in animal feeds or feed premixes.

ISOCONAZOLE for external treatment of animals.

ISOCYANATES, free organic, boiling below 300°C, **except** in:

(a) viscous polyurethane adhesives; or

(b) viscous polyurethane sealants;

containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.

ISOEUGENOL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of isoeugenol.

LAMBDA-CYHALOTHRIN:

1. in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or

(b) in other preparations containing 1.6 per cent or less of lambda-cyhalothrin

**except** when included in Schedule 5

LASALOCID **except** in animal feeds containing 100 mg/kg or less of antibiotic substances.

LAURETH CARBOXYLIC ACIDS (excluding its salts and derivatives) **except**:

(a) in leave-on preparations containing 1.5 per cent or less of laureth carboxylic acids;

(b) in wash-off preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(c) in other preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with warnings to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LAURYL ISOQUINOLINIUM BROMIDE.

LEAD COMPOUNDS **except**:

(a) when included in Schedule 4 or 5;

(b) in paints, tinters, inks or ink additives;

(c) in preparations for cosmetic use containing 100 mg/kg or less of lead;

(d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or

(e) in ceramic glazes when labelled with the warning statement:

CAUTION − Harmful if swallowed. Do not use on surfaces which contact food or drink.

written in letters not less than 1.5 mm in height.

LEPTOSPERMUM SCOPARIUM OIL (manuka oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:  
  
KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings;  
  
KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of *Leptospermum scoparium* oil.

LEVAMISOLE for the treatment of animals **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LINDANE **except** when included in Schedule 2, 4 or 5.

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MALATHION except:

(a) when included in Schedule 5;

(b) for human therapeutic use; or

(c) in dust preparations containing 2 per cent or less of malathion.

MCPA **except** when included in Schedule 5.

MEBENDAZOLE for the treatment of animals **except** when included in Schedule 5.

MECOPROP **except** when included in Schedule 5.

MECOPROP-P.

MEFLUIDIDE.

MELALEUCA OIL (tea tree oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of melaleuca oil.

MELENGESTROL ACETATE when used as an animal feed additive.

MENAZON.

2-MERCAPTOETHANOL in preparations for use as insect lures.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

MERCUROCHROME for the treatment of animals, in preparations for topical use.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.

METALAXYL **except** when included in Schedule 5.

METALDEHYDE **except** when included in Schedule 5.

METHACRIFOS in preparations containing 60 per cent or less of methacrifos.

METHAM.

METHANOL (excluding its derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 2 per cent or less of methanol.

METHIOCARB in preparations containing 20 per cent or less of methiocarb **except** when included in Schedule 5.

METHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.

Methylcyclopentadienyl Manganese Tricarbonyl in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.

METHYLDIBROMO GLUTARONITRILE **except** in preparations intended to be in contact with the skin, including cosmetic use.

METHYLENE BISTHIOCYANATE **except** in preparations containing 1 per cent or less of methylene bisthiocyanate.

METHYLEUGENOL **except** in preparations containing 1 per cent or less of methyleugenol.

METHYL ETHYL KETONE OXIME **except** in preparations containing 1 per cent or less of methyl ethyl ketone oxime.

METHYL ISOTHIOCYANATE.

METHYL METHACRYLATE (excluding its derivatives) **except**:

(a) for cosmetic use; or

(b) in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

METHYL NEODECANAMIDE **except** in liquid preparations containing 2 per cent or less of methyl neodecanamide.

METHYLNORBORNYLPYRIDINE.

N-METHYL-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE **except**:

(a) when included in Schedule 5;

(b) in preparations for therapeutic use; or

(c) in preparations containing 5 per cent or less of methyl salicylate.

METOFLUTHRIN except when included in Schedule 5.

METOSULAM.

METRAFENONE **except** when included in Schedule 5.

METRIBUZIN.

MICONAZOLE for the external treatment of animals.

MILBEMECTIN **except** when included in Schedule 5.

MONENSIN:

(a) in animal feed premixes containing 12.5 per cent or less of antibiotic substances; or

(b) in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic substances.

MORANTEL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of morantel.

MOXIDECTIN for external use:

(a) in preparations containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or

(b) in preparations containing 2 per cent or less of moxidectin for the treatment of animals,

**except** when included in Schedule 5.

MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.

NALED **except** when included in Schedule 5.

NAPHTHALENE (excluding its derivatives) **except** in liquid hydrocarbons as an impurity.

NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.

NARASIN in animal feed premixes containing 12 per cent or less of narasin.

NETOBIMIN for the treatment of animals **except** when included in Schedule 5.

NICKEL SULFATE.

NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.

NIMIDANE in preparations containing 25 per cent or less of nimidane.

NITENPYRAM **except** in divided preparations containing 100 mg or less of nitenpyram.

NITRIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.5 per cent or less of nitric acid (HNO3).

NITROBENZENE **except**:

(a) in solid or semi-solid polishes;

(b) in soaps containing 1 per cent or less of nitrobenzene; or

(c) in other preparations containing 0.1 per cent or less of nitrobenzene.

NITROPHENOLS, ortho, meta and para, **except** when separately specified in these Schedules.

NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides **except** when included in Schedule 4.

NITROXYNIL.

NONOXINOL 9 **except**:

(a) when included in Schedule 5;

(b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;

(c) in preparations containing 12.5 per cent or less of nonoxinol 9; or

(d) in preparations for human use.

1-Octen-3-ol **except** in preparations containing 5 per cent or less of 1-octen-3-ol.

OCTHILINONE **except** in paints, jointing compounds and sealants containing 1 per cent or less of octhilinone calculated on the non-volatile content.

N-(N-OCTYL)-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

OLAQUINDOX **except** in preparations containing 10 per cent or less of olaquindox.

N-OLEYL-1,3-DIAMINOPROPANE.

OMETHOATE in preparations containing 30 per cent or less of omethoate **except** when included in Schedule 5.

OXADIAZON.

OXALIC ACID **except** its derivatives and insoluble salts.

OXYCLOZANIDE.

PAECILOMYCES LILACINUS Strain 251.

PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:

(a) for human therapeutic use;

(b) in oral hygiene preparations;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;

(d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.

PARBENDAZOLE.

PEBULATE.

PENNYROYAL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(c) in preparations containing 4 per cent or less of d-pulegone.

PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.

PERACETIC ACID **except** when included in Schedule 5.

PERFLUIDONE.

PERMANGANATES **except** potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.

PERMETHRIN **except**:

(a) when included in Schedule 4 or 5;

(b) in preparations for human therapeutic use containing 5 per cent or less of permethrin; or

(c) in preparations containing 2 per cent or less of permethrin.

2-PHENOXYETHANOL **except:**

(a) in cosmetic preparations containing 1 per cent or less of 2-phenoxyethanol; or

(b) in other preparations containing 15 per cent or less of 2-phenoxyethanol.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, **except**:

(a) when separately specified in these Schedules;

(b) when included in Schedule 5; or

(c) in preparations containing 3 per cent or less of such substances.

PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10 per cent or less of phenothiazine.

PHENYLENEDIAMINES and alkylated phenylenediamines not elsewhere specified in these Schedules:

(a) in preparations packed and labelled for photographic purposes;

(b) in preparations packed and labelled for testing water **except** tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”;

(c) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

(d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING − This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

PHOSALONE.

PHOSMET.

PHOSPHORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);

(c) in solid or semi-solid preparations; or

(d) in professional dental kits.

PHOXIM.

ortho-PHTHALALDEHYDE **except** when included in Schedule 5.

PINDONE.

PINE OILs when packed and labelled as a herbicide **except** when included in Schedule 5.

PINOXADEN **except** when included in Schedule 5.

PIPEROPHOS.

PIRIMICARB **except** when included in Schedule 5.

PIRIMIPHOS-ETHYL.

PIRIMIPHOS-METHYL.

POLIXETONIUM SALTS **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of polixetonium salts.

POTASSIUM AZELOYL DIGLYCINATE **except** in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE **except** in preparations containing 0.5 per cent or less of potassium bromate.

POTASSIUM CYANATE.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 5 per cent or less of potassium hydroxide being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi-solid preparations, the pH of which is 11.5 or less; or

(c) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.

POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite **except**:

(a) when included in Schedule 5;

(b) in preparations containing 0.5 per cent or less of potassium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of potassium nitrite.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT **except**:

(a) when included in Schedule 5;

(b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or

(c) in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more; or

(ii) liquid or semi-solid preparations, the pH of which is 2.5 or more.

POTASSIUM PERSULFATE in hair preparations.

PRALLETHRIN (cis:trans=20:80) **except**:

(a) when included in Schedule 5; or

(b) in insecticidal mats containing 1 per cent or less of prallethrin.

PROCHLORAZ.

PROFENOFOS.

PROMACYL.

PROPACHLOR.

PROPARGITE.

PROPETAMPHOS.

PROPICONAZOLE **except** when included in Schedule 5.

PROPINEB.

PROPIONIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 30 per cent or less of propionic acid; or

(c) for therapeutic use.

PROPOXUR **except** when included in Schedule 5.

PROQUINAZID.

PROSULFOCARB.

PROSULFURON.

PROTHIOFOS.

d-PULEGONE **except** in preparations containing 4 per cent or less of d- pulegone.

PYRACLOFOS.

PYRAZOPHOS.

PYRIDABEN **except** when included in Schedule 5.

Pyridalyl.

PYRIDATE.

PYRIPROLE.

pyrithione copper.

PYRITHIONE ZINC **except**:

(a) when included in Schedule 2 or 5;

(b) for human use in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in semi-solid hair preparations for animal use;

(d) in shampoos for animal use containing 2 per cent or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”;

(e) when immobilised in solid preparations containing 0.5 per cent or less of pyrithione zinc; or

(f) in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content.

PYRIOFENONE.

PYROXASULFONE.

PYROXSULAM.

QUATERNARY AMMONIUM COMPOUNDS **except**:

(a) when separately specified in these Schedules;

(b) when included in Schedule 5;

(c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(d) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUIZALOFOP ETHYL.

QUIZALOFOP-P-ETHYL **except** when included in Schedule 5.

QUIZALOFOP-P-TEFURYL.

RESMETHRIN **except** when included in Schedule 5.

ROTENONE **except** in solid or semi-solid preparations containing 2 per cent or less of rotenone.

SAFROLE **except**:

(a) for internal use; or

(b) in other preparations containing 1 per cent or less of safrole.

SAGE OIL (Dalmatian) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(c) in preparations containing 4 per cent or less of thujone.

SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.

SASSAFRAS OIL **except**:

(a) for internal use; or

(b) in other preparations containing 1 per cent or less of safrole.

SELENIUM:

(a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:

(i) for the blueing of gun barrels;

(ii) for photographic purposes; or

(iii) for the colouring of lead or lead alloys;

(b) in coated granules containing 1 per cent or less of selenium for application to pasture **except** in fertilisers containing 200 g/tonne or less of selenium; or

(c) for the treatment of animals:

(i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;

(ii) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;

(iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or

(iv) as barium selenate in preparations for injection containing 5 per cent or less of selenium.

SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.

SILICOFLUORIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SILVER NITRATE **except**:

(a) when included in or expressly excluded from Schedule 2; or

(b) in preparations containing 1 per cent or less of silver.

SINBIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM ALUMINATE (excluding its salts and derivatives) **except**:

(a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(b) in liquid preparations, the pH of which is 11.5 or less.

SODIUM BROMATE **except** in preparations containing 0.5 per cent or less of sodium bromate.

SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 5 per cent or less of sodium hydroxide being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi-solid preparations, the pH of which is 11.5 or less; or

(c) liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.

SODIUM LAURYL SULFATE (excluding its salts and derivatives) **except:**

(a) in wash-off preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER;

(b) in leave-on preparations containing 1.5 per cent or less of sodium lauryl sulfate;

(c) in toothpaste and oral hygiene preparations containing 5 per cent or less of sodium lauryl sulfate;

(d) in other preparations for animal use containing 2 per cent or less of sodium lauryl sulfate; or

(e) in other preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with warnings to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite **except**:

(a) when included in Schedule 2 or 5;

(b) in preparations containing 0.5 per cent or less of sodium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of sodium nitrite.

SODIUM PERCARBONATE (CAS No. 15630-89-4) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM PERSULFATE:

(a) in hair preparations; or

(b) in products for the treatment of water for swimming pools and spas.

SODIUM SULFIDE in preparations for use as insect lures.

SPIROTETRAMAT.

SPIROXAMINE.

SULCOFURON in preparations for the treatment of carpets during manufacture.

SULFAMIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5.

SULFLURAMID.

SULFOXAFLOR **except** when included in Schedule 5.

SULFURIC ACID (excluding its salts and derivatives) **except**:

(a) in fire extinguishers; or

(b) in preparations containing 0.5 per cent or less of sulfuric acid (H2SO4).

SULFURYL FLUORIDE.

SULPROFOS.

2,4,5-T.

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.

TAR ACIDS distilling within the range 230-290°C inclusive.

TCMTB (2-[thiocyanomethylthio]benzothiazole).

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) **except** when included in Schedule 5.

TEBUFENPYRAD.

TEBUTHIURON.

TEMEPHOS **except** when in Schedule 5.

TERBUTHYLAZINE **except** in preparations containing 5 per cent or less of terbuthylazine.

TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

TETRACHLOROETHYLENE **except**:

(a) when included in Schedule 2 or 5;

(b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or

(c) in preparations for the treatment of animals.

TETRACONAZOLE **except** when included in Schedule 5.

TETRADIFON.

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2’,6,6’-tetraisopropyl-diphenyl-carbodiimide.

TETRAMISOLE in preparations for the treatment of animals.

THIACLOPRID.

THIAMETHOXAM **except** when included in Schedule 5.

THIAZAFLURON.

THIODICARB **except** when included in Schedule 5.

THIOMETON.

THIOPHANATE-METHYL **except** when included in Schedule 5.

THIOUREA AND ALKYL THIOUREAS **except**:

(a) when separately specified in these Schedules; or

(b) for therapeutic use.

THIRAM **except** in paint containing 0.5 per cent or less of thiram.

THUJONE **except** in preparations containing 4 per cent or less of thujone.

THYMOL when packed and labelled for the control of *Varroa* mites in bee hives.

TOLUENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of toluene or toluene and xylene.

TOLUENEDIAMINE not elsewhere specified in these Schedules:

(a) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

(b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING − This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

TOLYLFLUANID.

TRANSFLUTHRIN **except**:

(a) in preparations containing 1 per cent or less of transfluthrin; or

(b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRIADIMEFON **except**:

(a) when included in Schedule 5; or

(b) in fertilisers containing 5 g/kg or less of triadimefon.

TRICHLORFON **except** metrifonate included in Schedule 4.

TRICHLOROACETIC ACID **except**:

(a) when included in Schedule 4 or 5; or

(b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE **except** when included in Schedule 4.

TRICHLOROPHENOL.

TRICLABENDAZOLE **except** in preparations containing 20 per cent or less of triclabendazole.

TRICLOPYR.

TRICLOSAN in cosmetic preparations for human use containing more than 0.3 per cent of triclosan.

TRIDEMORPH.

TRIETHYL PHOSPHATE.

TRIFLUOROMETHANESULFONIC ACID.

TRINITROPHENOL (excluding its derivatives) **except**:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 5 per cent or less of trinitrophenol.

TRISODIUM NITRILOTRIACETATE **except** in preparations containing 20 per cent or less of trisodium nitrilotriacetate.

VAMIDOTHION.

WARFARIN **except** when included in Schedule 4 or 5.

XYLENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of xylene or xylene and toluene.

ZERANOL in ear implants for use as a growth promotant in steer cattle.

ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.

ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.

ZINC CHLORIDE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 5 per cent or less of zinc chloride.

ZINC para-PHENOLSULFONATE **except** in preparations containing 5 per cent or less of zinc para-phenolsulfonate.

ZINC SULFATE **except**:

(a) when included in or expressly excluded from Schedule 4; or

(b) in other preparations containing 5 per cent or less of zinc sulfate.

ZIRAM in granular preparations.

## SCHEDULE 7

ABAMECTIN **except** when included in Schedule 5 or 6.

ACIBENZOLAR-S-METHYL.

ACRIFLAVINE for veterinary use **except** when in Schedule 5.

ACROLEIN.

ACRYLONITRILE.

ALACHLOR.

ALDICARB.

ALDOXYCARB.

ALLYL ALCOHOL.

ALPHA-CYPERMETHRIN **except** when included in Schedule 5 or 6.

AMINACRINE for veterinary use **except** when included in Schedule 5.

AMINOCARB **except** when included in Schedule 6.

4-AMINOPYRIDINE **except** when included in Schedule 4.

AMITON.

ARPRINOCID.

ARSENIC **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 4 or 6;

(c) as selenium arsenide in photocopier drums;

(d) as 10,10’-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;

(e) as 10,10’-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other thanwhen included in articles:

(i) in contact with food stuffs, animal feeds or potable water;

(ii) of clothing and footwear in contact with the skin;

(iii) used as infant wear; or

(iv) intended for use as packaging materials;

(f) in animal feeds containing 75 g/tonne or less of arsenic; or

(g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content of the paint.

AZAFENIDIN.

AZINPHOS-ETHYL.

AZINPHOS-METHYL.

AZOCYCLOTIN.

BENDIOCARB **except** when included in Schedule 5 or 6.

BENOMYL **except** in paints containing 0.5 per cent or less of benomyl.

BENZENE (excluding its derivatives) **except**:

(a) preparations containing 15 mL/L or less of benzene; or

(b) petrol containing 50 mL/L or less of benzene.

BENZIDINE-BASED AZO DYES being:

2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[N-(4-chlorophenyl)-3-oxobutanamide]

CAS No. 94249-03-3

**Acid Red 85 (Acid Fast Red A)**

1,3-Naphthalenedisulfonic acid, 7-hydroxy-8-[[4'-[[4-[[(4-methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-, disodium salt

CAS No. 3567-65-5

**Direct Black 38**

2,7-Naphthalenedisulfonic acid, 4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)-, disodium salt

CAS No. 1937-37-7

**Direct Blue 2**

2,7-Naphthalenedisulfonic acid, 5-amino-3-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-4-hydroxy-, trisodium salt

CAS No. 2429-73-4

**Direct Blue 6**

2,7-Naphthalenedisulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[5-amino-4-hydroxy-, tetrasodium salt

CAS No. 2602-46-2

**Direct Brown 2**

5-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxy- benzoic acid disodium salt

CAS No. 2429-82-5

**Direct Brown 95**

Cuprate(2-), [5-[[4'-[[2,6-dihydroxy-3-[(2-hydroxy-5-sulfophenyl)azo]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxybenzoato(4-)]-, disodium salt

CAS No. 16071-86-6

**Direct Green 1**

2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-6-(phenylazo)-, disodium salt

CAS No. 3626-28-6

**Direct Green 6**

2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-3-[(4-nitrophenyl)azo]-, disodium salt

CAS No. 4335-09-5

**Direct Red 28 (Congo Red)**

1-Naphthalenesulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[4-amino-, disodium salt

CAS No. 573-58-0

**Direct Red 37**

1,3-Naphthalenedisulfonic acid, 8-[[4'-[(4-ethoxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-7-hydroxy-, disodium salt

CAS No. 3530-19-6

BETACYFLUTHRIN **except** when included in Schedule 5 or 6.

BIFENTHRIN **except**:

(a) when included in Schedule 6; or

(b) in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) **except** when included in Schedule 5 or 6.

BORON TRIFLUORIDE **except** when included in Schedule 5 or 6.

BRODIFACOUM **except** when included in Schedule 6.

BROMADIOLONE **except** when included in Schedule 6.

BROMETHALIN **except** when included in Schedule 6.

BROMINE (excluding its salts and derivatives).

BRUCINE **except** in alcohol containing 0.02 per cent or less of brucine as a denaturant.

CACODYLIC ACID **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 75 g/tonne or less of arsenic.

CADUSAFOS **except** when included in Schedule 6.

CALCIFEROL for use as a rodenticide **except** when included in Schedule 6.

CAPTAFOL.

CARBADOX.

CARBENDAZIM **except** in paints, jointing compounds and sealants containing 0.1 per cent or less of carbendazim.

CARBOFURAN.

CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.

CARBONYL SULFIDE when packed and labelled for use as a fumigant.

CARBOPHENOTHION.

CARBOSULFAN.

CHLORDECONE.

CHLORDIMEFORM.

CHLORFENAPYR **except** when included in Schedule 5 or 6.

CHLORFENVINPHOS.

CHLORINE (excluding its salts and derivatives).

CHLORHEXIDINE **except**:

(a) when included in Schedule 5 or 6;

(b) in preparations containing 1 per cent or less of chlorhexidine; or

(c) in solid preparations.

CHLOROMETHIURON.

5-CHLORO-3-METHYL-4-NITROPYRAZOLE.

4-CHLORO-o-TOLUIDINE.

CHLOROPICRIN **except** when included in Schedule 6.

CHLORTHIOPHOS.

COLECALCIFEROL for use as a rodenticide.

COUMAPHOS **except** when included in Schedule 6.

COUMATETRALYL **except** when included in Schedule 5 or 6.

CREOSOTE derived from coal.

CREOSOTE derived from beechwood.

CYANIDES, metallic **except**:

(a) ferricyanides;

(b) ferrocyanides; or

(c) when separately specified in these Schedules.

CYANOGEN.

CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.

CYHEXATIN.

DELTAMETHRIN **except**:

1. when included in Schedules 5 or 6; or
2. in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or
3. in preparations containing 0.1 per cent or less of deltamethrin.

DEMETON.

DEMETON-O-METHYL.

DEMETON-S-METHYL.

DIALIFOS.

4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).

1,2-DIBROMO-3-CHLOROPROPANE.

1,3-DICHLOROPROPENE.

DICHLORVOS **except** when included in Schedule 5 or 6.

DICROTOPHOS.

DIFENACOUM **except** when included in Schedule 6.

DIFETHIALONE **except** when included in Schedule 6.

DIMEFOX.

4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).

DIMETHYL SULFATE.

DIMETILAN.

DINITROCRESOLS **except** when included in Schedule 4 or 6.

DINITROPHENOLS **except** when included in Schedule 4 or 6.

DINOCAP.

DINOSEB.

DIQUAT **except** when included in Schedule 6.

DISULFOTON **except** when included in Schedule 6.

DORAMECTIN **except** when included in Schedule 5 or 6.

DSMA **except** when included in Schedule 6.

EMAMECTIN **except** when included in Schedule 5 or 6.

ENDOSULFAN **except** when included in Schedule 6.

ENDOTHAL **except** when included in Schedule 6.

ENDRIN.

EPICHLOROHYDRIN.

EPIDERMAL GROWTH FACTOR **except** in preparations for human therapeutic use.

EPRINOMECTIN **except** when included in Schedule 5.

ETACONAZOLE.

ETHION.

ETHOPROPHOS **except** when included in Schedule 6.

ETHYLENE DIBROMIDE.

ETHYLENE OXIDE.

FAMPHUR **except** when included in Schedule 6.

FENAMIPHOS **except** when included in Schedule 6.

FENOXACRIM **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FENSULFOTHION.

FENTHION **except** when included in Schedule 5 or 6.

FENTHION-ETHYL.

FLOCOUMAFEN **except** when included in Schedule 6.

FLUCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FLUCYTHRINATE.

FLUMIOXAZIN **except** when included in Schedule 6.

FLUOROACETAMIDE.

FLUOROACETIC ACID.

FOLPET.

FORMETANATE.

FOSTHIAZATE.

FURATHIOCARB **except** when included in Schedule 5.

GAMMA-CYHALOTHRIN **except** when included in Schedule 5.

HALOFUGINONE **except** when included in Schedule 4.

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any

fraction of which boils above 350°C **except**:

(a) when in solid polymers;

(b) when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or

(c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.

HYDROCYANIC ACID **except**:

(a) when included in Schedule 4; or

(b) its salts and derivatives other than cyanides separately specified in this Schedule.

HYDROFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN **except** when included in Schedule 4 or 5.

LAMBDA-CYHALOTHRIN **except** when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROOCTANE SULFONATE **except** in sealed bait stations containing 1 per cent or less of lithium perfluorooctane sulfonate.

MADURAMICIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use **except** when included in Schedule 5.

MAZIDOX.

MECARBAM.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 2, 4 or 6;

(c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;

(d) mercury (metallic) in scientific instruments;

(e) dental amalgams; or

(f) in a sealed device, for therapeutic use, which prevents access to the mercury.

METHACRIFOS **except** when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB **except** when included in Schedule 5 or 6.

METHOMYL **except** when included in Schedule 6.

METHOXYETHYLMERCURIC ACETATE.

METHOXYETHYLMERCURIC CHLORIDE.

METHYL BROMIDE.

Methylcyclopentadienyl Manganese Tricarbonyl **except**:

(a) when included in Schedule 6;

(b) when used in laboratory analysis; or

(c) when packed for industrial use in containers with a nominal capacity of 100 L or more.

4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA).

METHYLENE BLUE for veterinary use **except** when included in Schedules 4 or 5.

MEVINPHOS.

MIPAFOX.

MIREX.

MOLINATE.

MONOCROTOPHOS.

MOXIDECTIN **except** when included in Schedule 4, 5 or 6.

MSMA **except** when included in Schedule 6.

NAPHTHALOPHOS **except** when included in Schedule 6.

NICOTINE **except**:

(a) when included in Schedule 6;

(b) in preparations for human therapeutic use; or

(c) in tobacco prepared and packed for smoking.

NIMIDANE **except** when included in Schedule 6.

NITROFEN.

NITROPRUSSIDES **except** when included in Schedule 4 or 6.

2-NITROTOLUENE.

OMETHOATE **except** when included in Schedule 5 or 6.

OXAMYL.

OXYDEMETON METHYL.

PARAQUAT.

PARATHION.

PARATHION-METHYL **except** when included in Schedule 6.

PENTACHLOROPHENOL **except** when included in Schedule 6.

PHENYLMERCURIC ACETATE **except** in preparations containing 0.01 per cent or less of mercury as a preservative.

PHORATE.

PHOSFOLAN.

PHOSPHIDES, METALLIC.

PHOSPHINE.

PHOSPHORUS, YELLOW (excluding its salts and derivatives).

POTASSIUM NITRITE **except**:

(a) when included in Schedule 5 or 6;

(b) in preparations containing 0.5 per cent or less of potassium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of potassium nitrite.

PROCYMIDONE.

PROPYLENE OXIDE.

PYRINURON.

QUININE for veterinary use **except** when included in Schedule 5.

SAFLUFENACIL **except** when included in Schedule 5.

SCHRADAN.

SELENIUM **except**:

(a) when included in Schedule 6;

(b) as selenium arsenide in photocopier drums;

(c) in preparations for therapeutic use other than:

(i) drench concentrates containing 2.5 per cent or less of selenium; or

(ii) pour-on preparations containing 0.5 per cent or less of selenium;

(d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or

(e) in fertilisers containing 200 g/tonne or less of selenium.

SEMDURAMICIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

SODIUM NITRITE **except**:

(a) when included in Schedule 2, 5 or 6;

(b) in preparations containing 0.5 per cent or less of sodium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of sodium nitrite.

STRYCHNINE **except** when included in Schedule 4.

SULCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

SULFENTRAZONE.

SULFOTEP.

TEFLUTHRIN **except** when included in Schedule 5.

TEPP.

TERBUFOS.

TETRACHLOROETHANE.

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE **except** when included in Schedule 6.

THALLIUM.

THIOFANOX.

TIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:

(a) when separately specified in this Schedule;

(b) in plastics;

(c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or

(d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.

ortho-TOLIDINE **except** in solid-state diagnostic therapeutic reagents.

TRIAMIPHOS.

TRIAZBUTIL.

TRIBUFOS (s,s,s-tributylphosphorotrithioate).

VINCLOZOLIN.

VINYL CHLORIDE.

ZETA-CYPERMETHRIN **except** when included in Schedule 6.

ZIRAM **except** when included in Schedule 6.

## SCHEDULE 8

(Substances marked # are listed in Appendix D.)

ACETYLDIHYDROCODEINE.

ACETYLMETHADOL.

ACETYLMORPHINES.

ALFENTANIL.

ALPHACETYLMETHADOL.

ALPHAPRODINE.

# ALPRAZOLAM.

AMPHETAMINE.

AMYLOBARBITONE **except** when included in Schedule 4.

ANILERIDINE.

BENZYLMORPHINE.

BEZITRAMIDE.

BUPRENORPHINE.

BUTOBARBITONE.

BUTORPHANOL.

CARFENTANYL.

COCAINE.

CODEINE **except** when included in Schedule 2, 3 or 4.

CODEINE-N-OXIDE.

CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).

CYCLOBARBITONE.

DEXAMPHETAMINE.

DEXTROMORAMIDE.

DEXTROPROPOXYPHENE **except** when included in Schedule 4.

DIFENOXIN **except** when included in Schedule 4.

DIHYDROCODEINE **except** when included in Schedule 2, 3 or 4.

DIHYDROMORPHINE.

DIPHENOXYLATE **except** when included in Schedule 3 or 4.

DIPIPANONE.

# DRONABINOL (*delta*-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROTEBANOL.

ETHYLAMPHETAMINE.

ETHYLMORPHINE **except** when included in Schedule 2 or 4.

FENTANYL.

# FLUNITRAZEPAM.

HYDROCODONE.

HYDROMORPHINOL.

HYDROMORPHONE.

KETAMINE.

LEVAMPHETAMINE.

LEVOMETHAMPHETAMINE.

LEVOMORAMIDE.

LEVORPHANOL (excluding its stereoisomers).

LISDEXAMFETAMINE.

METHADONE.

METHYLAMPHETAMINE.

METHYLDIHYDROMORPHINE.

METHYLPHENIDATE.

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).

MORPHINE.

MORPHINE METHOBROMIDE.

MORPHINE-N-OXIDE.

NABILONE.

# NABIXIMOLS (botanical extract of *Cannabis sativa* which includes the following cannabinoids: tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acid, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinol and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use.

NORCODEINE.

NORMETHADONE.

OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.

OXYCODONE.

OXYMORPHONE.

PENTAZOCINE.

PENTOBARBITONE **except** when included in Schedule 4.

PETHIDINE.

PHENDIMETRAZINE.

PHENMETRAZINE.

PHENOPERIDINE.

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).

PHOLCODINE **except** when included in Schedule 2 or 4.

PIRITRAMIDE.

PROPIRAM.

QUINALBARBITONE.

RACEMORAMIDE.

REMIFENTANIL.

SECBUTOBARBITONE.

# SODIUM OXYBATE for human therapeutic use.

SUFENTANIL.

TAPENTADOL.

THEBACON.

THEBAINE.

TILIDINE.

## SCHEDULE 9

(Trivial or unofficial names are marked \*)

ACETORPHINE.

ACETYL-ALPHA-METHYLFENTANYL.

ALKOXYAMPHETAMINES and substituted alkoxyamphetamines **except** when separately specified in these schedules.

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines **except** when separately specified in these Schedules.

ALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamines **except** when separately specified in these schedules.

ALLYLPRODINE.

ALPHAMEPRODINE.

ALPHA-METHYLFENTANYL.

ALPHA-METHYLTHIOFENTANYL.

ALPHAMETHADOL.

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE \*(STP or DOM).

5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans **except** when separately specified in these schedules.

BENZETHIDINE.

BENZOYLINDOLES **except** when separately specified in these Schedules.

BENZYLPIPERAZINE \*(BZP).

BETACETYLMETHADOL.

BETA-HYDROXYFENTANYL.

BETA-HYDROXY-3-METHYLFENTANYL.

BETAMEPRODINE.

BETAMETHADOL.

BETAPRODINE.

1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE \*(Bromo-Dragonfly).

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE \*(BDMPEA).

BUFOTENINE.

CANNABIS **except**:

(a) when separately specified in these Schedules; or

(b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.

CATHINONE.

CLONITAZENE.

COCA LEAF.

CODOXIME.

4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE.

CYCLOHEXYLPHENOLS **except** when separately specified in these Schedules.

DESOMORPHINE.

DIAMPROMIDE.

DIBENZOPYRANS **except** when separately specified in these Schedules.

3,4-DICHLORO-N-{[1- (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE \*(AH-7921).

DIETHYLTHIAMBUTENE.

N,N-DIETHYLTRYPTAMINE \*(DET).

DIMENOXADOL.

DIMEPHEPTANOL.

2,5-DIMETHOXYAMPHETAMINE \*(DMA).

2,5-DIMETHOXY-4-BROMOAMPHETAMINE \*(DOB).

2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE \*(DOET).

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE \*(2C-T-2).

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE \*(2C-I).

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE \*(2C-T-7).

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE \*(PSILOCINE or PSILOTSIN).

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(DMHP).

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA).

N,N-DIMETHYLAMPHETAMINE (Dimetamfetamine).

DIMETHYLTHIAMBUTENE.

N,N-DIMETHYLTRYPTAMINE \*(DMT).

DIOXAPHETYL BUTYRATE.

ECGONINE.

N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE \*(N-ETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETICYCLIDINE \*(PCE).

ETONITAZENE.

ETORPHINE.

ETOXERIDINE.

FENETYLLINE.

4-FLUORO-N-METHYLAMPHETAMINE.

1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE \*(AM-694).

FURETHIDINE.

HARMALA ALKALOIDS **except** in herbs, or preparations, for therapeutic use:

(a) containing 0.1 per cent or less of harmala alkaloids; or

(b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.

HEROIN.

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(PARAHEXYL).

4-HYDROYXBUTANOIC ACID and its salts **except** for sodium oxybate when in Schedule 8. \*(GAMMA HYDROXYBUTYRATE (GHB)).

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL \*(Cannabicyclohexanol or CP 47,497 C8 homologue).

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL \*(CP 47,497).

HYDROXYPETHIDINE.

ISOMETHADONE.

KETOBEMIDONE.

LEVOMETHORPHAN (excluding its stereoisomers).

LEVOPHENACYLMORPHAN.

LYSERGIC ACID.

LYSERGIDE.

MECLOQUALONE.

METAZOCINE.

METHAQUALONE.

METHCATHINONE.

5-METHOXY- α -METHYLTRYPTAMINE \*(5-MeO-AMT).

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE \*(MMDA).

4-METHOXY- α -METHYLPHENYLETHYLAMINE \*(PMA).

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE \*(JWH-250).

METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE \*(SALVINORIN A).

4-METHYLAMINOREX.

METHYLDESORPHINE.

3,4-METHYLENEDIOXYAMPHETAMINE \*(MDA).

3,4-METHYLENEDIOXYPYROVALERONE \*(MDPV).

3-METHYLFENTANYL.

4-METHYLMETHCATHINONE \*(MEPHEDRONE).

N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE \*(N-HYDROXY MDA).

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE \*(MBDB).

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE \*(MPPP).

4-METHYLTHIOAMPHETAMINE.

3-METHYLTHIOFENTANYL.

METOPON.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MORPHERIDINE.

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE \*(JWH-200).

MUSCIMOL.

MYROPHINE.

NAPHTHOYLINDOLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDOLES **except** when separately specified in these Schedules.

NAPHTHOYLPYRROLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDENES **except** when separately specified in these Schedules.

NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE \*(JWH-073).

NICOCODINE.

NICODICODINE.

NICOMORPHINE.

NORACYMETHADOL.

NORLEVORPHANOL.

NORMORPHINE.

NORPIPANONE.

PARA-FLUOROFENTANYL.

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. \*(JWH-122).

1-PENTYL-3-(1-NAPHTHOYL)INDOLE \*(JWH-018).

PHENADOXONE.

PHENAMPROMIDE.

PHENAZOCINE.

PHENCYCLIDINE \*(PCP).

N-PHENETHYL-4-PIPERIDONE.

PHENOMORPHAN.

PHENYLACETYLINDOLES **except** when separately specified in these Schedules.

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE \*(PEPAP).

PIMINODINE.

PROHEPTAZINE.

PROPERIDINE.

PSILOCYBINE.

RACEMETHORPHAN.

RACEMORPHAN.

ROLICYCLIDINE \*(PHP or PCPY).

SALVIA DIVINORUM.

TENOCYCLIDINE \*(TCP).

SYNTHETIC CANNABINOMIMETICS **except** when separately specified in these Schedules.

TETRAHYDROCANNABINOLS and their alkyl homologues **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 8;

(c) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement:

Not for internal use; or

Not to be taken; or

(d) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols.

THIOFENTANYL.

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE \*(TFMPP).

TRIMEPERIDINE.

3,4,5-TRIMETHOXY- α -METHYLPHENYLETHYLAMINE \*(TMA).

3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine **except**:

(a) methoxyphenamine; or

(b) when separately specified in this Schedule.

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.

## SCHEDULE 10/APPENDIX C

## SUBSTANCES OF SUCH DANGER TO HEALTH AS TO WARRANT

## PROHIBITION OF SALE, SUPPLY AND USE

ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.

ACORUS CALAMUS (calamus) for human therapeutic use.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:

1. in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;
2. in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
3. in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5;

**except**:

1. when in Schedule 5; or
2. when in Scheule 6.

ALLYLISOPROPYLACETYLUREA for therapeutic use.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use **except**:

1. when in Schedule 4; or
2. when in Schedule 6.

AMYGDALIN for therapeutic use.

ANCHUSA OFFICINALIS for therapeutic use.

ARISTOLOCHIA spp. for therapeutic use.

ARISTOLOCHIC ACID(S) for human therapeutic use.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use **except:**

1. ‘debitterised neem seed oil’; or
2. when in Schedule 5; or
3. when in Schedule 6.

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when in Schedule 6.

1,2-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

1,3-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

BITHIONOL for human therapeutic use **except** when in Schedule 6.

BORAGO OFFICINALIS (Borage) for therapeutic use **except** the fixed oil derived from the seeds of Borago officinalis.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

BUCLOSAMIDE for therapeutic use.

BUNIODYL SODIUM for therapeutic use.

1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.

CACALIA spp. for therapeutic use.

CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18 per cent of carbamide peroxide **except:**

1. in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice; or
2. when in Schedule 5; or
3. when in Schedule 6.

CINCHOPHEN and its derivatives for therapeutic use.

CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use **except** when in Schedule 4 or when being used solely for experimental purposes in humans and where such use:

(a) is in accordance with:

(i) an approval granted under paragraph 19(1)(b) of the *Therapeutic Goods Act 1989*, including any conditions specified in the notice of approval; and

(ii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(1A) of the *Therapeutic Goods Act 1989*; and

(iii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(4A) of the *Therapeutic Goods Act 1989*; or

(b) is in accordance with the requirements of item 3 of Schedule 5A to the *Therapeutic Goods Regulations 1990*.

COAL TAR for cosmetic use other than in therapeutic goods.

CONIUM MACULATUM (coniine) for therapeutic use.

COTARNINE for therapeutic use.

CROTALARIA spp. for therapeutic use.

CROTON TIGLIUM for therapeutic use.

CYNOGLOSSUM spp. for therapeutic use.

DICOPHANE (DDT) for therapeutic use.

DIETHYLENE GLYCOL for use in toothpastes or mouthwashes **except:**

1. in preparations containing 0.25 per cent or less of diethylene glycol; or
2. when in Schedule 5; or
3. when in Schedule 6

DIETHYLHEXYL PHTHALATE for cosmetic use.

DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5 per cent or less of diethylphthalate.

5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline **except** when in Schedule 6.

1,3-DIMETHYLAMYLAMINE (DMAA).

DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5 per cent or less of dimethylphthalate.

DULCIN for therapeutic use.

ETHYLENE GLYCOL for use in toothpastes or mouthwashes **except:**

1. in preparations containing 0.25 per cent or less of ethylene glycol; or
2. when in Schedule 5; or
3. when in Schedule 6.

ETHYLHEXANEDIOL for human use **except** when in Schedule 4.

EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

FARFUGIUM JAPONICUM for therapeutic use.

FORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;

(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; o

(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde ;

**except:**

1. in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE;

1. when in Schedule 2; or
2. when in Schedule 6.

HELIOTROPIUM spp. for therapeutic use.

HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6 per cent (20 volume) of hydrogen peroxide **except:**

1. in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice;
2. when in Schedule 5; or
3. when in Schedule 6.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

LEAD COMPOUNDS in paints, tinters, inks or ink additives **except;**

1. in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive;
2. when in Schedule 4;
3. when in Schedule 5; or
4. when in Schedule 6.

LIGULARIA DENTATA for therapeutic use.

MELIA AZEDARACH including its extracts and derivatives.

METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use **except** when in Schedule 6.

METHYL METHACRYLATE for cosmetic use **except** in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer **except** when in Schedule 6.

OXYPHENISATIN for therapeutic use.

PARAFORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;

(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; o

(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde ;

**except:**

1. in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE;

1. when in Schedule 2; or
2. when in Schedule 6.

PETASITES spp. for therapeutic use.

PHENYLENEDIAMINES, including alkylated and arylated derivatives, in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5 **except**:

1. when in Schedule 5; or
2. when in Schedule 6.

PTERIDIUM spp. for therapeutic use.

PULMONARIA spp. for therapeutic use.

SAFROLE for internal therapeutic use **except**

1. in preparations containing 0.1 per cent or less of safrole; or
2. when in Schedule 6.

SENECIO spp. for therapeutic use.

SILICONES for injection or implantation **except** when included in Schedule 4.

SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5 **except**:

1. when in Schedule 5; or
2. when in Schedule 6.

SYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use **except** when included in Schedule 5.

2,4-TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.

TOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use **except** when in Schedule 5.

TRICHODESMA AFRICANA for therapeutic use.

TRIPARANOL for therapeutic use.

TUSSILAGO FARFARA for therapeutic use.

# **PART 5**

# **THE APPENDICES**

## APPENDIX A

## GENERAL EXEMPTIONS

This Standard does not apply to a poison in any of the following products:

ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition of an agvet chemical product.

BACTERIAL CULTURE MEDIA containing antibiotics.

CERAMICS.

CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4-2003 *Safety of toys* entitled *Part 4: Experimental sets for chemistry and related activities*.

COPPER COMPOUNDS in paints.

DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES− used as plasma substitutes/blood volume expanders.

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.

ELECTRONIC COMPONENTS.

ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.

EXPLOSIVES.

FOOD **except**:

(a) food additives before incorporation into food; or

(b) when used as a means of administering a poison for therapeutic use.

FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules.

GLASS (including CRYSTAL WARE).

GLAZED POTTERY.

HUMAN BLOOD PRODUCTS including:

(a) whole blood;

(b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and

(c) the following plasma-derived therapeutic proteins; and their equivalent recombinant alternatives:

(i) albumin;

(ii) anticoagulation complex;

(iii) C1 esterase inhibitors;

(iv) clotting factors;

(v) fibrinogen;

(vi) protein C;

(vii) prothrombin complex concentrate (PCC) ; and

(viii) thrombin.

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.

INTRAOCULAR VISCOELASTIC PRODUCTS.

LUBRICANTS **except** soluble oils and solvent-deposited lubricating agents.

MATCHES.

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS.

MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the *Therapeutic Goods (Medical Devices) Regulation 2002*, **except**:

(a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;

(b) medical devices which include anticoagulants;

(c) artificial tears;

(d) urinary catheters; or

(e) intra-articular fluids.

MOTOR, HEATING or FURNACE FUELS except:

(a) when the contrary intention appears in any Schedule;

(b) when containing methanol;

(c) toy or hobby fuels; or

(d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION.

PAPER **except**:

(a) when prepared for pesticidal use; or

(b) when containing a poison included in Schedule 8 or 9.

PHOTOGRAPHIC PAPER or FILM.

PIGMENTS when immobilised in a polymer.

PORCELAIN.

PRINTING INKS or INK ADDITIVES **except**:

(a) when containing a pesticide; or

(b) preparations containing more than 0.1 per cent of lead calculated on the non-volatile content of the ink or ink additive.

RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.

RADIOISOTOPES for therapeutic use.

SEEDS treated with seed protectants.

SINGLE-USE TUBES for the estimation of alcohol content of breath.

TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.

TIMBER or WALLBOARD.

VITREOUS ENAMELS.

WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5.

## APPENDIX B

## SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING

(This Appendix should be read in conjunction with Appendix A.)

## INTRODUCTION

Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.

Listing in Appendix B indicates that a decision has been taken not to list substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list i.e. there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling.

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

• the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;

• the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or

• the public access was limited such that scheduling was inappropriate or unnecessary.

The list was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.

**APPENDIX B**

**PART 1**

**REASONS FOR ENTRY**

a Low Toxicity.

b Use pattern restricts hazard.

c Presentation/packaging restricts hazard.

d Industrial use only.

**PART 2**

**AREAS OF USE**

1. Agricultural

1.1 Herbicide

1.2 Insecticide

1.2.1 Insecticide for codling moth

1.2.2 Termiticide

1.3 Fungicide

1.3.1 On seed fungicide

1.4 Bird Repellent

1.5 Fertiliser

1.6 Plant Growth Regulator

1.7 Insect Pheromone

1.8 Mushroom Bactericide

1.9 Acaricide

1.10 Biological control agent

2. Veterinary

2.1 For animal use

2.2 Treatment of mastitis in cows

2.3 Coccidiostat

2.4 Feed additive

2.5 Antiseptic

2.6 Scabicide

2.7 Anthelmintic

2.8 Vitamin/Mineral

2.9 Growth Promotant

2.10 Ectoparasiticide

3. Domestic

3.1 Aromatherapy

3.2 Food additive

3.3 Cosmetic

3.4 Human use

3.5 Miticide

4. Industrial

4.1 Water treatment

4.2 Biological control agent

5. Environmental

5.1 Mosquito control

6. Human therapeutic use

6.1 Diagnostic agent

6.2 Medical device

6.3 Antiseptic

6.4 Sunscreen

6.5 External use

6.6 Laxative

6.7 Antiseborrheic

6.8 Cytoprotective

6.9 Vitamin/Mineral

6.10 Eye Drops

7. General

7.1 Any use

7.2 Excipient

7.3 Synergist

7.4 Flux

7.5 Pesticide

7.6 Insect repellent

7.7 Solvent

7.8 Disinfectant

7.9 Preservative

7.10 Antioxidant

7.11 Resin activator/accelerant

7.12 Sweetener artificial

7.13 Food additive

**APPENDIX B**

**PART 3**

**SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL   
BY SCHEDULING**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**REASON AREA  
 DATE OF FOR OF  
SUBSTANCE ENTRY LISTING USE**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4-[4-(ACETYLOXY)PHENYL]-2-

BUTANONE Feb 2005 b 1.7

*AGROBACTERIUM RADIOBACTER* Nov 1989 a 1

ALCOHOL, DEHYDRATED Aug 2000 b 6

ALUM May 1997 a 7.1

ALUMINIUM AMMONIUM SULFATE May 1997 a 7.1

ALUMINIUM POTASSIUM SULFATE May 1997 a 7.1

ALUMINIUM SILICATE Nov 1974 a 7.1

ALUMINIUM tris (ETHYLPHOSPHONATE) Aug 1986 a 1

AMETOCTRADIN May 2012 a 1.3

AMMONIUM PHOSPHATE Nov 1974 a 7.1

AMMONIUM THIOSULPHATE Nov 1974 a 7.1

AMPROLIUM Jun 1969 a 2.3

AMYL ACETATE Nov 1974 a 7.1

α -AMYLASE derived from *Aspergillus niger* Feb 2005 a 2.4

ANDROSTENEDIONE ALBUMEN

 CONJUGATE WITH DEA DEXTRAN

 ADJUNCT Jun 2004 a 2.1

ASPARTIC ACID - a 6

ASULAM May 1986 a 1

AZIMSULFURON Jun 2003 a 1.1

*BACILLUS SPHAERICUS* STRAIN 2362 Feb 2003 a 5.1

*BACILLUS THURINGIENSIS* May 1992 a 5.1  
 (excluding endotoxin) Jun 2003 a 2.10

*BACILLUS TOYOI* Aug 1980 a 2.9

BACULOVIRUS *CYDIA POMONELLA* Jun 2006 a 1.2

BENFLURALIN - a 1.1

BENSULFURON-METHYL Aug 1987 a 1

BENTONITE Jun 2002 a 7.1

BENZYL BENZOATE Aug 1989 a 1.3.4

BETAINE HYDROCHLORIDE Nov 1974 a 7.1

BIFENAZATE Oct 2002 a 1.9

BISMUTH SUBNITRATE Nov 1999 b, c 2.1

BISTRIFLURON Feb 2014 a 1.2.2

BIURET Nov 1974 a 2.4

BOSCALID June 2003 a 1.3

BOVINE SOMATOTROPHIN May 1992 a 2

BROMACIL Aug 1987 a 1

BROMOPROPYLATE Nov 1994 a 1

BUPIRIMATE Nov 1990 a 1

BUTAFENACIL May 2000 a 1

BUTOXYPOLYPROPYLENE GYLCOL Nov 1974 a 7.7

n-BUTYL BUTYRATE - a 7.1

n-BUTYL LACTATE - a 7.1

CARBETAMIDE Aug 1991 a 1

CARBOXIN Aug 1987 a 1

CARFENTRAZONE-ETHYL Aug 1998 a 1

CELLULASE derived from  
 *Aspergillus niger* Feb 2005 a 2.4

CETYL ALCOHOL Nov 1974 a 7.1

CHAMOMILE OIL Feb 2000 a 3.1

CHINA CLAY Nov 1974 a 7.1

CHLORANTRANILIPROLE Sep 2008 a 1.2

CHLORFLUAZURON Oct 2005 a 1.2.2

CHLORFLURENOL Feb 1974 a 1.6

CHLORIDAZON May 1988 a 1

CHLOROXYLENOLS Feb 1975 a 7.8

CITRONELLA OIL Feb 2000 a 7.1

CLARY SAGE OIL Feb 2000 a 7.1

CLOPIDOL Nov 1974 d 2.3

COBALT NAPHTHENATE - d 7.1

COLOPHONY Feb 1997 b 7.4

CROSPOVIDONE Aug 1996 a 2

*CULICINOMYCES CLAVOSPORUS* Nov 1982 a 5.1

CYCLAMIC ACID Nov 1971 a 7.1

CYCLOHEXANE Nov 1974 a 7.7

CYCLOHEXANOL ACETATE - a 7.7

CYROMAZINE Nov 1980 a 2

DICLAZURIL Nov 2001 a 2.3

DIETHYL CARBONATE - a 7.1

DIFLUFENICAN Feb 1987 a 1

DIKEGULAC-SODIUM Mar 1980 a 1.6

DIMETHICONE a 7.1

DIMETHYL ETHER Nov 1988 d 4

DIPHENYLAMINE Feb 1988 a 1

DIPROPYLENE GLYCOL   
 MONOMETHYL ETHER Nov 1987 a 4

DIURON Nov 1987 a 1

DOCUSATE SODIUM   
 (DIOCTYL SODIUM SULFOSUCCINATE) Feb 1970 a 7.1

2,2-DPA Nov 1989 a 1

drometrizole trisiloxane Oct 2003 a 6.4

EPSIPRANTEL Nov 1991 a 2

ETHAMETSULFURON-METHYL Nov 2000 a 1.1

ETHOPABATE Jun 1969 d 2.3

ETHYL ACETATE Nov 1974 a 7.1

ETHYL ALCOHOL Nov 1974 a 7.1

ETHYLBUTYLACETYL-  
 AMINOPROPRIONATE Aug 2000 a 3.4

ETHYL BUTYRATE - a 7.1

ETHYL LACTATE - a 7.1

ETOXAZOLE Oct 2003 a 1.2

*EUBACTERIUM* sp. strain DSM11798 Sep 2013 a 2.4

FENFURAM May 1977 a 1.3.1

FENHEXAMID Feb 1999 a 1

FENOXYCARB Feb 1988 a 1

FLUFENOXURON Feb 1997 a 1

FLUMETSULAM Feb 1992 a 1

FLUOMETURON Aug 1989 a 1

FLUTOLANIL Nov 2001 a 1.3

FLUROXYPYR May 1986 a, c 1

FORCHLORFENURON Feb 2005 a 1.6

FULLERS EARTH Nov 1974 a 7.1

FUNGAL PROTEASE derived from

*Aspergillus niger* Feb 2005 a 2.4

GERANIUM OIL Feb 2000 a 7.1

GIBBERELLIC ACID Nov 1974 a 1.6

-GLUCANASE derived from *Aspergillus niger* Feb 2005 a 2.4

HALAUXIFEN METHYL Oct 2014 a 1, 1.1

HEXAFLURON Nov 1988 a 1

HEXYL ACETATE - a 7.7

HEXYTHIAZOX Feb 1988 a 1

HUMAN OSTEOGENIC PROTEIN-1 (OP-1) Aug 2001 b 6.2

HYDROPRENE Feb 1988 a 1

HYDROXYPROPYL CELLULOSE Nov 1982 a 7.1

ICODEXTRIN Nov 2000 b 6

INDOLE-3-ACETIC ACID Feb 1985 b 1.6

ISOPRENE ALCOHOL - a 7.1

IPRODIONE Feb 1997 a 1

ISOSTEARYL ALCOHOL ETHOXYLATE Nov 1999 a 5.1

KAOLIN Nov 1974 a 7.1

KRESOXIM-METHYL Aug 1999 a 1

KUNZEA OIL Feb 2000 a 7.1

LAURIC ACID Oct 2005 a 7.1

LAURYL ALCOHOL (1-DODECANOL) Nov 1974 a 7.1

LAVANDIN OIL Feb 2000 a 7.1

LAVENDER OIL Feb 2000 a 7.1

LEAD METALLIC - a 7.1

LEMONGRASS OIL Feb 2000 a 7.1

LEPIDOPTEROUS SEX PHEROMONES Nov 1990 a 1

LIMONENE (DIPENTENE) Jun 2002 a 7.1

LINOLEIC ACID Oct 2005 a 7.1

LINSEED FATTY ACIDS Aug 1990 a 2.1

LINURON Feb 1990 a 1

LIQUORICE, DEGLYCYRRHISINISED May 1999 a 7.1

MALEIC HYDRAZIDE Nov 1992 a 1

MANGANESE DIOXIDE May 1999 b 1

*MEGASPHAERA ELSDENII* strain 41125 Sep 2013 a 2.4

MESOLSULFURON-METHYL Feb 2002 a 1.1

*METARHIZIUM ANISOPLIAE* Feb 2000 b 4.2

*METARHIZIUM ANISOPLIAE* Jun 2003 a 1.10

METHOPRENE Aug 1987 a 1

METHOXYFENOZIDE Nov 2000 a 1

METHYL ACETATE - a 7.7

METHYL BENZOQUATE Nov 1974 d 2.3

1-METHYLCYCLOPROPENE Jun 2003 a 1.6

METHYL p-HYDROXYBENZOATE Nov 1974 a 7.9

METSULFURONMETHYL Nov 1985 a 1.1

MYRISTIC ACID Oct 2005 a 7.1

NAPROPAMIDE Aug 1987 a 1

NAPTHYL ACETAMIDE Nov 1974 a 1.6

NEROLI OIL Feb 2000 a 7.1

NICARBAZIN Jun 1969 d 2.3

NISIN Jun 2003 a 3.2

NORFLURAZON Nov 1983 a 1.1

NOVALURON Nov 2000 a 1

Nuclear Polyhedrosis Virus of   
 *Helicoverpa armigera* occlusion bodies Feb 2004 a 1.2

OCTYL ALCOHOLS Nov 1974 a 7.1

OLEIC ACID Oct 2005 a 7.1

ORANGE OIL, SWEET Aug 2000 a 7.1

OXABETRINIL Feb 1987 a 1

OXYFLUORFEN May 2001 a 1

PALMAROSA OIL Feb 2000 a 7.1

PALMITIC ACID Oct 2005 a 7.1

PATCHOULI OIL Feb 2000 a 7.1

PECTINASE derived from *Aspergillus niger* Feb 2005 a 2.4

PENCYCURON Aug 1994 a 1

PENTADECANOIC ACID Oct 2005 a 7.1

PEPPERMINT OIL Feb 2000 a 7.1

PHENMEDIPHAM May 1989 a 1.1

d-PHENOTHRIN Feb 1982 a 7.5, 1.2

PHYTASE Feb 1996 a 2.4

PICLORAM Aug 1987 a 1

PICOLINAFEN May 2000 a 1

PIMELIC ACID Oct 2005 a 7.1

PIPERONYL BUTOXIDE Aug 1991 a 7.5

POLOXALENE Nov 1974 a 7.1

POLY DIALLYL DIMETHYL AMMONIUM   
 CHLORIDE (PolyDADMAC) Nov 1997 a 4.1

POLYHEDROSIS VIRUS of   
  *Helico zea* occlusion bodies Nov 1996 a 1

POLY (GNRF) OVALBUMIN Feb 1990 a 2

POLYSORBATE 20 May 2001 a 1

PORCINE SOMATOTROPHIN Nov 1991 c 2

potassium sorbate Oct 2004 a 1.3

POTASSIUM BICARBONATE Jun 2004 a 1

PROPYL ACETATES - a 7.1

PROPYLENE GLYCOL Nov 1974 a 7.1

2-PROPYLENE GLYCOL 1-MONOMETHYL   
 ETHER Nov 1987 a 4

PROTHIOCONAZOLE June 2005 a 1.3.1

*PSEUDOMONAS FLUORESCENS* May 1985 a 1.8

PYRIMETHANIL Feb 1996 a 1

PYRIPROXYFEN Aug 1994 a 1

QUASSIA Nov 1974 d 6, 2.1

QUINOXYFEN Nov 2001 a 1.3

ROSEMARY OIL Feb 2000 a 7.1

SAGE OIL (Spanish) Feb 2000 a 7.1

SANDALWOOD OIL Feb 2000 a 7.1

SEAWEED & UNFRACTIONED   
  SEAWEED EXTRACTS Feb 1985 d 1.5

SIMAZINE Nov 1987 a 1.1

SODIUM BICARBONATE Jun 2004 a 1

sodium propionate Oct 2004 a 1.3

STERIC ACID Oct 2005 a 7.1

SUCRALFATE Aug 1982 a 6.8

SULESOMAB Jun 2002 b 6.1

SULFOSULFURON Feb 1998 a 1

SULPHATED POLYSACCHARIDES - a 7.1

TANNIC ACID Dec 1965 a 7.1

TANNIC ACID/BENZYL ALCOHOL   
 PRODUCT Nov 1993 a 7.1

TERBACIL Aug 1987 a 1

THAUMATIN Nov 1990 a 3.2

THIDIAZURON Nov 1989 a 1

TRIASULFURON Feb 1988 a 1

TRICHODERMA HARZIANUM May 1996 a 1

(Z)-9-TRICOSENE Aug 1991 a 1

TRIETHYLENE GLYCOL Nov 1974 a 7.1

TRIFLOXYSULFURON Feb 2002 a 1.1

TRIFLURALIN Aug 1990 a 1

TRIFORINE Aug 1987 a 1

Ulocladium oudemansii Oct 2003 a 1.10

UREA Nov 1974 a 7.1

13C-UREA May 2001 a 6.1

VETIVER OIL Feb 2000 a 7.1

VINYL ETHER Nov 1987 b 6

VITAMIN K Jul 1963 a 6.9, 2.8

XANTHOPHYLL (lutein) Nov 1974 a 7.1

XYLANASE derived from *Aspergillus niger* Feb 2005 a 2.4

YLANG YLANG OIL Feb 2000 a 7.1

ZINC NAPHTHENATE - a 1.3

## APPENDIX C (see SCHEDULE 10)

This Appendix is intentionally blank

## APPENDIX D

## ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8

(The following controls apply for the substances shown only when included in Schedule 4 or Schedule 8.)

**1. Poisons available only from or on the prescription or order of an authorised medical practitioner.**

CLOMIPHENE for human use.

CLOZAPINE for human use.

CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use.

CYCLOFENIL for human use.

DINOPROST for human use.

DINOPROSTONE for human use.

FOLLITROPIN ALPHA (recombinant human follicle-stimulating hormone) for human use.

FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use.

LUTEINISING HORMONE for human use.

NABIXIMOLS.

SODIUM OXYBATE for human use.

TERIPARATIDE for human use.

UROFOLLITROPIN (human follicle-stimulating hormone) for human use.

**2. Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age:**

(1) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(2) if the drug is -

(a) acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or

(b) bexarotene, isotretinoin or thalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

ACITRETIN for human use.

BEXAROTENE for human use.

ETRETINATE for human use.

ISOTRETINOIN for human oral use.

THALIDOMIDE for human use.

**3. Poisons available only from or on the prescription or order of a medical practitioner authorised or approved by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the *Therapeutic Goods Act 1989*.**

DRONABINOL (delta-9-tetrahydrocannabinol).

**4. Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age:**

(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(b) advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

LENALIDOMIDE.

RIOCIGUAT for human use.

TRETINOIN for human oral use.

**5. Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription).**

ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8.

DARBEPOETIN.

DEXTROPROPOXYPHENE.

EPHEDRINE.

EPOETINS.

ERYTHROPOIETIN.

ERYTHROPOIETINS **except** when separately specified in this Appendix.

FOLLISTATIN.

GLUTETHIMIDE.

INSULIN-LIKE GROWTH FACTORS.

PERAMPANEL for human use.

PHENTERMINE.

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4.

SOMATROPIN (human growth hormone).

**6. Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age:**

(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(b) advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.

AMBRISENTAN for human use.

BOSENTAN for human use.

MACITENTAN for human use.

SITAXENTAN for human use.

**7. Poisons available only from or on the prescription or order of a dermatologist.**

ALEFACEPT for human use.

## APPENDIX E

## FIRST AID INSTRUCTIONS FOR POISONS

(other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority and medicines for human use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*)

**INTRODUCTION**

**Directions for First Aid Attention**

Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in this Appendix may be varied provided that the intent is not changed.

The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.

These First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.

**Modified First Aid Instruction on Primary Pack**

Where a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

(a) each immediate container must be labelled with first aid instructions appropriate for its contents; and

(b) the primary pack must be labelled with the statement:

FIRST AID: See inner packs.

**Exempt Preparations**

This Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the Schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.

**Poisons Information Centre Telephone Numbers**

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

**APPENDIX E**

**PART 1**

**STANDARD STATEMENTS**

To be grouped together and prefaced with the words “FIRST AID” (see subparagraph 7(p) of this Standard).

*Basic*

A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).

Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

*General*

G1 Urgent hospital treatment is likely to be needed.   
(Note − the words ‘at once’ to be added to instruction A).

G2 If swallowed, give activated charcoal if instructed.   
(Note − the words ‘at once’ to be added to instruction A).

G3 If swallowed, do NOT induce vomiting.

G4 Immediately give a glass of water.

G5 Avoid giving milk or oils.

G6 If sprayed in mouth, rinse mouth with water.

*Eyes*

E1 If in eyes wash out immediately with water.

E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.

*Respiratory system*

R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.

R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.

*Skin*

S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).

*Special Purpose*

SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.

**APPENDIX E**

**PART 2**

**FIRST AID INSTRUCTIONS**

Standard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the Introduction to this Appendix).

**POISON** **STANDARD** **STATEMENT**S

ACeTIC ACID A,G3,E2,S1

ACETIC ANHYDRIDE A,G3,E2,S1

ACETONE A,G3

ACROLEIN A,G1,G2,G3,E2,R2,S2

ALKALINE SALTS A,G3,E2,S1

AMINES for use as curing agents A,G3,E1,S1

4-AMINOPYRIDINE A,G1,G2,E1,S1

AMMONIA

• 5 per cent or less A

• above 5 per cent A,G3,E1,R1,S1

AMMONIUM PERSULFATE A,G3,E2

AMMONIUM THIOCYANATE A

ANHYDRIDES, organic acid, for use as   
curing agents for epoxy resins A,G3,E1,S1

ANILINE A,E2,R1,S1

ANISE OIL A,G3

ANITMONY CHLORIDE A,E2,S2

ANTIMONY COMPOUNDS, **except** antimony chloride A

AZADIRACHTA INDICA (neem) including its extracts   
and derivatives when included in Schedule 6. A,E1

BARIUM SALTS, **except** barium sulfate A

BASIL OIL A,G3

BAY OIL A,G3

BENZALKONIUM CHLORIDE

• when included in Schedule 5 A,G3,E2

• when included in Schedule 6 A,G3,E2,S1

BENZENE A,G3,E1,R1,S1

1,2-BENZENEDIOL (Catechol) A,E1,S1

BENZOYL PEROXIDE

• above 20 per cent A,E2,S1

• above 10 per cent up to 20 per cent A,E1

• 10 per cent or less A

BERGAMOT OIL A,G3

BIFLUORIDES   
(including ammonium, potassium and sodium salts)

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

BORAX A

BORIC ACID A

BORON TRIFLUORIDE

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

BROMOFORM A,G3,E2,R1,S2

BRUCINE A,G1,G2,G3,R2

2-BUTOXYETHANOL and its acetates A,E2,S1

CADMIUM COMPOUNDS A

CAJUPUT OIL A,G3

CAMPHOR A,G1,G3,G5

CARBAMIDE PEROXIDE

• more than 9 per cent up to 60 per cent A,G3,E2,S1

• more than 60 per cent A,G1,G3,G4,E2,S1

CARBON DISULFIDE A,G3,E2,R1,S2

CARBON TETRACHLORIDE A,G3,E1,R1,S1

CASSIA OIL A,G3

CHLORINATING COMPOUNDS, **except** when   
separately specified, containing

• above 4 per cent and below 10 per cent   
 of available chlorine A,G3,E1,S1

• 10 per cent or more of available chlorine A,G3,E2,S1

CHLORIDE (gas) A,E1,R1

CHLOROCRESOL A,G3,E2,S2

CHLOROFORM A,G3,E1,R1,S1

CHROMATES A,G3,E2,S1

CHROMIUM TRIOXIDE A,G3,E2,S1

CINEOLE A,G1,G3

CINNAMON BARK OIL A,G3

CINNAMON LEAF OIL A,G3

CLIMBAZOLE A

CLOVE OIL A,G1,G3,E2

COCOYL GLYCINATE E1

COPPER SULFATE A,G3,E2,S1

CREOSOTE A,G3,E2,S1

CRESOLS A,G3,E2,S3

CRESOLS in pressurised spray packs A,G6,E1,S1

CYANIDES A,G1,E1,R2

CYANOACRYLIC ACID ESTERS A

CYANURIC ACID A

CYCLOHEXANONE PEROXIDE A,G3,E2,S1

CYCTEAMINE E1

ortho-DICHLOROBENZENE A,G3,E1,S1

para-DICHLOROBENZENE (PDB) A

DICHLOROETHYL ETHER A,G3,E1,R1,S1

DICHLOROISOCYANURATES A,G3,E1,S1

DICHLOROMETHANE (methylene chloride) A,G3,G5,E1,R1,S1

• in pressurised spray packs A,G6,S1

DICHROMATES A,G1,G3,E2,S1

DIDECYLDIMETHYLAMMONIUM SALTS A,G3

DIESEL (distillate) A,G3

DIETHANOLAMINE

• when included in Schedule 5 A,G3

• when included in Schedule 6 A,G3,E2,S1

5,6-DIHYDROXYINDOLINE E1

DIMETHYLFORMAMIDE

• less than 75 per cent A

• 75 per cent or more A,E1,R1,S1

DIMETHYL SULFOXIDE A,G3,E1,S1

DINITROCRESOLS A,G1,E1,S1

DINITROPHENOLS A,G1,E1,S1

DIOXANE A,G3,E1,R1,S1

DISTILLATE A,G3

N-(N-Dodecyl)-2-pyrrolidone

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

EPOXY RESINS liquid A,G3,E2,S1

Essential oils containing CAMPHOR as natural   
component unless otherwise specified. A,G3

ETHANOLAMINE

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

ETHER A,G3,E1,R1

ETHYL BROMIDE A,E2,S1,R1

ETHYLENE GLYCOL A

Ethylene glycol monoalkyl ethers and their   
acetates, **except** when separately specified A,G3,E2,S1

ETHYLENE OXIDE A,E2,R1

EUCALYPTUS OIL A,G1,G3

EUGENOL A,G1,G3,E2

FLUORIDE **except** when separately specified

• when included in Schedule 5 A

• when included in Schedule 6 A,G1,G3,E2,S1

FORMALDEHYDE (see also paraformaldehyde) A,G3,E2,R1,S1

FORMIC ACID A,G3,E2,S1

FURFURAL A,E1,S1

GLUTARALDEHYDE

• below 5 per cent A,G3,E1

• 5 per cent or more A,G3,E2,S1

GLYCOLIC ACID A,G3,E2

GUANIDINE when included in Schedule 6 A,G3,E2,S1

HEXACHLOROPHANE when included in Schedule 6 A

HEXYLOXYETHANOL A,G3,E2,S1

HYDRAZINE A,G1,G3,E2,R1,S1

HYDROCARBONS, liquid A,G3

HYDROCHLORIC ACID A,G3,E2,S1

• when included in Schedule 5 A,G3

Hydrofluoric acid and admixtures that   
generate hydrofluoric acid

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

HYDROGEN PEROXIDE

• more than 3 per cent up to 20 per cent A,G3,E2,S1

• more than 20 per cent A,G1,G3,G4,E2,S1

HYDROQUINONE

• when included in Schedule 2 A

• when included in Schedule 4 or 6 A,G2,G3,E2,R2,S1

HYDROSILICOFLUORIC ACID

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

IODINE (excluding salts, derivatives and iodophors)

• 2.5 per cent or more for human external use A,E2

• 2.5 per cent or more for other uses A,E2,S1

• below 2.5 per cent A

IODOPHORS A

ISOCYANATES, free organic A,E2,S1

ISOPHORONE A,G3,E2,S1

KEROSENE A,G3

LAURETH CARBOXYLIC ACIDS

• leave-on or wash-off preparations above 5 per cent E1

• other preparations above 5 per cent E1,S1

LAURYL ISOQUINOLINIUM BROMIDE A,E1

LEAD COMPOUNDS

• in hair cosmetics A

• in other preparations A,S1

LEMON OIL A,G3

*Leptospermum scoparium* oil (manuka oil) A,G1,G3

LIME OIL A,G3

MAGNESIUM CHLORATE A

MALATHION at 20 per cent or less A

MARJORAM OIL A,G3

MELALEUCA OIL A,G1,G3

MERURIC CHLORIDE

• for external therapeutic use A

• for other uses A,G1,G3,E2,R2,S1

MERCURIC IODIDE A,G1,G3,E2,R2,S1

MERCURIC NIRATE A,G1,G3,E2,R2,S1

MERCURIC OXIDE A,G1,G3

MERCURIC POTASSIUM IODIDE A,G1,G3,E2,R2,S1

MERCURIC THIOCYANATE A,G1,G3,E2,R2,S1

MERCUROCHROME A

MERCUROUS CHLORIDE A

MERCURY metallic A

MERCURY, organic compounds A,S1

• in preparations for human external use A

METALDEHYDE A,E1,S1

METHANOL

• above 10 per cent A,G3

• 10 per cent or less A

METHYLATED SPIRIT A,G3

METHYL ETHYL KETONE A,G3

METHYL ETHYL KETONE OXIME A,E1,S1

METHYL ETHYL KETONE PEROXIDE A,G3,E2,S1

METHYLEUGENOL A

METHYL ISOAMYL KETONE A,G3

METHYL ISOBUTYL KETONE A,G3

N-METHYL-2-PYRROLIDONE

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2

Methyl salicylate liquid when included   
in Schedule 5 or 6 A,G3,E1

NAPHTHALENE A,G1,G3

NITRIC ACID A,G3,E2,S1

NITROBENZENE A,G3,E1,S1

NITROPHENOL A,G3,E2,S1

NITROPRUSSIDES

• in aerosols A,G6,R1

• in other preparations A,G3

NONOXINOL 9 A,E2

NUTMEG OIL A,G3

2-Octyl-4-isothiazolin-3-one (Ocithilinone) A,G3,E2,S1

N-(N-Octyl)-2-pyrrolidone

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2

ORANGE OIL (bitter) A,G3

OXALIC ACID A,G3,E2,S1

PARAFORMALDEHYDE A,G3,E2,R1,S1

PENNYROYAL OIL A,G3

PERACETIC ACID

• when included in Schedule 5 A,G3,E1,S1

• when included in Schedule 6 A,G3,E2,S1

PETROL A,G3,R1

2-PHENOXYETHANOL A, E1

PHENOLS

• 25 per cent and less A,G3,E2,S3

• above 25 per cent A,G3,E2,S4

PEHNOLS in pressurised spray packs A,E1

Phenylenediamines and   
alkylated phenylenediamines

• in hair dyes A,E1

• in other preparations A,G1,G3,E1,S1

PHENYL METHYL KETONE

• as such, or in preparations of similar viscosity A,G3,E1

N,N-bis(phenylmethylene)-bicyclo  
-(2.2.1)heptane-2,5-dimethanamine A,E2,S1

N,N-bis(phenylmethylene)-bicyclo-  
(2.2.1)heptane-2,6-dimethanamine A,E2,S1

ortho-PHENYLPHENOL A,G3,E2,S1

• in pressurised spray packs A,G6,E2,S1

PHOSPHONIC ACID A,G3,E2,S1

• neutralised to pH 6 (approx) A

• in spray packs A,E2,S1

PHOSPHORIC ACID A,G3,E2,S1

PHOSPHORUS, yellow A,G1,G3,E2,R2,S2

ortho-PHTHALALDEHYDE

• when included in Schedule 5 A,E1

• when included in Schedule 6 A,G3,E2,S1

PICRIC ACID A,G1,G3,E2,R1,S1

Polyethanoxy (15) tallow amine A,E2,S1

Poly(oxy-1,2-ethanediyl), α -  
[2-[(2-hydroxyethyl)amino]-2-  
oxoethyl]- α -hydroxy-,mono-C13-15-alkyl ethers A,E1

POTASIUM BROMATE A

POTASIUM CHLORATE A

POTASSIUM CYANATE A,E1,S1

POTASSIUM HYDROXIDE A,G3,E2,S1

POTASSIUM METABISULPHITE A

POTASSIUM NITRITE

• when included in Schedule 7 A,G1,G3

• when included in Schedule 5 or 6 A,G3

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

POTASSIUM PERSULFATE A,G3,E2

POTASSIUM SULFIDE A,G3,E2,S1

PROPIONIC ACID A,G3,E1,S1

d-PULEGONE A,G3

PYRITHIONE ZINC A,E1

QUATERNARY AMMONIUM COMPOUDS**Error! Bookmark not defined.** **except**

when separately specified

• above 20 per cent A,G3,E2

• 20 per cent and below A,E2

• in pressurised spray packs A,E2,G6

SALFROLE A,G1,G3

SAGE OIL (Dalmatian) A,G3

SASSAFRAS OIL A,G1,G3

SELENIUM COMPOUNDS A,G1,E1,S1

SILICOFLUORIDES

• when included in Schedule 5 A

• when included in Schedule 6 A,G1,G3,E2,S1

SILVER SALTS A,E2

SODIUM ALUMINATE A,G3,E2,S1

SODIUM BROMATE A,G1

SODIUM CHLORATE A

SODIUM DIACETATE A,G3,E2,S1

SODIUM DICHLOROISOCYANURATE A,G3,E1,S1

SODIUM DODECYLBENZENE SULFONATE A,G3,E2,S1

SODIUM HYDROGEN SULFATE A,G3,E1,S1

SODIUMHYDROSULFITE A,G3,E2,S1

SODIUM HYDROXIDE A,G3,E2,S1

SODIUM LAURETH-6 CABOXYLATE A

SODIUM LAURYL SULFATE

• leave-on or wash-off preparations above 5 per cent E1

• other preparations above 5 per cent E1,S1

SODIUM METABISULPHITE A, G3

SODIUM NITRITE

• when included in Schedule 7 A,G1,G3

• when included in Schedule 5 or 6 A,G3

SODIUM PRECARBONATE

• when included in Schedule 5 A,G3,S1

• when included in Schedule 6 A,G3,E2,S1

SODIUM PERSULFATE A,G3,E2

SODIUM STANNATE A,E1

SODIUM SULFIDE A,G3,E2,S1

SODIUM TRICHLOROACETATE A

STRCHNINE A,G1,G2,G3,R2

STYRENE A,G3,S1,E1

SULCOFURON A

SULFAMIC ACID A,G3,E2,S1

SULFURIC ACID A,G3,E2,S1

TERPENES, chlorinated A,G3

TETRACHLOROETHANE A,G3,E1,R1,S1

TETRACHLOROETHYLENE A,G3,E2,R1,S1

THIOUREA A

THUJONE A,G3

THYME OIL A,G3

ortho-TOLIDINE A

TOLUENE

• above 75 per cent A,G3,E1,R1,S1

• 75 per cent and below A,G3

• in pressurised spray packs A

TOLUENEDIAMINE

• in hair dyes A,E1

• in other preparations A,G1,G3,E1,S1

TRICHLOROACETIC ACID A,G3,E2,S1

Trichloroacetic acid alkali salts A

1,1,1-TRICHLOROETHANE A,G3,E1,R1,S1

TRICHLOROETHYLENE A,G3,E1,R1,S1

TRICHLOROISOCYANURIC ACID A,G3,E1,S1

TRIETHANOLAMINE A,G3,E1,S1

TRIETHYL PHOSPHATE A,E1

TRIFLUOROMETHANESULFONIC ACID A,G3,E2

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE A,E1,S1

TURPENTINE (mineral) A,G3

TURPENTINE OIL (vegetable) A,G3,E2

WHITE SPIRIT A,G3

XYLENE

• above 75 per cent A,G3,E1,R1,S1

• 75 per cent and below A,G3

• in pressurised spray packs A,G6,E1,S1

XYLENOLS A,G3,E2,S3

• in pressurised spray packs A,E1

ZINC CHLORIDE A,G3,E2,S1

ZINC SULFATE A,G3,E2,S1

## APPENDIX F

## WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS

(other than agricultural and veterinary chemicals (including pesticides) registered by the

Australian Pesticides and Veterinary Medicines Authority and medicines for human use

when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*)

**INTRODUCTION**

**Warning Statements and Safety Directions**

It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.

Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. The following code has been prepared as a guide for this purpose.

The wording of warning statements and safety directions specified in this Appendix may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.

**Poisons Information Centre Telephone Numbers**

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

**APPENDIX F**

**PART 1**

**WARNING STATEMENTS**

1. Highly corrosive.

2. Corrosive.

3. Corrosive liquid.

4. Strongly alkaline.

5. Irritant.

6. May cause cancer.

7. WARNING − Causes birth defects.

8. WARNING − May be fatal to children.

9. Can be fatal to children if sucked or swallowed.

10. May produce severe burns.

11. WARNING − Vapour may be harmful.

12. Vapour is harmful to health on prolonged exposure.

13. May be fatal if inhaled, swallowed or absorbed through skin.

14. Dust will irritate and burn eyes, nose and skin.

15. Liquid will cause burns.

16. Forms dangerous gas near radiators or naked flames.

17. Contact with eyes even for short periods can cause blindness.

18. Product will irritate the eyes, nose, throat and skin.

19. WARNING − Skin contact may be dangerous. Take every precaution to avoid contact - wash off after spillage and after use.

20. May give off dangerous gas if mixed with other products.

21. WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

22. Highly reactive oxidising chlorine compound.

23. May cause fire or explosion.

24. For external washing only. Rinse skin thoroughly after use.

25. Do not use on broken skin. Wash hands thoroughly after use.

26. (Powder) (and) (concentrated solutions) are dangerous if swallowed.

27. Not for therapeutic use.

28. (Over) (Repeated) exposure may cause sensitisation.

29. If congestion persists, consult your doctor or pharmacist.

30. WARNING − Do not use on face or on anal or genital areas.

31. WARNING − Do not use on face or on anal or genital areas except on doctor’s advice.

32. This preparation should be part of an overall treatment plan regularly assessed with your doctor.

33. Do not take for periods longer than four weeks except on medical advice.

34. WARNING − This medication may be dangerous when used in large amounts or for a long time (period).

35. CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.

or

CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.

36. For use under medical supervision only.

37. Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.

38. CAUTION − Do not use for children under 2 years old unless a doctor has told you to.

39. This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.

40. This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.

41. Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.

42. WARNING − Overuse may stain the skin or mouth.

43. Use of this product is not necessary in areas supplied with fluoridated water.

44. WARNING − May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.

45. WARNING − If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice.

46. WARNING − Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).

47. WARNING − This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

48. WARNING − This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

49. WARNING − Do not mix with other medication except on veterinarian’s advice.

50. Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.

51. Irritant to skin, eyes, mucous membranes and upper respiratory tract.

52. Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.

53. CAUTION − (Name of substance) should not be used by pregnant women.

54. Seek medical advice before first course of treatment.

55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.

56. WARNING − Can cause elevated blood pressure and interact adversely with other medication.

57. Not to be applied to infants under 12 months of age unless on doctor’s advice.

58. Highly reactive oxidising bromine and chlorine compound.

59. May cause allergy.

60. Do not mix with detergents or other chemicals.

61. WARNING − Can react with other medicines. Ask your doctor or pharmacist before taking.

62. Do not use if pregnant.

63. See a doctor if you are pregnant or diabetic.

64. See a doctor (or) *(dentist)* if no better after (Insert number of days as per approved Product Information) days.

65. If getting better, keep using for (Insert number of days as per approved Product Information ) days.

66. See a doctor if problem returns.

67. Do not use if pregnant or likely to become pregnant.

68. If symptoms persist beyond 5 days consult a doctor (or) *(dentist)*.

69. If symptoms recur within two weeks of completing the course, consult a doctor.

70. Use only under medical supervision if you are taking other medicines.

71. Do not use during the last three months of pregnancy.

72. Do not use in the eyes.

73. Do not use for acne.

74. Do not use under waterproof bandages unless a doctor has told you to.

75. Do not use for more than 7 days unless a doctor has told you to.

76. Do not become pregnant during use or within (*Insert number of months as per approved Product Information*) month(s) of stopping treatment.

77. WARNING − May cause birth defects.

78. Attacks skin and eyes.

79. Will irritate eyes.

80. (Intentionally blank)

81. (Intentionally blank)

82. (Intentionally blank)

83. This paint is dangerous to health, even when dry.

For industrial use only.

Do not use on toys or furniture.

Do not use on, in or around the home.

84. Breathing the vapour is dangerous.

Provide adequate ventilation during application.

Do not use in the presence of a naked flame.

Do not smoke.

85. This paint contains lead and is dangerous to health, even when dry.

For industrial use only.

Do not use on toys or furniture.

Do not use for painting any building or fixed structure.

Do not use where contact with food or drinking water is possible.

86. This tinter contains lead.

Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.

87. (*Insert brand name*) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.

88. This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.

89. Application to skin may increase sensitivity to sunlight.

90. This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.

91. CAUTION − Total iodine intake may exceed recommended level when taking this preparation.

92. WARNING − Contains iodine - do not take when pregnant **except** on physician’s advice.

93. Causes severe burns, which are not likely to be immediately painful or visible.

94. WARNING − Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.

95.CAUTION − Do not use for children under 12 years old unless a doctor has told you to.

96. CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.

97*. Adults:* Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.

98. *Children and adolescents:* Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.

99. If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New  Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.

100. Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.

101. Don’t use [this product/name of the product]:  
If you have a stomach ulcer

In the last 3 months of pregnancy *[This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]*

If you are allergic to (name of substance) or anti-inflammatory medicines.

102. Unless a doctor has told you to, don’t use [*this prouct/name of the product*]:

For more than a few days at a time

With other medicines containing aspirin or other anti-inflammatory medicines

If you have asthma

In children under 12 years of age

In children 12-16 years of age with or recovering from chicken pox, influenza or fever

If you are pregnant.

103. See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [*This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients*.]

104. Unless a doctor has told you to, don’t use [this product/name of the product]:

For more than a few days at a time

With other medicines containing (name of substance) or other anti-inflammatory medicines

If you have asthma

If you are pregnant *[This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea]*.

105. Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.

106. Contains formaldehyde.

**APPENDIX F**

**PART 2**

**SAFETY DIRECTIONS - GENERAL**

To be grouped together and prefaced with the words “SAFETY DIRECTIONS” (see Part 2, Labels and Containers, subparagraph 7(n) to this Standard).

1. Avoid contact with eyes.

2. Attacks eyes − protect eyes when using.

3. Wear eye protection when mixing or using.

4. Avoid contact with skin.

5. Wear protective gloves when mixing or using.

6. Wash hands after use.

7. Wash hands thoroughly after use.

8. Avoid breathing dust (or) vapour (or) spray mist.

9. Use only in well ventilated area.

10. Ensure adequate ventilation when using.

11. No smoking.

12. Do not allow product to come into contact with other chemicals, especially acids.

13. Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.

14. Do not allow to get damp.

15. Store under cover in a dry, clean, cool, well ventilated place away from sunlight.

16. Store and transport in an upright container.

17. Do not mix with other chemicals.

18. Do not mix with different types of chlorinating chemicals.

19. Use clean containers for dispensing.

20. Mix with water only.

21. Do not add water to product − add product to water, but in case of fire drench with water.

22. In case of spillage flush with large quantities of water.

23. Keep away from heat, sparks and naked flames.

24. Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.

25. Avoid contact with food.

26. Avoid contact with clothing.

27. Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed.

28. Do not mix with hot water.

29. Obtain a supply of calcium gluconate gel.

30. (Intentionally blank.)

31. Do not use on broken skin.

32. Do not use under occlusive dressing.

33. Mix strictly according to instructions.

34. May cause fire if it comes into contact with other chemicals, paper or other flammable materials.

35. Wash gloves thoroughly, immediately after use.

36. Protect cuticles with grease or oil.

**APPENDIX F**

**PART 3**

**POISONS (other than agricultural and veterinary chemicals)   
TO BE LABELLED WITH WARNING STATEMENTS**

**OR SAFETY DIRECTIONS**

(Where more than one statement or direction is required, they may be combined to form simple sentences where appropriate.)

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**WARNING SAFETY**

**POISON** **STATEMENTS DIRECTION**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

ACETIC ACID in concentrations of 80 per cent 2 1,4,8

or more **except** when in Schedule 2.

ACETIC ANHYDRIDE 2 1,4,8

ACETONE in concentrations greater than 75 per cent. 1,4,8

ACITRETIN 7,62,76

ADAPALENE for topical use. 62,77

ALCLOMETASONE when included in Schedule 3. 38,72,73,74,75

ALKALINE SALTS 4 1,4

AMBRISENTAN 7,62,76

AMINES used as curing agentsfor epoxy resins. 1,3,4,5,8

AMMONIA/AMMONIUM HYDROXIDE in concentrations 4 1,4,8

greater than 20 per cent ammonia **except**

in smelling salts.

AMMONIUM PERSULFATE 5,21,25 1,5,23,33,34

ANHYDRIDES, organic acid, for use as curing agents 1,3,4,5,8

for epoxy resins.

ANILINE 13 1,4,8

ANTIHISTAMINES not separately specified 39 or 40

in this Appendix **except**:

(a) dermal, ocular, parenteral and   
paediatric preparations;

(b) oral preparations of astemizole,

desloratadine, fexofenadine,

loratadine or terfenadine;

(c) nasal preparations of azelastine; or

(d) preparations for the treatment of animals.

AROMATIC EXTRACT OILS 1,3,4,5,6

ASPIRIN

(a) for inhibition of platelet aggregation. 36

(b) in sustained release preparations 36  
containing 650 mg or more of aspirin.

(c) in other preparations. 101,102,103

ASTEMIZOLE 61

Azadirachta indica including its extracts  
and derivatives when included in Schedule 6. 67

AZOCYCLOTIN 48

BENOMYL 46

BENZENE 12 1,4,9

1,2-BENZENEDIOL (Catechol) 51,59 1,4,8

BENZOYL PEROXIDE when included in Schedule 2. 55

BENZOYL PEROXIDE when included in Schedule 5. 1,4,8

BERGAMOT OIL 89

BERYLLIUM 1,4,8

BEXAROTENE

(a) for human use. 7,62,76

(b) for topical use. 62,77

BIFLUORIDES (including ammonium, potassium and sodium salts)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

BITHIONOL for the treatment of animals. 1,4,8

BORON TRIFLUORIDE (including mixtures that

generate boron trifluoride)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

BOSENTAN 7,62,76

BROMOFORM 1,4,8

2-Butoxy-2’-thiocyanodiethyl ether 1,4,8

2-Butoxyethanol and its acetates 1,4,8

CAMPHOR

(a) in block, ball, disc, pellet or flake form, 9

enclosed in a device which, in normal use,

prevents removal or ingestion of its contents.

(b) in other forms. 9 1

CARAMIDE PEROXIDE

(a) more than 9 per cent up to 30 per cent. 5 1

(b) more than 30 per cent up to 60 per cent. 5 2

(c) more than 60 per cent. 2 2,4

CARBON DISULFIDE 12 1,4,8,9,23

CARBON TETRACHLORIDE 12 1,4,8,9

CASSIA OIL 4

CHLORINATING COMPOUNDS

(a) in household cleaning or bleaching 20

preparations.

(b) in preparations containing less than 11 1,4,10

10 per cent of available chlorine.

(c) in liquid preparations containing 3,18 1,4,6,8,10, 15,16,

10 per cent or more of available chlorine. 17,18, 19,20,22,26

(d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,

or more of available chlorine. 14,15,16,17, 18,

19,20,21, 22,26

(e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13,  
 or more of available chlorine certified by a 14,15,16,17,  
 relevant State or Territory authority as not 18,19,20,21,  
 being a Dangerous Good of Class 5, 22,26  
 Division 5.1:Oxidising substances, as

specified inthe *Australian Code for the*

*Transport of Dangerous Goods by Road*

*and Rail.*

(f) in compressed block or tablets containing 10,22,23 12,13,14,15,  
 10 per cent or more of available chlorine 17,18,19,21  
 **except** in preparations for use in toilet   
 cisterns only, containing 15 g or less of

trichloroisocyanuric acid.

(g) in other compressed blocks or tablets 10,22 12,13,14,15,

containing 10 per cent or more of available 17,18,19,21

chlorine certified by a relevant State or

Territory authority as not being a Dangerous

Good of Class 5, Division 5.1: Oxidising

substances, as specified inthe *Australian*

*Code for the Transport of Dangerous Goods*

*by Road and Rail* **except** in preparations for

use in toilet cisterns only, containing 15 g or

less of trichloroisocyanuric acid.

CHLOROFORM when included in Schedule 6 1,4,8

alpha-CHLOROHYDRIN 13,51 1,4,8,9

CHROMATES (including dichromates) of alkali metals or ammonia 1,4,8

CHROMIUM TRIOXIDE 2,14,15,23 1,4,8,13

CIMETIDINE when included in Schedule 3 70,96

CINNAMON BARK OIL 4

CLOBETASONE when included in Schedule 3. 72,73,74,75,95

CLOTRIMAZOLE in vaginal preparations when included 54,63,64,66

in Schedule 3.

CLOVE OIL 1

CYANIDES when included in Schedule 7. 13 4,8

CYANURIC ACID 1,4,8

CYCLOHEXANONE PEROXIDE 1,4,8

CYCTEAMINE 1

4,4-Diaminodiphenylmethane (methylene dianiline) 1,4,8

ortho-DICHLOROBENZENE 1,4,8

para-DICHLOROBENZENE 1,4

DICHLOROETHYLENE 1,4,8

DICHLOEOETHYL ETHER 1,4,8

DICHLOROISOCYANURATES

(a) in household cleaning or bleaching 20  
 preparations.

(b) in preparations containing less than 11 1,4,10  
 10 per cent of available chlorine. .

(c) in liquid preparations containing 10 per cent 3,18 1,4,6,8,10,  
 or more of available chlorine. 15,16,17,18,  
 . 19,20,22,26

(d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,14,  
 or more of available chlorine. 15,16,17,18,19,  
 . 20,21,22,26

(e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13,14,

or more of available chlorine certified by a 15,16,17,18,19,

relevant State or Territory authority as not 20,21,22,26

being a Dangerous Good of Class 5,

Division 5.1: Oxidising substances, as

specified in*the Australian Code for the*

*Transport of Dangerous Goods by Road*

*and Rail.*

(f) in anti-bacterial tablets containing 2.5 g or 60  
 less of sodium dichloroisocyanurate..

(g) in other compressed blocks or tablets containing 10,22,23 12,13,14,15,  
 10 per cent or more of available chlorine **except** 17,18,19,21  
 in preparations containing 21 g or less of sodium

dichloroisocyanurate for use in toilet cisterns only.

(h) in other compressed blocks or tablets containing 10,22 12,13,14,15,17,

10 per cent or more of available chlorine 18,19,21

certified by a relevant State or Territory authority

as not being a Dangerous Good of Class 5,

Division 5.1: Oxidising substances, as specified

in*the Australian Code for the Transport of*

*Dangerous Goods by Road and Rail* **except** in

preparations containing 21 g less of sodium

dichloroisocyanurate for use in toilet cisterns only.

(i) in other compressed blocks or tablets containing

10 per cent or more of available chlorine in

preparations containing 5 g or less of sodium

dichloroisocyanurate for use in toilet bowls only:

(i) during storage 10,22,23 12,13,14,15,17,

18,21

(ii) during use 5 1,4,7,12

(j) in other compressed blocks or tablets containing

10 per cent or more of available chlorine certified

by a relevant State or Territory authority as not

being a Dangerous Good of Class 5, Division 5.1:

Oxidising substances, as specified inthe

*Australian Code for the Transport of Dangerous*

*Goods by Road and Rail* in preparations

containing 5 g or less of sodium dichloroisocyanurate

for use in toilet bowls only.

(i) during storage 10,22 12,13,14,15,17,

18,21

(ii) during use 5 1,4,7,12

DICHLORMETHANE (methylene chloride)

(a) in paint or lacquer removers. 12,16 1,4,8,11

(b) other than in paint or lacquer removers 1,4,8,25

DICLOFENAC 101,104

DIENESTROL 67

DIETHANOLAMINE when included in Schedule 5. 5 1,4

DIETHANOLAMINE when included in Schedule 6. 2,11,18 1,4,8

DIETHYLTOLUAMIDE for human use. 44

5,6-DIHYDROXYINDOLINE 21,28

DIMETHYLFORMAMIDE 1,4,8

DIMETHYL SULFATE 2 1,4,8

DIMETHYL SULFOXIDE

(a) when not packed and labelled for therapeutic use. 27 1,4,5,8

(b) when packed and labelled for treatment of animals. 49 1,4,5,8

DINITROCRESOLS (and their homologues) **except** when for 1,4,8

therapeutic use.

DINITROPHENOLS (and their homologues) **except** when 1,4,8

for therapeutic use.

DINOCAP 47

DIOXANE 1,4,8

DIPHENOXYLATE when included in Schedule 3. 39 or 40,41

ECONAZOLE in vaginal preparations when included 54,63,64,66

in Schedule 3.

EPHEDRINE in nasal preparations for topical use. 29

EPICHLOROHYDRIN 2 1,4,8

EPOXY RESINS, liquid. 1,3,4,5,8

ETHANOLAMINE when included in Schedule 5. 5 1,4

ETHANOLAMINE when included in Schedule 6. 2,11,18 1,4,8

ETHER when included in Schedule 5 or 6. 1,4,8

ETHOXYETHYLMERCURIC CHLORIDE 1,4

ETHYL BROMIDE 1,4,8

ETHYLENE CHLOROHYDRIN 1,4,8

Ethylene glycol monoalkyl ethers and their acetates 1,4,8

except when separately specified.

ETHYLENE OXIDE 1,4,8

ETHYLMERCURIC CHLORIDE 1,4

ETHYL METHACRYLATE 28 4,9,23

ETRETINATE 7,62,76

EUGENOL 1

FAMOTIDINE when included in Schedule 2. 96

FENTEROL in metered aerosols. 32

FLUCONAZOLE in oral preparations when included in 64   
Schedule 3.

FLUORIDES (including silicofluorides) when included in 1,4

Schedule 5 or 6 **except** when separately specified.

FORMALDEHYDE

(a) in nail hardener cosmetics. 106 1,4,8,36

(b) in other preparations. 106 1,4,8

FORMIC ACID 1,4,8

FURFURAL 5 1,4

Glazing preparations containing LEAD COMPOUNDS. 50

GLUTARALDEHYDE **except** when in Schedule 2

(a) 25 per cent or less. 5,59 1,4,5

(b) more than 25 per cent. 3,59 1,4,5,8

GLYCOLIC ACID 79 1,5,6,31

HEXACHLOROPHANE in preparations for skin cleansing 24

purposes containing 3 per cent or less of

hexachlorophane.

HEXLOXYETHANOL 2 1,4,8

HYDRAZINE 1,4,8

HYDROCLORIC ACID

(a) 30 per cent or less of HCl. 1,4

(b) more than 30 per cent of HCl. 1,4,8

HYDROCORTISONE

(a) for dermal use when included in 38,72,73,74,75

Schedule 2 or 3.

(b) for topical rectal use when includeed 38,75

in Schedule 2 or 3.

HYDROCYANIC ACID when included in Schedule 7. 13 4,8

HYDROFLUORIC ACID (including mixtures that generate

hydrofluoric acid)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

HYDROGEN PEROXIDE

(a) more than 3 per cent up to 10 per cent. 5 1

(b) more than 10 per cent up to 20 per cent. 5 2

(c) more than 20 per cent. 2 2,4

HYDROQUINONE

(a) when in Schedule 2. 45

(b) **except** when in Schedule 2 or 4. 1,4

HYDROSILICOFLUORIC ACID (including mixtures

that generate hydrosilicofluoric acid)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

8-HYDROXYQUINOLINE (including salts and 33

derivatives) when prepared for

internal use.

IBUPROFEN 101,104

IODINE

(a) more than 20 per cent. 1,4,8

(b) in preparations for human internal therapeutic 91,92   
 use containing 300 micrograms or more of

iodine per recommended daily dose.

IPRATROPIUM BROMIDE in metered aerosols. 32

ISOCYANATES (free organic)

(a) when in paint. 28,52 1,5,8,10,27

(b) other than in paint. 28,52 1,4,8

ISOPRENALINE in metered aerosols 32

ISOTRETINOIN

(a) for human oral use. 7,62,76

(b) for topical use. 62,77

LEAD COMPOUNDS

(a) in hair cosmetics. 25

(b) when in Schedule 6. 1,4,8

LEFLUNOMIDE 7,62,87

LEMON OIL 89

LENALIDOMIDE 7,62,76

LEVOCABASTINE

(a) in eye or nasal preparations containing 62

0.5 mg/mL or less of levocabastine.

(b) in other preparations. 62 and

either 39 or 40

LIME OIL 89

LOPERAMIDE when in Schedule 2. 41

MAGNESIUM CHLORATE 1,4

MEFENAMIC ACID 101,104

MERCURIC THIOCYANATE 1,4

Metacresolsulphonic acid and formaldehyde 1,4

condensation product for the treatment of animals.

METHANOL **except** in methylated spirit. 1,4,8

METHOXAMINE in nasal preparations for topical use. 29

METHYL CHLORIDE 1,4,8

METHYL ETHYL KETONE 5 1,4,8

METHYL ETHYL KETONE OXIME 5,28 1,4

METHYL ETHYL KETONE PEROXIDE 2 2,3,4,6

Methyl isoamyl ketone 1,4,8

Methyl isobutyl ketone 1,4,8

Methyl isothiocyanate 5,12 1,4,8

Methyl methacrylate 28 4,9,23

METHYLDIBROMO GLUTARONITRILE 28 1,4,7

METHYLENE BISTHIOCYANATE 1,4

METHYLEUGENOL 1,6

METHYLNORBORNYLPYRIDINE 59

1-(beta-Methyl sulphonamidoethyl)- 2-amino-3-

N,N-diethylaminobenzene 1,4,8

MICONAZOLE in vaginal preparations when included 54,63,64,66

in Schedule 3.

MISOPROSTOL 53

NAPHAZOLINE in nasal preparations for topical use. 29

NAPHTHALENE

(a) in block, ball, disc, pellet or flake form, 9,105

enclosed in a device which, in normal

use, prevents removal or ingestion of its

contents.

(b) in other forms. 9,105 1

NAPROXEN 101,104

NICOTINE **except** when in tobacco or when included 1,4  
in Schedule 2.

NITRIC ACID

(a) 75 per cent or less HNO3. 2 1,4

(b) more than 75 per cent HNO3. 2 1,4,8

NITROBENZENE 1,4,8

NITROPHENOLS 1,4

NITROPRUSSIDES in aerosols. 84 8

NIZATIDINE when included in Schedule 2. 96

NORADRENALINE in metered aerosols. 32

NYSTATIN in vaginal preparations when included 54,63,64,65,66

in Schedule 3.

ORANGE OIL (bitter) 89

ORCIPRENALINE in metered aerosols. 32

OXALATES, metallic 4,8

OXALIC ACID 2 4,8

OXYMETAZOLINE in nasal preparations for topical use. 29

PAINT

(a) First Schedule paints. 83

(b) Second Schedule paints. 84

PARACETAMOL 97 and/or 98,99,100

PENTACHLOROPEHNOL 1,4,8

PERACETIC ACID 2 1,4,8

PERMANGANATES 2 24

2-PEHNOXYETHANOL 5 1

PHENOL and any other homologue of phenol. 1,4

PHENOLS 5

Phenylenediamines and alkylated   
phenylenediamines

(a) in hair dyes. 21

(b) in preparations other than hair dyes. 1,4,8

PHENYLEPHRINE in nasal preparations 29

for topical use.

N,N-bis(phenylmethylene)-bicyclo-

(2.2.1)heptane-2,5-dimethanamine 5,28 1,4,5,10

N,N-bis(phenylmethylene)-bicyclo-

(2.2.1)heptane-2,6-dimethanamine 5,28 1,4,5,10

ortho-PHENYLPHENOL **except** when in 1,4

antiseptics.

PHENYLPROPANOLAMINE 56

PHENYTOIN in pastes for the treatment of horses. 9

PHOSPHONIC ACID 1,4

PHOSPHORIC ACID 1,4

PHOSPHORUS (yellow) 2 1,4

ortho-PHTHALADEHYDE

(a) when included in Schedule 5. 51,52,59 1,4,5,8,10

(b) when included in Schedule 6. 51,52,59 2,4,5,8,10

PICRIC ACID (more than 20 per cent). 1,4

PODOPHYLLIN

(a) in preparations specifically for use on 36

anal or genital area.

(b) in other liquid preparations when included 31

in Schedule 2 or Schedule 3.

(c) in other solid or semi-solid preparations 30

when included in Schedule 2.

PODOPHYLLOTOXIN

(a) in preparations specifically for 36

use on anal or genital area.

(b) in other liquid preparations when included 31

in Schedule 2 or Schedule 3.

(c) in other solid or semi-solid preparations 30

when included in Schedule 2.

POLIHEXANIDE 1,4,8

Polyethanoxy (15) tallow amine 1,4

Poly(oxy-1,2-ethanediyl), α -[2-[(2-hydroxyethyl)amino] 5,88 1,5

-2-oxoethyl]- α -hydroxy-,mono-C13-15 -alkyl ethers

POTASSIUM HYDROXIDE

(a) in preparations containing 5 1,4,6  
 0.5 per cent or less of potassium

hydroxide.

(b) in solid preparations containing 2,10,78 3,5,28

more than 0.5 per cent of potassium   
 hydroxide.

(c) in liquid preparations containing 2,10,78 3,5  
 more than 0.5 per cent of potassium   
 hydroxide.

POTASSIUM METABISULPHITE 5,26 1,4

POTASSIUM NITRITE in pickling or curing salts. 94

POTASSIUM PERSULFATE 5,21,25 1,5,23,33,34

POTASSIUM SULFIDE 2 1,4

PROPIONIC ACID when in Schedule 6. 2 1,4

RANITIDINE when included in Schedule 2. 96

SAFROLE

(a) in preparations for therapeutic use. 1

(b) other than for therapeutic use. 1,4

SALBUTAMOL in metered aerosols or in dry 32  
powder formulations.

SALICYLAMIDE 34 or 35

SASSAFRAS OIL

(a) in preparations for therapeutic use. 1

(b) other than for therapeutic use. 1,4

SELENIUM COMPOUNDS **except** when for 1,4,8

therapeutic use (human or animal).

SLIVER in smoking deterrents. 42

SITAXENTAN 7, 62, 76

SODIUM ALUMINATE 2 1,4

SODIUM CHLORATE 1,4

Sodium dodecylbenzene sulfonate 79 1

SODIUM FLUORIDE in preparations for 43

human ingestion when in Schedule 2.

Sodium hydrogen sulfate 1,4,8

Sodium hydrosulfite 5,26 1,4,8

(more than 50 per cent)

SODIUM HYDROXIDE

(a) in preparations containing 0.5 per cent 5 1,4,6  
 or less of sodium hydroxide.

(b) in solid preparations containing more than 2,10,78 3,5,28  
 0.5 per cent of sodium hydroxide.

(c) in liquid preparations containing more than 2,10,78 3,5  
 0.5 per cent of sodium hydroxide.

Sodium laureth-6 carboxylate 79 1

SODIUM METABISULPHITE 5,26 1,4

(more than 50 per cent)

SODIUM NITRITE in pickling or curing salts 94

SODIUM PERSULFATE 5,21,25 1,5,23,33,34

SODIUM SULFIDE 2 1,4

STYRENE 1,4,8

SULFAMIC ACID 2 1,4

SULFURIC ACID 2 1,4

SYMPHYTUM SPP. (Comfrey) when included in Schedule 5. 31,32

TAZAROTENE for topical use. 77,62

TERBUTALINE in metered aerosols or in dry powder formulations. 32

TERFENADINE 61

TERIFLUNOMIDE. 7,62,87

TERPENES, chlorinated 1,4,8

TETRACHLOROETHANE 12 8

TETRACHLOROETHYLENE when in Schedule 5 or 6. 12,16 1,4,8,11

TETRAHYDROZOLINE in nasal preparations for topical use. 29

THALIDOMIDE 7,62,76

THIOUREA 1,4

TOLUENE 1,4,8

TOLUENEDIAMINE

(a) in hair dyes. 21

(b) in preparations other than hair dyes. 1,4,8

TRAMAZOLINE in nasal preparations for topical use. 29

TRETINOIN

(a) for human oral use. 7,62,76

(b) for topical use. 62,77

TRIAMCINOLONE when in topical preparations 64 or 68

for the treatment of mouth ulcers.

TRICHLOROACETIC ACID **except** when for 2 1,4

therapeutic use.

1,1,1-trichloroethane 8,9

TRICHLOROETHYLENE **except** when for 12 1,4,5,8,9  
therapeutic use.

TRICHLOROPHENOL 1,4,8

TRIETHANOLAMINE 5 1,4

TRIETHYL PHOSPHATE 1,4,8

Trifluoromethanesulfonic acid

(a) more than 10 per cent. 1,17 1,4,8

(b) 10 per cent or less. 1,4,8

Triisopropanolamine lauryl ether sulfate 1,4,6

3,6,9-TRIOXAUNDECANEDIOIC ACID 5 1

TYMAZOLINE in nasal preparations for topical use. 29

VINCLOZOLIN 46

XYLENE 1,4,8

XYLOMETAZOLINE in nasal preparations for topical use. 29

ZINC CHLORIDE 1,4

ZINC SULFATE when in Schedule 6. 1,4

## APPENDIX G

## DILUTE PREPARATIONS

The requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix at a concentration not more than that specified in Column 2 in respect of that poison.

**Column 1 Column 2**

**Poison Concentration**

**(quantity per litre**

**or kilogram**)

ACETYLCHOLINE 1 mg

ALDOSTERONE 10 micrograms

ANTIMONY COMPOUNDS 1 mg

APOMORPHINE 1 mg

ARSENIC 1 mg

ATROPA BELLADONNA (belladonna) 300 micrograms

ATROPINE 300 micrograms

CANTHARIDIN 10 micrograms

CHLORINE 5 mg

CROTON TIGLIUM (croton oil) 1 mg

DIOXANE 100 mg

ERYSIMUM spp. 1 mg

FOLLICLE-STIMULATING HORMONE 100 micrograms

GELSEMIUM SEMPERVIRENS 1 mg

GLUCAGON 100 micrograms

GLYCERYL TRINITRATE 100 micrograms

GROWTH HORMONE 10 micrograms

HALOPERIDOL 1 mg

HYDROCYANIC ACID 1 microgram

HYOSCINE 300 micrograms

HYOSCYAMINE 300 micrograms

HYOSCYAMUS NIGER 300 micrograms

HYPOTHALAMIC RELEASING FACTORS 10 micrograms

INDOMETHACIN 1 mg

MERCURY 1 mg

METHYLMERCURY 300 micrograms

NAPHTHALENE 1 mg

NERIUM OLEANDER 1 mg

OESTRADIOL 10 micrograms

OESTRONE 100 micrograms

OXYTOCIN 1 microgram

PHOSPHORUS 1 mg

PODOPHYLLUM RESIN (podophyllin) 1 mg

PROGESTERONE 1 mg

PROPRANOLOL 1 mg

SELENIUM 100 micrograms

STROPHANTHUS spp. 1 mg

STRYCHNINE 1 mg

TESTOSTERONE 1 mg

THYROXINE 10 micrograms

## APPENDIX H

## SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED

BUTOCONAZOLE.

CLOTRIMAZOLE.

DICLOFENAC.

DIMENHYDRINATE for the prevention and relief of motion sickness.

DIPHENOXYLATE.

ECONAZOLE.

FLUCONAZOLE.

HYDROCORTISONE.

MICONAZOLE.

NYSTATIN.

## APPENDIX I

This Appendix is intentionally blank

## APPENDIX J

## CONDITIONS FOR AVAILABILITY AND USE OF SCHEDULE 7 POISONS

**PART 1**

**CONDITIONS FOR AVAILABILITY AND USE**

The following controls are recommended for poisons only when included in Schedule 7. These conditions for availability and use may be implemented through poisons controls or other State or Territory legislation.

1. Not to be available except to authorised or licensed persons.

2. Not to be used in printing inks.

3. Not to be used except by or in accordance with the directions of accredited government vermin control officers.

4. Not to be used in industries which handle, process or store foods, animal feeds or packaging materials.

**APPENDIX J**

PART 2

A poison listed in this Appendix is to be available only in accordance with the conditions specified beside it in the “Conditions” column. The conditions apply only when the poison is included in Schedule 7.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**POISONS CONDITIONS**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

ABAMECTIN 1

ACIBENZOLAR-S-METHYL 1

ACROLEIN 1

ACRYLONITRILE 1

ALACHLOR 1

ALLYL ALCOHOL 1

4-AMINOPYRIDINE 1

ARPINOCID 1

ARSENIC 1

AZOCYCLOTIN 1

BENZENE 1

BIFLUORIDE (including ammonium, potassium and sodium salts) 1

BORON TRIFLUORIDE 1

BRODIFACOUM 1

BROMADIOLENE 1

BROMINE 1

BRUCINE 1

CALCIFEROL 1

CAPTAFOL 1

CARBADOX 1

CARBON TETRACHLORIDE 1

CARBONYL SULFIDE**Error! Bookmark not defined.** 1

CHLORDECONE 1

CHLORDIMEFORM 1

CHLORINE 1

CHLOROMETHIURON 1

CHLOROPRCRIN 1

4-CHLORO-O-TOLURIDINE 1

COLECALCIFEROL 1

COUMATETRALYL 1

CYANOGEN 1

CYCHEXATIN 1

4,4-DIAMINODIPHENYLMETHANE (methylene dianiline) 1

1,2-DIBROMO-3-CHLOROPROPANE 1

1,3-DICHLOROPROPENE 1

DIFENACOUM 1

4-DIMETHYLAMINOAZOBENZENE 1

DINITROCRESOLS 1

DINITROPHENOLS 1

DINOSEB 1

EPICHLOROHYDRIN 1

EPIDERMAL GROWTH FACTOR 1

ETACONAZOLE 1

ETHYLENE DIBROMIDE 1

ETHYLENE OXIDE 1

FLUROACETAMIDE 3

FLUOROACETIC ACID 3

FOLPET 1

HALOFUGINONE 1

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS 1

HCB 1

HYDROCYANIC ACID AND CYANIDES 1

HYDROFLUORIC ACID 1

HYDROSILICOFLUORIC ACID 1

IODOMETHANE 1

MADURAMICIN 1

MERCURY 1

METHACRIFOS 1

METHOXYETHYLMERCURIC ACETATE 1

METHOXYETHYLMERCURIC CHLORIDE 1

METHYL BROMIDE 1

4,4’-METHYLENEBIS[2-CHLOROANILINE] 1

MIREX 1

MOLINATE 1

NICOTINE 1

NITROFEN 1

PHENYLMERCURIC ACETATE 1

PHOSPHIDE, metallic 1

PHOSPHINE 1

PROPYLENE OXIDE 1

PYRINURON 1

STRYCHNINE 1

SULCOFURON 1

TETRACHLOROETHANE 1

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIMIDE 1

THALLIUM 3

ORTHO-TOLIDINE 1

TRICHLOROISOCYANURIC ACID 1

VINYL CHLORIDE 1

## APPENDIX K

## DRUGS REQUIRED TO BE LABELLED

## WITH A SEDATION WARNING

(see Part 2 – Controls on Medicines and Poisons, Section 1 – Labels, subsection 1.5.6)

Alprazolam

Amisulpride

Amitriptyline

Amylobarbitone

Aripiprazole

ASENAPINE

Azatadine

Baclofen

Benztropine

Bromazepam

Brompheniramine

Buclizine

Buprenorphine

Butobarbitone

Cetirizine

Chloral hydrate

Chlordiazepoxide

Chlormethiazole

Chlorpheniramine

Chlorpromazine

Clemastine

Clomipramine

Clonazepam

Clonidine

Clorazepate

Clozapine

Codeine **except** when included in Schedule 2 or 3.

Cyclizine

Cyclobarbitone

Cycloserine

Cyproheptadine

Cysteamine

Dantrolene

Desipramine

Dexchlorpheniramine

Dextromoramide

Dextropropoxyphene

Diazepam

Difenoxin

Dihydrocodeine

Dimenhydrinate

Dimethindene

Diphenhydramine

Diphenoxylate

Diphenylpyraline

Dothiepin

Doxepin

Doxylamine

Dronabinol (*delta*-9-tetrahydrocannabinol)

Droperidol

Duloxetine

Ethylmorphine

Fenfluramine

Flunitrazepam

Flupenthixol

Fluphenazine

Flurazepam

Gabapentin

Gemcitabine

Glutethimide

Haloperidol

Hydrocodone

Hydromorphone

Hydroxyzine

Imipramine

Lamotrigine

Levetiracetam

Levocabastine

Lorazepam

LURASIDONE.

Mazindol

Mebhydrolin

Meclozine

Medazepam

Meprobamate

Mepyramine

Methadone

Methdilazine

Methocarbamol

Methylphenobarbitone

Mianserin

Mirtazapine

Morphine

NABIXIMOLS .

Nalbuphine

Nitrazepam

Normethadone

Nortriptyline

Olanzapine

Opium in any form **except** the alkaloids noscapine and papaverine.

Oxazepam

Oxycodone

Paliperidone

Papaveretum

Pentazocine

Pentobarbitone

PERAMPANEL

Pericyazine

Perphenazine

Pethidine

Phenelzine

Pheniramine

Phenobarbitone

Phenoperidine

Phenyltoloxamine

Pholcodine

Pimozide

Pizotifen

Prazepam

Pregabalin

Prochlorperazine

Promazine

Promethazine

Protriptyline

Quetiapine

Quinalbarbitone

RETIGABINE

Risperidone

Rotigotine

RUPATADINE

Secbutobarbitone

suvorexant

TAPENTADOL

Temazepam

Thenyldiamine

Thiethylperazine

Thiopropazate

Thioridazine

Thiothixene

Tramadol

Tranylcypromine

Trifluoperazine

Trimeprazine

Trimipramine

Triprolidine

Ziprasidone

Zolpidem

Zonisamide

Zopiclone

## APPENDIX L

## REQUIREMENTS FOR DISPENSING LABELS FOR

## HUMAN AND VETERINARY MEDICINES

**PART 1**

**GENERAL REQUIREMENTS FOR DISPENSING LABELS**

(see Part 2, Labels and Containers, subparagraph 14(1))

(1) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 millimetres in height.

(2) All symbols, numbers and words on a label must be in durable characters.

(3) The label on a container of a substance for therapeutic use must contain the following details:

(a) the name, address and telephone number of the dispenser supplying the substance;

(b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);

(c) adequate directions for use;

(d) the strength and form of the substance;

(e) the total quantity of the goods in the container;

(f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;

(g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;

(h) if the substance is a medicine, the name of the person for whom it was dispensed; and

(i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.

(4) The label on a container of a medicine or veterinary chemical that is supplied on prescription must also include:

(a) the prescription reference number;

(b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and

(c) the directions for use set out in the prescription.

**APPENDIX L**

**PART 2**

**ADDITIONAL LABELLING REQUIREMENTS FOR CERTAIN HUMAN MEDICINES**

(see Part 2, Labels and Containers, subparagraph 14(2))

Medicines required to be labelled with certain warning statements A substance listed in Column 1 of the following table must be labelled with the warning statement in Appendix F, Part 1, as specified opposite in Column 2.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Column 1 Column 2**

**Substance Warning statement**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

ACITRETIN:

1. for oral use. 7,62 and 76
2. for topical use. 62 and 77

ADAPALENE:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

AMBRISENTAN. 7, 62 and 76

BEXAROTENE:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

BOSENTAN. 7, 62 and 76

DIENESTROL. 67

ETRETINATE:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

FINGOLIMOD. 76

ISOTRETINOIN:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

LEFLUNOMIDE. 7, 62 and 76

LENALIDOMIDE:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

LEVOCABASTINE. 62

MACITENTAN. 7, 62 and 76

MISOPROSTOL. 53

RIOCIGUAT. 7, 62 and 76

SITAXENTAN. 7, 62 and 76

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Column 1 Column 2**

**Substance Warning statement**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

TERIFLUOMIDE. 7, 62 and 87

THALIDOMIDE:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

TRETINOIN:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

**INDEX**

(

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE 213

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL 165

(Z)-9-TRICOSENE 233

1

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE. 215

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE 215

1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE 212

1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE 210

1-(beta-Methyl sulphonamidoethyl)- 2-amino-3- 269

1,1,1-TRICHLOROETHANE 156, 220, 251, 274

1,2-BENZENEDIAMINE 216

1,2-BENZENEDIOL 241, 261

1,2-DIBROMO-3-CHLOROPROPANE 200

1,2-DICHLOROPROPANE 171

1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE 140

1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE 155

1,3-BENZENEDIAMINE 217

1,3-DICHLOROPROPENE 200, 280

1,3-DIMETHYLAMYLAMINE 218

1,4-BUTANEDIOL 217

13C-UREA 233

19-NORANDROSTENEDIOL 103

19-NORANDROSTENEDIONE 103

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE. 159

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE 213

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID 208

1-METHYLCYCLOPROPENE 231

1-Octen-3-ol 184

1-PENTYL-3-(1-NAPHTHOYL)INDOLE 214

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE 214

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE 214

2

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE 213

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE 68

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE 193, 205, 281

2,2-DPA 229

2,3,6-TBA 154

2,4,5-T 192

2,4-D 138, 170

2,4-DB 138

2,4-DES 138

2,4-DICHLORPROP 171

2,4-DINITROCHLOROBENZENE 77

2,4-TOLUENEDIAMINE 220

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE 211

2,5-DIMETHOXY-4-BROMOAMPHETAMINE 211

2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE 211

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE 211

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE 211

2,5-DIMETHOXYAMPHETAMINE 211

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL 212

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL 212

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE 210

2-BUTOXY-2’-THIOCYANODIETHYL ETHER 163, 262

2-BUTOXYETHANOL 163, 241, 262

2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE 166

2-MERCAPTOETHANOL 181

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID 213

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE 147

2-NITROTOLUENE 204

2-Octyl-4-isothiazolin-3-one 247

2-PHENOXYETHANOL 185, 247, 270

2-PROPYLENE GLYCOL 1-MONOMETHYL 232

3

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN 211

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE 211

3,4,5-TRIMETHOXY- α -METHYLPHENYLETHYLAMINE 215

3,4,5-TRIMETHOXYPHENETHYLAMINE 215

3,4-DICHLORO-N-{[1- (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE 211

3,4-METHYLENEDIOXYAMPHETAMINE 213

3,4-METHYLENEDIOXYPYROVALERONE 213

3,6,9-TRIOXAUNDECANEDIOIC ACID 157, 274

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN 212

3-IODO-2-PROPYNYL BUTYL CARBAMATE 144, 178

3-METHYLFENTANYL 213

3-METHYLTHIOFENTANYL 213

4

4,4’-METHYLENEBIS[2-CHLOROANILINE] 203, 281

4,4-DIAMINODIPHENYLMETHANE 200, 263, 280

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE 171

4-[4-(ACETYLOXY)PHENYL]-2- 228

4-AMINOPYRIDINE 57, 196, 240, 280

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE 210

4-CHLOROMETHANDIENONE 68

4-CHLORO-O-TOLURIDINE 199, 280

4-CPA 136

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE 207

4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE 211

4-DIMETHYLAMINOAZOBENZENE 200, 280

4-FLUORO-N-METHYLAMPHETAMINE 212

4-HYDROYXBUTANOIC ACID 212

4-METHOXY- α -METHYLPHENYLETHYLAMINE 213

4-METHYLAMINOREX. 213

4-METHYLMETHCATHINONE 213

4-METHYLTHIOAMPHETAMINE 213

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER 209

5

5-(2-AMINOPROPYL)INDAN 210

5,6-DIHYDROXYINDOLINE 171, 218, 243, 265

5-AMINOLEVULINIC ACID 57

5-CHLORO-3-METHYL-4-NITROPYRAZOLE 199

5-METHOXY- α -METHYLTRYPTAMINE 213

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE 213

8

8-HYDROXYQUINOLINE 40, 267

A

ABACAVIR 54

ABAMECTIN 131, 158, 196, 280

ABATACEPT 54

ABCIXIMAB 54

ABIRATERONE ACETATE 54

ABRUS PRECATORIUS 216

ABSCISIC ACID 131

ACAMPROSATE CALCIUM 54

ACARBOSE 54

ACEBUTOLOL 54

ACEPHATE 158

ACEPROMAZINE 54

ACETAMIPRID 158

ACETANILIDE 54

ACETARSOL 54

ACETAZOLAMIDE 54

ACETIC ACID 33, 131, 158, 240, 260

ACETIC ANHYDRIDE 158, 240, 260

ACETOHEXAMIDE 54

ACETONE 131, 240, 260

ACETORPHINE 210

ACETYL ISOVALERYLTYLOSIN 54

ACETYL-ALPHA-METHYLFENTANYL 210

ACETYLCARBROMAL 54

ACETYLCHOLINE 54, 276

ACETYLCYSTEINE 33, 54

ACETYLDIGITOXIN 54

ACETYLDIHYDROCODEINE. 207

ACETYLMETHADOL 207

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE 54

ACETYLMORPHINES 207

ACETYLSTROPHANTHIDIN 54

ACIBENZOLAR-S-METHYL 196, 280

ACICLOVIR 54

ACIFLUORFEN 158

ACINITRAZOLE 158

ACIPIMOX 54

ACITRETIN 54, 235, 260, 286

ACLIDINIUM BROMIDE 54

ACOKANTHERA OUABAIO 54

ACOKANTHERA SCHIMPERI 54

ACONITUM spp. 33, 54

ACORUS CALAMUS 216

ACRIFLAVINE 131, 196

ACRIVASTINE 55

ACROLEIN 196, 240, 280

ACRYLONITRILE 196, 280

ADALIMUMAB 55

ADAPALENE 55, 260, 286

ADEFOVIR 55

ADENOSINE 55

ADIPHENINE 55

ADONIS VERNALIS 55

ADRAFINIL 55

ADRENALINE 48, 55

ADRENOCORTICAL HORMONES 55

AFAMELANOTIDE 55

afatinib dimaleate 55

AFLIBERCEPT 55

AFOXOLANER 131

AGALSIDASE 55

AGLEPRISTONE 55

AGOMELATINE 55

*AGROBACTERIUM RADIOBACTER* 228

AKLOMIDE 131

ALACHLOR 196, 280

ALATROFLOXACIN MESYLATE 55

ALBENDAZOLE 55, 131, 158

ALCLOFENAC 55

ALCLOMETASONE 48, 55, 260

ALCOHOL, DEHYDRATED 228

ALCURONIUM 55

ALDESLEUKIN 55

ALDICARB 196

ALDOSTERONE 56, 276

ALDOXYCARB 196

ALDRIN 158

ALEFACEPT 56, 236

ALEMTUZUMAB 56

ALENDRONIC ACID 56

ALFACALCIDOL 56

ALFENTANIL 207

ALFUZOSIN 56

ALGICIDES 222

ALGLUCERASE 56

ALGLUCOSIDASE 56

ALISKIREN 56

ALKALINE SALTS 131, 158, 216, 240, 260

ALKOXYAMPHETAMINES 210

ALKOXYLATED FATTY ALKYLAMINE POLYMER 131, 158

ALKOXYPHENYLETHYLAMINES 210

alkylated phenylenediamines 248

ALKYLTHIOAMPHETAMINES 210

ALLERGENS 56

ALLETHRIN 131, 158

ALLOPURINOL 56

ALLOXYDIM 131

ALLYL ALCOHOL 196, 280

ALLYLISOPROPYLACETYLURE 216

ALLYLOESTRENOL 56

ALLYLPRODINE 210

ALOGLIPTIN 56

ALOSETRON 56

ALOXIPRIN 33

ALPHA1-PROTEINASE INHIBITOR (HUMAN) 56

ALPHACETYLMETHADOL 207

ALPHA-CHLOROHYDRIN 165, 263

ALPHA-CYPERMETHRIN 131, 159, 196

ALPHADOLONE 56

ALPHAMEPRODINE 210

ALPHAMETHADOL 210

ALPHA-METHYLFENTANYL 210

ALPHA-METHYLTHIOFENTANYL 210

ALPHAPRODINE 207

ALPHAXALONE 56

ALPRAZOLAM 207, 282

ALPRENOLOL 56

ALPROSTADIL 56

ALSEROXYLON 56

ALTEPLASE 56

ALTRENOGEST 56

ALTRETAMINE (hexamethylmelamine) 56

ALUM 228

ALUMINIUM AMMONIUM SULFATE 228

ALUMINIUM POTASSIUM SULFATE 228

ALUMINIUM SILICATE 228

ALUMINIUM tris (ETHYLPHOSPHONATE) 228

AMANTADINE 56

AMBENONIUM CHLORIDE 56

AMBRISENTAN 56, 236, 260

AMBRISENTAN. 286

AMBUCETAMIDE 56

AMBUTONIUM BROMIDE. 56

AMCINONIDE 56

AMETHOCAINE 33, 56

AMETOCTRADIN 228

AMETRYN 132

AMICARBAZONE 159

AMIDITHION 159

AMIFOSTINE 57

AMIKACIN 57

AMILORIDE 57

AMINACRINE 132, 196

AMINES 132, 240, 260

AMINOCAPROIC ACID 57

AMINOCARB 159, 196

AMINOCYCLOPYRACHLOR 132

AMINOETHOXYVINYLGLYCINE 159

AMINOGLUTETHIMIDE 57

AMINOMETRADINE 57

AMINOPHENAZONE 57, 216

AMINOPHYLLINE 48, 57

AMINOPTERIN 57

AMINOPYRALID 132, 159

AMINOREX 57

AMINOSALICYLIC ACID 57

AMIODARONE 57

AMIPHENAZOLE 57

AMISOMETRADINE 57

AMISULPRIDE 57, 282

AMITON 196

AMITRAZ 159

AMITRIPTYLINE 57, 282

AMITROLE 132

AMLODIPINE 57

AMMI VISNAGA 57

AMMONIA 132, 159, 240, 260

AMMONIUM BROMIDE 57

AMMONIUM HYDROXIDE 260

AMMONIUM PERSULFATE 159, 240, 260

AMMONIUM PHOSPHATE 228

AMMONIUM THIOCYANATE 132, 240

AMMONIUM THIOSULPHATE 228

AMODIAQUINE 57

AMOROLFINE 33, 57

AMOXAPINE 57

AMOXYCILLIN 57

AMPHETAMINE 207

AMPHOMYCIN 57

AMPHOTERICIN 58

AMPICILLIN 58

AMPRENAVIR 58

AMPROLIUM 228

AMRINONE 58

AMSACRINE 58

AMYGDALIN 216

AMYL ACETATE 228

AMYL NITRITE 58

α -AMYLASE derived from *Aspergillus niger* 228

AMYLOBARBITONE 58, 207, 282

AMYLOCAINE 58

ANABOLIC STEROIDAL AGENTS 58, 236

ANAGRELIDE 58

ANAKINRA 58

ANASTROZOLE 58

ANCESTIM 58

ANCHUSA OFFICINALIS 216

ANCROD 58

ANDROGENIC STEROIDAL AGENTS 58, 236

ANDROISOXAZOLE 58

ANDROSTANOLONE 58

ANDROSTENEDIOL 58

ANDROSTENEDIONE 58

ANDROSTENEDIONE ALBUMEN 228

ANECORTAVE 58

ANGIOTENSIN AMIDE 58

ANHYDRIDES 240, 260

ANHYDRIDES, ORGANIC ACID 132

ANIDULAFUNGIN 58

ANILERIDINE 207

ANILINE 159, 240, 260

ANISE OIL 132, 240

ANISTREPLASE 58

ANITMONY CHLORIDE 240

ANTAZOLINE 33, 58

ANTIBIOTIC SUBSTANCES 58

ANTIGENS 58

ANTIHISTAMINES 58, 260

ANTIMONY 59

ANTIMONY COMPOUNDS 159, 240, 276

ANTISERA 59

APIXABAN 59

APOCYNUM spp. 59

APOMORPHINE 59, 276

APRACLONIDINE 59

APRAMYCIN 59

APREPITANT 59

APRONAL 59

APROTININ 59

ARECOLINE 59

ARIPIPRAZOLE 59, 282

ARISTOLOCHIA spp. 216

ARISTOLOCHIC ACID(S) 216

AROMATIC EXTRACT OILS 261

ARPINOCID 280

ARPRINOCID 196

ARSENIC 59, 159, 196, 276, 280

ARTEMETHER 59

ARTICAINE 59

ASARUM spp 216

ASENAPINE 59, 282

ASPARTIC ACID 228

ASPIRIN 33, 59, 132, 159, 261

ASTEMIZOLE 59, 261

ASULAM 228

ATAMESTANE 59

ATAZANAVIR 59

ATENOLOL 59

ATIPAMEZOLE 59

ATOMOXETINE 59

ATORVASTATIN 59

ATOSIBAN 59

ATOVAQUONE 59

ATRACURIUM BESYLATE 60

ATRAZINE 132

ATROPA BELLADONNA (belladonna) 34, 60, 276

ATROPINE 34, 60, 276

ATROPINE METHONITRATE 60

AURANOFIN 60

AUROTHIOMALATE SODIUM 60

AVILAMYCIN 60

AVIPTADIL 60

AVOPARCIN 60

AXITINIB 60

AZACITIDINE 60

AZACONAZOLE 160

AZACYCLONOL 60

AZADIRACHTA INDICA 160, 216, 240, 261

AZADIRACHTA INDICA EXTRACTS 132

AZAFENIDIN 197

AZAMETHIPHOS 160

AZAPERONE 60

AZAPROPAZONE 60

AZARIBINE 60

Azatadine 282

AZATADINE 48, 60

AZATHIOPRINE 60

AZELAIC ACID 34, 60

AZELASTINE 34, 60

AZIMSULFURON 228

AZINPHOS-ETHYL 197

AZINPHOS-METHYL 197

AZITHROMYCIN 60

AZLOCILLIN 60

AZOBENZENE 160

AZOCYCLOTIN 197, 261, 280

AZOXYSTROBIN 132

AZTREONAM 60

B

BACAMPICILLIN 60

*BACILLUS SPHAERICUS* STRAIN 2362 228

*BACILLUS THURINGIENSIS* 228

BACILLUS THURINGIENSIS delta endotoxin 132

*BACILLUS TOYOI* 228

BACITRACIN 60

BACLOFEN 60, 282

BACTERIAL CULTURE MEDIA 222

BACTERIOCIDES 222

BACULOVIRUS *CYDIA POMONELLA* 228

BALSALAZIDE 60

BAMBERMYCIN 61, 160

BAMBUTEROL 61

BAMETHAN 61

BAMIPINE 61

BARBITURATES 61

BARIUM SALTS 160, 240

BARIUM SILICOFLUORIDE 132

BASIC ORANGE 31 160, 216

BASIL OIL 133, 240

BASILIXIMAB 61

BAY OIL 160, 240

BAZEDOXIFENE 61

BEAUVERIA BASSIANA 133, 161

BECAPLERMIN 61

BECLAMIDE 61

BECLOMETHASONE 34, 61

BELATACEPT 61

BELIMUMAB 61

BEMEGRIDE 61

BENACTYZINE 61

BENALAXYL 133

BENAZEPRIL 61

BENDAMUSTINE 61

BENDIOCARB 133, 161, 197

BENDROFLUAZIDE 61

BENETHAMINE PENICILLIN 61

BENFLURALIN 228

BENOMYL 197, 261

BENORYLATE 61

BENOXAPROFEN 61

BENPERIDOL 61

BENQUINOX 161

BENSERAZIDE 61

BENSULFURON-METHYL 228

BENSULIDE 161

BENTAZONE 133

BENTONITE 228

BENZALKONIUM CHLORIDE 133, 161, 241

BENZATHINE PENICILLIN 61

BENZENE 197, 241, 261, 280

BENZETHIDINE 210

BENZHEXOL 61

BENZIDINE-BASED AZO DYES 197

BENZILONIUM 61

BENZOCAINE 34, 61

BENZODIAZEPINE DERIVATIVES 62, 236

BENZOFENAP 133

BENZOYL PEROXIDE 34, 62, 133, 241, 261

BENZOYLINDOLES 210

BENZPHETAMINE 62

BENZTHIAZIDE 62

BENZTROPINE 62, 282

BENZYDAMINE 34, 62

BENZYL BENZOATE 228

BENZYLMORPHINE 207

BENZYLPENICILLIN 62

BENZYLPIPERAZINE 210

BEPHENIUM SALTS 34

BEPRIDIL 62

BERACTANT 62

BERGAMOT OIL 133, 241, 261

BERYLLIUM 161, 261

BESIFLOXACIN 62

BETACETYLMETHADOL 210

BETACYFLUTHRIN 133, 161, 198

BETA-CYPERMETHRIN 161

BETAHISTINE 62

BETA-HYDROXY-3-METHYLFENTANYL 210

BETA-HYDROXYFENTANYL 210

BETAINE HYDROCHLORIDE 228

BETAMEPRODINE 210

BETAMETHADOL 210

BETAMETHASONE 62

BETAPRODINE 210

BETAXOLOL 62

BETHANECHOL CHLORIDE 62

BETHANIDINE 62

BEVACIZUMAB 62

BEVANTOLOL 62

BEXAROTENE 62, 235, 261, 286

BEZAFIBRATE 62

BEZITRAMIDE 207

BHC 161

BICALUTAMIDE 62

BIFENAZATE 228

BIFENTHRIN 162, 198

BIFLUORIDES 133, 162, 198, 241, 261, 280

BIFONAZOLE 35, 62

BIMATOPROST 62

BIOALLETHRIN 134, 162

BIORESMETHRIN 134

BIPERIDEN 63

BISMUTH COMPOUNDS 63

BISMUTH SUBNITRATE 228

BISOPROLOL 63

BISPYRIBAC 134

BISTRIFLURON 228

BITHIONOL 217, 261

BIURET 228

BIVALIRUDIN 63

BLEOMYCIN 63

BOCEPREVIR 63

BOLANDIOL 63

BOLASTERONE 63

BOLAZINE 63

BOLDENONE (dehydrotestosterone) 63

BOLENOL 63

BOLMANTALATE 63

BORAGO OFFICINALIS 217

BORAX 241

BORIC ACID 134, 241

BORON 63

BORON TRIFLUORIDE 134, 162, 198, 241, 261, 280

BORTEZOMIB 63

BOSCALID 228

BOSENTAN 63, 236, 261, 286

BOSUTINIB 63

BOTULINUM TOXINS 63

BOVINE SOMATOTROPHIN 228

BRAGANTIA spp 217

BRENTUXIMAB VEDOTIN 63

BRETYLIUM TOSYLATE 63

BRIMONIDINE 63

BRINZOLAMIDE 63

BRODIFACOUM 162, 198, 280

BROMACIL 228

BROMADIOLENE 280

BROMADIOLONE 162, 198

BROMAZEPAM 63, 282

BROMETHALIN 162, 198

BROMHEXINE 35

BROMIDES 64

BROMINE 198, 280

BROMOCRIPTINE 64

BROMOFORM 64, 162, 241, 262

BROMOPHOS 162

BROMOPHOS-ETHYL 163

BROMOPROPYLATE 229

BROMOXYNIL 163

BROMPHENIRAMINE 35, 48, 64, 282

BROMUCONAZOLE 134, 163

BROMVALETONE 64

BROTIANIDE 163

BRUCINE 198, 241, 280

BRUGMANSIA spp 64

Buclizine 282

BUCLIZINE 48, 64

BUCLOSAMIDE 217

BUDESONIDE 35, 64

BUFEXAMAC 64

BUFOTENINE 210

BUMETANIDE 64

BUNAMIDINE 163

BUNIODYL SODIUM 217

BUPHENINE 64

BUPIRIMATE 229

BUPIVACAINE 64, 134

BUPRENORPHINE 207, 282

BUPROFEZIN 134

BUPROPION 64

BUSERELIN 64

BUSPIRONE 64

BUSULPHAN 64

BUTACAINE 64

BUTACARB 163

BUTAFENACIL 229

BUTHIDAZOLE 134

BUTOBARBITONE 207, 282

BUTOCONAZOLE 48, 64, 277

BUTORPHANOL 207

BUTOXYCARBOXIM 134, 163

BUTOXYPOLYPROPYLENE GYLCOL 229

BUTRACONAZOLE 64

BUTRALIN 134

BUTROXYDIM 134

BUTYL AMINOBENZOATE 64

BUTYL NITRITE 64

BUTYLCHLORAL HYDRATE 64

BUTYRIC ACID 163

C

CABAZITAXEL 64

CABERGOLINE 64

CACALIA spp 217

CACODYLIC ACID 163, 198

CADMIUM COMPOUNDS 64, 163, 241

CADUSAFOS 163, 198

CAJUPUT OIL 163, 241

CALCIFEROL 164, 198, 280

CALCIPOTRIOL 64

CALCITONIN 64

CALCITRIOL 65

CALCIUM CARBIMIDE 65

CALCIUM HYDROXYLAPATITE 65

CALCIUM POLYSTYRENE SULPHONATE 65

CALOTROPIS GIGANTEA 65

CALOTROPIS PROCERA 65

CALUSTERONE 65

CAMBENDAZOLE 164

CAMPHOR 134, 164, 241, 262

CAMPHORATED OIL 65

CAMPHOTAMIDE 65

CANAGLIFLOZIN 65

CANAKINUMAB 65

CANDESARTAN CILEXETIL 65

CANDICIDIN 65

CANINE TICK ANTI-SERUM 65

CANNABIS 210

CANTHARIDIN 65, 276

CAPECITABINE 65

CAPREOMYCIN 65

CAPTAFOL 198, 280

CAPTAN 164

CAPTODIAME 65

CAPTOPRIL 65

CAPURIDE 65

CARAMIDE PEROXIDE 262

CARAMIPHEN 65

CARBACHOL 65

CARBADOX 198, 280

CARBAMAZEPINE 65

CARBAMIDE PEROXIDE 134, 164, 217, 241

CARBARYL 65, 134, 164

CARBAZOCHROME 65

CARBENDAZIM 198

CARBENICILLIN 65

CARBENOXOLONE 65

CARBETAMIDE 229

CARBETAPENTANE 35

CARBETOCIN 65

CARBIDOPA 66

CARBIMAZOLE 66

CARBOCISTEINE 35

CARBOCROMEN 66

CARBOFURAN 198

CARBON DISULFIDE 164, 241

CARBON TETRACHLORIDE 198, 242, 262, 280

CARBONYL SULFIDE 198

CARBOPHENOTHION 198

CARBOPLATIN 66

CARBOPROST 66

CARBOSULFAN 198

CARBOXIN 229

CARBROMAL 66

CARBUTAMIDE 66

CARBUTEROL 66

CARFENTANYL 207

CARFENTRAZONE-ETHYL 229

CARGLUMIC ACID 66

CARINDACILLIN 66

CARISOPRODOL 66

CARMUSTINE 66

CARNIDAZOLE 66

CARPROFEN 66

CARVEDILOL 66

CASPOFUNGIN 66

CASSIA OIL 134, 242, 262

CASTOR OIL, MONOMALEATE 165

CATHINE 66

CATHINONE 211

CATUMAXOMAB 66

CEFACETRILE 66

CEFACLOR 66

CEFADROXIL 66

CEFALORIDINE 66

CEFAMANDOLE 66

CEFAPIRIN 66

CEFAZOLIN 66

CEFEPIME 66

CEFETAMET 66

CEFIXIME 66

CEFODIZIME 66

CEFONICID 66

CEFOPERAZONE 67

CEFOTAXIME 67

CEFOTETAN 67

CEFOTIAM 67

CEFOVECIN 67

CEFOXITIN 67

CEFPIROME 67

CEFPODOXIME 67

CEFQUINOME 67

CEFSULODIN 67

CEFTAROLINE FOSAMIL 67

CEFTAZIDIME 67

CEFTIBUTEN 67

CEFTIOFUR 67

CEFTRIAXONE 67

CEFUROXIME 67

CELECOXIB 67

CELIPROLOL 67

CELLULASE 229

CEPHAELIS ACUMINATA 67

CEPHAELIS IPECACUANHA 67

CEPHALEXIN 67

CEPHALONIUM 67

CEPHALOTHIN 67

CEPHRADINE 67

CERAMICS 222

CERIVASTATIN 67

CERTOLIZUMAB PEGOL 67

CERULETIDE 67

Cetirizine 282

CETIRIZINE 35, 67

CETRORELIX 68

CETUXIMAB 68

CETYL ALCOHOL 229

CHAMOMILE OIL 229

CHEMISTRY SETS 222

CHENODEOXYCHOLIC ACID 68

CHINA CLAY 229

CHLOPHEDIANOL 35

CHLORAL FORMAMIDE 68

CHLORAL HYDRATE 68, 282

CHLORALOSE 68, 165

CHLORAMBUCIL 68

CHLORAMPHENICOL 48, 68

CHLORANDROSTENOLONE 68

CHLORANTRANILIPROLE 229

CHLORAZANIL 68

CHLORBUTOL 35, 48

CHLORCYCLIZINE 68

CHLORDANE 165

CHLORDECONE 198, 280

CHLORDIAZEPOXIDE 68, 282

CHLORDIMEFORM 199, 280

CHLORFENAC 135

CHLORFENAPYR 135, 165, 199

CHLORFENETHOL 165

CHLORFENSON 135

CHLORFENVINPHOS 199

CHLORFLUAZURON 229

CHLORFLURENOL 229

CHLORHEXIDINE 135, 165, 199

CHLORIDAZON 229

CHLORIDE 242

CHLORINATING COMPOUNDS 135, 165, 242, 262

CHLORINE 199, 276, 280

CHLORMEQUAT 165

CHLORMERODRIN 68

CHLORMETHIAZOLE 68, 282

CHLORMEZANONE 68

CHLORNIDINE 135

CHLOROCRESOL 135, 242

CHLOROFORM 35, 68, 165, 242, 263

CHLOROMETHIURON 199, 280

CHLOROPHACINONE 165

CHLOROPICRIN 165, 199

CHLOROPRCRIN 280

CHLOROQUINE 68

CHLOROTHALONIL 166

CHLOROTHIAZIDE 68

CHLOROTRIANISENE 68

CHLOROXYDIENONE 68

CHLOROXYLENOLS 229

CHLORPHENIRAMINE 35, 48, 68, 282

CHLORPHENTERMINE 68

CHLORPROMAZINE 68, 282

CHLORPROPAMIDE 68

CHLORPROPHAM 135

CHLORPROTHIXENE 68

CHLORPYRIFOS 135, 166

CHLORPYRIFOS-METHYL 166

CHLORQUINALDOL 69

CHLORSULFURON 135

CHLORTETRACYCLINE 69, 135

CHLORTHAL-DIMETHYL 135

CHLORTHALIDONE 69

CHLORTHIAMID 166

CHLORTHIOPHOS 199

CHLORZOXAZONE 69

CHOLERA VACCINE 69

CHOLESTYRAMINE 69

CHROMATES 166, 242, 263

CHROMIUM TRIOXIDE 166, 242, 263

CHYMOPAPAIN 69

CICLACILLIN 69

CICLESONIDE 69

CICLOPIROX 35, 48, 69

CIDOFOVIR 69

CILASTATIN 69

CILAZAPRIL 69

CILOSTAZOL 69

CIMETIDINE 48, 69, 263

CINACALCET 69

CINCHOCAINE 36, 69

CINCHOPHEN 217

CINEOLE 166, 242

CINMETHYLIN 136

CINNAMEDRINE 36

CINNAMON BARK OIL 136, 242, 263

CINNAMON LEAF OIL 166, 242

CINOXACIN 69

CIPROFLOXACIN 69

CISAPRIDE 69

CISATRACURIUM BESYLATE 69

CISPLATIN 69

CITALOPRAM 69

CITRONELLA OIL 229

CLADRIBINE 69

CLANOBUTIN 69

CLARITHROMYCIN 69

CLARY SAGE OIL 229

CLAVULANIC ACID 69

Clemastine 282

CLEMASTINE 48, 69

CLEMIZOLE 70

CLENBUTEROL 70

CLETHODIM 136

CLEVIDIPINE 70

CLIDINIUM BROMIDE 70

CLIMBAZOLE 136, 167, 242

CLINDAMYCIN 70

CLIOQUINOL 70, 217

CLOBAZAM 70

CLOBETASOL 70

CLOBETASONE 48, 70, 263

CLOCORTOLONE 70

CLODINAFOP-PROPARGYL 167

CLODRONIC ACID 70

CLOFARABINE 70

CLOFAZIMINE 70

CLOFENAMIDE 70

CLOFENTEZINE 136

CLOFIBRATE 70

CLOMAZONE 167

CLOMIPHENE 70, 235

CLOMIPRAMINE 70, 282

CLOMOCYCLINE 70

CLONAZEPAM 70, 282

Clonidine 282

CLONIDINE 70

CLONITAZENE 211

CLOPAMIDE 70

CLOPIDOGREL 70

CLOPIDOL 229

CLOPROSTENOL 70

CLOPYRALID 136

CLOQUINTOCET-MEXYL 136

CLORAZEPATE 70, 282

CLOREXOLONE 70

CLORPRENALINE 70

CLORSULON 136

CLOSANTEL 167

CLOSTEBOL 70

CLOTHIANIDIN 136, 167

CLOTRIMAZOLE 36, 48, 70, 167, 263, 277

CLOVE OIL 136, 167, 242, 263

CLOXACILLIN 71

CLOZAPINE 71, 235, 282

COAL TAR 217

COBALT 71

COBALT NAPHTHENATE 229

COBICISTAT 71

COCA LEAF 211

COCAINE 207

COCOYL GLYCINATE 168, 242

CODEINE 36, 48, 71, 207, 282

CODEINE-N-OXIDE 207

CO-DERGOCRINE 71

CODOXIME 211

COLASPASE 71

COLCHICINE 71

COLCHICUM AUTUMNALE 71

COLECALCIFEROL 199, 280

COLESTIPOL 71

COLFOSCERIL PALMITATE 71

COLISTIN 71

COLLAGEN 71

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM 71

COLOPHONY 229

CONCENTRATE OF POPPY STRAW 207

CONIUM MACULATUM 217

CONVALLARIA KEISKI 71

CONVALLARIA MAJALIS 71

COPPER ACETATE 136, 168

COPPER COMPOUNDS 71, 136, 168, 222

COPPER HYDROXIDE 136, 168

COPPER NITRATE 168

COPPER OXIDES 136, 168

COPPER OXYCHLORIDE 136, 168

COPPER SULFATE 136, 169, 242

CORIFOLLITROPIN ALFA 71, 235

CORONILLA spp. 71

CORTICOSTERONE 71

CORTICOTROPHIN 71

CORTISONE 72

COTARNINE 217

CO-TRIMOXAZOLE 72

COUMAPHOS 169, 199

COUMARIN 72

COUMATETRALYL 136, 169, 199, 280

CREOSOTE 36, 169, 199, 242

CRESOLS 242

CRIZOTINIB 72

CROFELEMER 72

CROSPOVIDONE 229

CROTALARIA spp. 217

CROTON TIGLIUM 217, 276

CROTOXYPHOS 169

CRUFOMATE 169

CRYSTAL VIOLET 72

*CULICINOMYCES CLAVOSPORUS* 229

CUPRIMYXIN 72

CURARE 72

CYANAMIDE 169

CYANATRYN 136

CYANAZINE 169

CYANIDES 199, 242, 263

CYANOACRYLATE ESTERS 136

CYANOACRYLIC ACID ESTERS 242

CYANOGEN 199, 280

CYANTRANILIPROLE 137

CYANURIC ACID 137, 242, 263

CYAZOFAMID 137

CYCHEXATIN 280

CYCLAMIC ACID 229

CYCLANDELATE 72

CYCLANILIDE 169

CYCLIZINE 49, 72, 282

CYCLOBARBITONE 207, 282

CYCLOBENZAPRINE 72

CYCLOFENIL 72, 235

CYCLOHEXANE 229

CYCLOHEXANOL ACETATE 229

CYCLOHEXANONE PEROXIDE 137, 242, 263

CYCLOHEXIMIDE 72

CYCLOHEXYLPHENOLS 211

CYCLOPENTHIAZIDE 72

CYCLOPENTOLATE 72

CYCLOPHOSPHAMIDE 72

CYCLOPROPANE 72

CYCLOPROTHRIN 137

CYCLOSERINE 72, 282

CYCLOSPORIN 72

CYCLOTHIAZIDE 72

CYCLOXYDIM 137

CYCRIMINE 72

CYCTEAMINE 242, 263

CYFLUFENAMID 137

CYFLUTHRIN 137, 169

cyhalofop-butyl 137

CYHALOTHRIN 199

CYHEXATIN 199

CYMARIN 72

CYMIAZOLE 137

CYNOGLOSSUM spp 217

CYOMETRINIL 169

CYPERMETHRIN 137, 169

CYPHENOTHRIN 137, 169

CYPROCONAZOLE 137

CYPRODINIL 137

CYPROHEPTADINE 49, 72, 282

CYPROTERONE 72

CYROMAZINE 229

CYSTEAMINE 72, 137, 169, 282

CYTARABINE 72

CYTHIOATE 137, 170

D

DABIGATRAN 72

DABRAFENIB MESILATE 72

DACARBAZINE 72

DACLIZUMAB 72

DACTINOMYCIN 73

DALFOPRISTIN 73

DALTEPARIN 73

DAMINOZIDE 138

DANAPAROID 73

DANAZOL 73

DANTHRON 73

DANTROLENE 73, 282

DAPAGLIFLOZIN 73

DAPOXETINE 73

DAPSONE 73

DAPTOMYCIN 73

DARBEPOETIN 73, 236

DARIFENACIN 73

DARUNAVIR 73

DASATINIB 73

DATURA spp 36, 73

DATURA STRAMONIUM 36, 73

DATURA TATULA 36, 73

DAUNORUBICIN 73

DAZOMET 170

DEANOL 73

DEBRISOQUINE 73

DECAMETHONIUM 73

DECOQUINATE 138

DEFERASIROX 73

DEFERIPRONE 73

DEFLAZACORT 74

DEGARELIX 74

DEHYDROCHLOROMETHYLTESTOSTERONE 74

DEHYDROCORTICOSTERONE 74

DELAVIRDINE 74

DELPHINIUM STAPHISAGRIA 37

DELTAMETHRIN 138, 170, 199

DEMBREXINE 74, 138

DEMECARIUM 74

DEMECLOCYCLINE 74

DEMETON 199

DEMETON-O-METHYL 200

DEMETON-S-METHYL 200

DENOSUMAB 74

DEOXYCORTONE 74

DEOXYRIBONUCLEASE 74

DERACOXIB 74

DERQUANTEL 170

DESFERRIOXAMINE 74

DESFLURANE 74

DESIPRAMINE 74, 282

DESIRUDIN 74

DESLANOSIDE 74

DESLORATADINE 37, 74

DESLORELIN 74

DESMOPRESSIN 74

DESOGESTREL 74

DESOMORPHINE 211

DESONIDE 74

DESOXYMETHASONE 74

DESVENLAFAXINE 74

DETOMIDINE 74

DEXAMETHASONE 74

DEXAMPHETAMINE 207

DEXCHLORPHENIRAMINE 37, 49, 74, 282

DEXFENFLURAMINE 74

DEXMEDETOMIDINE 75

DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES 222

DEXTROMETHORPHAN 37, 75

DEXTROMORAMIDE 207, 282

DEXTROPROPOXYPHENE 75, 207, 236, 282

DEXTRORPHAN 75

DIAFENTHIURON 138

DIALIFOS 200

DIAMPROMIDE 211

DIAMTHAZOLE 75

DIAVERIDINE 75

DIAZEPAM 75, 282

DIAZINON 138, 170

DIAZOXIDE 75

DIBENZEPIN 75

DIBENZOPYRANS 211

DIBOTERMIN 75

DIBROMOPROPAMIDINE 37, 75

DICAMBA 138, 170

DICHLOBENIL 170

DICHLOEOETHYL ETHER 263

DICHLOFENTHION 170

DICHLOFLUANID 170

DICHLONE 138

DICHLORALPHENAZONE 75

DICHLORMETHANE 265

DICHLOROBENZENE 138, 170, 242

DICHLOROETHYL ETHER 170, 242

DICHLOROETHYLENE 263

DICHLOROISOCYANURATES 243, 263

DICHLOROISOCYANURIC ACID 138, 170

DICHLOROMETHANE 138, 243

DICHLOROPHEN 75, 139, 171

DICHLORPHENAMIDE 75

DICHLORVOS 139, 171, 200

DICHROMATES 243

DICLAZURIL 229

DICLOBUTRAZOL 139

DICLOFENAC 37, 49, 75, 265, 277

DICLOFOP-METHYL 171

DICLORAN 139

DICLOXACILLIN 75

DICOFOL 139

DICOPHANE 217

DICROTOPHOS 200

DICYCLANIL 171

DICYCLOMINE 75

DIDANOSINE 75

DIDECYLDIMETHYLAMMONIUM SALTS 171

DIELDRIN 171

DIENESTROL 75, 265, 286

DIENOGEST 75

DIESEL 243

DIETHANOLAMINE 139, 171, 243, 265

DIETHAZINE 75

DIETHYL CARBONATE 229

DIETHYLCARBAMAZINE 75

DIETHYLENE GLYCOL 139, 171, 217

DIETHYLENE GLYCOL MONOBUTYL ETHER 139

DIETHYLHEXYL PHTHALATE 218

DIETHYLPHTHALATE 218

DIETHYLPROPION 75

DIETHYLTHIAMBUTENE 211

DIETHYLTOLUAMIDE 265

DIETHYLTOLUAMIDE (DEET) 139

DIFENACOUM 171, 200, 280

DIFENOCONAZOLE 139

Difenoxin 282

DIFENOXIN 75, 207

DIFENZOQUAT 171

DIFETHIALONE 171, 200

DIFLORASONE 76

DIFLOXACIN 76

DIFLUBENZURON 139

DIFLUCORTOLONE 76

DIFLUFENICAN 229

DIFLUNISAL 76

DIGITALIS LANATA 76

DIGITALIS PURPUREA 76

DIGITOXIN 76

DIGOXIN 76

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab) 76

DIHYDRALAZINE 76

DIHYDROCODEINE 37, 49, 76, 207, 282

DIHYDROERGOTOXINE 76

DIHYDROLONE 76

DIHYDROMORPHINE 207

DIHYDROSTREPTOMYCIN 76

DIHYDROTACHYSTEROL 76

DI-IODOHYDROXYQUINOLINE 49, 76

DIISOPROPYLAMINE DICHLOROACETATE 76

DIKEGULAC-SODIUM 229

DILTIAZEM 76

DIMEFOX 200

DIMENHYDRINATE 37, 49, 76, 277, 282

DIMENOXADOL 211

DIMEPHEPTANOL 211

DIMERCAPROL 76

DIMETHANDROSTANOLONE 76

DIMETHAZINE 76

DIMETHENAMID-P 171

DIMETHICODIETHYLBENZALMALONATE 139

DIMETHICONE 229

DIMETHINDENE 49, 76, 282

DIMETHIPIN 171

DIMETHIRIMOL 139

DIMETHOATE 172

DIMETHOMORPH 140

DIMETHOTHIAZINE 76

DIMETHOXANATE 77

DIMETHYL ETHER 229

DIMETHYL FUMARATE 77

DIMETHYL SULFATE 200, 265

DIMETHYL SULFOXIDE 77, 172, 243, 265

DIMETHYLACETAMIDE 140, 172

DIMETHYLFORMAMIDE 140, 172, 243, 265

DIMETHYLPHTHALATE 218

DIMETHYLTHIAMBUTENE 211

DIMETILAN 200

DIMETRIDAZOLE 77

DINICONAZOLE 140

DINITROCRESOLS 77, 172, 200, 243, 280

DINITRONAPHTHOLS 77

DINITROPHENOLS 77, 172, 200, 243, 265, 280

DINITROTHYMOLS 77

DINOCAP 200, 265

DINOPROST 77, 235

DINOPROSTONE 77, 235

DINOSEB 200, 280

DI-N-PROPYL ISOCINCHOMERONATE 140

DIOXACARB 172

DIOXANE 172, 243, 265, 276

DIOXAPHETYL BUTYRATE 211

DIPERODON 77

DIPHACINONE 172

DIPHEMANIL 77

DIPHENAMID 140

DIPHENHYDRAMINE 37, 49, 77, 282

DIPHENIDOL 77

DIPHENOXYLATE 49, 77, 208, 265, 277, 282

DIPHENYLAMINE 229

DIPHENYLPYRALINE 77, 282

DIPHTHERIA TOXOID 77

DIPIPANONE 208

DIPIVEFRIN 77

DIPROPYLENE GLYCOL 229

DIPYRIDAMOLE 77

DIQUAT 172, 200

DIRITHROMYCIN 77

DIRLOTAPIDE 77

DISOPHENOL 77

DISOPYRAMIDE 77

DISTIGMINE 77

DISTILLATE 243

DISULFIRAM 77, 172

DISULFOTON 172, 200

DISULPHAMIDE 77

DITHIANON 172

DITHIAZANINE 78, 172

DITHIOPYR 140

DITHRANOL 49

DITIOCARB 78

DIUREDOSAN 172

DIURON 229

DOBUTAMINE 78

DOCETAXEL 78

DOCUSATE SODIUM 229

DODINE 173

DOFETILIDE 78

DOLASETRON 78

DOLUTEGRAVIR 78

DOMPERIDONE 78

DONEPEZIL 78

DOPAMINE 78

DOPEXAMINE 78

DORAMECTIN 140, 173, 200

DORIPENEM 78

DORNASE 78

DORZOLAMIDE 78

DOTHIEPIN 78, 282

DOXANTRAZOLE 78

DOXAPRAM 78

DOXAZOSIN 78

DOXEPIN 78, 282

DOXORUBICIN 78

DOXYCYCLINE 78

DOXYLAMINE 38, 49, 78, 282

d-PHENOTHRIN 232

d-PULEGONE 188, 249

drometrizole trisiloxane 229

DRONABINOL 208, 235, 282

DRONEDARONE 78

DROPERIDOL 78, 282

DROSPIRENONE 78

DROSTANOLONE 78

DROTEBANOL 208

DROTRECOGIN 78

DSMA 173, 200

DUBOISIA LEICHHARDTII 38, 78

DUBOISIA MYOPOROIDES 38, 78

DULCIN 218

DULOXETINE 78, 282

DUTASTERIDE 79

DYDROGESTERONE 79

E

ECGONINE 211

ECONAZOLE 38, 49, 79, 173, 265, 277

ECOTHIOPATE 79

ECTYLUREA 79

ECULIZUMAB 79

EDETIC ACID 79

EDOXUDINE 79

EDROPHONIUM 79

EFALIZUMAB 79

EFAVIRENZ 79

EFLORNITHINE 79

EFORMOTEROL 79

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS 222

ELECTRONIC COMPONENTS 222

ELETRIPTAN 79

ELOSULFASE ALFA 79

ELTENAC 79

ELTROMBOPAG 79

ELVITEGRAVIR 79

EMAMECTIN 140, 173, 200

EMEPRONIUM 79

EMETINE 79

EMODEPSIDE 140, 173

EMPAGLIFLOZIN 79

EMTRICITABINE 79

ENALAPRIL 79

ENDOSULFAN 173, 200

ENDOTHAL 173, 200

ENDRIN 200

ENESTEBOL 79

ENFLURANE 79

ENFUVIRTIDE 80

ENHANCING AGENTS 222

ENOBOSARM 80

ENOXACIN 80

ENOXAPARIN 80

ENOXIMONE 80

ENPROSTIL 80

ENROFLOXACIN 80

ENTACAPONE 80

ENTECAVIR 80

EPHEDRA spp 80

EPHEDRINE 80, 236, 265

EPICHLOROHYDRIN 200, 265, 280

EPICILLIN 80

EPIDERMAL GROWTH FACTOR 200, 280

EPINASTINE 80

EPIRUBICIN 80

EPITIOSTANOL 80

EPLERENONE 80

EPOETINS 80, 236

EPOPROSTENOL 80

EPOXICONAZOLE 140

EPOXY RESINS 243, 265

EPOXY RESINS, LIQUID 140

EPRINOMECTIN 140, 200

EPROSARTAN 80

EPSIPRANTEL 229

EPTC 173

EPTIFIBATIDE 80

ERGOMETRINE 80

ERGOT 80

ERGOTAMINE 80

ERGOTOXINE 80

ERIBULIN MESYLATE 80

ERLOTINIB 80

ERTAPENEM 80

ERYSIMUM spp. 80, 276

ERYTHRITYL TETRANITRATE 49

ERYTHROMYCIN 80

ERYTHROPOIETIN 80, 236

ERYTHROPOIETINS 81, 236

ESBIOTHRIN 140, 173

ESCITALOPRAM 81

ESFENVALERATE 140, 173

ESMOLOL 81

ESOMEPRAZOLE 50, 81

ESTRAMUSTINE 81

ESTROPIPATE 81

ETACONAZOLE 200, 280

ETAFEDRINE 38

ETANERCEPT 81

ETHACRYNIC ACID 81

ETHAMBUTOL 81

ETHAMETSULFURON-METHYL 230

ETHAMIVAN 81

ETHANOLAMINE 81, 140, 173, 243, 266

ETHCHLORVYNOL 81

ETHEPHON 173

ETHER 38, 81, 140, 173, 243, 266

ETHINAMATE 81

ETHINYLOESTRADIOL 81

ETHIOFENCARB 173

ETHION 200

ETHIONAMIDE 81

ETHISTERONE 81

ETHOATE-METHYL 173

ETHOFUMESATE 140

ETHOGLUCID 81

ETHOHEPTAZINE 81

ETHOPABATE 230

ETHOPROPAZINE 81

ETHOPROPHOS 173, 201

ETHOSUXIMIDE 81

ETHOTOIN 81

ETHOXYETHYLMERCURIC CHLORIDE 266

ETHOXYQUIN 140

ETHOXYSULFURON 140

ETHOXZOLAMIDE 81

ETHYL ACETATE 230

ETHYL ALCOHOL 230

ETHYL BROMIDE 173, 243, 266

ETHYL BUTYRATE 230

ETHYL CHLORIDE 81

Ethyl formate 173

ETHYL LACTATE 230

ETHYL METHACRYLATE 141, 266

ETHYLAMPHETAMINE 208

ETHYLBUTYLACETYL- 230

ETHYLDIENOLONE 81

ETHYLENE CHLOROHYDRIN 173, 266

ETHYLENE DIBROMIDE 201, 280

ETHYLENE DICHLORIDE 173

ETHYLENE GLYCOL 141, 173, 218, 244

Ethylene glycol monoalkyl ethers 174, 244, 266

ETHYLENE OXIDE 201, 244, 266, 280

ETHYLHEXANEDIOL 81, 218

ETHYLMERCURIC CHLORIDE 266

ETHYLMETHYLTHIAMBUTENE 212

ETHYLMORPHINE 38, 81, 208, 282

ETHYLOESTRENOL 82

ETHYNODIOL 82

ETICYCLIDINE 212

ETIDOCAINE 82

ETIDRONIC ACID 82

ETILEFRIN 82

ETIPROSTON 82

ETODOLAC 82

ETOFENAMATE 38, 82

ETONITAZENE 212

ETONOGESTREL 82

ETOPOSIDE 82

ETORICOXIB 82

ETORPHINE 212

ETOXAZOLE 230

ETOXERIDINE 212

ETRAVIRINE 82

ETRETINATE 82, 235, 266, 286

ETRIDIAZOLE 141

ETRIMFOS 174

*EUBACTERIUM* sp. strain DSM11798 230

EUCALYPTUS OIL 174, 244

EUGENOL 141, 174, 244, 266

EUPATORIUM CANNABINUM 218

EVEROLIMUS 82

EXEMESTANE 82

EXENATIDE 82

EXPLOSIVES 222

EXTRACT OF LEMON EUCALYPTUS 141

EZETIMIBE 82

F

FAMCICLOVIR 50, 82

FAMOTIDINE 38, 82, 266

FAMPHUR 175, 201

FARFUGIUM JAPONICUM 218

FEBANTEL 175

FEBUXOSTAT 82

FELBINAC 38, 82

FELODIPINE 82

FELYPRESSIN 82

FENAMIPHOS 175, 201

FENARIMOL 141

FENAZAFLOR 175

FENBENDAZOLE 141

FENBUCONAZOLE 141

FENBUFEN 82

FENBUTATIN OXIDE 175

FENCAMFAMIN 82

FENCHLORAZOLE-ETHYL 141

FENCHLORPHOS 175

FENCLOFENAC 82

FENETYLLINE 212

FENFLURAMINE 82, 282

FENFURAM 230

FENHEXAMID 230

FENITROTHION 175

FENOFIBRATE 82

FENOLDOPAM 83

FENOPROFEN 83

FENOPROP 141

FENOTEROL 83

FENOXACRIM 175, 201

FENOXAPROP-ETHYL 141

FENOXAPROP-P-ETHYL 141

FENOXYCARB 230

FENPIPRAMIDE 83

FENPIPRANE 83

FENPROPOREX 83

FENPROSTALENE 83

FENPYROXIMATE 175

FENSON 141

FENSULFOTHION 201

FENTANYL 208

FENTEROL 266

FENTHION 141, 175, 201

FENTHION-ETHYL 201

FENVALERATE 175

FEXOFENADINE 38, 83

FIBRINOLYSIN 83

FIDAXOMICIN 83

FILGRASTIM 83

FINASTERIDE 83

FINGOLIMOD 83, 286

FIPRONIL 141, 175

FIROCOXIB 83

FLAMPROP-METHYL 141

FLAMPROP-M-METHYL 141

FLAVOXATE 50

FLAZASULFURON 141

FLECAINIDE 83

FLEROXACIN 83

FLOCOUMAFEN 175, 201

FLOCTAFENINE 83

FLONICAMID 175

FLORASULAM 141

FLORFENICOL 83

FLUANISONE 83

FLUAZIFOP-BUTYL 175

FLUAZIFOP-P-BUTYL 175

FLUAZINAM 175

FLUAZURON 141

FLUBENDAZOLE 141

FLUBENDIAMIDE 141

FLUCHLORALIN 142

FLUCLOROLONE 83

FLUCLOXACILLIN 83

FLUCOFURON 175, 201

FLUCONAZOLE 50, 83, 266, 277

FLUCYTHRINATE 201

FLUCYTOSINE 83

FLUDARABINE 83

FLUDIOXONIL 142

FLUDROCORTISONE 83

fluensulfone 176

FLUFENAMIC ACID 84

FLUFENOXURON 230

FLUMAZENIL 84

FLUMETHASONE 84

FLUMETHIAZIDE 84

FLUMETHRIN 142, 176

FLUMETSULAM 230

flumiclorac pentyl 142

FLUMIOXAZIN 176, 201

FLUNISOLIDE 84

Flunitrazepam 282

FLUNITRAZEPAM 208

FLUNIXIN MEGLUMINE 84

FLUOCINOLONE 84

FLUOCINONIDE 84

FLUOCORTIN 84

FLUOCORTOLONE 84

FLUOMETURON 230

FLUORESCEIN 84

FLUORIDES 39, 50, 84, 142, 176, 244, 266

FLUOROACETAMIDE 201

FLUOROACETIC ACID 201, 280

FLUOROMETHOLONE 84

FLUOROURACIL 84

FLUOXETINE 84

FLUOXYMESTERONE 84

FLUPENTHIXOL 84, 283

FLUPHENAZINE 84, 283

FLUPROPANATE 176

FLUPROSTENOL 84

FLUQUINCONAZOLE 176

FLURALANER 142

FLURANDRENOLONE 84

FLURAZEPAM 84, 283

FLURBIPROFEN 39, 84

FLUROACETAMIDE 280

FLUROXENE 84

FLUROXYPYR 230

FLUSILAZOL 176

FLUSPIRILENE 84

FLUTAMIDE 84

FLUTICASONE 39, 84

FLUTOLANIL 230

FLUTRIAFOL 176

FLUVALINATE 142, 176

FLUVASTATIN 84

FLUVOXAMINE 84

FLUXAPYROXAD 142

FOLIC ACID 39, 84

FOLINIC ACID 39, 84

FOLLICLE-STIMULATING HORMONE 85, 276

FOLLISTATIN 85, 236

FOLLITROPIN ALPHA 85, 235

FOLLITROPIN BETA 85, 235

FOLPET 201, 280

FOMIVIRSEN 85

FONDAPARINUX 85

FOOD 222

FORAMSULFURON 142

FORCHLORFENURON 230

FORMALDEHYDE 39, 176, 218, 244, 266

FORMALDEHYDE CONDENSATION PRODUCT 181

FORMEBOLONE 85

FORMESTANE 85

FORMETANATE 201

FORMIC ACID 142, 244, 266

FORMOTHION 176

FOSAMPRENAVIR 85

FOSAPREPITANT 85

FOSCARNET 85

FOSFESTROL 85

FOSINOPRIL 85

FOSPHENYTOIN 85

FOSPIRATE 142, 176

FOSTHIAZATE 201

FOTEMUSTINE 85

FRAMYCETIN 85

FRITTED GLAZING OR ENAMELLING PREPARATIONS 222

FULLERS EARTH 230

FULVESTRANT 85

FUMAGILLIN 176

FUNGAL PROTEASE derived from 230

FURALAXYL 142

FURALTADONE 85

FURATHIOCARB 142, 201

FURAZABOL 85

FURAZOLIDONE 85

FURETHIDINE 212

FURFURAL 176, 244, 266

FUROSEMIDE 85

FUSIDIC ACID 85

G

GABAPENTIN 85, 283

GALANTAMINE 85

GALANTHUS spp 85

GALLAMINE 85

GALSULFASE 85

GAMMA HYDROXYBUTYRATE 212

GAMMA-CYHALOTHRIN 142, 201

GANCICLOVIR 85

GANIRELIX 85

GATIFLOXACIN 85

GEFITINIB 86

GELSEMIUM SEMPERVIRENS 40, 276

GEMCITABINE 86, 283

GEMEPROST 86

GEMFIBROZIL 86

GEMIFLOXACIN 86

GEMTUZUMAB OZOGAMICIN 86

GENTAMICIN 86

GERANIUM OIL 230

GESTODENE 86

GESTONORONE 86

GESTRINONE 86

GHRH INJECTABLE PLASMID 86

GIBBERELLIC ACID 230

GITALIN 86

GLASS 222

GLATIRAMER ACETATE 86

GLAZED POTTERY 222

GLIBENCLAMIDE 86

GLIBORNURIDE 86

GLICLAZIDE 86

GLIMEPIRIDE 86

GLIPIZIDE 86

GLISOXEPIDE 86

GLUCAGON 50, 276

-GLUCANASE derived from *Aspergillus niger* 230

GLUFOSINATE-AMMONIUM 142

GLUTARALDEHYDE 40, 142, 176, 244, 266

GLUTATHIONE 86

GLUTETHIMIDE 86, 236, 283

GLYCERYL THIOGLYCOLLATE 177

GLYCERYL TRINITRATE 50, 86, 276

GLYCOLIC ACID 177, 244, 266

GLYCOPYRRONIUM 50, 86

GLYMIDINE 86

GLYPHOSATE 142

GnRH VACCINE 86

GOLIMUMAB 86

GONADORELIN 86

GONADOTROPHIC HORMONES 86

GOSERELIN 86

GRAMICIDIN 86

GRANISETRON 87

GREPAFLOXACIN 87

GRISEOFULVIN 87

GROWTH HORMONE 276

GUAIPHENESIN 40, 87

GUANABENZ 87

GUANACLINE 87

GUANETHIDINE 87

GUANIDINE 87, 177, 244

GUAZATINE 177

H

HACHIMYCIN 87

HAEMATIN 87

HAEMOPHILUS INFLUENZAE VACCINE 87

HALAUXIFEN METHYL 230

HALCINONIDE 87

HALOFANTRINE 87

HALOFENATE 87

HALOFUGINONE 87, 201, 281

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS 201, 281

HALOPERIDOL 87, 276, 283

HALOSULFURON-METHYL 142

HALOTHANE 87

HALOXON 177

HALOXYFOP 177

HARMALA ALKALOIDS 212

HCB 201, 281

HELIOTROPIUM spp. 218

HEMEROCALLIS 87

HEPARINS 87

HEPATITIS A VACCINE 87

HEPATITIS B VACCINE 87

HEPTACHLOR 177

HEROIN 212

HETACILLIN 87

HEXACHLOROPHANE 40, 87, 177, 244, 267

HEXACONAZOLE 142

HEXAFLURON 230

HEXAMETHONIUM 88

HEXAZINONE 142, 177

HEXETIDINE 88

HEXLOXYETHANOL 267

HEXOBENDINE 88

HEXOCYCLIUM 88

HEXOPRENALINE 88

HEXYL ACETATE 230

HEXYLOXYETHANOL 177, 244

HEXYTHIAZOX 230

HISTAMINE 88

HMG-CoA REDUCTASE INHIBITORS 88

HOMATROPINE 88

HUMAN BLOOD PRODUCTS 222

HUMAN CHORIONIC GONADATROPHIN 88

HUMAN OSTEOGENIC PROTEIN-1 (OP-1) 230

HUMAN PAPILLOMAVIRUS VACCINE 88

HYALURONIC ACID AND ITS POLYMERS 88

HYDRALAZINE 88

HYDRAMETHYLNON 142, 177

HYDRARGAPHEN 88

HYDRAZINE 177, 244, 267

HYDROCARBONS 244

HYDROCARBONS LIQUID AROMATIC 201

HYDROCARBONS, LIQUID 143

HYDROCHLORIC ACID 143, 177, 244, 267

HYDROCHLOROTHIAZIDE 88

HYDROCODONE 208, 283

HYDROCORTISONE 40, 50, 88, 267, 277

HYDROCORTISONE ACETATE 40, 50

HYDROCYANIC ACID 88, 202, 267, 276

HYDROCYANIC ACID AND CYANIDES 281

HYDROFLUMETHIAZIDE 88

HYDROFLUORIC ACID 143, 177, 202, 281

HYDROGEN PEROXIDE 143, 177, 218, 245, 267

HYDROGEN SULFIDE 202

HYDROMORPHINOL 208

HYDROMORPHONE 208, 283

HYDROPRENE 230

HYDROQUINONE 40, 88, 178, 245, 267

HYDROSILICOFLUORIC ACID 143, 178, 202, 245, 267

HYDROXYCHLOROQUINE 88

HYDROXYEPHEDRINE 88

HYDROXYPETHIDINE 212

HYDROXYPHENAMATE 89

HYDROXYPROGESTERONE 89

HYDROXYPROPYL CELLULOSE 230

HYDROXYSTENOZOL 89

HYDROXYUREA 89

HYDROXYZINE 89, 283

HYGROMYCIN 89

HYOSCINE 40, 89, 276

HYOSCINE BUTYLBROMIDE 40

HYOSCYAMINE 41, 276

HYOSCYAMUS NIGER 41, 276

HYPOTHALAMIC RELEASING FACTORS 89, 276

HYPROMELLOSE 89

I

IBAFLOXACIN 89

IBANDRONIC ACID 89

IBOGAINE 89

IBRITUMOMAB 89

IBUFENAC 89

IBUPROFEN 41, 51, 89, 268

IBUTEROL 89

IBUTILIDE 89

ICATIBANT 89

ICODEXTRIN 230

IDARUBICIN 89

IDOXURIDINE 89

IDURSULFASE 89

IFOSFAMIDE 89

ILOPROST 89

IMATINIB 89

IMAZALIL 143

IMAZAMOX 143

IMAZAPIC 143

IMAZAPYR 143

IMAZETHAPYR 143

IMEPITOIN 90

IMIDACLOPRID 143, 178

IMIDAPRIL 90

IMIDOCARB 178

IMIGLUCERASE 90

iminoctadine trialbesilate 178

IMIPENIM 90

IMIPRAMINE 90, 283

IMIPROTHRIN 143, 178

IMIQUIMOD 90

IMMUNOGLOBULINS 90

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS 223

INDACATEROL 90

INDANAZOLINE 41

INDAPAMIDE 90

INDAZIFLAM 178

INDINAVIR 90

INDOLE-3-ACETIC ACID 230

INDOMETHACIN 41, 90, 276

INDOPROFEN 90

INDORAMIN 90

INDOXACARB 144, 178

INFLIXIMAB 90

INFLUENZA AND CORYZA VACCINES 90

INGENOL MEBUTATE 90

INOSITOL NICOTINATE 51

INSULIN GLARGINE 90

INSULIN-LIKE GROWTH FACTOR I 90

INSULIN-LIKE GROWTH FACTORS 90, 236

INSULINS 90

INTERFERONS 90

INTERLEUKINS 90

INTRAOCULAR VISCOELASTIC PRODUCTS 223

IODINE 41, 178, 245, 268

IODOMETHANE 202, 281

IODOPHORS 178, 245

IODOSULFURON-METHYL-SODIUM 144

IODOTHIOURACIL 90

IOXYNIL 178

IPCONAZOLE 144, 178

IPILIMUMAB 90

IPRATROPIUM 42, 90

IPRATROPIUM BROMIDE 268

IPRIFLAVONE 90

IPRINDOLE 90

IPRODIONE 230

IPRONIAZID 90

IRBESARTAN 91

IRINOTECAN 91

IRON COMPOUNDS 42, 91, 144, 178

ISOAMINILE 91

ISOAMYL NITRITE 91

ISOBUTYL NITRITE 91

ISOCARBOPHOS 202

ISOCARBOXAZID 91

ISOCONAZOLE 42, 51, 91, 179

ISOCYANATES 179, 245, 268

ISOETARINE 91

ISOEUGENOL 144, 179

ISOFENPHOS 202

ISOFLURANE 91

ISOMETHADONE 212

ISOMETHEPTENE 91

ISONIAZID 91

ISOPHORONE 144, 245

ISOPRENALINE 91, 268

ISOPRENE ALCOHOL 230

ISOPRINOSINE 91

ISOPROPAMIDE 42, 91

ISOPROTURON 202

ISOSORBIDE DINITRATE 51, 91

ISOSORBIDE MONONITRATE 91

ISOSTEARYL ALCOHOL ETHOXYLATE 230

ISOTRETINOIN 91, 235, 268, 286

ISOXABEN 144

ISOXAFLUTOLE 144

ISOXICAM 91

ISOXSUPRINE 91

ISRADIPINE 91

ITRACONAZOLE 91

IVABRADINE 91

IVACAFTOR 91

IVERMECTIN 91, 144, 202

IXABEPILONE 91

J

JAPANESE ENCEPHALITIS VACCINE 91

JUNIPERUS SABINE 219

K

KANAMYCIN 91

KAOLIN 230

KEROSENE 245

KETAMINE 208

KETANSERIN 92

KETAZOLAM 92

KETOBEMIDONE 212

KETOCONAZOLE 42, 92

KETOPROFEN 51, 92

KETOROLAC 92

KETOTIFEN 42, 92

KHELLIN 92

KITASAMYCIN 92, 144

KRESOXIM-METHYL 230

KUNZEA OIL 230

L

LABETALOL 92

LACIDIPINE 92

LACOSAMIDE 92

LAMBDA-CYHALOTHRIN 144, 179, 202

LAMIVUDINE 92

Lamotrigine 283

LAMOTRIGINE 92

LANATOSIDES 92

LANREOTIDE 92

LANSOPRAZOLE 51, 92

LANTHANUM 92

LAPATINIB 92

LARONIDASE 92

LAROPIPRANT 92

LASALOCID 179

LATAMOXEF 92

LATANOPROST 92

LAUDEXIUM 93

LAURETH CARBOXYLIC ACIDS 179, 245

LAURIC ACID 230

LAUROMACROGOLS 93

LAURYL ALCOHOL (1-DODECANOL) 230

LAURYL ISOQUINOLINIUM BROMIDE 179, 245

LAVANDIN OIL 230

LAVENDER OIL 230

LEAD 93

LEAD COMPOUNDS 145, 179, 219, 245, 266, 268

LEAD METALLIC 231

LEFETAMINE 93

LEFLUNOMIDE 93, 268, 286

LEMON OIL 145, 245, 268

LEMONGRASS OIL 231

LENALIDOMIDE 93, 235, 268, 286

LENOGRASTIM 93

LEPIDOPTEROUS SEX PHEROMONES 231

LEPIRUDIN 93

LEPTAZOL 93

LEPTOPHOS 202

*Leptospermum scoparium* oil 245

LEPTOSPERMUM SCOPARIUM OIL 180

LERCANIDIPINE 93

LETROZOLE 93

LEUPRORELIN 93

LEVALLORPHAN 93

LEVAMISOLE 93, 145, 180

LEVAMPHETAMINE 208

LEVETIRACETAM 93, 283

LEVOBUNOLOL 93

LEVOBUPIVACAINE 93

LEVOCABASTINE 42, 93, 268, 286, 283

LEVODOPA 93

LEVOMEPROMAZINE 93

LEVOMETHAMPHETAMINE 208

LEVOMETHORPHAN 212

LEVOMORAMIDE 208

LEVONORGESTREL 51, 93

LEVOPHENACYLMORPHAN 212

LEVORPHANOL 208

LEVOSIMENDAN 93

LIDOFLAZINE 93

LIGNOCAINE 42, 93, 145

LIGULARIA DENTATA 219

LIME OIL 145, 245, 268

LIMONENE 231

LINAGLIPTIN 94

LINCOMYCIN 94

LINDANE 42, 94, 145, 180

LINEZOLID 94

LINOLEIC ACID 231

LINSEED FATTY ACIDS 231

LINURON 231

LIOTHYRONINE 94

LIQUORICE, DEGLYCYRRHISINISED 231

LIRAGLUTIDE 94

LISDEXAMFETAMINE 208

LISINOPRIL 94

LISURIDE 94

LITHIUM 42, 94

LITHIUM PERFLUOROOCTANE SULFONATE 202

LIXISENATIDE 94

LOBELIA INFLATA 43

LOBELINE 43

LODOXAMIDE 43, 94

LOFEXIDINE 94

LOGIPARIN 94

LOMEFLOXACIN 94

LOMUSTINE 94

LOPERAMIDE 43, 94, 268

LOPINAVIR 94

LOPRAZOLAM 94

LORACARBEF 94

LORATADINE 43, 94

LORAZEPAM 95, 283

LORMETAZEPAM 95

LOSARTAN 95

LOTEPREDNOL 95

LOXAPINE 95

LUBRICANTS 223

LUFENURON 145

LUMEFANTRINE 95

LUMIRACOXIB 95

LURASIDONE 95, 283

LUTEINISING HORMONE 95, 235

LYMECYCLINE 95

LYSERGIC ACID 212

LYSERGIDE 212

M

MACITENTAN 95, 236, 286

MACROGOLS 43, 51

MADURAMICIN 145, 202, 281

MAFENIDE 95, 180

MAGNESIUM CHLORATE 145, 245, 268

MAGNESIUM SULFATE 51

MALACHITE GREEN 145, 202

MALATHION 51, 146, 180, 245

MALEIC HYDRAZIDE 231

MANCOZEB 146

MANDIPROPAMID 146

MANDRAGORA OFFICINARUM 95

MANGANESE DIOXIDE 231

MANNITYL HEXANITRATE 51

MANNOMUSTINE 95

MAPROTILINE 95

MARAVIROC 95

MARBOFLOXACIN 95

MARJORAM OIL 146, 246

MAROPITANT 95

MATCHES 223

MAVACOXIB 95

MAZIDOX 202

MAZINDOL 95, 283

MCPA 146, 180

MCPB 146

MEASLES VACCINE 95

MEBANAZINE 95

MEBENDAZOLE 43, 146, 181

MEBEVERINE 95

MEBHYDROLIN 95, 283

MEBOLAZINE 95

MEBUTAMATE 95

MECAMYLAMINE 95

MECARBAM 202

MECASERMIN 96

MECILLINAM 96

MECLOCYCLINE 96

MECLOFENAMATE 96

MECLOFENAMIC ACID 146

MECLOFENOXATE 96

MECLOQUALONE 212

MECLOZINE 43, 96, 283

MECOPROP 146, 181

MECOPROP-P 181

MEDAZEPAM 96, 283

MEDETOMIDINE 96

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS 223

MEDICAL DEVICES 223

MEDIGOXIN 96

MEDROXYPROGESTERONE 96

MEDRYSONE 96

MEFENAMIC ACID 43, 96, 268

MEFENOREX 96

MEFENPYR-DIETHYL 146

MEFLOQUINE 96

MEFLUIDIDE 181

MEFRUSIDE 96

*MEGASPHAERA ELSDENII* strain 41125 231

MEGESTROL 96

MELAGATRAN 96

MELALEUCA OIL 181, 246

MELATONIN 96

MELENGESTROL 96

MELENGESTROL ACETATE 181

MELIA AZEDARACH 219

MELOXICAM 96

MELPHALAN 96

MEMANTINE 96

MENAZON 181

MENINGOCOCCAL VACCINE 96

MENOTROPHIN 96

MEPACRINE 96

MEPENZOLATE 96

MEPHENESIN 96

MEPHENTERMINE 96

MEPINDOLOL 96

MEPIQUAT 146

MEPITIOSTANE 96

MEPIVACAINE 97

Meprobamate 283

MEPROBAMATE 97

MEPTAZINOL 97

Mepyramine 283

MEPYRAMINE 43, 51, 97

MEQUITAZINE 97

MERCAPTOMERIN 97

MERCAPTOPURINE 97

MERCURIC CHLORIDE 202

MERCURIC IODIDE 246

MERCURIC NIRATE 246

MERCURIC OXIDE 181, 246

MERCURIC POTASSIUM IODIDE 246

MERCURIC THIOCYANATE 246, 268

MERCUROCHROME 43, 97, 181, 246

MERCUROUS CHLORIDE 246

MERCURY 43, 97, 202, 276, 281

MERCURY metallic 246

MERCURY, organic compounds 246

MEROPENEM 97

MERSALYL 97

MERURIC CHLORIDE 246

MESABOLONE 97

MESALAZINE 97

MESNA 97

MESOLSULFURON-METHYL 231

MESOTRIONE 146

MESTANOLONE 97

MESTEROLONE 97

MESTRANOL 97

METACRESOLSULPHONIC ACID 181, 268

METAFLUMIZONE 146

METALAXYL 146, 181

METALDEHYDE 146, 181, 246

METANDIENONE 97

METARAMINOL 97

*METARHIZIUM ANISOPLIAE* 231

METAZOCINE 212

METENOLONE 97

METERGOLINE 97

METFORMIN 97

METHABENZTHIAZURON 146

METHACHOLINE 97

METHACRIFOS 181, 203, 281

METHACYCLINE 97

METHADONE 208, 283

METHALLENOESTRIL 97

METHAM 181

METHAMIDOPHOS 203

METHANDRIOL 97

METHANOL 146, 181, 246, 269

METHANTHELINIUM 97

METHAPYRILENE 203

METHAQUALONE 212

METHAZOLAMIDE 97

METHAZOLE 203

METHCATHINONE 212

METHDILAZINE 51, 98, 283

METHENOLONE 98

METHICILLIN 98

METHIDATHION 203

METHIMAZOLE 98

METHIOCARB 146, 182, 203

METHISAZONE 98

METHIXENE 98

METHOCARBAMOL 98, 283

METHOFLUTHRIN 147

METHOHEXITONE 98

METHOIN 98

METHOMYL 182, 203

METHOPRENE 231

METHOTREXATE 98

METHOXAMINE 43, 98, 269

METHOXSALEN 98

METHOXYCHLOR 147

METHOXYETHYLMERCURIC ACETATE 203, 281

METHOXYETHYLMERCURIC CHLORIDE 203

METHOXYFENOZIDE 231

METHOXYFLURANE 98

METHOXYPHENAMINE 43

METHSUXIMIDE 98

METHYCLOTHIAZIDE 98

METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE 213

METHYL ACETATE 231

METHYL AMINOLEVULINATE 98

METHYL BENZOQUATE 231

METHYL BROMIDE 203, 281

METHYL CHLORIDE 269

METHYL ETHYL KETONE 147, 246, 269

METHYL ETHYL KETONE OXIME 182, 246, 269

METHYL ETHYL KETONE PEROXIDE 147, 246, 269

METHYL ISOAMYL KETONE 147, 246

METHYL ISOBUTYL KETONE 147, 246

METHYL ISOTHIOCYANATE 182

METHYL MERCURY 98

Methyl methacrylate 269

METHYL METHACRYLATE 182, 219

METHYL NEODECANAMIDE 182

METHYL p-HYDROXYBENZOATE 231

METHYL SALICYLATE 98, 147, 182

Methyl salicylate liquid 247

METHYLAMPHETAMINE 208

METHYLANDROSTANOLONE 98

METHYLATED SPIRIT 246

METHYLATED SPIRIT(S) 147

METHYLCLOSTEBOL 98

Methylcyclopentadienyl Manganese Tricarbonyl 182, 203

METHYLDESORPHINE 213

METHYLDIBROMO GLUTARONITRILE 182, 219, 269

METHYLDIHYDROMORPHINE 208

METHYLDOPA 98

METHYLENE BISTHIOCYANATE 182, 269

METHYLENE BLUE 98, 147, 203

METHYLEPHEDRINE 43

METHYLERGOMETRINE 98

METHYLEUGENOL 182, 246, 269

METHYLMERCURY 276

METHYLNALTREXONE 98

METHYLNORBORNYLPYRIDINE 182

METHYLPENTYNOL 98

METHYLPHENIDATE 208

METHYLPHENOBARBITONE 98

METHYLPREDNISOLONE 98

METHYLTESTOSTERONE 98

METHYLTHIOURACIL 99

METHYLTRIENOLONE 99

METHYPRYLONE 99

METHYSERGIDE 99

METIRAM 147

METOCLOPRAMIDE 51, 99

METOFLUTHRIN 182

METOLACHLOR 147

METOLAZONE 99

METOPON 213

METOPROLOL 99

METOSULAM 182

METRAFENONE 147, 182

METRIBOLONE 99

METRIBUZIN 183

METRIFONATE 99

METRONIDAZOLE 99

METSULFURONMETHYL 231

METYRAPONE 99

MEVINPHOS 203

MEXILETINE 99

MEZLOCILLIN 99

MIANSERIN 99, 283

MIBEFRADIL 99

MIBOLERONE 99

MICAFUNGIN 99

MICONAZOLE 43, 51, 99, 183, 269, 277

MIDAZOLAM 99

MIDODRINE 99

MIFEPRISTONE 99

MIGLITOL 99

MIGLUSTAT 99

MILBEMECTIN 147, 183

MILBEMYCIN OXIME 99, 147

MILRINONE 99

MINOCYCLINE 99

MINOXIDIL 43, 99

MIPAFOX 203

MIRABEGRON 99

MIREX 203, 281

MIRTAZAPINE 100, 283

MISOPROSTOL 100, 269, 286

MITOBRONITOL 100

MITOMYCIN 100

MITOTANE 100

MITOXANTRONE 100

MITRAGYNA SPECIOSA 213

MITRAGYNINE 213

MITRATAPIDE 100

MIVACURIUM CHLORIDE 100

MOCLOBEMIDE 100

MODAFINIL 100

MOLGRAMOSTIM 100

MOLINATE 203, 281

MOLINDONE 100

MOMETASONE 43, 100

MONENSIN 100, 147, 183

MONEPANTEL 147

MONOBENZONE 100

MONOCLONAL ANTIBODIES 100

MONOCROTOPHOS 203

MONTELUKAST 100

MOPERONE 100

MORANTEL 147, 183

MORAZONE 100

MORICIZINE 100

MORPHERIDINE 213

MORPHINE 208, 283

MORPHINE METHOBROMIDE 208

MORPHINE-N-OXIDE 208

MOTOR, HEATING or FURNACE FUELS 223

MOTRAZEPAM 100

MOTRETINIDE 100

MOXIDECTIN 100, 147, 183, 203

MOXIFLOXACIN 100

MOXONIDINE 100

MSMA 183, 203

MUMPS VACCINE 101

MUPIROCIN 101

MURAGLITAZAR 101

MUROMONAB 101

MUSCIMOL 213

MUSTINE 101

MYCLOBUTANIL 148

MYCOPHENOLIC ACID 101

MYRISTIC ACID 231

MYROPHINE 213

N

N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE 213

N-(N-DODECYL)-2-PYRROLIDONE 140, 172, 243

N-(N-OCTYL)-2-PYRROLIDONE 148, 184, 247

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE 211

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE 162, 248, 271

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE 162, 248, 271

N,N-DIALLYLDICHLOROACETAMIDE 138

N,N-DIETHYLTRYPTAMINE 211

N,N-DIMETHYLAMPHETAMINE 211

N,N-DIMETHYLTRYPTAMINE 211

NAA 148

NABILONE 208

NABIXIMOLS 208, 235, 283

NABUMETONE 101

NADOLOL 101

NADROPARIN 101

NAFARELIN 101

NAFTIDROFURYL 101

NALBUPHINE 101, 283

NALED 148, 183

NALIDIXIC ACID 101

NALMEFENE 101

NALORPHINE 101

NALOXONE 101

NALTREXONE 101

NANDROLONE 101

NAPHAZOLINE 43, 269

NAPHTHALENE 183, 247, 269, 276

NAPHTHALOPHOS 183, 203

NAPHTHOYLINDOLES 213

NAPHTHOYLPYRROLES 213

NAPHTHYLMETHYLINDENES 213

NAPHTHYLMETHYLINDOLES 213

NAPROPAMIDE 231

NAPROXEN 43, 51, 101, 269

NAPTALAM 148

NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE 214

NAPTHYL ACETAMIDE 231

NARASIN 101, 183

NARATRIPTAN 101

NATALIZUMAB 101

NATAMYCIN 101

NATEGLINIDE 101

n-BUTYL BUTYRATE 229

n-BUTYL LACTATE 229

N-COCO-1,3-DIAMINOPROPANE 168

N-cyclohexyldiazeniumdioxy-potassium 169

NEBACUMAB 101

NEBIVOLOL 101

NEDOCROMIL 101

NEFAZODONE 101

NEFOPAM 102

NELFINAVIR 102

NEOMYCIN 102

NEOSTIGMINE 102

NEPAFENAC 102

NERIUM OLEANDER 102, 276

NEROLI OIL 231

NESIRITIDE 102

N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE 212

NETILMICIN 102

NETOBIMIN 148, 183

NEVIRAPINE 102

NIALAMIDE 102

NICARBAZIN 231

NICARDIPINE 102

NICERGOLINE 102

NICKEL SULFATE 183

NICLOSAMIDE 43

NICOCODINE 214

NICODICODINE 214

NICOFURANOSE 102

NICOMORPHINE 214

NICORANDIL 102

NICOTINE 102, 183, 203, 269, 281

NICOTINIC ACID 51, 102

NICOTINYL ALCOHOL 52

NICOUMALONE 102

NIFEDIPINE 102

NIFENAZONE 102

NIKETHAMIDE 102

NILOTINIB 102

NILUTAMIDE 102

NIMESULIDE 102

NIMIDANE 183, 203

NIMODIPINE 102

NIMORAZOLE 102

NIRIDAZOLE 102

NISIN 231

NISOLDIPINE. 103

NITENPYRAM 183

NITISINONE 103

NITRAZEPAM 103, 283

NITRENDIPINE 103

NITRIC ACID 148, 183, 247, 269

NITRIC OXIDE 103

NITROBENZENE 183, 247, 270

NITROFEN 203, 281

NITROFURANTOIN 103

NITROFURAZONE 103

NITROPHENOLS 184, 247, 270

NITROPRUSSIDES 184, 204, 247, 270

NITROSCANATE 148

NITROUS OXIDE 103

NITROXOLINE 103

NITROXYNIL 184

NIZATIDINE 43, 103, 270

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE 213

N-METHYL-2-PYRROLIDONE 147, 182, 246

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE 148

N-OLEYL-1,3-DIAMINOPROPANE 184

NOMEGESTROL 103

NOMIFENSINE 103

NONOXINOL 9 148, 184, 247

NORACYMETHADOL 214

NORADRENALINE 103, 270

NORANDROSTENOLONE 103

NORBOLETHONE 103

NORBORMIDE 148

NORCLOSTEBOL 103

NORCODEINE 208

NORELGESTROMIN 103

NORETHANDROLONE 103

NORETHISTERONE 103

NORFLOXACIN 103

NORFLURAZON 231

NORGESTREL 103

NORIBOGAINE 103

NORLEVORPHANOL 214

NORMAL HUMAN IMMUNOGLOBULIN 103

NORMETHADONE 209, 283

NORMETHANDRONE 103

NORMORPHINE 214

NORPIPANONE 214

NORTRIPTYLINE 103, 283

NOSCAPINE 44

NOVALURON 231

NOVOBIOCIN 103

NOXIPTYLINE 103

N-PHENETHYL-4-PIPERIDONE 214

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE 192

NUTMEG OIL 148

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION 223

NYSTATIN 44, 52, 103, 270, 277

O

OCLACITNIB 104

OCRIPLASMIN 104

OCTAMYLAMINE 104

OCTATROPINE 104

OCTHILINONE 184

OCTREOTIDE 104

OCTYL ALCOHOLS 231

OCTYL NITRITE 104

OESTRADIOL 104, 149, 276

OESTRIOL 104

OESTROGENS 104

OESTRONE 104, 276

OFATUMUMAB 104

OFLOXACIN 104

Olanzapine 283

OLANZAPINE 104

OLAQUINDOX 184

OLEANDOMYCIN 104, 149

OLEANDRIN 104

OLEIC ACID 231

OLMESARTAN 104

OLODATEROL 104

OLOPATADINE 104

OLSALAZINE 104

OMALIZUMAB 104

OMEGA-3-ACID ETHYL ESTERS 104

OMEPRAZOLE 52, 104

OMETHOATE 149, 184, 204

ONDANSETRON 104

OPIPRAMOL 104

Opium 283

OPIUM 209

ORANGE OIL 247

ORANGE OIL (BITTER) 149

ORANGE OIL, SWEET 231

ORBIFLOXACIN 104

ORCIPRENALINE 104, 270

ORGANOPHOSPHORUS COMPOUNDS 104

ORLISTAT 52, 105

ORNIDAZOLE 105

ORNIPRESSIN 105

ORPHENADRINE 105

ortho-DICHLOROBENZENE 263

ortho-PHENYLPHENOL 248, 271

ortho-PHTHALADEHYDE 271

ortho-PHTHALALDEHYDE 248

ORTHOPTERIN 105

ORTHO-TOLIDINE 281

OSELTAMIVIR 105

OUABAIN 105

OVANDROTONE 105

OXABETRINIL 231

OXABOLONE 105

OXACILLIN 105

OXADIARGYL 149

OXADIAZON 184

OXADIXYL 149

OXALATES 270

OXALIC ACID 184, 247, 270

OXALIPLATIN 105

OXAMYL 204

OXANDROLONE 105

OXANTEL EMBONATE 149

OXAPROZIN 105

OXAZEPAM 105, 283

OXCARBAZEPINE 105

OXEDRINE 105

OXETACAINE 44, 105

OXFENDAZOLE 149

OXIBENDAZOLE 149

OXICONAZOLE 44, 52, 105

OXITROPIUM 105

OXOLAMINE 105

OXOLINIC ACID 105

OXPENTIFYLLINE 105

OXPRENOLOL 105

OXYBUPROCAINE 105

OXYBUTYNIN 105

OXYCARBOXIN 149

OXYCLOZANIDE 184

Oxycodone 283

OXYCODONE 209

OXYDEMETON METHYL 204

OXYFLUORFEN 231

OXYMESTERONE 105

OXYMETAZOLINE 44, 270

OXYMETHOLONE 106

OXYMORPHONE 209

OXYPHENBUTAZONE 106

OXYPHENCYCLIMINE 106

OXYPHENISATIN 219

OXYPHENONIUM 106

OXYTETRACYCLINE 106, 149

OXYTHIOQUINOX 149

OXYTOCIN 106, 276

P

PACLITAXEL 106

PACLOBUTRAZOL 149

PAECILOMYCES LILACINUS Strain 251 184

PAINT 270

PALIFERMIN 106

PALIPERIDONE 106, 283

PALIVIZUMAB 106

PALMAROSA OIL 231

PALMITIC ACID 231

PALONOSETRON 106

PAMAQUIN 106

PAMIDRONIC ACID 106

PANCREATIC ENZYMES 106

PANCURONIUM 106

PANITUMUMAB 106

PANTOPRAZOLE 52, 106

Papaveretum 283

PAPAVERINE 44, 106

PAPER 223

PARACETAMOL 44, 52, 106, 270

para-DICHLOROBENZENE 263

PARA-FLUOROFENTANYL 214

PARAFORMALDEHYDE 44, 184, 219, 247

PARALDEHYDE 106

PARAMETHADIONE 106

PARAMETHASONE 107

PARAQUAT 204

PARATHION 204

PARATHION-METHYL 185, 204

PARBENDAZOLE 185

PARECOXIB 107

PARICALCITOL 107

PAROMOMYCIN 107

PAROXETINE 107

PASIREOTIDE 107

PATCHOULI OIL 231

PAZOPANIB 107

PEBULATE 185

PECAZINE 107

PECTINASE derived from *Aspergillus niger* 231

PEFLOXACIN 107

PEGAPTANIB 107

PEGFILGRASTIM 107

PEGINTERFERON 107

PEGVISOMANT 107

PEHNOLS 247

PEMETREXED 107

PEMOLINE 107

PEMPIDINE 107

PENBUTOLOL 107

PENCICLOVIR 44, 107

PENCONAZOLE 149

PENCYCURON 231

PENDIMETHALIN 149

PENETHAMATE 107

PENFLUFEN 149

PENICILLAMINE 107

PENNYROYAL OIL 185, 247

PENTACHLOROPEHNOL 270

PENTACHLOROPHENOL 185, 204

PENTADECANOIC ACID 231

PENTAERYTHRITYL TETRANITRATE 107

PENTAGASTRIN 107

PENTAMETHONIUM 107

PENTAMIDINE 107

PENTAZOCINE 209, 283

PENTHIENATE 107

PENTHIOPYRAD 149

PENTOBARBITONE 107, 209, 283

PENTOLINIUM 107

PENTOSAN POLYSULFATE SODIUM 107

PEPPERMINT OIL 231

PERACETIC ACID 149, 185, 247, 270

PERAMPANEL 107, 236, 283

PERFLUIDONE 185

PERGOLIDE 107

PERHEXILINE 108

PERICYAZINE 108, 283

PERINDOPRIL 108

PERMANGANATES 185, 270

PERMETHRIN 108, 149, 185

PERPHENAZINE 108, 283

PERTUSSIS ANTIGEN 108

PERTUZUMAB 108

PETASITES spp 219

PETHIDINE 209, 283

PETROL 150, 247

PHEDRAZINE 44

PHENACEMIDE 108

PHENACETIN 108

PHENADOXONE 214

PHENAGLYCODOL 108

PHENAMPROMIDE 214

PHENAZOCINE 214

PHENAZONE 44, 108, 150

PHENAZOPYRIDINE 108

PHENCYCLIDINE 214

PHENDIMETRAZINE 209

PHENELZINE 108, 283

PHENETICILLIN 108

PHENFORMIN 108

PHENGLUTARIMIDE 108

PHENINDIONE 108

PHENIRAMINE 44, 52, 108, 283

PHENISATIN 108

PHENISOPHAM 150

PHENMEDIPHAM 231

PHENMETRAZINE 209

PHENOBARBITONE 108, 283

PHENOL 45, 108, 150, 185, 270

PHENOLPHTHALEIN 108

PHENOLS 247, 270

PHENOMORPHAN 214

PHENOPERIDINE 209, 283

PHENOTHIAZINE 186

PHENOXYBENZAMINE 108

PHENOXYMETHYLPENICILLIN 108

PHENSUXIMIDE 108

PHENTERMINE 108, 236

PHENTHIMENTONIUM 108

PHENTOLAMINE 108

PHENYL METHYL KETONE 150, 248

PHENYLACETYLINDOLES 214

PHENYLBUTAZONE 108

PHENYLENEDIAMINES 186, 219, 248, 270

PHENYLEPHRINE 45, 108, 270

PHENYLMERCURIC ACETATE 204, 281

PHENYLPHENOL 150

PHENYLPROPANOLAMINE 109

PHENYLTOLOXAMINE 109, 283

PHENYTOIN 109, 271

PHOLCODINE 45, 109, 209, 283

PHORATE 204

PHOSALONE 186

PHOSFOLAN 204

PHOSMET 186

PHOSPHIDE 281

PHOSPHIDES, METALLIC 204

PHOSPHINE 204, 281

PHOSPHODIESTERASE TYPE 5 INHIBITORS 109

PHOSPHONIC 150

PHOSPHONIC ACID 248, 271

PHOSPHORIC ACID 150, 186, 248, 271

PHOSPHORUS 271, 276

PHOSPHORUS, 248

PHOSPHORUS, YELLOW 204

PHOTOGRAPHIC PAPER or FILM 223

PHOXIM 186

PHTHALALDEHYDE 150, 186

PHTHALYLSULFATHIAZOLE 109

PHYSOSTIGMINE 109

PHYTASE 232

PICARIDIN 150

PICLORAM 232

PICOLINAFEN 232

PICRIC ACID 248, 271

PICROTOXIN 109

PIGMENTS 223

PILOCARPINE 109

PIMECROLIMUS 109

PIMELIC ACID 232

PIMINODINE 214

PIMOBENDAN 109

PIMOZIDE 109, 283

PINACIDIL 109

PINDOLOL 109

PINDONE 186

PINE OILS 150, 186

PINOXADEN 150, 187

PIOGLITAZONE 109

PIPECURONIUM 109

PIPEMIDIC ACID 109

PIPENZOLATE 109

PIPER METHYSTICUM 109

PIPERACILLIN 110

PIPERAZINE 45, 150

PIPERIDINE 110

PIPERIDOLATE 110

PIPERONYL BUTOXIDE 232

PIPEROPHOS 187

PIPOBROMAN 110

PIPOTHIAZINE 110

PIPRADROL 110

PIRACETAM 110

PIRBUTEROL 110

PIRENOXINE 110

PIRENZEPINE 110

PIRETANIDE 110

PIRIMICARB 150, 187

PIRIMIPHOS-ETHYL 187

PIRIMIPHOS-METHYL 187

PIRITRAMIDE 209

PIROXICAM 110

PIRPROFEN 110

PITAVASTATIN 110

PITUITARY HORMONES 110

PIVAMPICILLIN 110

PIZOTIFEN 110, 283

PLERIXAFOR 110

PLICAMYCIN 110

PNEUMOCOCCAL VACCINE 110

PODOPHYLLIN 271

PODOPHYLLOTOXIN 45, 52, 110, 271

PODOPHYLLUM EMODI 45, 52, 110

PODOPHYLLUM PELTATUM 45, 52, 111

PODOPHYLLUM RESIN 276

POLIDEXIDE 111

POLIHEXANIDE 150, 271

POLIOMYELITIS VACCINE 111

POLIXETONIUM SALTS 150, 187

POLOXALENE 232

POLY (GNRF) OVALBUMIN 232

POLY DIALLYL DIMETHYL AMMONIUM 232

POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS 150, 248

POLYACRYLAMIDE 111

POLYCAPROLACTONE 111

POLYESTRADIOL 111

POLYETHANOXY (15) TALLOW AMINE 150, 248

POLYHEDROSIS VIRUS of 232

POLYLACTIC ACID 111

POLYMYXIN 111

POLYSORBATE 20 232

POLYSULFATED GLYCOSAMINOGLYCANS 111

POLYTHIAZIDE 111

PORACTANT 111

PORCELAIN 223

PORCINE SOMATOTROPHIN 232

POSACONAZOLE 111

POTASIUM BROMATE 248

POTASIUM CHLORATE 248

POTASSIUM AZELOYL DIGLYCINATE 187

POTASSIUM BICARBONATE 232

POTASSIUM BROMATE 187

POTASSIUM BROMIDE 111

POTASSIUM CHLORATE 45, 150

POTASSIUM CHLORIDE 111

POTASSIUM CYANATE 187, 248

POTASSIUM HYDROXIDE 150, 187, 219, 248, 272

POTASSIUM METABISULPHITE 151, 272

POTASSIUM NITRITE 151, 187, 204, 248, 272

POTASSIUM PERCHLORATE 112

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT 151, 187

POTASSIUM PERSULFATE 188, 249, 272

potassium sorbate 232

POTASSIUM SULFIDE 151, 249, 272

PRACTOLOL 112

PRADOFLOXACIN 112

PRALATREXATE 112

PRALIDOXIME 112

PRALLETHRIN 151, 188

PRAMIPEXOLE 112

PRAMOCAINE 112

PRAMPINE 112

PRASTERONE 112

PRASUGREL 112

PRAVASTATIN 112

PRAZEPAM 112, 283

PRAZIQUANTEL 112

PRAZOSIN 112

PREDNISOLONE 112

PREDNISONE 112

PREGABALIN 112, 283

PREGNENOLONE 112

PRENALTEROL 112

PRENYLAMINE 112

PRILOCAINE 45, 112

PRIMAQUINE 112

PRIMIDONE 112

PRINTING INKS or INK ADDITIVES 223

PROBENECID 112

PROBUCOL 112

PROCAINAMIDE 112

PROCAINE 112

PROCAINE PENICILLIN 112

PROCARBAZINE 112

PROCHLORAZ 188

Prochlorperazine 283

PROCHLORPERAZINE 52, 112

PROCYCLIDINE 45, 113

PROCYMIDONE 204

PROFENOFOS 188

PROFOXYDIM 151

PROGESTERONE 113, 151, 276

PROGESTOGENS 113

PROGLUMIDE 113

PROGUANIL 113

PROHEPTAZINE 214

PROHEXADIONE CALCIUM 151

PROLINTANE 113

PROMACYL 188

PROMAZINE 113, 283

PROMETHAZINE 45, 52, 113, 283

PROMETRYN 151

PROMOXOLANE 113

PROPACHLOR 188

PROPAFENONE 113

PROPAMIDINE 46, 113

PROPAMOCARB 151

PROPANIDID 113

PROPANIL 151

PROPANTHELINE 113

PROPAQUIZAFOP 151

PROPARGITE 188

PROPENTOFYLLINE 113

PROPERIDINE 214

PROPETAMPHOS 188

PROPETANDROL 113

PROPICONAZOLE 151, 188

PROPINEB 188

PROPIONIBACTERIUM ACNES 113

PROPIONIC ACID 151, 188, 249, 272

PROPIRAM 209

PROPOFOL 113

PROPOXUR 151, 188

PROPRANOLOL 113, 276

PROPYL ACETATES 232

PROPYLENE 204

PROPYLENE GLYCOL 232

PROPYLENE OXIDE 281

PROPYLHEXEDRINE 113

PROPYLTHIOURACIL 113

PROPYPHENAZONE 113

PROPYZAMIDE 152

PROQUAZONE 113

PROQUINAZID 188

PROSCILLARIDIN 113

PROSTAGLANDINS 113

PROSTIANOL 113

PROSULFOCARB 188

PROSULFURON 188

PROTAMINE 113

PROTHIOCONAZOLE 232

PROTHIOCONAZOLE-DESCHLORO 152

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE 152

PROTHIOFOS 188

PROTHIONAMIDE 113

PROTHIPENDYL 113

PROTIRELIN 113

PROTOVERATRINES 113

Protriptyline 283

PROTRIPTYLINE 114

PROXYMETACAINE 114

PRUCALOPRIDE 114

PSEUDOEPHEDRINE 52, 114

*PSEUDOMONAS FLUORESCENS* 232

PSILOCYBINE 214

PTERIDIUM spp 219

PULMONARIA spp 219

PYMETROZINE 152

PYRACLOFOS 188

PYRACLOSTROBIN 152

PYRAFLUFEN-ETHYL 152

PYRANTEL 46

PYRASULFOTOLE 152

PYRAZINAMIDE 114

PYRAZOPHOS 188

PYRETHRINS 46, 152

PYRIDABEN 152, 188

Pyridalyl 188

PYRIDATE 188

PYRIDINOLCARBAMATE 114

PYRIDOSTIGMINE 114

PYRIDOXAL 114

PYRIDOXAMINE 114

PYRIDOXINE 114

PYRIFENOX 152

PYRIMETHAMINE 114

PYRIMETHANIL 232

PYRINURON 204, 281

PYRIOFENONE 189

PYRIPROLE 188

PYRIPROXYFEN 232

PYRITHIOBAC SODIUM 152

pyrithione copper 188

PYRITHIONE ZINC 46, 152, 188, 249

PYROVALERONE 114

PYROXASULFONE 189

PYROXSULAM 189

PYRVINIUM 114

Q

QUASSIA 232

QUATERNARY AMMONIUM COMPOUNDS 152, 189

QUAZEPAM 114

QUETIAPINE 114, 284

QUINAGOLIDE 114

QUINALBARBITONE 209, 284

QUINAPRIL 114

QUINBOLONE 114

QUINCLORAC 152

QUINETHAZONE 114

QUINIDINE 114

QUININE 114, 152, 204

QUINISOCAINE 114

QUINOXYFEN 232

QUINTOZENE 152

QUINUPRISTIN 114

QUIZALOFOP ETHYL. 189

QUIZALOFOP-P-ETHYL 153, 189

QUIZALOFOP-P-TEFURYL 189

R

RABEPRAZOLE 52, 114

RABIES VACCINE 114

RACEMETHORPHAN 214

RACEMORAMIDE 209

RACEMORPHAN 214

RACTOPAMINE 114, 153

RADIOGRAPHIC CONTRAST MEDIA 224

RADIOISOTOPES 224

RALOXIFENE 114

RALTEGRAVIR 114

RALTITREXED 115

RAMIPRIL 115

RANIBIZUMAB 115

RANITIDINE 46, 115, 272

RAPACURONIUM 115

RASAGILINE 115

RASBURICASE 115

RAUWOLFIA SERPENTINA 115

RAUWOLFIA VOMITORIA 115

RAZOXANE 115

REBOXETINE 115

RED YEAST RICE 115

REGORAFENIB 115

REMIFENTANIL 209

REMOXIPRIDE 115

REPAGLINIDE 115

RESERPINE 115

RESMETHRIN 153, 189

RETAPAMULIN 115

RETEPLASE 115

RETIGABINE 115, 284

RIBAVIRIN 115

RIDAFOROLIMUS 115

RIFABUTIN 115

RIFAMPICIN 115

RIFAMYCIN 115

RIFAPENTINE 115

RIFAXIMIN 115

RILPIVIRINE 115

RILUZOLE 116

RIMEXOLONE 116

RIMITEROL 116

RIMONABANT 116

RIMSULFURON 153

RIOCIGUAT 116, 235, 286

RISEDRONIC ACID 116

RISPERIDONE 116, 284

RITODRINE 116

RITONAVIR 116

RITUXIMAB 116

RIVAROXABAN 116

RIVASTIGMINE 116

RIZATRIPTAN 116

ROBENACOXIB 116

ROBENIDINE 153

ROFECOXIB 116

ROFLUMILAST 116

ROLICYCLIDINE 214

ROLITETRACYCLINE 116

romidepsin 116

ROMIFIDINE 116

ROMIPLOSTIM 116

RONIDAZOLE 116

ROPINIROLE 116

ROPIVACAINE 116

ROSEMARY OIL 232

ROSIGLITAZONE 116

ROSOXACIN 116

ROSUVASTATIN 116

ROTENONE 189

ROTIGOTINE 116, 284

ROXIBOLONE 116

ROXITHROMYCIN 116

RUBELLA VACCINE 117

RUBOXISTAURIN 117

RUPATADINE 117, 284

RUXOLITINIB 117

S

SAFLUFENACIL 153, 204

SAFROLE 189, 219, 272

SAGE OIL 189, 249

SAGE OIL (Spanish) 232

SALBUTAMOL 52, 117, 272

SALCATONIN 117

SALFROLE 249

SALICYLAMIDE 46, 117, 272

SALICYLANILIDE 153

SALICYLIC ACID 53

SALINOMYCIN 117, 190

SALMETEROL 117

SALVIA DIVINORUM. 214

SANDALWOOD OIL 232

SANTONIN 53

SAPROPTERIN 117

SAQUINAVIR 117

SASSAFRAS OIL 190, 249, 272

SAXAGLIPTIN 117

SCHOENOCAULON OFFICINALE 117

SCHRADAN 204

SCOPOLIA CARNIOLICA 117

SEAWEED & UNFRACTIONED 232

SECBUTOBARBITONE 209, 284

SEDAXANE 153

SEEDS 224

SELAMECTIN 153

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM) 117, 236

SELEGILINE 117

SELENIUM 46, 117, 190, 204, 276

SELENIUM COMPOUNDS 249, 272

SEMDURAMICIN 190, 205

SENECIO spp. 220

SERELAXIN 117

SERMORELIN 117

SERTINDOLE 117

SERTRALINE 118

SETHOXYDIM 153

SEVELAMER 118

SEVOFLURANE 118

SEX HORMONES 118

SIBUTRAMINE 118

SIDURON 153

SILANDRONE 118

SILDENAFIL 118

SILICOFLUORIDES 153, 190

SILICONES 118, 220, 272

SILVER 46

SILVER NITRATE 190

SILVER SALTS 249

SILVER SULFADIAZINE 118

SIMAZINE 232

SIMEPREVIR 118

SIMVASTATIN 118

SINBIOALLETHRIN 153, 190

SINGLE-USE TUBES 224

SIROLIMUS 118

SISOMICIN 118

SITAGLIPTIN 118

SITAXENTAN 118, 236, 272, 286

SLIMICIDES 222

SODIUM ALUMINATE 191, 249, 272

SODIUM BICARBONATE 232

SODIUM BROMATE 191, 249

SODIUM BROMIDE 118

SODIUM CELLULOSE PHOSPHATE 118

SODIUM CHLORATE 153, 249, 272

SODIUM CROMOGLYCATE 46, 118

SODIUM DIACETATE 153, 249

SODIUM DICHLOROISOCYANURATE 249

Sodium dodecylbenzene sulfonate 273

SODIUM DODECYLBENZENE SULFONATE 153, 249

SODIUM FLUORIDE 273

SODIUM HYDROGEN SULFATE 153, 250, 273

SODIUM HYDROSULFITE 153, 273

SODIUM HYDROXIDE 153, 191, 220, 250, 273

SODIUM LAURETH-6 CARBOXYLATE 153, 250, 273

SODIUM LAURYL SULFATE 250

SODIUM METABISULPHITE 153, 250, 273

SODIUM MORRHUATE 118

SODIUM NITRITE 46, 153, 191, 205, 250, 273

SODIUM NITROPRUSSIDE 118

SODIUM OXYBATE 209, 235

SODIUM PERCARBONATE 154, 191

SODIUM PERSULFATE 192, 250, 273

SODIUM PHOSPHATE 53, 118

SODIUM PICOSULFATE 53

SODIUM POLYSTYRENE SULPHONATE 118, 154

SODIUM PRECARBONATE 250

sodium propionate 232

SODIUM SALICYLATE 118

SODIUM STANNATE 154, 250

SODIUM SULFIDE 154, 192, 250, 273

SODIUM TETRADECYLSULFATE 118

SODIUM TRICHLOROACETATE 250

SODIUMHYDROSULFITE 250

SOFOSBUVIR 118

SOLASODINE 118

SOLIFENACIN 118

SOMATOSTATIN 118

SOMATOTROPIN EQUINE 118

SOMATROPIN 119, 236

SONTOQUINE 119

SORAFENIB 119

SOTALOL 119

SPARFLOXACIN 119

SPARTEINE 119

SPECTINOMYCIN 119

SPINETORAM 154

SPINOSAD 154

SPIRAMYCIN 119

SPIRAPRIL 119

SPIRONOLACTONE 119

SPIROTETRAMAT 192

SPIROXAMINE 192

SQUILL 46

STANOLONE 119

STANOZOLOL 119

STAR ANISE OIL 154

STAVUDINE 119

STENBOLONE 119

STERIC ACID 232

STEROID HORMONES 119

STILBOESTROL 119

STRCHNINE 250

STREPTODORNASE 119

STREPTOKINASE 119

STREPTOMYCIN 119

STRONTIUM RANELATE 119

STROPHANTHINS 119

STROPHANTHUS spp. 119, 276

STRYCHNINE 119, 205, 276, 281

STRYCHNOS spp. 119

STYRAMATE 119

STYRENE 154, 250, 273

SUCCIMER 119

SUCRALFATE 232

SUFENTANIL 209

SUGAMMADEX 119

SULBACTAM 119

SULCOFURON 192, 205, 250, 281

SULCONAZOLE 46, 119

SULESOMAB 232

SULFACETAMIDE 53, 119, 154

SULFADIAZINE 120, 154

SULFADIMETHOXINE 120

SULFADIMIDINE 120, 154

SULFADOXINE 120

SULFAFURAZOLE 120

SULFAGUANIDINE 120

SULFAMERAZINE 120, 154

SULFAMETHIZOLE 120

SULFAMETHOXAZOLE 120

SULFAMETHOXYDIAZINE 120

SULFAMETHOXYPYRIDAZINE 120

SULFAMETROLE 120

SULFAMIC ACID 154, 192, 250, 273

SULFAMONOMETHOXINE 120

SULFAMOXOLE 120

SULFAPHENAZOLE 120

SULFAPYRIDINE 120

SULFAQUINOXALINE 120

SULFASALAZINE 120

SULFATHIAZOLE 120, 154

SULFATROXAZOLE 120

SULFENTRAZONE 205

SULFINPYRAZONE 120

SULFLURAMID 192

SULFOMETURON-METHYL 154

SULFOMYXIN 120

SULFONAMIDES 120

SULFONMETHANE 120

SULFOSULFURON 232

SULFOTEP 205

SULFOXAFLOR 154, 192

SULFURIC ACID 192, 250, 273

SULFURYL FLUORIDE 192

SULINDAC 120

SULPHATED POLYSACCHARIDES 232

SULPROFOS 192

SULTAMICILLIN 120

SULTHIAME 120

SUMATRIPTAN 121

SUNITINIB 121

SUPROFEN 121

SUTILAINS 121

suvorexant 284

SUVOREXANT 121

SUXAMETHONIUM 121

SUXETHONIUM 121

SYMPHYTUM spp. 154, 220, 273

SYNTHETIC CANNABINOMIMETICS 214

T

TACRINE 121

TACROLIMUS 121

TADALAFIL 121

TAFLUPROST 121

TALIGLUCERASE ALFA 121

TALLOW ALKYLAMINE ACETATES 192

TAMOXIFEN 121

TAMSULOSIN 121

TANACETUM VULGARE 121

TANNIC ACID 232

TANNIC ACID/BENZYL ALCOHOL 232

TAPENTADOL 209, 284

TAR ACIDS 192

TASONERMIN 121

TAZAROTENE 121, 273

TAZOBACTAM 121

T-CELL RECEPTOR ANTIBODY 121

TCMTB 192

TDE 192

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) 154

TEBUCONAZOLE 155

TEBUFENOZIDE 155

TEBUFENPYRAD 192

TEBUTHIURON 192

TEFLUTHRIN 155, 205

TEGAFUR 121

TEGASEROD 121

TEICOPLANIN 121

TELAPREVIR 121

TELBIVUDINE 121

TELITHROMYCIN 121

TELMISARTAN 121

TEMAZEPAM 121, 284

TEMEPHOS 155, 192

TEMOZOLOMIDE 121

TEMSIROLIMUS 121

TENECTEPLASE 121

TENIPOSIDE 122

TENOCYCLIDINE 214

TENOFOVIR 122

TENOXICAM 122

TEPOXALIN 122

TEPP 205

TEPRALOXYDIM 155

TERAZOSIN 122

TERBACIL 232

TERBINAFINE 46, 122

TERBUFOS 205

TERBUTALINE 53, 122, 273

TERBUTHYLAZINE 192

TERBUTRYN 155

TERFENADINE 122, 273

TERIFLUNOMIDE 122, 273

TERIFLUOMIDE 287

TERIPARATIDE 122, 235

TERLIPRESSIN 122

TERMITE BARRIERS 224

TERODILINE 122

TEROPTERIN 122

TERPENES 250, 273

TERPENES, CHLORINATED 192

TESTOLACTONE 122

TESTOSTERONE 122, 192, 276

TETANUS ANTITOXIN 122

TETANUS TOXOID 122

TETRABENAZINE 122

TETRACHLOROETHANE 205, 250, 273, 281

TETRACHLOROETHYLENE 46, 155, 192, 250, 273

TETRACHLORVINPHOS 155

TETRACONAZOLE 155, 193

TETRACOSACTRIN 122

TETRACYCLINE 122, 155

TETRADIFON 193

TETRAETHYLAMMONIUM 122

TETRAHYDROCANNABINOLS 214

TETRAHYDROZOLINE 46, 273

TETRAMETHRIN 155

TETRAMISOLE 193

TETROXOPRIM 122

THALIDOMIDE 122, 235, 274, 287

THALLIUM 205, 281

THAUMATIN 232

THEBACON 209

THEBAINE 209

THENYLDIAMINE 122, 284

THEOPHYLLINE 53, 122

THEVETIA PERUVIANA 122

THEVETIN 122

THIABENDAZOLE 46, 155

THIACETARSAMIDE 122

THIACLOPRID 193

THIAMBUTOSINE 123

THIAMETHOXAM 155, 193

THIAZAFLURON 193

THIAZOPYR 155

THIAZOSULFONE 123

THIDIAZURON 232

THIETHYLPERAZINE 123, 284

THIFENSULFURON 155

THIOACETAZONE 123

THIOBENCARB 155

THIOCARLIDE 123

THIODICARB 155, 193

THIOFANOX 205

THIOFENTANYL 215

THIOGUANINE 123

THIOMESTERONE 123

THIOMETON 193

THIOPENTONE 123

THIOPHANATE-METHYL 155, 193

THIOPROPAZATE 123, 284

THIOPROPERAZINE 123

THIORIDAZINE 123, 284

THIOSTREPTON 123

THIOTEPA 123

THIOTHIXENE 123, 284

THIOURACIL 123

THIOUREA 123, 250, 274

THIOUREA AND ALKYL THIOUREAS 193

THIRAM 193

THUJONE 193, 250

THYME OIL 156, 250

THYMOL 193

THYMOXAMINE 123

THYROID 123

THYROTROPHIN 123

THYROXINE 123, 276

TIAGABINE 123

TIAMULIN 123

TIAPROFENIC ACID 123

TIARAMIDE 123

TIBOLONE 123

TICAGRELOR 123

TICARCILLIN 123

TICLOPIDINE 123

TIEMONIUM 123

TIENILIC ACID 123

TIGECYCLINE 124

TIGLOIDINE 124

TILDIPIROSIN 124

TILETAMINE 124

TILIDINE 209

TILMICOSIN 124

TILUDRONIC ACID 124

TIMBER or WALLBOARD 224

TIMOLOL 124

TIN ORGANIC COMPOUNDS 205

TINIDAZOLE 124

TINZAPARIN 124

TIOCARBAZIL 156

TIOCONAZOLE 46, 53, 124

TIOTROPIUM 124

TIPEPIDINE 124

TIPRANAVIR 124

TIRILAZAD 124

TIROFIBAN 124

TOBRAMYCIN 124

TOCAINIDE 124

TOCERANIB 124

TOCILIZUMAB 124

TOLAZAMIDE 124

TOLAZOLINE 124

TOLBUTAMIDE 124

TOLCAPONE 124

TOLCLOFOS-METHYL 156

TOLFENAMIC ACID 124

TOLIDINE 206, 251

TOLMETIN 124

TOLONIUM 124

TOLPROPAMINE 124

TOLRESTAT 124

TOLTERODINE 125

TOLTRAZURIL 156

TOLUENE 193, 251, 274

TOLUENEDIAMINE 193, 220, 251, 274

TOLVAPTAN 125

TOLYLFLUANID 194

TOPIRAMATE 125

TOPOTECAN 125

TORASEMIDE 125

TOREMIFENE 125

TOXOIDS 125

TRALKOXYDIM 156

TRAMADOL 125, 284

TRAMAZOLINE 46, 274

trametinib dimethyl sulfoxide 125

TRANDOLAPRIL 125

TRANEXAMIC ACID 125

TRANSFLUTHRIN 194

TRANYLCYPROMINE 125, 284

TRASTUZUMAB 125

Trastuzumab emtansine 125

TRAVOPROST 125

TRAZODONE 125

TRENBOLONE 125, 156

TREOSULPHAN 125

TREPROSTINIL 125

TRESTOLONE 125

TRETAMINE 125

TRETINOIN 125, 236, 274, 287

TRIACETYLOLEANDOMYCIN 125

TRIADIMEFON 156, 194

TRIADIMENOL 156

TRI-ALLATE 156

TRIAMCINOLONE 47, 53, 125, 274

TRIAMIPHOS 206

TRIAMTERENE 125

TRIASULFURON 233

TRIAZBUTIL 206

TRIAZIQUONE 125

TRIAZOLAM 125

TRIBENURON-METHYL 156

TRIBUFOS 206

TRICHLORFON 194

TRICHLORMETHIAZIDE 125

TRICHLOROACETIC ACID 125, 156, 194, 251, 274

Trichloroacetic acid alkali salts 251

TRICHLOROETHYLENE 126, 194, 251, 274

TRICHLOROISOCYANURIC ACID 251, 281

TRICHLOROPHENOL 194, 274

TRICHODERMA HARZIANUM 233

TRICHODESMA AFRICANA 220

TRICLABENDAZOLE 194

TRICLOFOS 126

TRICLOPYR 194

TRICLOSAN 194

TRICYCLAMOL 126

TRIDEMORPH 194

TRIDIHEXETHYL 126

TRIDIPHANE 156

TRIETAZINE 157

TRIETHANOLAMINE 126, 157, 251, 274

TRIETHYL PHOSPHATE 194, 251

TRIETHYLENE GLYCOL 233

TRIFLOXYSTROBIN 157

TRIFLOXYSULFURON 233

TRIFLUMIZOLE 157

TRIFLUMURON 157

TRIFLUOPERAZINE 126, 284

TRIFLUOROMETHANESULFONIC ACID 194, 251, 274

TRIFLUPERIDOL 126

TRIFLUPROMAZINE 126

TRIFLURALIN 233

TRIFORINE 233

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE 157, 251, 274

TRILOSTANE 126

Trimeprazine 284

TRIMEPRAZINE 47, 53, 126, 284

TRIMETAPHAN 126

TRIMETHOPRIM 126

TRIMIPRAMINE 126, 284

TRIMUSTINE 126

TRINEXAPAC-ETHYL 157

TRINITROPHENOL 126, 194

TRIOXYSALEN 126

TRIPARANOL 220

TRIPELENNAMINE 126

TRIPLE ANTIGEN VACCINE 126

TRIPROLIDINE 47, 53, 126, 284

TRIPTORELIN 126

TRISODIUM NITRILOTRIACETATE 194

TRITICONAZOLE 157

TROGLITAZONE 126

TROMETAMOL 126

TROPICAMIDE 126

TROPISETRON 126

TROVAFLOXACIN 126

TROXIDONE 126

TRYPTOPHAN 126

TUAMINOHEPTANE 47

TUBERCULIN 126

TUBOCURARINE 126

TULATHROMYCIN 126

TULOBUTEROL 127

TURPENTINE 251

TURPENTINE OIL 157, 251

TUSSILAGO FARFARA 220

TYLOSIN 127

TYMAZOLINE 47, 274

TYPHOID VACCINE 127

U

Ulocladium oudemansii 233

UMECLIDINIUM 127

UNOPROSTONE 127

URACIL 127

URAPIDIL 127

UREA 233

URETHANE 127

UROFOLLITROPIN 127, 235

UROKINASE 127

URSODEOXYCHOLIC ACID 127

USTEKINUMAB 127

V

VACCINES 127

VACCINIA VIRUS VACCINE 127

VALACICLOVIR 127

VALDECOXIB 127

VALGANCICLOVIR 127

VALNOCTAMIDE 127

VALPROIC ACID 127

VALSARTAN 127

VAMIDOTHION 194

VANCOMYCIN 127

VANDETANIB 127

VARDENAFIL 127

VARENICLINE 127

VARICELLA VACCINE 127

VASOPRESSIN 127

VECURONIUM 128

VEDAPROFEN 128

vEDOLIZUMAB 128

VELAGLUCERASE ALFA 128

VEMURAFENIB 128

VENLAFAXINE 128

VERAPAMIL 128

VERATRUM 128

VERNAKALANT 128

VERNOLATE 157

VERTEPORFIN 128

VETIVER OIL 233

VIDARABINE 128

VIGABATRIN 128

VILANTEROL 128

VILDAGLIPTIN 128

VILOXAZINE 128

VINBLASTINE 128

VINCAMINE 128

VINCLOZOLIN 206, 274

VINCRISTINE 128

VINDESINE 128

VINFLUNINE 128

VINORELBINE 128

VINYL CHLORIDE 206, 281

VINYL ETHER 128, 233

VIRGINIAMYCIN 128, 157

VISMODEGIB 128

VISNADINE 128

VITAMIN A 128

VITAMIN D 53, 129

VITAMIN K 233

VITREOUS ENAMELS 224

VORICONAZOLE 129

VORINOSTAT 129

VORTIOXETINE 129

W

WARFARIN 129, 157, 194

WHITE SPIRIT 251

WRITING CORRECTION PENS 224

X

XAMOTEROL 129

XANTHINOL NICOTINATE 129

XANTHOPHYLL 233

XIMELAGATRAN 129

XIPAMIDE 129

XYLANASE derived from *Aspergillus niger* 233

XYLAZINE 129

XYLENE 194, 251, 274

XYLENOLS 251

XYLOMETAZOLINE 47, 274

Y

YLANG YLANG OIL 233

YOHIMBINE 129

Z

ZAFIRLUKAST 129

ZALCITABINE 129

ZALEPLON 129

ZANAMIVIR 129

ZERANOL 129, 195

ZETA-CYPERMETHRIN 195, 206

ZIDOVUDINE 129

ZILPATEROL 129

ZIMELDINE 129

ZINC BORATE 195

ZINC CHLORIDE 47, 251

ZINC COMPOUNDS 129

ZINC NAPHTHENATE 233

ZINC para-PHENOLSULFONATE 195

ZINC SULFATE 195, 251, 275

ZINEB 157

ZIPRASIDONE 129, 284

ZIRAM 195, 206

ZOLAZEPAM 129

ZOLEDRONIC ACID 129

ZOLMITRIPTAN 129

ZOLPIDEM 129, 284

Zonisamide 284

ZONISAMIDE 130

ZOPICLONE 130, 284

ZOXAZOLAMINE 130

ZUCLOPENTHIXOL 130

# 

1

1,1,1-TRICHLOROETHANE

*See also* DESIGNATED SOLVENT

1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE

*See* TDE

1-DODECANOL

*See* LAURYL ALCOHOL

2

2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM CHLORIDE

*See* BASIC ORANGE 31

2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE

*See* TCMTB

2C-I

*See* 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE

2C-T-2

*See* 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE

2C-T-7

*See* 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE

2-(dimethylamino)ethanol

*See* DMEA, DIMETHYL MEA, DEANOL

2-furancarboxaldehyde

*see* furfural

3

3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE

*See* N,A-DIMETHYL-3,4-(METHYLENEDIOXYL)PHENYLETHYLAMINE

4

4-CHLOROTESTOSTERONE

*See* CLOSTEBOL

4-FLUORO-N-METHAMPHETAMINE

*See* 4-FLUORO-N-METHYLAMPHETAMINE

4-METHYLHEXANE-2-AMINE

*See* 1,3-DIMETHYLAMYLAMINE

5

5-MeO-AMT

*See* 5-METHOXY--METHYLTRYPTAMINE

8

8-HYDROXYQUINOLINE

*See also* CLIOQUINOL

A

Acetone

*See also* DESIGNATED SOLVENT

ALBUMIN

*See* HUMAN BLOOD PRODUCTS

ALKYL ACETANILIDES

*See* ACETANILIDE

ALKYL SULFONALS

*See* SULFONMETHANE

ALKYL THIOUREAS

*See* THIOUREA AND ALKYL THIOUREAS

ALKYLATED PHENYLENEDIAMINES

*See* PHENYLENEDIAMINES

ALUMINIUM PHOSPHIDE

*See* PHOSPHIDES, METALLIC

ALPHA-CHLORALOSE

*See* CHLORALOSE

AM-694

*See* 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE

AMFEBUTAMONE

*See* BUPROPION

AMIDOPYRINE

*See* AMINOPHENAZONE

2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM CHLORIDE

*See* BASIC ORANGE 31

Ammonia

See also CHROMATES

AMMONIUM BIFLUORIDE

*See* BIFLUORIDES

AMMONIUM CHROMATE

*See* CHROMATES

*See* CHROMIUM

AMMONIUM hydroxide

*See* AMMONIA

S*ee* AMMONIA/AMMONIUM HYDROXIDE

AMMONIUM SALTS

*See* BIFLUORIDES

ANALYTICAL PREPARATIONS

*See* IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS

ANDROSTALONE

*See* MESTANOLONE

ANDROSTERONE

*See* ANABOLIC STEROIDAL AGENTS

ANTIBIOTIC SUBSTANCES

*See also* BACTERIAL CULTURE MEDIA

ANTICOAGULANT MEDICAL DEVICES

*See* MEDICAL DEVICES

ANTICOAGULATION COMPLEX

*See* HUMAN BLOOD PRODUCTS

ANTIMONY

*See also* ANTIMONY COMPOUNDS

ANTIMONY CHLORIDE

*See also* ANTIMONY COMPOUNDS

ANTIMONY COMPOUNDS

*See also* ANTIMONY

ANTIMONY TITANATE

*See* ANTIMONY COMPOUNDS

*See* ANTIMONY

ARBUTIN

*See* HYDROQUINONE

ARISTOLOCHIC ACID

*See also* bragantia

*See also* ASARUM spp

AROMATIC EXTRACT OILS

*See also* HYDROCARBONS LIQUID AROMATIC

ARSENIC

*See also* CACODYLIC ACID

*See also* TERMITE BARRIERS

ARSENIC TRIOXIDE

*See* ARSENIC

ARTIFICIAL TEARS

*See* MEDICAL DEVICES

ASPERGILLUS NIGER

*See* -AMYLASE

*See* CELLULASE

*See* FUNGAL PROTEASE

*See* -GLUCANASE

*See* PECTINASE

*See* XYLANASE

ASPIDOSPERMA QUEBRACHO

*See* YOHIMBINE

ASPIRIN

*See* *also* DIHYDROCODEINE (+ aspirin)

*See also* PARACETAMOL(*+* aspirin)

*See also* SALICYLAMIDE (+ aspirin)

ASTEMIZOLE

*See also* Antihistamines

ATROPINE METHONITRATE

*See also* ATROPINE

ATROPINE SULFATE

*See* DIFENOXIN (+ atropine sulfate)

*See* DIPHENOXYLATE (+ atropine sulfate)

AZELASTINE

*See also* ANTIHISTAMINES

B

BARIUM

*See* BARIUM SALTS

BARIUM CHROMATE

*See* CHROMATES

*See* CHROMIUM

BARIUM metaborate

*See* BARIUM SALTS

BARIUM salts

BARIUM SELENATE

*See* SELENIUM

BARIUM SILICOFLUORIDE

*See also* SILICOFLUORIDES

BARIUM SULFATE

*See* BARIUM SALTS

BATTERIES

*See* ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS OR LAMPS

BDMPEA

*See* 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE

BEECHWOOD

*See* CREOSOTE

BELLADONNA

*See* ATROPA BELLADONNA

BENZALKONIUM CHLORIDE

*See also* QUATERNARY AMMONIUM COMPOUNDS

BENZATHINE PENICILLIN

BENZATROPINE

*See* BENZTROPINE

Benzene

*See also* HYDROCARBONS, LIQUID

BENZOYL METRONIDAZOLE

*See* METRONIDAZOLE

BISMUTH CITRATE

*See* BISMUTH COMPOUNDS

BISMUTH FORMIC IODIDE

*See* BISMUTH COMPOUNDS

BISMUTH OXYCHLORIDE

*See* BISMUTH COMPOUNDS

BISMUTH SUBIODIDE

*See* BISMUTH COMPOUNDS

BIS(TROBUTYLTINOXIDE)

*See* TRIBUTYL TIN OXIDE

BLEACHES

*See* CHLORINATING AGENTS

BLOOD

*See also* BLOOD COMPONENTS

*See also* DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES

*See also* HUMAN BLOOD PRODUCTS

Borage

*See* BORAGO OFFICINALIS

BORATES

*See* BORON

BORAX

*See* also BORON

BORIC ACID

See also BORON

BORON

*See also* BORIC ACID

BORON COMPOUNDS

*See* BORON

BORON TRIFLUORIDE

*See* also BORON

BROMO-DRAGONFLY

*See* 1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE

BROMOCHLORODIMETHYLHYDANTOIN

*See* CHLORINATING COMPOUNDS

BUTYPHENONES

*See* HALOPERIDOL

BZP

*See* BENZYLPIPERAZINE

C

C1 ESTERASE INHIBITORS

*See* HUMAN BLOOD PRODUCTS

CADMIUM

*See also* CADMIUM COMPOUNDS

CADMIUM ACETATE

*See* CADMIUM COMPOUNDS

CADMIUM CHLORIDE

*See* CADMIUM COMPOUNDS

CADMIUM COMPOUNDS

*See also* CADMIUM

CADMIUM NITRATE

*See* CADMIUM COMPOUNDS

CAFFEINE

*See* ASPIRIN (+ caffeine)

*See* SALICYLAMIDE (+ caffeine)

calamus

*See* ACORUS CALAMUS

CALCIUM FOLINATE

*See* FOLINIC ACID

CALCIUM HYPOCHLORITE

*See* CHLORINATING COMPOUNDS

CALOMEL

*See* MERCURIC CHLORIDE

CAMPHOR

*See also* ESSENTIAL OILS

CAMPHOR OIL (white)

*See* CINEOLE

CANNABICHROMENE

*See* NABIXIMOLS

CANNABICYCLOHEXANOL

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL

CANNABIDIOL

*See* NABIXIMOLS

CANNABIDIOLIC ACID

*See* NABIXIMOLS

CANNABIDIVAROL

*See* NABIXIMOLS

CANNABIGEROL

*See* NABIXIMOLS

CANNABINOIDS

*See* NABIXIMOLS

CANNABINOL

*See* NABIXIMOLS

CANNABIS SATIVA

S*ee* HEMP SEED OIL

*See* NABIXIMOLS

CARDIAC GLYCOSIDES

*See* UNDER INDIVIDUAL ENTRIES

CATALIN

*See* PIRENOXINE

CATECHOL  
 *See* 1,2-BENZENEDIOL

CEPHACETRILE

*See* CEFACETRILE

CEPHALORIDINE

*See* CEFALORIDINE

CEPHAMANDOLE

*See* CEFAMANDOLE

CEPHAPIRIN

*See* CEFAPIRIN

CEPHAZOLIN

*See* CEFAZOLIN

CETYL TRANEXAMATE

*See* TRANEXAMIC ACID

CHILD-RESISTANT CLOSURE

*See also* NON-ACCESS PACKAGING

CHILD-RESISTANT PACKAGING

*See also* NON-ACCESS PACKAGING

CHLORINATED TERPENES

*See* TERPENES, CHLORINATED

chlorine

*See also* CHLORINATING COMPOUNDS

*See also* DICHLOROISOCYANURATES

*See also* DICHLOROISOCYANURIC ACID

CHLOROMESTERONE

*See* DEHYDROCHLOROMETHYLTESTOSTERONE

4-CHLOROTESTOSTERONE

*See* CLOSTEBOL

CHLORQUINALDOL

*See also* CLIOQUINOL

CHOLECALCIFEROL

*See* COLECALCIFEROL

CHOLINE SALICYLATE

*See* SALICYLIC ACID

Chromates

See also CHROMIUM

CHROMIC ACID

*See* CHROMIUM TRIOXIDE

CHROMIUM

*See also* CHROMATES

chrysanthemic ACID ESTERS

*See* PYRETHRINS

2C-I

*See* 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE

CINEROLONE

*See* PYRETHRINS

CLOTTING FACTORS

*See* HUMAN BLOOD PRODUCTS

COLECALCIFEROL

*See also* VITAMIN D

COLESTYRAMINE

*See* CHOLESTYRAMINE

COLLAGEN

*See also* MEDICAL DEVICES

COLTSFOOT

*See* TUSSILAGO

COMFREY

*See* SYMPHYTUM spp.

coniine

*See* CONIUM MACULATUM

CONTAINERS

*See also*  IMMEDIATE CONTAINER

*See also* SELECTED CONTAINER

CONTRAST MEDIA, RADIOGRAPHIC (RADIOPAQUES)

*See* RADIOGRAPHIC CONTRAST MEDIA

COPPER CHLORIDE

*See* COPPER NITRATE

COPPER-CHROME-ARSENIC

*See* CHROMATES, AND ARSENIC

COPPER SALICYLATE

*See* DIMETHYL SULFOXIDE

COPPER

*See* COPPER COMPOUNDS

CORROSIVE SUBLIMATE

*See* MERCUROUS CHLORIDE

CORYMBIA CITRIODORA

*See* EXTRACT OF LEMON EUCALYPTUS

CP 47,497 C8 HOMOLOGUE

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL

CP 47,497

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL

CREOSOTE

See also PHENOL

CROTON OIL

*See* CROTON TIGLIUM

CRYOPRECIPITATE

*See* HUMAN BLOOD PRODUCTS

CRYSTAL WARE

*See* GLASS

2C-T-2

*See* 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE

2C-T-7

*See* 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE

CUBE

*See* ROTENONE

curing agents FOR EPOXY RESINS

*See* AMINES FOR USE AS CURING AGENTS FOR EPOXY RESIN

*See* Anhydrides, organic acid FOR USE AS CURING AGENTS FOR EPOXY RESINS

*See* EPOXY RESINS

Cyanides

*See also* HYDROCYANIC ACID AND CYANIDES

CYPERMETHRIN

*See also* ZETA-CYPERMETHRIN, ALPHA-CYPERMETHRIN AND BETA-CYPERMETHRIN

D

DALMATIAN

*See* SAGE OIL

D.D.A.V.P.

*See* DESMOPRESSIN

DDT

*See* DICOPHANE

DEANOL  
 *See* 2-(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA

DEET

*See* DIETHYLTOLUAMIDE

DEHYDROEPIANDROSTERONE

*See* PRASTERONE

DEHYDROISOANDROSTERONE

*See* PRASTERONE

DEHYDROTESTOSTERONE

*See* BOLDENONE

DELAVIRDINE MESYLATE

*See* DELAVIRDINE

DELTA-9-TETRAHYDROCANNABINOL

*See* DRONABINOL

DENATONIUM BENZOATE

*See* BENDIOCARB

*See* DIETHYLENE GLYCOL

*See* ETHYLENE GLYCOL

*See* METHOMYL

*See* METHYLATED SPIRIT(S)

DESLORATADINE

*See also* ANTIHISTAMINES

DET

*See* N,N-DIETHYLTRYPTAMINE

DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS

*See* QUATERNARY AMMONIUM COMPOUNDS

dialkyl TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

DIBENZODIOXINS, HALOGENATED

*See* HALOGENATED DIBENZODIOXINS

DIBENZOFURANS, HALOGENATED

*See* HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS

DIBUTYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE

*See* TDE

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE

DICHLOROETHYL ETHER

*See also* CHLORINATING COMPOUNDS

DICHROMATES

*See also* CHROMATES

DICOBALT EDETATE

*See* COBALT

*See* EDETIC ACID

DIESEL (DISTILLATE)

*See also* HYDROCARBONS, LIQUID

DIETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

DIETHYL-PARA-PHENYLENEDIAMINE

*See* PHENYLENEDIAMINES

DIETHYLSTILBOESTROL

*See* STILBOESTROL

DIETHYLSTILBOESTROL DIPHOSPHATE

*See* FOSFESTROL

DI-IODOHYDROXYQUINOLINE (iodoquinol)

DIMETAMFETAMINE

*See* N,N-DIMETHYLAMPHETAMINE

DIMETHISOQUIN

*See* QUINISOCAINE

DIMETHYL MEA  
 *See* 2-(DIMETHYLAMINO)ETHANOL, DEANOL, DMEA

DIMETHYL SULFONE

*See* METHYLSULFONYLMETHANE

DIMETHYL TIN DICHLORIDE

*See* TIN ORGANIC COMPOUNDS

DIMETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

DIMETHYLFORMAMIDE

*See also* DESIGNATED SOLVENT

DIMETHYL-PARA-PHENYLENEDIAMINE

*See* PHENYLENEDIAMINES

DI-N-PROPYL ISOCINCHOMERONATE

DIOCTYL SODIUM SULFOSUCCINATE

*See* DOCUSATE SODIUM

DIOXINS

*See* HALOGENATED DIBENZODIOXINS

DIPENTENE

*See* LIMONENE

DIPROPYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

DISODIUM ETIDRONATE

*See* ETIDRONIC ACID

DISODIUM PAMIDRONATE

*See* PAMIDRONIC ACID

DISODIUM TILUDRONATE

*See* TILUDRONIC ACID

DISTILLATE (DIESEL)

*See* Diesel

*See also* HYDROCARBONS, LIQUID

DITHIOCARBAMATES

*See* UNDER INDIVIDUAL ENTRIES

DMA

*See* 2,5-DIMETHOXYAMPHETAMINE

DMAA

S*ee* 1,3-DIMETHYLAMYLAMINE

DMEA

*See* 2-(DIMETHYLAMINO)ETHANOL, DEANOL, DIMETHYL MEA

DMHP

*See* 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN

DMT

*See* N,N-DIMETHYLTRYPTAMINE

DOB

*See* 2,5-DIMETHOXY-4-BROMOAMPHETAMINE

1-DODECANOL

*See* LAURYL ALCOHOL

DOET

*See* 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE

DOM

*See* 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE

DRONABINOL (delta-9-TETRAHYDROCANNABINOL)

*See also* NABIXIMOLS

DRY CLEANING FLUID

*See* LIQUID HYDROCARBONS

*See* HYDROCARBONS, LIQUID

E

ECOTHIOPATE IODIDE

*See* ECOTHIOPATE

EMETINE

*See also* CEPHAELIS ACUMINATA

ENAMELLING PREPARATIONS

*See* FRITTED GLAZING OR ENAMELLING PREPARATIONS

ENDOTOXIN

*See* BACILLUS THURINGIENSIS

ENILCONAZOLE

*See* IMAZALIL

EPHEDRINE

*See also* EPHEDRA

EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN

*See* IMMUNOGLOBULINS

ERGOCACIFEROL

*See* VITAMIN D

ESSENTIAL OILS

*See* also CAMPHOR

ETHANEDINITRILE

*See* CYANOGEN

ETHANOL

*See* METHYLATED SPIRIT(S)

*See also* ETHYL ALCOHOL

ETHOXYETHYLMERCURIC CHLORIDE

*See* also MERCURY

ETHOXYQUIN

*See also* MERCURY

ETHYL ALCOHOL

*See also* ETHANOL

F

FAMPRIDINE

*See* 4-AMINOPYRIDINE

FENBUTATIN OXIDE

*See also* TIN ORGANIC COMPOUNDS

FERRICYANIDES

*See* CYANIDES

FERROCYANIDES

*See* CYANIDES

FEXOFENADINE

*See also* Antihistamines

FIBRINOGEN

*See* HUMAN BLOOD PRODUCTS

FILM OR PAPER, PHOTOGRAPHIC

*See* PHOTOGRAPHIC PAPER or FILM

FLAVOPHOSPHOLIPOL

*See* BAMBERMYCIN

FLUORESCEIN

*See also* METHYLATED SPIRIT(S)

FLUORIDES

*See also* SILICOFLUORIDES

4-FLUORO-N-METHAMPHETAMINE

*See* 4-FLUORO-N-METHYLAMPHETAMINE

FLUOROSILICATES

*See* SILICOFLUORIDES

FLUOROSILICIC ACID

*See* HYDROSILICOFLUORIC ACID

FOLLICLE STIMULANT, RECOMBINANT

*See* CORIFOLLITROPIN ALFA

FOLLICLE-STIMULATING HORMONE, HUMAN

*See* UROFOLLITROPIN

FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN

*See* FOLLITROPIN ALPHA

*See* FOLLITROPIN BETA

FORMALDEHYDE

*See* *also* METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT

*See also* FREE FORMALDEHYDE

FORMOTEROL

*See* EFORMOTEROL

FREE FORMALDEHYDE

*See also* FORMALDEHYDE

*See also* PARAFORMALDEHYDE

FRUSEMIDE

*See* FUROSEMIDE

FUELS

*See* MOTOR, HEATING or FURNACE FUELS

FUELS, HOBBY

*See* MOTOR, HEATING or FURNACE FUELS

FUELS, TOY

*See* MOTOR, HEATING or FURNACE FUELS

G

GAMMA HYDROXYBUTYRATE (GHB)

*See* 4-HYDROXYBUTANOIC ACID

GENTIAN VIOLET

*See* CRYSTAL VIOLET

GHB (GAMMA HYDROXYBUTYRATE)

*See* 4-HYDROXYBUTANOIC ACID

GLYCOSYLATED HYDROQUINONE

*See* HYDROQUINONE

GUAIPHENESIN

*See also* PARACETAMOL (+ guaiphenesin)

H

H5N1 INFLUENZA VIRUS HAEMAGGLUTININ

*See* INFLUENZA AND CORYZA VACCINES

HALQUINOL

*See* CLIOQUINOL

HELICOZEAOCCLUSION BODIES

*See* POLYHEDROSIS VIRUS

HELICOVERPA ARMIGERA

*See* NUCLEAR POLYHEDROSIS VIRUS

HEMP AGRIMONY

*See* EUPATORIUM CANNABINUM

HEMP

*See* CANNABIS

HEMP SEED OIL

*See also* TETRAHYDROCANNABINOLS

HEXACHLOROPHANE

See also HCB

HEXAFLUOROSILICATES

*See* SILICOFLUORIDES

HEXAFLUOROSILIC ACID

*See* HYDROSILICOFLUORIC ACID

HEXAMETHYLMELAMINE

*See* ALTRETAMINE

HOBBY FUELS

*See* MOTOR, HEATING or FURNACE FUELS

HORMONE, FOLLICLE-STIMULATING

*See also* FOLLICLE-STIMULATING HORMONE

HORMONE, GROWTH

*See* GROWTH HORMONE

HORMONE, HUMAN FOLLICLE-STIMULATING

*See* UROFOLLITROPIN

HORMONE, HUMAN GROWTH

*See* SOMATROPIN

HORMONE, RECOMBINANT HUMAN FOLLICLE-STIMULATING

*See* FOLLITROPIN ALPHA

*See* FOLLITROPIN BETA

HUMAN BLOOD PRODUCTS

See also BLOOD

HUMAN FOLLICLE-STIMULATING HORMONE

*See* UROFOLLITROPIN

human growth hormone

*See* SOMATROPIN

HYDROCARBONS, LIQUID

*See also* DESIGNATED SOLVENT

*See also* NAPHTHALENE

See alsoLIQUID HYDROCARBONS

HYDROCHLORIC ACID

HYDROCARBONS LIQUID AROMATIC

*See also* HYDROCARBONS, LIQUID

HYDROFLUOSILICIC ACID

*See* HYDROSILICOFLUORIC ACID

HYDROGEN FLUORIDE

*See* HYDROFLUORIC ACID

HYDROQUINONE

*See also* MONOBENZONE

8-HYDROXYQUINOLINE

*See also* CLIOQUINOL

HYOSCINE BUTYLBROMIDE

*See* *also* HYOSCINE

I

IBUPROFEN

*See also* PARACETAMOL (+ ibuprofen)

IMMUNOSERA

*See* ANTISERA

INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS

*See* MEDICAL DEVICES

INK ADDITIVES

*See* PRINTING INKS OR INK ADDITIVES

INTRA-ARTICULAR FLUIDS

*See* MEDICAL DEVICES

Iodine

See also IODOPHORS

3-IODO-2-PROPYNYL BUTYL CARBAMATE (iodocarb)

Iodocarb

*See* 3-IODO-2-PROPYNYL BUTYL CARBAMATE

IODOPHORS

See also IODINE

iodoquinol

*See* DI-IODOHYDROXYQUINOLINE

IPECACUANHA

*See* CEPHAELIS IPECACUANHA

*See* CEPHAELIS ACUMINATA

IRON OXIDES

*See* IRON COMPOUNDS

J

JASMOLONE

*See* PYRETHRINS

JEQUIRITY

*See* ABRUS PRECATORIUS

JWH-018

*See* 1-PENTYL-3-(1-NAPHTHOYL)INDOLE

JWH-073

*See* NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE

JWH-122

*See* 1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE

JWH-200

*See* 1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE

JWH-250

*See* 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE

K

KAVA

*See* PIPER METHYSTICUM

KAVALACTONES

*See* PIPER METHYSTICUM

KEROSENE

*See also* LIQUID HYDROCARBONS

*See also* HYDROCARBONS, LIQUID

*See also* MOTOR, HEATING or FURNACE FUELS

K-HDO

*See* N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM

L

LABELS

*See also* DISPENSING LABEL

*See also* MAIN LABEL

LAMP OIL

*See* LIQUID HYDROCARBONS

*See* HYDROCARBONS, LIQUID

LAMPS

*See* ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS OR LAMPS

LAURETH-9

*See* LAUROMACROGOL

LAVANDIN OIL

See also CAMPHOR

LEAD & LEAD COMPOUNDS

*See also* PRINTING INKS or INK ADDITIVES

*See also* SELENIUM

*See also* GLAZING PREPARATIONS

LEMON EUCALYPTUS OIL

*See* EXTRACT OF LEMON EUCALYPTUS

LEVOCETIRIZINE

*See* CETIRIZINE

LIDOCAINE

*See* LIGNOCAINE

LIGHT MINERAL OILS

*See* HYDROCARBONS, LIQUID

LINDANE

See also BHC

LINSEED OIL

*See* ETHOPROPHOS

LIPASE

*See* PANCREATIC ENZYMES

LIQUID AROMATIC HYDROCARBONS

*See* HYDROCARBONS, LIQUID

LIQUID Hydrocarbons

*See also* HYDROCARBONS, LIQUID

*See also* NAPHTHALENE

LORATADINE

*See also* ANTIHISTAMINES

LUTEIN

*See* XANTHOPHYLL

LYE WATER

*See* ALKALINE SALTS, SODIUM HYDROXIDE OR POTASSIUM HYDROXIDE

M

MAGNESIUM FLUOSILICATE

*See* FLUORIDES

MAGNESIUM PHOSPHIDE

*See* PHOSPHIDES, METALLIC

MAGNETIC RESONANCE IMAGING ENHANCING AGENTS

*See* ENHANCING AGENTS

Malathion

*See also* ORGANOPHOSPHORUS COMPOUNDS

MALDISON

*See* MALATHION

MANCOZEB

*See also* DITHIOCARBAMATES

MANUKA oil

*See* LEPTOSPERMUM SCOPARIUM OIL

MBDB

*See* N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE

MDA

*See* 3,4-METHYLENEDIOXYAMPHETAMINE

MDMA

*See* N,-DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE

MDPV

*See* 3,4-METHYLENEDIOXYPYROVALERONE

MELANOCYTE STIMULATING HORMONE

*See* AFAMELANOTIDE

5-MeO-AMT

*See* 5-METHOXY--METHYLTRYPTAMINE

MEPHEDRONE

*See* 4-METHYLMETHCATHINONE

MERCURY

*See also* PHENYLMERCURIC ACETATE

MESCALINE

*See* 3,4,5-TRIMETHOXYPHENETHYLAMINE

METHADONE INTERMEDIATE

*See* 4-CYANO-2-DIMETHYLAMINO-4,4-DIPHENYLBUTANE

METHAM SODIUM

*See* METHAM

METHAMPHETAMINE

*See* METHYLAMPHETAMINE

METHANOL

*See also* MOTOR, HEATING or FURNACE FUELS

METHOTRIMEPRAZINE

*See* LEVOMEPROMAZINE

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

*See* EPOETINS

METHOXYPHENAMINE

*See also* 3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE)

METHOXY-PHENYLETHYLAMINE

*See* 3,4,5-TRIMETHOXYPHENETHYLAMINE

METHYL CHAVICOL

*See* BASIL OIL

METHYL ETHYL KETONE

*See also* DESIGNATED SOLVENT

METHYL ISOAMYL KETONE

*See also* DESIGNATED SOLVENT

METHYL ISOBUTYL KETONE

*See also* DESIGNATED SOLVENT

*See also* METHYLATED SPIRIT(S)

METHYL SALICYLATE

*See also* DIMETHYL SULFOXIDE

METHYLDIGOXIN

*See* MEDIGOXIN

METHYLENE chloride

*See* DICHLOROMETHANE

METHYLENE dianiline

*See* 4,4-DIAMINODIPHENYLMETHANE

METHYLENE GLYCOL

*See* FREE FORMALDEHYDE

*See* FORMALEDHYDE

3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE

*See* N,A-DIMETHYL-3,4-(METHYLENEDIOXYL)PHENYLETHYLAMINE

4-METHYLHEXANE-2-AMINE

*See* 1,3-DIMETHYLAMYLAMINE

METHYLPHENOBARBITONE

*See also* BARBITURATE METHYLPREDNISOLONE

METHYLSULFONYLMETHANE

*See* DIMETHYL SULFONE

METRIFONATE (trichlorfon)

*See also* TRICHLORFON

MINERAL OILS

*See* HYDROCARBONS, LIQUID

MINERAL OILS, LIGHT

*See* HYDROCARBONS, LIQUID

MINERAL TURPENTINE

*See* LIQUID HYDROCARBONS

*See* HYDROCARBONS, LIQUID

MMDA

*See* 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE

MOCA

*See* 4-DIMETHYLAMINOAZOBENZENE

MONOBENZONE

*See also* HYDROQUINONE

MORAMIDE

*See* DEXTROMORAMIDE

MORAMIDE INTERMEDIATE

*See* 2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACIDMPPP

*See* 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE

MYCOPHENOLATE MOFETIL

*See* MYCOPHENOLIC ACID

N

N-(N-DODECYL)-2-PYRROLIDONE

*See also* DESIGNATED SOLVENT

*See also* N-(N-OCTYL)-2-PYRROLIDONE

*See also* N-METHYL-2-PYRROLIDONE

N-(N-octyl)-2- PYRROLIDONE

*See also* DESIGNATED SOLVENT

*See also* N-(N-DODECYL)-2-PYRROLIDONE

*See also* N-METHYL-2-PYRROLIDONE

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE

*See also* N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE

N,N-bIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE

*See also* N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE

N,N-DIMETHYL-4-[PHENYLAZO]-BENZENAMINE

*See* 4-DIMETHYLAMINOAZOBENZENE

NAPTHALENEACETIC ACID

*See* NAA

NEEM

*See* DEBITTERISED NEEM SEED OIL

*See* Azadirachta indica

NEFAZODONE

N-ETHYL MDA

*See* N-ETHYL--METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE

N-HYDROXY MDA

*See* N--[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE

NICOTINAMIDE

*See* NICOTINIC ACID

NISIN

*See also* ANTIBIOTIC SUBSTANCES

nitrogen mustard

*See* MUSTINE

N-METHYL-2-PYRROLIDONE

*See also* DESIGNATED SOLVENT

*See also* N-(N-DODECYL)-2-PYRROLIDONE

*See also* N-(N-OCTYL)-2-PYRROLIDONE

N-METHYLMETHANAMINE

*See* 1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE and N-METHYLMETHANAMINE

NON-ACCESS PACKAGING

*See also* CHILD-RESISTANT CLOSURE

*See also* CHILD-RESISTANT PACKAGING

NOSCAPINE

See also OPIUM

NUX VOMICA

*See* STRYCHNINE

O

OCITHILINONE

*See* 2-OCTYL-4-ISOTHIAZOLIN-3-ONE

OIL OF LEMON EUCALYPTUS (Corymbia citriodora)

*See* EXTRACT OF LEMON EUCALYPTUS

OIL OF TANSY

*See* TANACETUM VULGARE

ORGANO TIN-COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

OXALONITRILE

*See* CYANOGEN

OXETHAZAINE

*See* OXETACAINE

P

PACKAGING

S*ee* LABELS & CONTAINERS

S*ee also* PRIMARY PACK

S*ee also* MEASURE PACK

PAPAVERINE

See also OPIUM

PAPER

*See also* PHOTOGRAPHIC PAPER or FILM

Paracetamol

*See also* ASPIRIN (+ paracetamol)

*See also* METOCLOPRAMIDE (+ paracetamol)

*See also* SALICYLAMIDE (+ paracetamol)

PARAFFIN OILS

*See* HYDROCARBONS, LIQUIDPARAHEXYL

*See* 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN

PCBS

*See* POLYCHLORINATED BIPHENYLS

PCE

*See* ETICYCLIDINE

PCP

*See* PHENCYCLIDINE

PCPY

See ROLICYCLIDINE

PDB

*See* PARA-Dichlorobenzene

PENTACHLORONITROBENZENE

*See* QUINTOZENE

PENTOXIFYLLINE

*See* OXPENTIFYLLINE

PEPAP

*See* 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE

PETHIDINE INTERMEDIATE A

*See* 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE

PETHIDINE INTERMEDIATE B

*See* 4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER

PETHIDINE INTERMEDIATE C

*See* 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID

Petrol

See also BENZENE

*See also* MOTOR, HEATING or FURNACE FUELS

PETROLEUM OILS

*See* HYDROCARBONS, LIQUID

PHENOLS

*See also* CREOSOTE

PHENYL MERCURIC CHLORIDE

*See* MERCURY

PHENYL METHYL KETONE

*See also* DESIGNATED SOLVENT

Phenylephrine

*See also* CODEINE (+ phenylephrine)

*See also* PARACETAMOL (+ phenylephrine)

*See also* IBUPROFEN (+ phenylephrine)

PHOSPHOURUS ACID

*See* PHOSPHONIC ACID

PHP

*See* ROLICYCLIDINE

PHYTOMENADIONE

*See* VITAMIN K

PIMARCIN

*See* NATAMYCIN

PIPERAZINE OESTRONE SULFATE

*See* ESTROPIPATE

PLASMA

*See* BLOOD COMPONENTS

*See* HUMAN BLOOD PRODUCTS

PLASMA SUBSTITUTES

*See* DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES

PLASMA-DERIVED THERAPEUTIC PROTEINS

*See* HUMAN BLOOD PRODUCTS

PLATELETS

*See* BLOOD COMPONENTS

*See* HUMAN BLOOD PRODUCTS

PMA

*See* 4-METHOXY--METHYLPHENYLETHYLAMINE

PODOPHYLLIN

*See also* PODOPHYLLUM EMODI

*See also* PODOPHYLLUM PELTATUM

*See also* PODOPHYLLUM RESIN

POLYDADMAC

*See* POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE

POLYSILICONE-15

*See* DIMETHICODIETHYLBENZALMALONATE

POTASSIUM CARBONATE

*See* ALKALINE SALTS

POTASSIUM CHROMATE

*See* CHROMATES

*See* CHROMIUM

POTASSIUM PERMANGANATE

s*ee* PERMANGANATES

POTASSIUM PHOSPHATE

*See* ALKALINE SALTS

POTASSIUM SALTS

*See* ALKALINE SALTS

*See* BIFLUORIDES

POTASSIUM SILICATE

*See* ALKALINE SALTS

propineb

*See also* DITHIOCARBAMATES

PROTEIN C

*See* HUMAN BLOOD PRODUCTS

PROTHROMBIN COMPLEX CONCENTRATE (PCC)

*See* HUMAN BLOOD PRODUCTS

PSILOCINE

*See* 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE

PSILOTSIN

*See* 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE

PYRETHRIC ACIDS

*See* PYRETHRINS

PYRETHROLONE

*See* PYRETHRINS

Q

QUIZALOFOP ETHYL (D + ISOMER)

*See* QUIZALOFOP ETHYL

R

RADIOPAQUES

*See* RADIOGRAPHIC CONTRAST MEDIA

RASML

*See* REQUIRED ADVISORY STATEMENTS FOR MEDICINE LABELS

RECOMBINANT FOLLICLE STIMULANT

*See* CORIFOLLITROPIN ALFA

RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE

*See* FOLLITROPIN ALPHA

*See* FOLLITROPIN BETA

RED CELLS

*See* BLOOD COMPONENTS

*See* HUMAN BLOOD PRODUCTS

REDUCERS

*See* HYDROCARBONS, LIQUID

*See* LIQUID HYDROCARBONS

ROSEMARY OIL

See also CAMPHOR

See also CINEOLE

S

s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE

*See* TRIBUFOS

SABADILLA

*See* SCHOENOCAULON OFFICINALE

Safrole

*See also* SASSAFRAS OIL

SAGE OIL (Spanish)

See also CAMPHOR

Salicylamide

*See also* ASPIRIN (+ salicylamide)

*See also* PARACETAMOL(*+* salicylamide)

SALVINORIN A

*See* METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE

SARM

*See* SELECTIVE ANDROGEN RECEPTOR MODULATORS

SAVIN(E)

*See* JUNIPERUS SABINE

SECOBARBITAL

*See* QUINALBARBITONE

SELENIUM ARSENIDE

*See* ARSENIC

*See* SELENIUM

SELENIUM SULFIDE

*See* SELENIUM

SHUI OIL

*See* CAMPHOR

SILICOFLUORIC ACID

*See* HYDROSILICOFLUORIC ACID

SILICOFLUORIDES

See also FLUORIDES

SILVER SALTS

*See also* SILVER NITRATE

SODIUM CARBONATE

*See* ALKALINE SALTS

SODIUM CHROMATE

*See* CHROMATES

*See* CHROMIUM

SODIUM CLODRONATE

*See* CLODRONIC ACID

SODIUM DICHLOROISOCYANURATE

*See also* DICHLOROISOCYANURATES

SODIUM 2,2-DICHLOROPROPIONATE

*See* 2,2-DPA

SODIUM HYPOCHLORITE

*See* CHLORINATING COMPOUNDS

SODIUM OXYBATE

*See* 4-HYDROXYBUTANOIC ACID

SODIUM SALTS

*See* ALKALINE SALTS

*See* BIFLUORIDES

SODIUM SILICATE(S)

*See* ALKALINE SALTS

STABAXOL

*See* 2,2',6'6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE

STAPHISAGRIA

*See* DELPHINIUM STAPHISAGRIA

STATINS

*See* HMG-CoA REDUCTASE INHIBITORS

STEM CELLS

*See* BLOOD COMPONENTS

*See also* HUMAN BLOOD PRODUCTS

STEROIDAL AGENTS

*See* ANABOLIC STEROIDAL AGENTS

*See* ANDROGENIC STEROIDAL AGENTS

STP

*See* 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE

STRAMONIUM

*See* DATURA STRAMONIUM

*See* DATURA TATULA

STRONTIUM CHROMATE

*See* CHROMATES

*See* CHROMIUM

Styrene

*See also* DESIGNATED SOLVENT

SULFACETAMIDE

*See also* SULFONAMIDES

SULFONAL

*See* SULFONMETHANE

SULPHANILAMIDE

*See* SULFONAMIDES

SYNEPHRINE

*See* OXEDRINE

T

TANSY OIL

*See* TANACETUM VULGARE

TAPENTADOL

TAR

*See* PHENOL

TBTO

*See* TRI-ALKYL TIN COMPOUNDS/SALTS

TCP

*See* TENOCYCLIDINE

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane)

TEA TREE OIL

*See* MELALEUCA OIL

TERBUCONAZOLE

*See* TEBUCONAZOLE

TERFENADINE

*See also* ANTIHISTAMINES

TETRACAINE

*See* AMETHOCAINE

Tetrachloroethylene

*See also* DESIGNATED SOLVENT

TETRAHYDROCANNABINOLIC ACID

*See* NABIXIMOLS

TETRAHYDROCANNABINOLS

*See also* NABIXIMOLS

TETRAHYDROCANNABIVAROL

*See* NABIXIMOLS

TETRAPION

*See* FLUPROPANATE

TFMPP

*See* 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE

Thallium

THALLIUM SULFATE

*See* THALLIUM

THIACETARSAMIDE

*See also* ARSENIC

THIAMAZOLE

*See* METHIMAZOLE

THINNERS

*See* HYDROCARBONS, LIQUID

*See* LIQUID HYDROCARBONS

2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE

*See* TCMTB

thiram

*See also* DITHIOCARBAMATES

THROMBIN

*See* HUMAN BLOOD PRODUCTS

Thujone

*See also* SAGE OIL

TIOMESTERONE

*See* THIOMESTERONE

TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS − INJECTABLE

*See* MEDICAL DEVICES

TMA

*See* 3,4,5-TRIMETHOXY--METHYLPHENYLETHYLAMINE

TOLUENE

*See also* HYDROCARBONS, LIQUID

*See also* XYLENE

TOY

TOY FUELS

*See* MOTOR, HEATING or FURNACE FUELS

TRIALKYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

TRIBUTYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

TRICHLORFON

*See* *also* METRIFONATE

1,1,1-TRICHLOROETHANE

*See also* DESIGNATED SOLVENT

TRICHLOROETHENE

*See* TRICHLOROETHYLENE

TRICHLOROISOCYANURIC ACID

*See also* CHLORINATING COMPOUNDS

TRICOSENE

*See* (Z)-9-TRICOSENE

TRIENBOLONE

*See* TRENBOLONE

TRIENOLONE

*See* TRENBOLONE

TRIETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

TRIETHYLENE THIOPHOSPHORAMIDE

*See* THIOTEPA

TRIIODOTHYRONINE

*See* LIOTHYRONINE SODIUM

TRIMETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

TRIPHENYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

TRIPROPYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

TSH

*See* THYROTROPHIN

TURPENTINE OIL

*See* *also* OIL OF TURPENTINE

U

ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING AGENTS

*See* ENHANCING AGENTS

UNICONAZOLE-P

*See* (E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL

URINARY CATHETERS

*See* MEDICAL DEVICES

V

VINCA ALKALOIDS

*See* UNDER INDIVIDUAL ENTRIES

VIPRYNIUMA

*See* PYRVINIUM

W

WALLBOARD

*See* TIMBER

WHITE CELLS

*See* BLOOD COMPONENTS

*See* HUMAN BLOOD PRODUCTS

WHITE LEAD

*See* BASIC LEAD CARBONATE

WHITE MINERAL OILS

*See* HYDROCARBONS, LIQUID

WHITE PETROLEUM SPIRIT

*See* LIQUID HYDROCARBONS

*See* HYDROCARBONS, LIQUID

WHITE SPIRIT

*See also* HYDROCARBONS, LIQUID

WHOLE BLOOD

*See* HUMAN BLOOD PRODUCTS

WOOD

*See* CREOSOTE

X

Xylene

*See also* HYDROCARBONS, LIQUID

*See also* TOLUENE

XYLENOLS

See also PHENOL

Y

YELLOW PHOSPHORUS

*See* PHOSPHORUS, YELLOW

Z

ZINC CHROMATE

*See* CHROMATES

*See* CHROMIUM

ZINC PHOSPHIDE

*See* PHOSPHIDES METALLIC

zineb

*See also* DITHIOCARBAMATES